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ABSTRACT 
 
Currently, clinical trials in patients are required by most regulatory authorities for the 
assessment of bioequivalence of topical products where the drug is not intended for systemic 
absorption. Hence there is a dire need for suitable methods for the assessment of 
bioavailability and bioequivalence of such products since clinical safety and efficacy studies 
are expensive, time-consuming and require very large numbers of patients. Except for topical 
corticosteroid products where the human skin blanching assay/vasoconstrictor assay has 
been approved by the US FDA for bioequivalence assessment of those products, no other 
method has been “officially” approved for use in those investigations. However, a few 
alternative methods such as tape stripping and microdialysis have been pursued and 
considered to have the potential for use in bioequivalence/bioavailability studies. 
 
The human skin blanching assay was used to assess the bioequivalence of commercially 
available topical products containing 0.05% clobetasol propionate. Both visual and 
chromameter data were obtained and a commercially available topical corticosteroid product, 
Dermovate® cream was used as both the “Test” and the “Reference” product. The results 
indicated that both visual and chromametric assessments were comparable to each other and 
that either could be used for the assessment of the bioequivalence of topical products 
containing clobetasol propionate. The screening procedure was optimized to identify 
potential “detectors” for inclusion in the bioequivalence studies. This resulted in fewer 
subjects being required in a bioequivalence pivotal study, still having the necessary power to 
confirm bioequivalence using the human skin blanching assay.  
 
Another objective of this research was to re-visit tape stripping and other possible alternative 
methods such as dermal microdialysis and to optimize these procedures for bioequivalence 
assessment of topical formulations where the drug is not intended for systemic absorption. 
 
In the past few decades, tape stripping has been used to investigate 
bioavailability/bioequivalence of various topical formulations. This technique involves the 
removal of the stratum corneum to assess drug penetration through the skin. A draft FDA 
guidance for tape stripping was initially published but was subsequently withdrawn due to 
high variability and poor reproducibility. This research project used an optimized tape 
  
iv 
stripping procedure to determine bioavailability and establish bioequivalence between three 
commercially available formulations containing 0.05 % m/m clobetasol propionate. 
Furthermore, tape stripping was validated by undertaking a study to assess the 
bioequivalence of a 0.05% topical cream formulation (Dermovate® cream) using the same 
cream as both the “Test” and “Reference” product, in which  bioequivalence was confirmed. 
The findings highlight the potential of tape stripping as an alternative method for the 
assessment of bioequivalence of clobetasol propionate formulations and may possibly be 
extended for use in other topical products. 
 
Microdialysis is another useful technique that can assess the penetration of topically applied 
substances which diffuses through the stratum corneum and into the dermis. Microdialysis 
has previously been successfully used for in vivo bioavailability and bioequivalence 
assessments of topical formulations. However, the drugs which were under investigation 
were all hydrophilic in nature. A major problem with the use of microdialysis for the 
assessment of lipophilic substances is the binding/adherence of the substance to the 
membrane and other components of the microdialysis system. As a result, this necessitates 
the development of a microdialysis system which can be used to assess lipophilic drugs. 
Intralipid® 20% was investigated and successfully utilized as a perfusate to recover a 
lipophilic topical corticosteroid, clobetasol propionate, in microdialysis studies. Hence, the 
bioavailability of clobetasol propionate from an extemporaneous preparation was determined 
in healthy human volunteers using microdialysis. These findings indicate that in vivo 
microdialysis can be used to assess lipophilic drug penetration through the skin.  
 
A novel approach to investigate drug release from topical formulations containing 0.05% 
clobetasol propionate using in vitro microdialysis was also undertaken. The in vitro findings 
were found to be in agreement with the results obtained using tape stripping to assess 
bioequivalence of the same commercially available products, namely Dermovate® cream, 
Dovate® Cream and Dermovate® ointment. These results indicate the potential to correlate in 
vitro with in vivo data for bioequivalence assessment of such topical dosage forms.  
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1. CHAPTER 1 
1.1. TOPICAL CORTICOSTEROIDS 
 
Soon after the introduction of hydrocortisone, the first effective topical corticosteroid for the 
treatment of inflammatory dermatoses, a range of corticosteroid derivatives have been 
developed and marketed for the treatment of inflammatory skin conditions. The large 
varieties of topical corticosteroids have an extensive range of potencies, concentrations and 
vehicles (see Table 1.1). The choice of topical corticosteroid therapy depends on the nature,  
severity and location of the dermatological condition to be treated [1,2]. 
 
Whereas the use of topical hydrocortisone and its acetate ester derivative was not associated 
with significant side effects, the introduction of other and more potent topical corticosteroids 
was accompanied by more serious side effects. Thus, researchers have attempted to create 
topical corticosteroid derivatives which still retain the same efficacy but with a significant 
reduction and even elimination of some side effects [3].   
 
Since the site of action is considered to be in the dermis, topical corticosteroids are only 
minimally absorbed following application onto normal, healthy skin. However, the 
penetration of topical corticosteroids may be altered when applied under occlusion using a 
plastic covering or when applied to broken skin where the dermis may be breached, resulting 
in enhanced penetration [2]. In such situations, considerable absorption may occur resulting 
in suppression of endocrinal function and associated undesirable systemic effects [2,4]. 
Various  other factors that affect the absorption of topically applied corticosteroids  include 
application to different anatomical skin sites, age, skin disease, skin hydration and drug 
concentration [5,6].  
 
Over the years, the development and utilization of topical corticosteroids have encouraged 
researchers to study the uses and side effects associated with a specific chemical structure 
and/or ester derivative in order to determine its potency and biopharmaceutical properties. 
These studies have been performed by applying various techniques and assessment methods 
which involve skin and/or blood assays. 
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1.1.1. Classification of the clinical potency of topical corticosteroid preparations  
 
Since there are many topical corticosteroids available on the market, a classification system 
has been developed to differentiate between the different corticosteroid derivatives according 
to their anti-inflammatory activities. This system of classifying topical corticosteroid 
molecules is recommended mainly for clinicians to provide information on the relative anti-
inflammatory potency of the various topical products. This system has the advantage of 
indicating not only the relative potency of a specific proprietary preparation but also has the 
ability to classify both local and systemic side effects of corticosteroids assuming the 
potency and side effects run parallel to each other. The human skin blanching assay (HSBA) 
also known as the  vasoconstriction assay (VCA) and clinical efficacy trials have been used 
as standard methods for evaluating the relative anti-inflammatory potency of various topical 
corticosteroid proprietary preparations. The HSBA assesses the degree of vasoconstriction 
following application of the topical corticosteroid which affects the cutaneous capillaries in 
healthy human volunteers where normal human skin is used 
 
In northern Europe a four-category system is used but may not be sufficient to indicate 
significant biological differences amongst the various corticosteroid preparations available. 
This system regards class I as mildly potent and class IV, very highly potent [7]. In the U.S., 
a six-category system (Stoughton’s system) was set up utilizing the HSBA as well as clinical 
efficacy trial data where the topical corticosteroids were used in patients suffering with skin 
diseases. In this system, the most potent was designated class I and the least potent was class 
VI [8].  Whenever a new topical corticosteroid is developed and does not fit into any of the 
divisions, a new roman numeral class is added which will shift all the previously designated 
preparations by one numeral.  
 
In some instances, the bioavailability of a particular corticosteroid may be enhanced by 
formulation which can result in a change in potency of that particular corticosteroid. For 
example, the introduction of an optimized ointment of betamethasone dipropionate which 
significantly increased the bioavailability of the corticosteroid to the skin compared to the 
previously available formulation, a new class had to be created with this formulation being 
promoted to a class I classification. Instead of having six classes, there are now seven classes 
[9,10]. The current classification system is shown below (Table 1.1)  
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Table 1.1.  Potency ranking of some topical corticosteroid preparations and their strengths 
utilizing Stoughton’s system [10] 
Classification and Substance Formulation Type(s) Strength (%) 
Class I (superpotent)   
Clobetasol propionate Ointment, cream 0.05% 
Betamethasone dipropionate Ointment, cream 0.05% 
Class II (potent)   
Mometasone furoate Ointment, cream 0.1% 
Fluocinonide  Ointment, cream, gel 0.05% 
Class III (potent)   
Fluticasone propionate Ointment 0.005% 
Flucortolone Cream 0.25% 
Class IV (midstrength)   
Hydrocortisone valerate Ointment 0.2% 
Desoximetasone  Cream, gel 0.05% 
Class V (midstrength)   
Betamethasone dipropionate  Lotion 0.05% 
Fluocinolone acetonide Cream, oil 0.025%,0.01% 
Class VI (mild)   
Betamethasone valerate Lotion 0.05% 
Alclometasone dipropionate Ointment, cream 0.05% 
Class VII (least potent)   
Dexamethasone Cream  0.1% 
Hydrocortisone All types 0.5%, 1%, 2.5% 
1.1.2. Clobetasol 17-propionate 
 
In this thesis, the focus is on clobetasol 17-propionate (CP) which falls under the category of 
high-potency corticosteroids i.e. Class I (US classification system). CP has been used since 
1973 for the short-term topical treatment of inflammatory and pruritic manifestations of 
moderate-to-severe corticosteroid-responsive dermatoses [11]. It is also indicated for plaque 
and scalp psoriasis (moderate to severe) [12].  
 
CP was the first potent topically active corticosteroid investigated at an optimal 
concentration of 0.05% in a cream and ointment formulation [13]. 
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The treatment of more severe skin disorders using CP with or without the inclusion of other 
drug substances were compared in several clinical studies. To-date, CP has demonstrated 
excellent recovery, rapid relief and reduced relapses of different skin conditions and 
symptoms [3,14,15].  It was also proven to be the first topical corticosteroid that 
demonstrated satisfactory results in the treatment for psoriasis [13,15]. 
 
Although CP is a commonly used potent corticosteroid which has been on the market since 
the early ‘70s, not much research has been emphasized on its properties and this dearth of 
information promoted a need to further investigate this particular molecule. It was therefore 
chosen as the topical corticosteroid drug candidate for this research in order to gain more 
insight into this drug’s transdermal behaviour in the skin and its bioavailability.  
 
1.1.2.1. Physicochemical properties 
1.1.2.1.1. Chemical structure 
 
CP (CAS No. 25122-46-7) [16] is a 21-chloro-9α-fluoro-11β-hydroxy-16β-methyl-3,20-
dioxopregna-1,4-dien-17α-yl propionate, and it is a synthetic corticosteroid that has a 
molecular weight of 467.0 g/mol with the empirical formula, C25H32ClFO5 [4,17].   
 
 
Figure 1.1 Chemical structure of clobetasol 17-propionate 
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CP is a white or almost white, crystalline powder [4]. 
 
1.1.2.1.2. Structure-activity relationships 
 
The skin possesses a variety of enzymes that facilitate a range of metabolic activities [18-23].  
Identifying the different enzymes and their activities facilitates the design and development 
of a drug with required optimal activities. The level of activity of a synthetic topical 
corticosteroid depends on three factors: 
1. Better penetration through the skin. 
2. Slower degradation by enzymes. 
3. Greater affinity to the receptors in the cells.   
This can be optimized by adding, removing or altering the functional groups on the steroid 
nucleus [24]. This indicates that the relationship between the drug’s structural and functional 
activity is important.   
 
 
Figure 1.2.  Basic steroid structure 
The topical corticosteroids are based on the typical steroid nucleus structure (Figure 1.2) that 
comprises of 17 carbon atoms arranged into 4 rings. There are three 6 membered rings and 
one 5 membered ring fused to form the basic nucleus. Structural features considered 
desirable for topical activity are the double bonds at C1 and C4, a C3 keto group, β-methyl 
groups at C18 and C19, and a C20 keto group [25]. 
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Referring to the structure of CP (Figure 1.1), the introduction of a double bond at the C1-C2 
position led to an increase in glucocorticosteroid and anti-inflammatory activity and a 
decrease in mineralocorticoid properties [6,24,26,27]. Fluorination on carbon 9-α produces 
the largest increase in glucocorticoid activity, but also enhances the unwanted 
mineralocorticoid effects [24,26]. The hydroxyl group at carbon 11 is required for 
inflammatory activity [6,27] and allows the drug to be topically active [24]. Esterification of 
the hydroxyl group on carbon 17 with lipophilic halogenated forms on the different sites of 
the molecule enhances skin penetration and effectiveness thus increasing potency, slows 
down degradation by biological enzymes and increases the affinity of the drug to the 
receptors in the cells [28,29]. Enhanced penetration is obtained by optimising lipophilicity 
based on alteration of the free-OH groups [6,24,27,28]. Typical derivatives include the 
acetates, propionates, butyrates, valerates, pivalates and acetonides. The addition of these 
esters do not alter the intrinsic activity of the active substance, however, they increase the 
lipophilicity of the molecule which enhances the compound penetration through the skin by 
providing a more favourable partition coefficient and becoming more effective [6,25,30,31]. 
Esterification of the CP molecule at carbon 17 with a propionate group resulted in enhanced 
potency. The chlorination of the 21-hydroxyl group also resulted in an increase in 
lipophilicity and enhanced activity [26,32].   
 
As stated above, the slowing down of drug degradation also plays a role in altering the level 
of activity of a corticosteroid. The degradation of a corticosteroid molecule involves all or 
some of the following chemical reactions; oxidation of the 11-hydroxyl group, reduction of 
the C4-C5 double bond, reduction of the keto-oxygen C20, hydroxylation at C6 and 
degradation of the carbon side chain at C17 [33]. In order to slow down the degradation 
process in the body, it was found that the introduction of 16α- or β-methyl groups will 
protect the corticosteroid against metabolizing enzymes [24,26]. From further research 
[24,29], the C17 esters were found to be more resistant to degradation by cutaneous esterases 
than the C21 esters. Being more resistant to degradation, the chance of reservoir formation 
on the skin is higher which will allow the drug to act for a longer period of time thus 
increasing the potency.   
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1.1.2.1.3. Solubility 
 
CP is relatively insoluble in water (3.86 mg/L at 25 °C) [16]. It is slightly soluble in benzene 
and diethyl ether, soluble in chloroform and methanol, freely soluble in acetone and in 
dichloromethane, and sparingly soluble in ethanol (96 %). 
 
1.1.2.1.4. Melting point 
 
It has a melting point of ~196 °C.   
 
1.1.2.1.5. Optical activity  
 
The specific optical rotation in a 1% w/v solution in 1,4-dioxan, calculated with reference to 
the dried substance, is between +96° to +104° [4]. 
 
1.1.2.1.6. Partition coefficient (Log P) and dissociation constant (pKa) 
 
The partition coefficient, Log P (octanol-water) value is 3.5. Since CP is a neutral compound 
it does not ionize and thus does not have a dissociation constant (pKa) [16].   
 
1.1.2.2. Pharmacology  
1.1.2.2.1. Pharmacokinetics 
 
Pharmacokinetics explains the time course of drug concentration in the body. The 
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recognition of clearance and volume of distribution has provided an important link to the 
physiological determinants of drug disposition. Mathematical models of absorption, 
distribution, metabolism and elimination have been extensively applied, and their predictions 
agree well with actual observations. Pharmacokinetics is used to describe the process 
controlling drug concentration at any time after one or more doses [34].  
 
Pharmacokinetics after topical application of drugs differs from pharmacokinetics after all 
other routes of administration in that the site of action (the skin) is accessible to immediate 
drug analysis.  The development of new topical glucocorticoids has two aims: 1) to produce 
preparations which assure sufficiently high concentrations at the site of action in the skin, 
and 2) to keep systemic corticosteroid load as low as possible to reduce the risk of systemic 
effects [35].  
 
The pharmacokinetic properties of topical corticosteroids still remain poorly understood.  In 
general, corticosteroids which enter the systemic circulation are metabolized in the liver and 
in other tissues, and are excreted in the urine. The synthetic corticosteroids have lower 
protein-binding affinity which in turn causes slower metabolism and this may explain their 
increased potency [27]. Most topical corticosteroids and their derivatives can be absorbed 
through the skin and penetrate into dermal blood vessels. Some of the molecules are 
metabolized in the skin sites and excreted as occurs when they are systemically administered.   
 
It has been established that the rate of penetration through the stratum corneum (SC) is the 
rate-limiting step in the percutaneous absorption of the topical corticosteroids. According to 
Bronaugh et al [36], some compounds are metabolized extensively during skin absorption 
whereas for many, metabolism may be small or undetectable. Cutaneous metabolism occurs 
at the epidermis where certain similar enzymes as those found in the liver (including a 
cytochrome P450 system) may be involved and induced. Topical corticosteroids may 
undergo hydrolysis sulphate conjugation within the epidermis [6].  
 
It has been found that betamethasone-17- and -21- valerates undergoes hydrolysis by 
esterases found in the skin. It is shown that the 17-ester topical corticosteroids are resistant to 
both liver and hepatic esterases whilst the 21-esters are rapidly hydrolyzed to the free steroid 
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alcohol. Hence, this resistance of enzymatic hydrolysis of the 17-ester, as in the case with 
clobetasol 17-propionate, leads to a more pronounced reservoir effect in the skin [29].  
 
1.1.2.2.2. Mode of action 
 
Inflammation is a dominant feature of many skin diseases, including dermatitis, psoriasis and 
eczema [1,2,4]. The inflammation process involves the recruitment and activation of 
inflammatory cells and changes in structural cells. This process is characterized by an 
increased expression of cytokines, chemokines, growth factors, enzymes, receptors and 
adhesion molecules [37]. Hence, topical corticosteroid use is based on their primary 
therapeutic effect i.e. anti-inflammatory activity.   
 
The mode of action of corticosteroids is still not clear, however there are postulations on 
their anti-inflammatory activities. One hypothesis that has been widely accepted proposed 
that the inflammatory process results from the release of hydrolytic enzymes of  lysosomes 
and that the glucocorticoids stabilize lysosomal membranes, preventing the rupture of the 
organelles [38,39].  Greaves et al [40] reported that prostaglandins were recovered from 
several types of inflammatory reactions and are capable of mediating most of the 
components of inflammation. Hence, the possibility arises that corticosteroids may owe their 
anti-inflammatory activity in part to the inhibition of the prostaglandin biosynthesis process. 
It has been suggested by Lewis et al [41] that corticosteroids inhibit the release of 
prostaglandin by preventing the transport of prostaglandin from inside the fat cell to the 
extracellular space where it would normally act on blood vessels. It has also been postulated 
[42,43] that corticosteroids block arachidonic acid release from phospholipids by enhancing 
the production of lipocortin, this in turn inhibits the activity of phospholipase A2. The 
activity of topical corticosteroids is thought to be due to the binding of the drug to steroid 
receptors located in the cytoplasm or on the outside of the nuclear membrane to form 
complexes that enter the cell nucleus. These complexes then bind to DNA and modify 
mRNA transcription and the subsequent synthesis of proteins, this effect is ultimately 
responsible for the anti-inflammatory activity of the corticosteroid [6,44,45]. As mentioned 
earlier, clobetasol 17-propionate is a highly potent synthetic corticosteroid, and it has been 
found that high-potency corticosteroids appear to bind more effectively to the receptors [11]. 
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It has also been reported that corticosteroids inhibit DNA synthesis in many types of cells 
and therefore assist in the treatment of proliferative inflammations such as keloids [24]. The 
anti-inflammatory effects of the corticosteroids may, in part, be explained by the above 
postulations since the arachidonic acid cascade generates several inflammatory mediators.  
1.1.2.3. General side effects 
 
There are several safety concerns with the use of topical corticosteroids especially that of 
Class I. Often the misuse and abuse of a topical corticosteroid leads to numerous local and 
systemic side effects. Factors that contribute to the occurrence of these side effects include 
the amount applied, percentage of body surface covered, frequency of application, 
application to thin skin or naturally occluded areas, age of patient, skin quality (i.e. diseased), 
and steroid potency [46]. The majority of the side effects are reversible. Appropriate 
management will be either stopping the use of a specific topical corticosteroid or switching 
to an alternative corticosteroid with lower potency [3]. According to reports in the published 
literature [14,47], CP demonstrated greater occurrences of side effects than other topical 
corticosteroids and is therefore recommended  for  short term therapy only. 
 
1.1.2.3.1. Local side effects 
 
The onset of local side effects from topical corticosteroids is due to application on the same 
skin site over a long period of time at relatively high concentrations [37]. The more common 
local side effects consist of atrophy, striae, purpura, acne, and telangiectases. The less 
commonly occurring side effects are local hypertrichosis, hypopigmentation, and allergic 
contact dermatitis [3,37,46].   
 
Dermal atrophy in both the epidermis and the dermis was found to be the most common side 
effect of topical corticosteroid therapy [10,37,48]. This results in increased transparency, 
shininess of the skin and striae [10].  Skin atrophy is mainly caused by suppressive effects 
on cutaneous cell proliferation and protein synthesis by the corticosteroid [48]. 
Corticosteroids also stimulate human dermal microvascular endothelial cells, leading to the 
occurrence of telangiectasia which is characterized by an abnormal dilatation of capillary 
vessels and arterioles [10,48]. Striae are visible linear scars that develop with an initial 
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inflammation and oedema of dermis, followed by the deposition of dermal collagen along 
the lines of mechanical stress. Development of striae generally accompanies the occurrence 
of atrophy [49,50]. Topical steroids can induce an acneform eruption which is due to the 
degradation of the follicular epithelium, resulting in extrusion of the follicular content 
[51,52].  
 
It has been reported that steroids can induce hypertrichosis (growth of vellus hair) by means 
of an unknown mechanism [3,10]. Acne and hirsutism have been reported to be 
pharmacological effects of glucocorticoids. However, these effects are caused by metabolic 
degradation products resulting in the loss of the side chain at C17 forming 17-ketosteroid 
compounds which tend to be androgenic. A positive use of a potent corticosteroid is the 
reduction of the dosage administered thereby reducing  the quantity of 17-ketosteroids being 
formed [53]. 
 
1.1.2.3.2. Systemic side effects 
 
The potential systemic adverse effects upon topical administration include hypothalamic-
pituitary-adrenal (HPA) axis suppression, retarded growth in children, and hyperglycemia 
[10,46,47]. Many studies have shown that high-potency topical agents can suppress the HPA 
axis. The application of as little as 2g a day of CP 0.05% cream can cause a decrease in 
morning cortisol levels after only a few days. In some cases, the suppression of the HPA axis 
brings about the elevation of endogenous cortisol levels which manifests physical features to 
that of Cushing’s syndrome. Clinical features of Cushing’s syndrome include round face, 
hypertension, depression, central obesity and thin extremities to name a few [10,46,47].   
 
These systemic side effects usually occur as a result of an increase in steroid penetration and 
absorption  through the skin when corticosteroids are applied to large surface areas, under 
occlusion using higher concentrations or more potent derivatives, especially in children [54-
56].  Although patients find CP preparations to be more effective in treating stubborn skin 
diseases, it is recommended that patients should be warned by their physicians to avoid using 
more than 50g a week [47].  
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1.1.2.4. Precautions 
 
There is always a risk of systemic absorption following the application of topical 
corticosteroids. Potent topical corticosteroids should not be used with any occlusive dressing 
nor should they be applied to large areas of the body. Long-term topical treatment should 
best be avoided, especially in children. Topical corticosteroids should also not be used for 
the treatment of ulcerative conditions, rosacea and for pruritis. When used in combination 
therapy with an antimicrobial substance, hypersensitivity reactions can occur [27]. Failure to 
heal may be evidence of allergy rather than exacerbation of the condition. Use of topical 
corticosteroids in uncontrolled skin infections should be avoided [12]. 
 
1.1.2.5. Contraindications 
 
Patients who present with rosacea, acne vulgaris, peri-oral dermatitis, peri-anal and genital 
prurities should avoid using formulations containing CP. The same applies to patients with 
skin lesions caused by infection with viruses, fungi or bacteria; dermatoses in children under 
one year of age, including dermatitis and napkin eruptions. Use of CP in pregnant women 
and in patients with hypersensitivity towards corticosteroids should also be avoided. These 
contraindications were mentioned in the patient information leaflet of Dermovate® cream 
(published: June 1981). 
 
1.1.2.6. Dosage and directions for use 
 
As indicated in the patient information leaflet of Dermovate® cream, the formulation must be 
applied sparingly to the affected area once or twice daily until improvement occurs. As with 
other highly potent topical steroid preparations, therapy should be discontinued when control 
is achieved. If a longer course is needed, it is recommended that treatment should not be 
continued for more than four weeks without the patient’s condition being reviewed. 
Repeated short courses using CP formulations may be used to control exacerbations.  
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1.1.2.7. Commercially available formulations 
 
Topical formulations containing CP on the South African market include creams, ointments 
and scalp lotion (see Table 1.2 below). All these topical preparations contain a concentration 
of 0.05 % m/m CP [57]. 
 
Table 1.2.  Table of commercially available CP topical formulations in South Africa. 
Product name Manufacturer Concentration  
Dermovate® cream Glaxo Wellcome, South Africa 0.05 % m/m 
Dermovate® scalp application GlaxoSmithKline, Bryanston, South Africa 0.05 % m/m 
Dermovate® ointment Sekpharma, South Africa 0.05 % m/m 
Dovate® cream Aspen Pharmacare, South Africa 0.05 % m/m 
Dovate® ointment Aspen Pharmacare, South Africa 0.05 % m/m 
Xenovate® cream Aspen Pharmacare, South Africa 0.05 % m/m 
Xenovate® ointment Aspen Pharmacare, South Africa 0.05 % m/m 
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2. CHAPTER 2 
2.1. PERCUTANEOUS ABSORPTION 
 
The skin, the largest organ of the body, is a possible route for the absorption of chemical 
agents, although this is usually not intended. Before any topically applied agent can act 
either locally or systemically, it must penetrate the “barrier layer” of the skin known as the 
SC. Penetration of this layer not only produces therapeutic action of applied drugs, but also 
possible local or systemic toxicity and injuries by chemical agents or antigenic substances 
[58,59]. The skin’s impermeability depends upon its integrity, thus damaged or diseased 
skin is often very permeable. In view of its thickness and chemical structure, it is also a site 
where numerous drugs can accumulate and are only very slowly removed by absorption. 
This occurrence is known as the “reservoir effect” where it permits the development of 
prolonged effects after a single topical application.   
 
The skin is capable of metabolizing various chemical compounds. In order to study the 
percutaneous absorption of a compound, knowledge of the metabolic capability of the skin 
is important. It allows the investigator to understand the transformation of the parent 
compound into its metabolite form and this facilitates the determination of bioavailability 
and the associated permeation properties of the topically applied compound. However, 
percutaneous absorption is a complex process where it is more than just diffusion through 
the SC. It involves sequential steps of several transport processes. First, the molecules must 
be adsorbed onto the SC, diffuse through it, move into the viable epidermis, diffuse 
through the epidermis and dermis until they reach the capillary bed, and finally be 
transferred to the circulating blood. The rate-limiting step in percutaneous absorption is the 
diffusion through the SC [58].   
 
A great deal of experiments have been performed to explain skin structure, physiology, 
barrier properties, and the mechanisms by which substances enter and cross the skin. In the 
previous 20 to 30 years, the scientific study of percutaneous absorption has moved from 
emphasizing descriptive detail to correlating physicochemical factors to try and understand 
the types of molecules that may penetrate the protective barrier especially through the 
influence of vehicles [59].   
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2.1.1. The structure and function of human skin 
 
The skin is a vital organ and its most important function is to act as a barrier preventing the 
entry of exogenous substances and retain essential endogenous substances in the human 
body. The skin is not just the largest organ in the body, but possibly the most complex 
owing to the variety of cell types contributing to its structure. The function of the skin is 
primarily to provide protection from physical and chemical damage, UV radiation, and free 
radical attack. Its other functions include thermoregulation and also acting as a sensory 
(allow the sensation of feeling) and endocrine organ (for example, the synthesis of vitamin 
D).   
 
The skin is made up of two distinct layers: an outer, unvascularized epithelial layer 
(epidermis); and an inner vascularized layer (dermis). The epidermis is further divided into 
several layers which is characterized by the various stages of differentiation of cells [60]. 
The most superficial layer, the SC of the epidermis, is recognized as the major barrier. 
Although much thicker than the epidermis, the dermis offers little resistance to drugs and 
water [61].   
 
Since the term “epidermis” usually includes the SC together with the various other layers 
described above, the term “viable epidermis” is used to exclude reference to the SC layer.  
 The thickness of the outermost layer is ~10µm, whereas the other layers are ~100µm and 
~100-200µm, respectively [62].   
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Figure 2.1 Structure of the skin (http://www.methodisthealth.com/tmhs/basic.do?channelId=-
1073830178&contentId=1073790565&contentType=HEALTHTOPIC_CONTENT_TYPE, accessed on 04-
10-2009) 
2.1.1.1. Epidermis 
 
The epidermis is chiefly made up of approximately 95% of keratinocytes and the rest are 
melanocytes, Langerhans cells and Merkel cells. The avascular, stratified epidermis is 
approximately 100 – 150 µm thick and is divided into four layers. This multi-lamellar 
structure represents the different stages of cell differentiation which are the stratum basale, 
stratum spinosum, stratum granulosum and the SC [63,64].  
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Figure 2.2.  A representation of epidermal cell differentiation [65] 
2.1.1.1.1. Stratum basale (basal layer) 
 
The stratum basale is a monolayer of cubic basal cells which are attached to the basement 
membrane via hemidesmosomes. This layer is made up of epidermal stem cells and 
transiently amplifying cells derived from them. These cells have a high nucleo-cytoplasmic 
ratio and contain cell organelles such as keratin filaments (tonofilaments), and are involved 
in hemidesmosome formation which links neighbouring and overlying cells. Two types of 
keratins (K14 and K15) are expressed in the basal cells [64]. 
 
2.1.1.1.2. Stratum spinosum (spinous layer) 
 
The stratum spinosum cells have a spiny appearance in histological sections due to the 
large quantity of desmosomes. In addition to the typical cell organelles found in the basal 
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layer, the stratum spinosum also contains lipid-enriched lamellar bodies called Odland 
bodies, keratinosomes and membrane-coating granules. The lamellar bodies are 
approximately 0.2 – 0.5 µm in diameter with parallel stacks of lipid-enriched disks 
enclosed by a tri-laminar membrane. In cross sections, each lamellar displays a major 
electron dense band divided centrally by a minor electron dense band. Their appearance 
marks the dual aspects of epidermal differentiation, namely protein and lipid synthesis. 
There is a noticeable increase in cellular keratin filaments in this layer compared to the 
basal cells. Keratins 1 and 10 are the biochemical markers for this layer. In the upper layers 
of the stratum spinosum, the cells begin to flatten and elongate before migrating to the 
stratum granulosum [64]. 
 
2.1.1.1.3. Stratum granulosum (granular layer) 
 
Keratohyalin granules characterize this layer and these granules are composed of 
profilaggarin, loricin, and a cysteine-rich protein as well as keratins 1 and 10. They become 
progressively larger in the upper granulocytes, indicating a quantitative increase in keratin 
synthesis. The filaggrin subunits of profilaggrin play the role of aggregating and aligning 
the keratin filaments. Keratin filaments in upper granular layers have extensive disulfide 
bonds and are highly phosphorylated compared to cell layers below. The progressive cell 
differentiation is accompanied by increased protein synthesis and lipogenesis, evident by 
the presence of large numbers of lamellar bodies which reach their highest density in the 
uppermost granulocytes (about 20% of the cell cytosol). The uppermost cells in the stratum 
granulosum terminally differentiate into corneocytes, during which the lamellar bodies are 
secreted to the extracellular domains [64].   
 
2.1.1.1.4. Stratum corneum 
 
The SC is composed of corneocytes (terminally differentiated keratinocytes) and secreted 
contents of lamellar bodies which are generated in the basal layer of the epidermis. As cells 
move towards the surface they lose their nuclei and develop keratohyalin to form an 
inactive layer of dead, flattened, interlocked cells. During this migration, the lipid content 
also undergoes modification [66]. Lipid is contained within intracellular lamellar bodies 
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inside the stratum granulosum.  As the cells move towards the SC, this lipid is extruded 
out of the lamellar bodies and into the intercellular spaces to form lipid bilayers around and 
between the corneocytes [63,67-69]. The lipid composition in the SC is a mixture of 
cholesterol, ceramides, cholesteryl esters, a small fraction of cholesterol sulfate and free 
fatty acids [70]. The arrangements of intercellular lipids and the degree of cohesion 
between cells seem to be vital for the maintenance of an effective epidermal barrier. As the 
cells migrate towards the skin surface, the intercellular lipids become fragmented, the 
cohesive forces lessen and desquamation occurs [61].   
 
This layer consists of eight to sixteen layers of flattened, stratified and fully keratinized 
dead cells. Each cell is approximately 34 – 44 µm long, 25 – 36 µm wide and 0.15 – 0.20 
µm thick. The life span of a cell on the surface of the skin is two to three weeks [71]. The 
barrier function of the SC has a water permeability of 1000 times less than the other 
membranes [72].   
 
2.1.1.2. Dermis 
 
The dermis has two distinct layers i.e. the papillary layer (which is adjacent to the 
epidermis) and the reticular layer (which provides structural support) [71]. The dermis is 
made up of collagen, elastin and glycosaminoglycans as well as fibroblasts that extend the 
extracellular matrix [64]. This layer also consists of a blood supply network which is made 
up of a deep plexus of arteries and veins. A second network of capillaries is located on the 
sub-papillary region of the dermis where small branches of capillaries are sent towards the 
surface layers of the skin. The capillaries only reach up to 150 – 200 µm before the surface 
and do not enter the epidermis [71].  
 
2.1.1.3. Skin appendages 
 
Hair and glands are known to be distributed unevenly in the skin on the human body 
except on glabrous skin. Glabrous skin is hairless (and without hair follicles) and is found 
on fingers, palmar surfaces of hands, soles of feet, lips, labia minora and the penis.  Hair 
follicles are found at different densities on the body. A majority of the hair follicles in man 
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are found on the face (600-800cm-2) whereas hair is also found over the rest of the body 
(60-80cm-2) as well. The amount of appendages on the total skin surface has been 
estimated to be up to 0.1% [73]. A recent study had shown that the highest follicular 
density and orifices are on the forehead whereas the least was found on the forearm. 
However, the amount of skin appendages contradicts the former hypothesis of the skin 
appendages measuring not more than 0.1% of the total skin surface area [74].   
 
Sebaceous glands that are found in the upper third of the hair follicle secrete sebum into 
the hair follicle which eventually ends on the surface of the skin. Eccrine sweat glands 
possesses a coiled section in the lower dermis, and make up 1/10 000 of the total skin 
surface area [71].   
 
2.1.2. Routes of penetration 
 
Percutaneous delivery of a drug can occur via several possible routes (Figure 2.3).  One of 
the ways is via the transepidermal route which involves diffusion through the SC and the 
viable cells of the epidermis, and finally through the upper layers of the dermis into the 
microcirculation [72]. The degree of diffusion is usually limited by the intact SC. However, 
the rate determining step for very lipophilic drugs lies in the essential aqueous nature of the 
viable epidermis [75,76]. Other percutaneous routes include via the skin appendages i.e. 
through sebaceous glands and eccrine glands.  
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Figure 2.3.  Possible routes of percutaneous delivery of drugs A) Transcellular, B) Intercellular, C) through sebaceous 
ducts, D) transfollicular, and E) through sweat ducts [77] 
2.1.2.1. Intercellular route 
 
This route involves the passage of drugs through the SC between the lipid channels 
between the cells. The lipoidal nature of the lipid channels favours the passage of lipophilic 
molecules. Since a majority of topical drugs on the market are hydrophobic, this becomes 
the main entry into the skin [71].   
 
2.1.2.2. Transcellular route 
 
The permeation of drug substances occurs through the hydrophilic keratinized cells. It has 
been shown that hydration of the skin increases the penetration of polar molecules more 
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than non-polar ones [78]. 
 
2.1.2.3. Skin appendages 
The permeation of drugs across the skin includes diffusion through the epidermis and skin 
appendages such as hair follicles and eccrine glands which form shunt pathways.  These 
skin appendages occupy only 0.1-0.5% of the total skin surface and thus the contribution of 
this pathway is generally not considered to be significant except in a few cases [58,79].   
 
Previous studies have found increased penetration rates of topical substances in skin areas 
with high follicular density [80,81]. Otberg et al [74] have demonstrated that each 
anatomical site has its own arrangement of hair follicle characteristics, which suggests that 
the variations and distributions of skin appendages in the different body sites are also vital 
for the evaluation and quantification of the penetration process for the different topical 
drugs and their vehicles/formulations.  
 
2.1.3. Enhancement of percutaneous absorption 
 
Over the years there has been a general perception that the bioavailability of topically 
administered drugs is very low. In order to improve topical bioavailability, it is necessary to 
employ enhancement strategies. The ideal characteristics of a dermal permeation enhancer 
would be that it should be pharmacologically inert, non-toxic, immediate in action, reversible 
in action, chemically and physically compatible and cosmetically appealing. Owing to all 
these characteristics, it is doubtful that any enhancer will have all of these properties and 
compromises are generally made with benefit to risk calculations [82].  
 
To understand the percutaneous absorption of a specific drug, one must know the type of 
formulation and content of certain excipients in the formulation. The formulation affects the 
way in which the drug penetrates through the skin. It is important to formulate an active 
ingredient in a vehicle so as to allow contact and then penetration into healthy or diseased 
skin for the desired result. The ability of a drug in a topical formulation to penetrate the skin 
and exert its effect is dependent on two physical events. Firstly the drug must be able to 
diffuse out of the vehicle onto the skin surface and then it must penetrate this natural barrier 
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en route to the site of action. Depending on either process, it could affect the overall 
effectiveness of the topical dosage form. These two processes are related and are thus 
dependent on the physical properties of the drug, vehicle and the skin barrier.   
 
The drug-vehicle factors that need to be considered when formulating a topical preparation 
have been suggested by Poulsen [83]: 
 
I. Effects of vehicles on the integrity of the skin barrier or permeability. 
II. Particle size of poorly soluble suspended drugs. 
III. Chemical nature of the drug. 
IV. Partition coefficient of the drug between the skin and vehicle. 
V. Drug concentration in the vehicle. 
 
In many studies [84-86], it has been found that vehicles do affect the therapeutic potency of a 
topical corticosteroid.  It is important that an appropriate base must be used in order to obtain 
maximal clinical response. Vehicles may provide beneficial effects on diseased skin such as 
emolliency, occlusion or astringent properties. However, the combination of the vehicle and 
the drug must be compatible with each other to exert a non-deleterious effect.  
 
Topical corticosteroids are available in a variety of vehicles. Depending on the type of 
vehicle used in the particular formulation, each steroid will respond differently in its ability 
to penetrate and be biologically active [11,87]. A variety of vehicles are available for topical 
formulations such as ointments, creams, lotions, gels, liquids and sprays. 
 
2.1.3.1. Effect of concentration of the active ingredient 
 
It is known that the higher the concentration of a single topical corticosteroid component, the 
more potent it would become since a larger amount will likely penetrate into the skin.  
However, the result is not always linear with corticosteroids and may result in wastage i.e. a 
10-fold increase in concentration may not necessarily yield a 10-fold increase in absorption 
[6,88].   
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2.1.3.2. Hydration of the epidermis 
 
Emollients are often found in topical corticosteroid formulations which includes propylene 
glycol, oils of vegetable and animal origin, and fluid silicone [11].  
 
The rationale for including an emollient is to re-hydrate and soften the SC which creates a 
higher likelihood for the penetration of both hydrophilic and hydrophobic substances [58]. 
The emollient assists in restoring intercellular lipids and improving water retention by 
forming a barrier over the skin which results in an occluding effect [59,89]. Baker [84] has 
demonstrated that various pharmaceutical vehicles may influence the rate of penetration of 
therapeutic substances through the skin via their occlusive potential, i.e. their ability to 
suppress transepidermal water loss. This occlusion re-hydrates the SC and enhances the 
penetration of therapeutic substances [90]. In fact, occlusion following application of a 
topical corticosteroid formulation using an occlusive dressing is a commonly used practice to 
improve drug penetration through the SC. 
 
2.1.3.3. Increasing the solubility of the active ingredient 
 
A way in which excipients can modify skin permeability is to shift the solubility parameter 
of the skin in the direction of that of the diffusing drug. An increase in the solubility of the 
drug in the outer layers of the skin will also lead to an increase in the rate at which the drug 
diffuses through the skin, i.e. the flux [91]. Simple solvent types such as propylene glycol 
and ethanol are known to improve the solubility of many relatively insoluble drug 
compounds.  
 
The inclusion of propylene glycol into a formulation generally enhances the penetration of 
topical corticosteroids due to increased solubility of the active substance [3,92]. Studies have 
shown that dissolved drug particles penetrate faster than that of undissolved crystal or 
microcrystal forms [5,59]. On the basis of the results obtained from studies performed by 
Ostrenga et al [92,93] the following were suggested: 
I. The concentration of the diffusible drug in the vehicle should be optimized by ensuring 
all the drug is in solution. 
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II. Minimum amount of solvent should be used to dissolve the drug completely and yet 
yield a favourable partition coefficient with the skin. 
III. The excipients should affect the permeability of the SC in a positive manner. 
 
Dempski et al [94] showed findings in their study that corresponded well with some of the 
results of Ostrenga et al [93]. 
 
Only a fraction of a corticosteroid has been shown to penetrate into the SC when dissolved in 
ethanolic solution following the spreading of the solution over the skin surface. The ethanol 
keeps the corticosteroid in solution in its dissolved form and prevents interaction occurring 
between the corticosteroid and the protein-lipid-water matrix of the SC. However, after some 
time, when most of the ethanol has evaporated and/or diffused into the skin, a layer of 
corticosteroid (in its undissolved form) is left behind in the SC [5,90]. Consequently, when 
including ethanol in a vehicle, the initial enhancement of penetration of the corticosteroid is 
off-set after the disappearance of the ethanol. It is also interesting to note that finer drug 
particles or particles in solution penetrate the skin more effectively than drug particles in the 
form of  large or  insoluble crystals [95]. 
 
2.1.3.4. Penetration enhancement using chemicals 
 
Penetration enhancers are chemical compounds which should be pharmacologically inactive 
but can partition into and interact with the SC constituents. It can be used alone as a pre-
formulation application or incorporated into the formulation to reduce the resistance of the 
skin to drug diffusion [96-98]. A penetration enhancer may also alter the thermodynamic 
activity of the SC resulting in enhanced drug flux [91,99].   
 
Baker [84] showed that solvents which have been proposed as pharmaceutical vehicles can 
alter the integrity of the SC due to modification or dehydration, allowing therapeutic 
substances to move easily across the skin surface in any direction.   
 
Surfactants are frequently included in topical preparations and have demonstrated their 
capability of enhancing the penetration of topically administered compounds by altering the 
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skin’s barrier function [100]. Normally, anionic surfactants tend to be more effective than 
cationic surfactants, and non-ionic surfactants are less effective than the previous two [59]. 
Among the anionic surfactants, the laurate ion has been reported to have the best penetration 
activity and penetration effects on other solutes [101,102]. The anionic surfactants promote 
absorption possibly by a denaturing action on epidermal proteins [103,104]. This denaturing 
effect is caused by anionic surfactants interacting with the SC causing an increase in the local 
water concentration with consequent swelling and expansion of the tissue and possibly 
reducing the cohesion between the lipid bilayers [103,105]. The main mechanism by which 
certain cationic surfactants lead to enhanced skin permeability is to act on the keratin fibrils 
of cornified cells resulting in disruption of the cell/lipid matrix. Non-ionic surfactants cause 
fluidization of lipid components of the SC enhancing absorption via penetration through the 
cholesterol monolayers [100]. 
 
The largest class of penetration enhancers seems to act by fluidizing the lipid channels.  
These include dimethyl sulphoxide (DMSO) at high concentrations, decylmethyl 
sulphoxide, ethanol and azone. The most commonly used penetration enhancer is ethanol 
due to its recurrent use in cosmetics and pharmaceutical formulations [106]. These 
excipients are known to influence the SC at the molecular level, and several modes of 
action can be observed. Depending on the structure of the penetration enhancer, it may 
cause a decrease in the intermolecular interaction between the polar head groups or a laxity 
of the carbon chains found in the lipid bilayers of the SC. The disorder induced by these 
perturbations permits an increase in the percutaneous penetration of active substances 
[106].  
 
2.1.3.5. Physical penetration enhancement 
 
Penetration enhancement of all drug molecules may not be easily achieved with chemicals 
alone. Specific physical penetration techniques may be a better alternative for improving 
permeation. Possible alternative approaches to augment the flux of a substance through the 
skin include the use of electrical techniques such as iontophoresis [107] and 
electroporation [108], or the application of ultrasound [109].   
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Iontophoresis is a technique which requires passing a small electrical current across the 
skin (electro-repulsion and electro-osmotic flow) which promotes drug penetration into the 
skin [110]. This assists the delivery of ionized drug molecules and peptides at a faster rate 
[107,111,112]. Fundamentally, the charged molecule is forced into the SC as it is repelled 
from the electrode of similar polarity. The advantage of iontophoretic delivery is that the 
flux of the diffusing drug molecule can be controlled by altering the applied current, thus 
tailoring therapy for specific conditions. After the termination of electrical current 
application, the alteration of skin permeability is maintained for a brief period and the 
normal barrier function is generally subsequently restored. However, it has been shown 
that iontophoretic permeation enhancement is more suitable for ionized polar compounds 
[113,114] 
 
The application of ultrasound can alternatively be used to enhance permeability of 
permeants through the skin. The mechanism through which ultrasound is thought to act 
may be by increasing the fluidity of the barrier domains and kinetic energy of the permeant 
molecules with subsequent heat generation within the SC. However, the use of this 
technique destroys skin structures if the frequency and intensity of application are 
extensive [109,115]. This technique can also be harmful when used improperly. As a result, 
the proper frequency, power level, and duration should be extensively studied before it can 
be considered as a safe practice. Ultrasound transdermal enhancement may be a solution to 
one of the major problems facing the field of transdermal drug delivery i.e. lag time and 
low drug penetration. In addition to its enhancement capabilities, it may control 
transdermal penetration rate and function as a responsive delivery system [116]. 
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3. CHAPTER 3 
3.1. BIOAVAILABILITY AND BIOEQUIVALENCE 
 
Bioavailability (BA) for systemically delivered oral products can be defined as the measure 
of both the rate and total amount (extent) of drug reaching the general circulation from an 
administered dosage form [117]. This assesses the process by which the drug is released 
from the dosage form and moves to the site of action and therefore, the drug’s absorption, 
distribution, metabolism and the elimination processes can be determined [118].  
 
BA studies are conducted to determine a systemic exposure profile by measuring the 
concentration of drug and/or metabolite in the systemic circulation over time. Often, the 
concentration of the active moiety or moieties is determined by collecting and analyzing 
samples of biological fluids such as plasma and urine. The major parameters which represent 
the rate and extent of drug absorption are [119]:  
 
1. Cmax – The peak plasma drug concentration is used to measure the rate of drug BA. 
2. AUC – the area under the plasma level-time curve is a measure of the extent of drug 
BA 
3. Tmax – the time of peak plasma concentration, corresponds to the time required to reach 
maximum drug concentration after drug administration. 
 
As a result, therapeutic dosage regimens can be established which is vital for the 
development of new drugs. The systemic exposure profile of drug formulations can then 
serve as a benchmark for subsequent bioequivalence (BE) studies [118].  
 
BE implies that the drug is absorbed from a test dosage form at a comparable rate and extent 
to the innovator product. Demonstrating BE amongst drug products often necessitates the 
measurement of drug and/or metabolite levels either in the blood or urine over a fixed period 
of time following drug administration. Comparison of therapeutic performances in two 
formulations containing the same active substance is a critical means of assessing the 
possibility that a similar medicinal product can be used as an alternative to the innovator 
product. Assuming that in the same subject a similar plasma concentration time course will 
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result in similar concentrations at the site of action and thus a similar effect. Pharmacokinetic 
data can be used instead of therapeutic results to establish equivalence between products i.e. 
BE [118,120].  
 
In order to show BE, it can be measured in at least three ways: chemically, biologically, or 
therapeutically [121]. However, for topically applied products, standard BA studies used to 
establish BE of orally administered drugs are often difficult to carry out because blood levels 
are too low and/or they may provide an inappropriate measure of BE. Topical doses tend to 
be so small that serum and/or urine concentrations are often undetectable unless a suitable 
highly-sensitive analytical assay can be developed. Furthermore, systemic availability may 
not properly reflect cutaneous BA for medications intended to treat local skin disorders.  
 
Assessment of BE of topical formulations may be established through a well-controlled 
clinical trial or through the measurement of a pharmacological or pharmacodynamic end 
point e.g. the human skin blanching assay (HSBA) (as described in chapter 4). Other 
techniques used to assess BA/BE include punch biopsies, tape stripping, dermal 
microdialysis, in vitro dissolution studies and animal studies. However, much work needs to 
be done in these particular areas before such approaches can find general acceptance.  
 
The advantage for patients using generic substitution of certain medications is that a generic 
product is identical to the innovator product in terms of BA, safety and efficacy but is more 
affordable. A generic product may be used as a substitute for a prescribed drug if it complies 
with the regulatory requirements and law in a particular country and meets certain criteria, i.e. 
the generic product must show that it is BE before being placed on the market. Hence, there 
is a need for appropriate BE testing methods for topical formulations.  
 
Factors found to influence the assessment of the BA and BE of topical products include 
biological factors in the case of BA testing and formulation factors in the case of BE testing. 
Formulation factors refer to the effect that different excipients and manufacturing methods 
have on the diffusion of the active drug to the site of action. Biological factors include sex 
[122], age [123,124], anatomical sites [81,125,126], race [127,128] and diseases [129,130]. 
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3.1.1. BE assessment methods for topical products 
 
BE assessment of topical products has been studied using several different techniques. 
However, the only internationally acceptable technique other than the use of clinical trials 
conducted in patients is the human skin blanching assay (HSBA) for topical corticosteroid 
products. A major problem in the study of dermal BE has been the interpretation of results 
from various investigators. It is very difficult to draw valid conclusions and comparisons due 
to the diverse test systems exploited in vitro and in vivo, anatomical locations, various times 
and modes of application, and the experimentation on the different types of animal species 
[59,131].  
 
The development of in vitro systems for the estimation of the percutaneous delivery of drugs 
across the skin has proven to be useful when used accurately and properly [132]. In such 
systems, it becomes plausible to conduct research on toxic compounds without involving the 
ethical issues associated with the use of human volunteers.  However, a problem arises when 
attempting to correlate data between animals and humans [133,134]. It is difficult to know 
how closely dermal penetration in animals mimics penetration through human skin. Thus in 
percutaneous absorption studies, the exposure/risk assessment scenarios do not take into 
account the variation in the permeability of animal vs. human skin, and the 
metabolic/pharmacokinetic/dose response relationships between animals and humans. 
Predictive models based on animal data are nevertheless a necessity for estimating tissue 
dose and target tissue dose response in humans [135].  
 
Numerous methods have been attempted to assess BE of topical products by using in vitro 
and in vivo study test systems. 
 
3.1.1.1. In vivo methods 
3.1.1.1.1. Biological/pharmacological response 
 
The HSBA (vide infra chapter 4) is an extremely sensitive physiological marker for the 
presence of minute amounts of corticosteroids in the skin. This assay is based on the ability 
of topically applied corticosteroids to cause a blanching (pallor) effect on healthy human skin 
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at the site of application.  
 
3.1.1.1.2. Tape stripping 
 
A dermatopharmacokinetic approach, vide infra chapter 6, has been proposed for the BE 
testing of topical drug products by comparing drug content kinetics in the human SC. This 
kinetic approach is based on drug delivery into the rate-limiting barrier of the skin i.e. SC. It 
uses the SC as the sampling matrix in combination with a validated bioanalytical assay for 
quantifying the analyte in the stripped skin sample. This method has proven to be an 
effective and promising tool but has currently not been recommended by regulatory agencies 
for use to assess BE in spite of published data that indicate its potential application. The 
major advantages of this technique are the use of non-radiolabeled substances and hence a 
less sensitive analytical method can be used due to the adequate concentration found in 
stripped skin samples.  
 
3.1.1.1.3. Dermal microdialysis 
 
Dermal microdialysis (MD) (vide infra chapter 7) is a technique that measures topically 
applied substances in the extracellular space beneath the exposed skin site. It is a slightly 
more invasive technique than TS, which necessitates the superficial insertion of a MD fibre 
under the skin via the use of a cannula. The drug diffuses from the surrounding tissue across 
a semi-permeable membrane by passive diffusion into the MD fibre which acts as the 
receptor medium (perfusate). The perfusate is then collected at various time intervals for 
analysis. The advantage of using dermal MD is the suitability of the technique to measure the 
analyte before it enters the systemic circulation or acts locally in the epidermis layer. The 
major drawback is the need of a highly sensitive analytical method to quantitatively 
determine the analyte.  
 
3.1.1.1.4. Other in vivo assessment techniques 
 
With the exception of topical corticosteroids, the only other means of demonstrating BE of 
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topical dermatological product to an innovator’s product is through the use of comparative 
clinical trials with a BE endpoint. However, these clinical efficacy trials are time consuming 
and costly. Additionally, to gain adequate statistical power to show BE, it is necessary to use 
a large number of patients [132]. Often, hundreds of patients are required in such studies due 
to the fact that in many clinical endpoint studies, the topical products assessed do not have a 
specific dosage i.e. the amount of the active ingredient applied on a day-to-day basis and 
between patients can be quite different. Additionally, while the patient is outside of the 
investigators direct control, the evaluation of clinical response in this type of study may last 
for weeks [136]. 
 
A pharmacokinetic endpoint is normally preferable to a pharmacodynamic or clinical 
endpoint for better accuracy, sensitivity, ease of study conduct, cost and timing. A decision 
tree (Figure 3.1) may be useful in determining the type of study required for any particular 
product [136]. 
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Figure 3.1.  A decision tree to determine whether a clinical endpoint BE study is required [119] 
 
Chapter 3 – Bioavailability and Bioequivalence 
 
34 
Other possible methods for assessing the concentration of the analyte in the skin following 
topical application include surface biopsy, surface scraping, sebum collection, fluid 
collection from suction blisters, shave biopsy, and punch biopsy [132]. 
 
Although these above listed methods have proven to be useful, the major drawback is the 
invasiveness of the technique. These procedures were not only found to be painful by the 
subjects but also did not result in compelling data to validate their use for the assessment of 
BE.  
 
It is thus clear, that whereas well-established methods for the determination of BE of 
extravascularly administered drugs exist, there is a dearth of methods for use with topical 
dosage forms not intended to be absorbed into the systemic circulation. 
 
3.1.1.2. In vitro methods 
 
The initial development of dermatological and transdermal drugs requires knowledge about 
the percutaneous permeation and absorption (systemic) of the drug. The ultimate testing of a 
new drug or formulation is in vivo human testing. However, a compromise on safety, 
relevance and cost needs to be made, thus alternative test procedures are desirable. In vitro 
experimental techniques have progressed over the years and are yielding valuable data on 
routes of absorption, barriers to absorption, degree of systemic absorption after topical 
application, and the effects of various physical and chemical parameters.  
 
The standard method for measuring drug permeation across the skin is the use of a diffusion 
cell system (Figure 3.2). The classic diffusion cell utilizes a skin section which acts as the 
membrane that divides the donor and receptor compartments. The rate of drug penetration 
from the donor chamber to the receptor chamber is determined by quantifying the amount of 
drug permeated over time with the use of an analytical method e.g. high-performance liquid 
chromatography. The source of skin [137-139], skin layers used [140,141] and the properties 
of the receptor solution [142] can have a significant effect on the permeation. The 
shortcoming of this type of methodology is thought to be that it does not truly reflect the role 
of the skin in vivo e.g. sink conditions are absent because there is no blood supply system 
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and there is also a lack of biological enzymes. Attempts have been made to develop vehicles 
acting as “sinks” or receptor skin phases and the results have established fair correlations 
[143-146]. In this type of study, it is wise to do a material balance study i.e. analyse the drug 
contents in the skin layer and the formulation to obtain data on drug partitioning from the 
donor chamber to the skin layer and from the skin layer into the receptor phase. This will 
determine a rough estimate of the partitioning effect through the skin in vivo [147]. 
 
 
Figure 3.2. A schematic representation of a diffusion cell [91] 
 
An alternative method to determine drug permeation through the SC is to use ATR-FTIR 
spectroscopy. In this system, the SC is sandwiched between a reflectance and a drug donor 
solution, the diffusion of the substance into the deeper layers of the SC is monitored by the 
appearance and increase of a drug-specific infra-red absorbance as a function of time. 
However, this technique is limited to measuring IR-active substances only [148,149].     
 
In vitro penetration studies can imitate transdermal drug absorption only if the penetration 
process is rate limiting in vivo as well as in vitro. Not only the permeation of substances 
through the SC, but also the microcirculation of the skin may be rate-limiting for certain 
substances [146]. Several researchers [150-152] have proven that data obtained from such in 
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vitro systems are comparable with those in vivo. However, there are only a few experiments 
where the data correlated well. The advantage of an in vitro system is the total control of 
environment which permits the demonstration of the significance of individual factors in 
determining percutaneous absorption of a particular substance. Another advantage is 
applicability of the in vitro system which allows the screening of new products and 
hazardous chemicals [59].  
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4. CHAPTER 4 
4.1. THE HUMAN SKIN BLANCHING ASSAY (HSBA) also known as the 
VASOCONSTRICTOR ASSAY (VCA) 
 
The determination of the BA/BE of oral dosage forms involves the comparison of drug 
concentrations found in biological fluids (blood plasma/serum/urine) following 
administration of the dosage form. However, this approach cannot be used for medicinal 
products not intended for absorption into the systemic circulation, such as topical dosage 
forms used for local action.  
 
Topical corticosteroid products have been extremely effective for the treatment of various 
skin disorders such as eczema, psoriasis and keloids, amongst others [153-157]. The advent 
of generic topical corticosteroid products necessitated the development of a suitable 
technique for the assessment of BE of such products which resulted in the publication of a 
Guidance by the USA Food and Drugs Administration (FDA) in 1995 [158].  
 
Various techniques have been studied to assess the effectiveness of topical corticosteroids. 
These include the vasoconstrictor assay [132,159-161], ultraviolet [162-164] and croton oil 
inflammation suppression studies [165-167], psoriasis assay [168,169] and adhesive TS 
methods [5,14,170-175].   
 
The HSBA is a reliable and convenient assay for the comparison of the BA and BE of topical 
corticosteroids products [176] where a great advantage is that it can be preformed on healthy 
human subjects. This assay, initially introduced by McKenzie and Stoughton in 1962 [159], 
relies on the unique ability of topical corticosteroids to produce a blanching response (a skin 
whitening effect) on the skin following application and is illustrated in Figure 4.1. This 
blanching response relates to the amount of corticosteroid which has penetrated into the skin 
[158].   
 
This method was initially utilized for the potency ranking of corticosteroids. However, it was 
also found that the method has limitations and does not necessarily rank the corticosteroids 
in the same order when compared to other assessment methods [177]. In practice, however, 
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topical corticosteroids are usually applied to diseased skin thus penetration of the drug will 
differ due to less resistance by the SC barrier. As a result, information on topical BA [177] 
obtained from studies on healthy skin may not reflect the penetration of the drug into 
diseased skin. Notwithstanding, the HSBA has been found to be very effective for the 
determination of the effect of formulation on the activity and efficacy of topical 
corticosteroid products and to examine the comparative bioavailabilities of such topical 
preparations [95] as indicators of the efficacy of those products, i.e. for BE assessment. 
 
 
Figure 4.1.  A typical blanching response after application of Dermovate® cream (0.05% CP) [178] 
 
Initially skin blanching was investigated using a simple “Yes/No” assessment to establish 
whether a blanching response was present or absent after application [179-181]. However, 
this type of assessment does not provide useful information on the degree of BA of the 
product and it is thus not suitable for the assessment of BE by comparing BA between 
different topical corticosteroids and/or their formulations.  
 
The HSBA was subsequently optimized to facilitate comparisons by evaluating time-
response profiles, potencies and formulations of topical corticosteroids. The optimizations 
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included the application of appropriate statistics, establishment of requisite duration of 
application of the drug or drug product (dose duration) and observation intervals of time 
following application at which the response could be assessed and also a scoring system to 
facilitate visual assessment [158,161,182-184] 
 
4.1.1. Mechanism of skin blanching 
 
The exact mechanism of blanching produced by topical corticosteroids remains unresolved. 
Several investigators have suggested that a relationship exists between noradrenalin and 
corticosteroids [185-187]. However, some investigators have found that although 
noradrenalin may be involved, there are also other existing factors that may account for the 
blanching response. Solomon et al [187] postulated that there are several explanations for the 
cause of skin blanching, as follows: 
1) corticosteroids, similar to sympathomimetic agents, directly affect sodium transfer 
systems across the smooth muscle cellular membranes causing contractions of the smooth 
muscles of vessels [188] 
2) locally bound stores of norepinephrine are released by corticosteroids thereby causing  
smooth muscle contraction  
3) various enzyme systems including those involved in the release of bradykinin, 
norepinephrine and serotonin are affected by corticosteroids which upsets normal vascular 
tone. It has thus been suggested that steroids mediate the release of norepinephrine in 
normotensive subjects only [187]. It has also been proposed that glucocorticoids may act by 
opposing various natural vasodilators such as histamine, bradykinin and prostaglandins 
[189,190]. Haynes [53] stated that the slow development of vasoconstriction provides 
sufficient time for major alterations to occur in the tissue under the influence of 
glucocorticoids and suggested that since they act to regulate synthesis of proteins, the altered 
vascular tone may be the result of a basic change in the proteins in the blood vessels or some 
components of the tissue that affect the blood vessels.   
 
Another mechanism which could cause a skin blanching response may be the effect of 
melanocytes. Edwards et al [191] studied the effect of corticosteroids on melanosome 
aggregation in frog skin. They found that cortisol reversed skin darkening by isoproterenol, 
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caffeine as well as melanocyte-stimulating hormone (MSH). The results suggested that 
cortisol binds specifically to a novel type of receptor that has not yet been characterized on 
the melanophore and which may influence certain steps between the adenylate cyclase and 
melanosome movement thereby causing the skin whitening effect.  It has been postulated 
that the cause of hypopigmentation may be due to interference by steroids with the synthesis 
of melanin by smaller melanocytes, leading to patchy areas of decreased pigmentation [3,10] 
 
4.1.2. Methods for the evaluation of skin blanching 
4.1.2.1. Visual assessment 
 
The initial methodology for the assessment of topical corticosteroids formulations involved 
the visual assessment of the degree of skin blanching following application to the skin. 
Visual assessment remained for some period of time as the most commonly used tool when 
applying the HSBA to compare skin blanching activities between different topical 
corticosteroids and also formulations [161,192-194] as well as for the assessment of BA/BE. 
However, a Guidance [158] document was issued by the US FDA in 1995 wherein an 
instrumental method using a chromameter was recommended although the visual assessment 
method was also retained.  
 
Colour is a matter of perception of electromagnetic radiations in the wavelength range of 400 
to 700 nm by the eye, followed by subjective interpretation by the brain. Colour vision is 
trichromatic combining the blue, red and green registrations. Although the human eye is 
sensitive enough for the discrimination of small colour changes in skin blanching, different 
people usually draw upon different references and may express the exact same colour in 
different words. As a consequence, this is perceived as an apparent weakness when using the 
human eye to evaluate skin whitening owing to the observer’s subjectivity. A further 
criticism on visual assessment relates to the inability to validate the eye as one is able to do 
when using an instrument [195-197]. However, if observers undergo sufficient training and 
gain experience in visual evaluation of skin blanching, reproducibility and reliability of 
visual assessment can be established [198-200].   
 
Visual assessment of skin blanching involves the use of a scoring system to measure skin 
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blanching intensity. As mentioned previously, the initial scoring system only used a 
“Yes/No” assessment, which simply indicated whether or not a skin blanching response 
occurred following application of the topical corticosteroid, i.e. using a score of 1 or 0, 
respectively. The scoring system subsequently evolved to a graded response based upon the 
following criteria; absent, faint, faint – moderate, moderate – strong and strong – intense 
blanching using the scores of  0, 1, 2, 3 and 4, respectively. This remains the commonly used 
visual assessment scoring system based on the 0 – 4 scale introduced by Barry and 
Woodford [201,202]. The data are reported in terms of the percentage of the total possible 
score calculated as follows [161]; 
 
The maximum score per site   =  4 
The number of independent observers   =  n 
The number of sites per preparation per arm   =  S 
The number of subjects   =  V 
Total possible score (TPS)   =  4 x n x S x V 
 
Percent total possible score (%TPS)  =  (Actual score / TPS) x 100    (equation 4.1) 
 
4.1.2.2. Chromameter assessment 
 
An instrumental method involving a tristimulus colorimeter was subsequently introduced as 
an objective and thus “preferred” method. The Minolta® chromameter, which is a portable 
instrument that uses tristimulus colorimetery involving reflectance spectroscopy was adapted 
for use to measure skin blanching. This approach had subsequently been used for the 
objective measurement of skin color [203,204].  The chromameter functions by emitting a 
white light (using a pulsed xenon arc lamp) onto the chosen area of assessment and 
measuring the intensity of reflected light through three particular wavelength filters 
(analyzed at wavelengths of 450, 560 and 600 nm) or using a photodiode array in more 
recent instruments. The detected signal is converted into three coordinates: L* (luminosity), 
a* (the amount of green or red), and b* (the amount of yellow or blue). These three 
coordinates record color in a three-dimensional color system recommended by CIE 
(Commission International de l’Eclairage) [196,197,205] 
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Figure 4.2. The L*a*b* color space (adapted from Waring [206]) 
The skin blanching response is measured relative to the color change in the skin. As the skin 
blanching response develops, the skin becomes lighter and its redness fades. As the skin 
becomes more pale the L* scale increases, a* scale decreases and b* scale increases very 
slightly. It [207] has been shown that the L* and a* coordinates are more discriminative than 
the b* coordinate in determining skin blanching responses, thus the latter coordinate is 
omitted from data analysis. However, following release of the FDA guidance, only the a-
scale data has been recommended for  use in the  statistical analysis [158]. This is possibly 
due to better correlation with visual skin blanching data found by Pershing et al [160]. 
 
The chromameter can offer reliable and repeatable results provided that certain drawbacks 
are avoided such as manipulation of the measuring head of the instrument which can affect 
the quality of the data produced. Skin compression by the measuring head and the angle 
alignment of the chromameter play a role in obtaining repeatable data [198,205,206]. To 
obtain optimal results, each subject’s assessment site as well as ambient temperature should 
ideally be controlled. It is also important for the operator to hold the chromameter head in 
such a way that variation in pressure is avoided [198]. The presence of hair and variations in 
skin glossiness related to the amount of water and lipid on the skin surface, scarring, uneven 
skin tone, etc. can influence the data obtained [208]. As a result, it is important to avoid these 
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areas of the skin to achieve reliable and reproducible data. 
 
4.1.3. Study Designs 
4.1.3.1. Types of studies (pilot and pivotal) 
 
The FDA Guidance recommends that two in vivo studies, i.e. a pilot and pivotal study, be 
conducted in order to determine BE between topical corticosteroid products. A pilot study 
provides information on an appropriate dose duration required for the subsequent BE testing 
in a pivotal study. The pilot study utilizes a dose duration-response approach which controls 
the dose of topical corticosteroid being delivered by comparing different times of exposure 
of the product on the skin (dose duration is the period of time that the formulation/product is 
left in contact with the skin). This study is usually conducted only using the reference 
product.  
 
Dose durations required for the pivotal study as recommended by the Topical Corticosteroid 
FDA guidance [158] are ED50, D1 (half of ED50) and D2 (two times ED50), where ED50 is the 
dose duration at which 50% of the maximum blanching response is achieved. The ED50 is 
chosen since it represents the portion of a dose-response relationship plot where the optimum 
discrimination of relevant differences can be detected. Using longer dose durations may 
dampen the assessment of relatively small but significant differences in blanching between a 
test and a reference product.  Furthermore, using shorter dose durations will influence the 
reliability and repeatability of the assessments. 
 
The development and validation of a dose-response curve is therefore essential to determine 
ED50, D1 and D2. These values are determined from an Emax model, in accordance to the 
relevant FDA guidance [158], shown as follows: 
 
 
                                    (equation 4.2) 
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where E = effect elicited 
 E0 = baseline effect in the absence of ligand 
 Emax = maximum effect elicited 
 ED50 = dose duration (D) at which effect is half maximal 
 
The pivotal study is then conducted where a comparison between the responses of a test and 
reference product is investigated for BE using the ED50. Furthermore, the Guidance 
recommends that a subject must be a ‘detector’ in order for inclusion of their data for 
statistical analyses supporting in vivo BE assessment. Hence, subjects’ responses are 
expected to meet the specified minimum D2/D1 ratio of AUEC greater or equal to 1.25 in the 
pivotal study, where AUEC is the area under the effect curve following the plotting of the 
particular response (visual response or chromameter response) versus time 
 
4.2. PILOT STUDY 
4.2.1. Experimental 
4.2.1.1. Instrumentation 
 
A Minolta Chromameter® (Model CR 400, Minolta, Osaka, Japan) that provides 
measurements based on three scales, the L-scale, a-scale and b-scale, was used. An 
Eppendorf pipette was used to dispense the accurate dose of topical formulation to each 
application site. 
 
4.2.1.2. Formulations 
 
Several Dermovate® creams, the currently marketed innovator product in South Africa, from 
the same batch, were purchased from a local pharmacy in Grahamstown. The preparations 
were kept away from direct sunlight and stored at room temperature controlled at 22 ± 1 °C. 
A new tube of corticosteroid cream was used for each study. The first gram of each tube of 
cream was discarded in case of any interaction between the closure of the tube and the 
corticosteroid formulation.   
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4.2.1.3. Subjects 
 
Healthy male and female subjects in the age range of 18-50 years of age were screened for 
skin blanching response to the reference product, Dermovate® cream. The subjects were 
screened by applying ~11mg (SD ±0.17 mg – vide infra section 4.2.1.5) of the cream from a 
calibrated applicator at a demarcated site on the upper forearm for six hours unoccluded. The 
spot of cream was washed off after six hours and assessed for any skin blanching response. 
Those subjects who demonstrated a skin blanching response (referred to as a ‘responder’ in 
accordance with the FDA’s guidance document [158]) to the reference product (Dermovate® 
cream) were included into the experimental study. According to the FDA Guidance, none of 
the subjects had received any corticosteroid treatment for the past 6 weeks, none had any 
skin disorders or allergy to the corticosteroid or the formulation, and none had skin defects 
that may interfere with evaluation of test sites [158]. Written informed consent was obtained 
from all the subjects before the study (vide infra appendix I).   
 
From a number of subjects screened, 12 subjects were initially selected to participate in this 
pilot study. However, 2 of these responders dropped out due to alcohol consumption the 
night before and only one reserve subject out of three reserves were contactable to participate 
in the study. Hence, 11 responders in total were used for this pilot study.  
 
4.2.1.4. Product application and removal 
 
The flexor aspects of the two forearms were used for this experiment. Eight square 
application sites were demarcated with adhesive labels (Tower®, South Africa, Cape Town) 
avoiding areas with large blood vessels, scar or skin blemishes and approximately 4 cm away 
from the wrist and elbow regions on each forearm (as seen in Figure 4.3).  
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Figure 4.3.  Demarcated forearm using adhesive labels 
Adhesive labels were punched to produce a 1.1 x 1.1 cm square application site. Each 
application site was marked with two dots below each site with a template and an appropriate 
marker to allow correct placement of the chromameter during assessment.  The chromameter 
head had also been marked with the corresponding marks to those on the sites. 
Approximately 12µL (equivalent to approximately 11mg) of the product was applied per site 
with a pre-loaded calibrated Eppendorf pipette. The 0.2ml Eppendorf pipette tips (Eppendorf, 
Eppendorf AG, Germany) were filled immediately prior to use to minimize any possible 
interaction between the corticosteroid and the plastic matrix of the tips.  The tips were 
discarded after single use. The method of staggered application and synchronized removal 
was chosen. The application of the products on each demarcated site was done in a random 
manner so as to prevent bias during visual assessment. A glass rod was used to spread the 
product evenly over each site. The glass rod tip was cleaned with a paper towel to remove 
any remaining product before continuing onto the next application site. The application sites 
on the two forearms were protected with a non-occluding arm guard to prevent any smearing 
or removal of the creams during the entire cream application period (Figure 4.4). Before the 
removal of the product, the labels were first peeled off gently. The removal of the product 
was done by washing the forearm with mild soap and water and then blotted dry with a paper 
towel.   
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Figure 4.4. Protection of the application sites with a non-occluding armguard 
4.2.1.5. Determination of the mass of product applied 
 
Following the FDA Guidance [158], approximately 10 mg of product per 1 x 1 cm site is 
required. For an application site of 1.1 x 1.1 cm, it was calculated that about 12.1 mg of the 
product would be needed per site. The mass of preparation applied was determined by 
weighing the amount of the product being extruded from a 0.2 ml Eppendorf pipette tip at 
the different dial settings (Table 4.1). The different dial settings yielded the following 
volumes: 1 = 4µL, 2 = 8µL, 3 = 12µL, and 4 = 16µL with a 0.2ml tip. The different masses 
were weighed with a Mettler® Torledo weighing balance.  
 
Table 4.1.  The determination of an appropriate dial setting to yield the required mass of 
cream for application. 
 Mass of cream weighed (mg)    
Volume 
(µL) 1 2 3 4 5 6 
Average 
(mg) 
SD 
(mg) 
RSD 
(%) 
4 3.6 3.8 3.8 4 3.7 3.7 3.76 0.13 3.46 
8 7.7 7 7.2 7.7 7.7 7 7.38 0.35 4.74 
12 11.1 11.2 10.8 11.2 11.3 11.2 11.13 0.17 1.53 
16 14.8 15.8 15.6 13 14.6 14.7 14.75 0.99 6.71 
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Weight of cream vs. volume
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Figure 4.5.  Mass of cream at the different volumes from the dial settings 
As shown in Figure 4.5, the curve gave an R2 value of 0.9999 indicating that the pipette 
releases a mass proportional to the dial setting/volume. The standard deviation was not large 
at the required amount i.e. the dial setting at 3 with a mass of 11 ± 0.17 mg, thus the results 
indicated that the Eppendorf pipette released a repeatable mass of the cream. This setup was 
considered suitable and was subsequently used for the application of the products in all 
further studies.   
 
4.2.1.6. Assessment of the skin blanching response 
 
The arms were evaluated visually by trained observers and with a mechanically-mounted 
chromameter (patent pending) at the various time intervals after the removal of the products 
to obtain a blanching profile. There were no oblique light sources.  Standard lighting by 
overhead fluorescent lamps were used for all the studies. The arms were placed horizontally 
on a desk directly in front of each trained observer for the assessments.  Visual scoring was 
done at a 0 – 4 scale where: 
0 = no blanching, application site appeared identical to surrounding area of skin. 
1 = faint blanching observed, but outline of application square was not seen. 
2 = faint – moderate blanching, with one or two sides of the application square seen. 
3 = moderate – strong blanching, the square outline of the application square is clearly 
Chapter 4 – The Human Skin Blanching Assay/Vasoconstrictor Assay 
 
49 
visible. 
4 = strong – intense blanching, intense pallor observed over the entire square of application 
site.   
Each site was be assigned a blanching score by comparing skin at the site of application to 
the adjacent skin unaffected by the product.   
 
A mechanically mounted chromameter was used for the assessment of blanching over the 
whole application site. The chromameter was aligned into position directly over and 
covering the application site with the measuring head. The same orientation of the 
chromameter was maintained to get accurate readings for each assessment time for each site. 
Three consecutive readings were taken on each site without moving the chromameter. The 
three readings were averaged and the mean value reported. Prior to colour measurement, the 
instrument was calibrated with its own calibration tile.   
 
 
Figure 4.6.  The Minolta® chromameter 
All estimations of skin blanching responses using both visual and chromameter assessments 
were performed in a double-blind manner without reference to the application charts. Skin 
blanching responses were measured at 0, 2, 4, 6, 8, 10, 12, 14, 18, 22, and 26 hours post 
product removal. 
 
Chapter 4 – The Human Skin Blanching Assay/Vasoconstrictor Assay 
 
50 
4.2.1.7. Confinement of the subjects 
 
Subjects that were accepted into the study were confined within the Biopharmaceutics 
Research Institute clinic for the initial part of the study i.e. the first day and night. On the 
final day of the study, the subjects were allowed to leave the clinic and return 20 minutes 
before their next scheduled assessment. This allows the subject’s body to stabilise to the 
clinic’s environment before their assessment. The clinic’s environment was controlled to 
maintain the same temperature (± 22 °C), humidity, and lighting and environmental factors 
should therefore not have affected the blanching response of each subject. It also prevented 
the subjects from undertaking any restricted actions, and avoided any changes in ambient 
temperatures and atmospheric humidity.   
 
4.2.1.8. Data and statistical analysis 
 
Visual data were converted to %TPS as shown in section 4.1.2.1 above. The chromameter 
data only used the a-scale data as stipulated by the FDA guidance [158]. 
 
The Trapezoidal rule was used to calculate the AUEC values using visual and chromameter 
data vs. time in hours after the removal of the excess formulations. Statistical analyses were 
carried out using Graphpad® Prism 4 and Kinetica® software packages, both of which gave 
similar results.  The t-test and goodness of fit test were performed, and the Emax model was 
established.  
 
4.2.2. Results and discussion 
 
Dose duration-response data of all 11 subjects (6 females and 5 males, ten of whom were 
Caucasians and one Asian) were obtained for Dermovate® cream. No adverse drug reactions 
or other clinical events were encountered during the conduct of this study. Only 11 subjects 
were used as previously explained.  
 
After the different times of exposure (i.e. at 0.25, 0.5, 1, 2, 4 and 6 hours dose durations), the 
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blanching effect for Dermovate® cream peaked at 12 hours after product removal, decreasing 
thereafter. The visual mean score values and a-scale values were plotted against the time 
after product removal illustrating the pooled blanching response of the 11 subjects (Figures 
4.7 and 4.8).   
 
The graphs also show that as the dose durations increase, there is a corresponding increase in 
the skin blanching response. However, the skin blanching response becomes maximal at a 
certain point of time following application, thereafter any increase in dose duration will not 
result in any changes in the AUEC thereby losing discriminatory power to differentiate 
between products, if indeed differences do exist. Hence, the appropriate dose duration is 
extremely important for use in the pivotal study to determine BE between products.   
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Figure 4.7 Blanching profile from visual assessment data 
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Figure 4.8.  Blanching profile from chromameter assessment data 
Pharmacokinetic models describe drug concentrations as a function of dose and time. This is 
the simplest model that describes drug effect over the whole range of concentrations based 
on the hyperbolic relationship found by the Emax model [34]. The hyperbolic Enax model was 
used to determine the dose duration-response data as stated in the FDA guidance in this case 
[158].  This type of graph can predict 2 important properties, i.e. the maximum effect a drug 
can achieve and the absence of an effect when no drug is present. The product’s data sets 
were analyzed with the naive pooled data method approach to fit the Emax model (see 
equation 4.2 above) [158]. 
 
The baseline effect was incorporated into the Emax model to reflect changes from baseline 
value depending on the nature of the effect and experimental design [34]. The AUEC values 
were calculated to yield a dose-duration versus AUEC profile of all the subjects to illustrate 
the response at the various different dose durations (Figures 4.9 and 4.10). Notice that both 
figures have different y-axes due to the different unit values obtained from the visual and the 
chromameter data.   
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Figure 4.9.  Emax model of the chromameter’s a-scale data 
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Figure 4.10.  Emax model of the visual data 
Table 4.2.  Emax model parameters for both visual and chromameter data 
Parameters Visual Chromameter 
ED50 [hrs] 0.5457 0.6582 
Standard Error 0.2101 0.3529 
D1 [hrs] 0.2729 0.3291 
D2 [hrs] 1.0914 1.3164 
 Average of visual and chromameter data 
ED50 [hrs] (averaging visual and chromameter) 0.6025 
D1 [hrs] (averaging visual and chromameter) 0.3012 
D2 [hrs] (averaging visual and chromameter) 1.2049 
Goodness-of-fit (Spearman’s correlation) 0.97  
p-value p < 0.05 
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The reason for choosing an ED50 value is that when testing is done at high dose durations, 
the change in response is minimal resulting in a loss of sensitivity and discriminatory power, 
as seen with the dose duration at 4 and 6 hours. When testing with lower dose durations, the 
reliability and repeatability, and even achieving a reasonable skin blanching response will 
become an issue. As a result, the dose duration where 50% of the response will be achieved 
will be at the most sensitive range and still yield reliable and reproducible data.   
 
From the above Table 4.2, the dose durations (ED50, D1 and D2 values) were utilized in the 
subsequent pivotal study.  From visual inspection of the data, it can be seen that when 
comparing the graphs between the visual and chromameter data, the profiles are very similar 
to each other. The Spearman’s correlation between the Emax models of both assessment 
techniques was determined and gave an r value of 0.97 indicating that these two graphs are 
statistically similar to each other.  The p-value was calculated by the software and gave a 
value less that 0.05 showing that there is no significant difference between the two Emax 
models.  From this, we can deduce that both evaluation techniques were comparable to each 
other and should be equally applicable for the establishment of the appropriate dose-response 
for subsequent use in the assessment of BE of CP creams.   
 
4.3. PIVOTAL STUDY 
4.3.1. Experimental 
4.3.1.1. Instrumentation 
 
Vide infra section 4.2.1.1 
 
4.3.1.2. Formulations 
 
The formulations used were the same as those mentioned in section 4.2.1.2 of the pilot study 
described previously. The same tube of cream was used as both the reference and test 
product in all the clinical trials. The test application was labeled as in-house batch no. WL2-
01 and the reference application was labeled as in-house batch no. WL2-02. 
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4.3.1.3. Subjects 
 
Subjects were screened as previously described in section 4.2.1.3 and also in appendix II. In 
addition, a slightly different screening procedure was used in this pivotal study. In pivotal 
studies, one requires a “qualified” subject to be a ‘detector’ as well as having been a 
‘responder’. In order to be a ‘detector’, the subject must be able to show skin blanching 
responses that are able to differentiate between the D2 dose duration and D1 dose duration. 
The equation used to evaluate the blanching responses is 
 
AUEC at D2 / AUEC at D1  ≥  1.25          (equation 4.3) 
 
The dose durations, D2 and D1, were obtained from the pilot study data, and were determined 
to be 72 minutes and 18 minutes, respectively. Three sites were demarcated on the left and 
right forearm. The reference product was applied onto two of the three sites on the volar 
aspect of each forearm using the D1 and D2 dose durations. The third site was reserved as a 
control site during the course of the screening test. A brief skin blanching profile was 
generated by plotting the a-scale chromameter data at 0, 6, 8, 12 and 24 hours post removal 
of the product.  
 
A maximum of 12 subjects were used per clinical study due to time constraints on the use of 
the chromameter. The study was split into three separate days and a total of 34 subjects 
participated (12 on the first study, 11 on both the second and third studies). Subjects absent 
from the second and third trial were due to voluntary withdrawal from the study and 
alcoholic consumption, respectively.   
 
4.3.1.4. Product application and removal 
 
As mentioned above in section 4.2.1.4. in the experimental section of the pilot study. 
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4.3.1.5. Assessment of the skin blanching response 
 
As mentioned above in section 4.2.1.6. The skin blanching responses were measured at 0, 2, 
4, 6, 8, 10, 12, 15, 22, 25 and 30 hours after product removal. 
 
4.3.1.6. Confinement of the subjects 
 
Same as section 4.2.1.7 stated above.  
 
4.3.1.7. Data and statistical analysis 
 
The a-scale and %TPS data were determined as previously mentioned in section 4.2.1.8. 
Statistical analyses were carried out using Microsoft® Excel. The 90% confidence interval 
(CI) was calculated according to Locke’s method [158,209].   
 
4.3.2. Results and discussion [210] 
 
No adverse reactions were observed during the conduct of this study. However, slight 
sensitivity towards the adhesive on the labels was seen. The adhesive caused slight redness 
and inflammation on the contact area for approximately one hour after removal of the label. 
This sensitivity reaction did not affect the visual assessment. 
 
Out of the 34 subjects who participated in the pivotal study, 17 were Caucasian, 4 were 
Coloured, 3 were Asian, 5 were Indian and 5 were African. The study group included 22 
females and 12 males in total. According to the Fitzpatrick skin type classification [211], the 
skin type ranged from type I to type V in the subjects. Subjects with skin type VI did not 
blanch or showed only very slight blanching and were therefore excluded from the study.  
 
Figures 4.11 and 4.12 represent the mean visual blanching profiles for the CP creams 
obtained from the groups of ‘detectors’ and all the subjects, respectively. Figures 4.13 and 
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4.14 depict the mean chromameter blanching profiles for the CP creams obtained from the 
groups of ‘detectors’ and all the subjects, respectively. The four graphs showed very similar 
blanching profiles and all the profiles showed blanching that peaked at 15 hours after product 
removal. Comparison of the ‘detectors’ and of all the subjects revealed that the curves were 
quite similar to each other. This indicated that the exclusion of ‘non-detectors’ appears to 
have very little effect on the overall profiles.  
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Figure 4.11.  Visual data of ‘detectors’ (n=23) 
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Figure 4.12.  Visual data of all subjects (n=34) 
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Figure 4.13. Chromameter a-scale data of ‘detectors’ (n =23) 
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Figure 4.14. Chromameter a-scale data of all subjects (n=34) 
As seen from Table 4.3 below, the visual data obtained from ‘detectors’ (n=23) fell within 
the BE range of 80 – 125% whereas the corresponding chromameter data slightly exceeded 
the upper limit of the range. However, when the data from all subjects (n=34) were used, 
both visual data and chromameter data were within the acceptance range. Overall, the visual 
data yielded a narrower interval compared to the chromameter data and using the data from 
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all subjects yielded a narrower range than using only ‘detectors’ data.  
 
Table 4.3.  90% CI calculated using the Locke’s method for visual and chromameter data 
90% CI Visual Chromameter 
Detectors:   
Group 1 (9 subjects) 94.2 – 125.9 67.7 – 156.5 
Group 2 (7 subjects) 88.9 – 119.3 82.2 – 172.6 
Group 3 (7 subjects) 99.0 – 138.6 76.2 – 141.5 
Group 1 & 2 (16 subjects) 96.3 – 110.2 82.5 – 145.1 
Group 1,2 & 3 (23 subjects) 99.3 – 111.6 86.5 – 129.3 
   
All subjects:   
Group 1 (12 subjects) 97.0 – 118.8 75.8 – 141.3 
Group 2 (11 subjects) 88.8 – 108.6 97.7 – 148.0 
Group 3 (11 subjects) 96.5 – 121.7 71.0 – 114.4 
Group 1&2 (23 subjects) 95.7 – 109.4 90.4 – 133.3 
Group 1,2 & 3 (34 subjects) 97.9 – 109.2 90.2 – 120.7 
 
Table 4.4.   AUECs for visual and chromameter 
 VISUAL CHROMAMETER 
 Detectors 
(n=23) 
All subjects 
(n=34) 
Detectors 
(n=23) 
All subjects 
(n=34) 
TEST PRODUCT     
Mean AUEC 907.518 853.891 30.831 28.637 
SD 453.674 431.579 16.138 16.715 
CV% 50.0 50.5 52.3 58.4 
REFERENCE 
PRODUCT 
    
Mean AUEC 891.803 829.534 28.302 27.460 
SD 515.240 492.395 17.598 16.535 
CV% 57.8 59.4 62.2 60.2 
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The acceptance criteria for BE of oral dosage forms must fall within the range of 80-125 % 
[118]. However, whether this acceptance range should be applied for the assessment of BE 
of topical products is moot.  
 
In view of the relatively high variability [160,198,212] in percutaneous drug absorption 
amongst subjects and as reflected in Table 4.4 using visual or chromameter methods, 
consideration could be given to widening the acceptance range for the declaration of BE of 
topical formulations. Notwithstanding, blanching data from the 23 “detectors” in this study 
using the visual method and data from all the subjects using either visual or chromameter 
methods, resulted in the products falling within the BE acceptance interval. When, however, 
chromameter “detector” data were used, the products did not meet the criteria for the 
declaration of BE. It was, however, interesting to note that the chromameter data yielded 
wider BE intervals than the corresponding data obtained from the visual method. 
Furthermore, these results clearly indicate that the eye is a reliable evaluating tool for the 
assessment of skin blanching. In addition, whereas the FDA guidance recommended that 40 
to 60 evaluable subjects are required for a typical HSBA, data obtained from this study 
indicate that this number may not be necessary. BE criteria were met with visual data using 
23 “detectors” as well as data from all 34 subjects, where 90% CIs were similarly narrow for 
both sets. Furthermore, although the 90% CIs for chromameter data was wider for the 23 
“detectors”, all subject data showed that 34 subjects were sufficient to demonstrate BE with 
a power of >95%. This further supports our earlier suggestion that less than 40 evaluable 
subjects can be adequate. 
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Figure 4.15.  Correlation of chromameter and visual mean AUEC data of all subjects at dose durations of 
ED50 for test and reference products, and dose duration of D1 and D2 for the reference product 
Several reports have been published on the use of these assessment techniques [195,207] and 
whilst the chromameter is currently perceived to be the method of choice [158], claims that 
the use of the visual assessment technique is more accurate have been reported 
[160,198,206,212]. The visual method involves subjective assessment of the intensity of 
blanching at the application site in comparison to surrounding untreated skin. It also requires 
considerable training and subsequent use of experienced observers and is difficult if not 
impossible to standardize and validate. An instrumental method largely overcomes the 
limitations of subjective assessment by providing objective measurements from a calibrated 
instrument, which can be validated by establishing the reproducibility of measurements. 
However, it should be noted that training and experience in the use of a chromameter is 
essential to obtain reproducible and reliable results [199,200]. Although the chromameter 
method seems to be a reasonable choice, the results from the present study show that visual 
and chromameter assessments are equally applicable for the BE assessment of topical 
corticosteroid products. Furthermore, the visual assessment data correlate well with 
chromameter results as demonstrated in Figure 4.15 with a R2- value of 0.92.  
 
4.4. CONCLUSIONS 
 
In conclusion, the use of an optimized screening method (as explained in section 4.3.1.3) for 
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potential ‘detectors’ reduced the number of required subjects to establish BE between topical 
products containing a corticosteroid. Furthermore, the results have clearly shown reliability 
and appropriateness of using visual assessment. Hence, visual assessment is comparable to 
chromameter assessment for the evaluation of topical corticosteroid preparations in the 
human skin blanching assay.  
 
These HSBA BE study data are used as the basis for comparing and correlating data from a 
BE study using TS. 
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5. CHAPTER 5 
5.1. DEVELOPMENT AND VALIDATION OF A QUANTITATIVE HPLC 
METHOD FOR THE ANALYSIS OF CP  
 
Various methods for the quantitative analysis of CP have been published in the literature, the 
most common method being HPLC coupled with UV detection although a few methods 
using HPLC together with mass spectrometry have also been reported [213-216]. 
Compendial methods for the analysis of CP also exist [4,17].  
 
A radioimmunoassay (RIA) [217,218] has previously been used for the analysis of tritiated 
CP found in the plasma after topical application from an extemporaneous formulation 
containing the tagged molecule. However, this RIA method is currently not often used.  
 
5.1.1. High-performance liquid chromatography (HPLC) 
 
This technique utilizes a liquid mobile phase that is pumped under high pressure through a 
stainless steel column (stationary phase) for separating substances. The analyte is loaded on 
the head of the column via a loop valve and separation of a mixture occurs according to the 
relative lengths of time spent by its components in the column. All the components in a 
mixture spend a certain amount of time in the mobile phase on the column before exiting 
[219]. HPLC is usually coupled with a suitable detector for the quantitative analysis of 
substance(s).  
 
A standard instrumental system for isocratic elution consists of (Figure 5.1): 
1) a solvent reservoir,  
2) a pump capable of pumping solvent up to a pressure of 4000 psi and flow rates up to 
10ml/min (depending on the column type),  
3) a loop injector fitted with a fixed volume loop between 1 and 200 µl (20µl is the standard) 
4) a column, which is a stainless steel tube packed, usually, with a stationary phase, most 
commonly consisting of reverse-phase material such as octadecylsilane (ODS) coated silica 
gel with a particle diameter of 3, 5 or 10 µm. 
5) a detector, which may be an ultraviolet detector, fluorescence detector or mass 
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spectrometer to name a few 
6) A data capture system, which may be an integrator/chart recorder/PC with software for 
processing chromatographic data. 
7) The column is connected to the injector and detector with tubing of relatively narrow 
internal diameter  
8) The more advanced instruments have an automatic sample injection system and a column 
oven and are capable of mixing two or more solvents in varying proportions to produce a 
mobile phase gradient. 
 
 
Figure 5.1.  High-performance liquid chromatography system 
(http://www.waters.com/waters/nav.htm?locale=zh_TW&cid=10049055, accessed on 03-10-2009). 
HPLC analysis can be readily controlled and ensures precise sample introduction for 
accurate quantitative measurement. It is also one of the most commonly used analytical 
techniques for drug analysis. A large variety of columns and equipment including pumps, 
detectors, sample injection systems and associated hardware are commercially available.  
 
5.1.1.1. The column 
 
The object of HPLC is to separate sample components within a reasonable time and the 
HPLC column is the component usually responsible for achieving this separation. HPLC 
columns containing ODS silica gel or related phases are used to obtain the required 
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selectivity for use in bioanalytical and formulation analysis. HPLC columns containing 
polymeric stationary phases are also available for certain applications. The polymeric phases 
are stable to extremes of pH and have the advantage of overcoming secondary interactions of 
analytes with uncapped silanol groups. However, these are expensive and have a tendency to 
swell when in contact with lipophilic mobile phases (can damage the column). These 
polymeric phases are best used with aqueous-based mobile phase [219].   
 
A HPLC column is packed with a solid stationary phase with a liquid mobile phase flowing 
through it. If the compound does not partition substantially into the stationary phase, it will 
flow through the column at the same rate as the solvent. The length of time it takes a retarded 
substance to pass through the column depends on its capacity factor (K´). The capacity factor 
is a measure of the degree with which the substance partitions into the stationary phase from 
the mobile phase and can be derived by [219]: 
 
K´ = (tr – t0)/t0                     (equation 5.1) 
 
where t0 is the time taken for an unretained molecule to pass through the column, and tr is the 
time taken for the compound to pass through the column [219].  
 
 
Figure 5.2.  Schematic diagram of bands for two different compounds traveling through an HPLC column. 
The compound with the largest capacity factor emerges last.  
tr 
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The efficiency of a column, i.e. the effectiveness of the separation, can be assessed by the 
following methods: 
 
The most common measure of efficiency of a chromatographic system is the plate number N. 
The efficiency of the column is assessed from the width of the peak at half its height and its 
retention time using equation 5.2: 
 
     N = 5.54 (tr/W1/2)         (equation 5.2) 
 
Column efficiency is expressed in theoretical plates per meter: N x 100/L 
 
Hence, the broader the chromatographic peak is relative to its retention time the less efficient 
the column.   
 
The greater the efficiency of a column, the better the degree of resolution produced between 
closely eluted peaks. The resolution between two peaks (Rs) is expressed as [219]: 
 
           Rs = 2 (trB – trA)/(WbB + WbA)     (equation 5.3) 
 
Where trB and trA are the retention times of the different peaks 
   WbB and WbA are the widths of the different peaks at baseline 
An Rs of 1.2 is an indication of complete separation between the different peaks. Any value 
less than 1.2 is indicative of unresolved peaks [219].   
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Figure 5.3.  Illustration of unresolved and resolved peaks 
 
Another factor which can result in poor efficiency of a column is where peaks are tailing thus 
having a high element of asymmetry. Equation 5.4 helps determine peak asymmetry [219]. 
 
Asymmetry factor (AF) = b/a      (equation 5.4) 
 
Where a is the leading half of the peak measured at 10% of the peak height, and b is the 
latter half of the peak measured at 10% of the peak height (Figure 5.4). The ideal value for 
symmetrical peak is in the range of 0.95 – 1.15 [219].   
 
 
Figure 5.4.  Determination of peak symmetry 
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5.1.1.2. Liquid chromatography modes 
 
Normal phase chromatography is the oldest separation mode applied in column 
chromatography which is often governed by the interaction between adsorbent, solute and 
solvent molecules. This mode of chromatography employs polar stationary phases and non-
polar mobile phases. All solids that are insoluble in common liquids can be used as the 
stationary phase provided they have high surface area. Normal phase chromatography is well 
suited for the separation of non-polar to medium polar substances. Silica and alumina are the 
adsorbents that are found used in HPLC [220].  
 
Reversed phase (RP) chromatography utilizes non-polar stationary phases and a polar eluent 
which is the opposite of normal phase chromatography. Advantages of using RP 
chromatography includes compatibility with many biological samples, compatibility with 
electrochemical detectors, and the ability to control secondary chemical equilibria and 
gradient elution methods [220,221].  
 
5.1.2. Method validation 
 
Analytical methods used for the quantitative determination of drugs in samples play a 
significant role in evaluation and interpretation of BA, BE and pharmacokinetic data. It is 
necessary to utilize well-characterized and fully validated analytical methods to yield reliable 
results which can be satisfactorily interpreted. It is also important to highlight that each 
analytical technique has its own characteristics which will vary from drug to drug. Specific 
validation criteria are needed for methods intended for analysis of each analyte. Method 
validation includes all the procedures needed to demonstrate that a particular method for the 
quantitative measurement in a particular matrix is reliable. The parameters which are crucial 
to ensure the acceptability of the performance of an analytical method are stability of the 
drug in the matrix under study storage conditions, accuracy, precision, sensitivity, specificity, 
response function and repeatability [222-224]. Validation of the extraction method is also 
essential and best done in accordance with internationally acceptable guidelines [223].  
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5.1.2.1. Linearity 
 
For quantitative purposes, the detector response should be linear for the amount of solute to 
be determined over a reasonable range of solute concentrations. Linearity should be 
evaluated by appropriate statistical methods e.g. regression line (using least squares method).  
 
5.1.2.2. Range (standard curve) 
 
The range is normally derived from linearity studies and depends on the application of the 
procedure. It is necessary to use a sufficient number of standards to adequately define the 
relationship between concentration and response, and must be demonstrated to be continuous 
and repeatable. The number of standards used will be a function of the dynamic range and 
nature of the concentration-response relationship. Concentrations of 5-8 standards (excluding 
blank standard) should define the standard curve. The standard curve should cover the entire 
range of expected concentrations [222].  
 
5.1.2.3. Accuracy and precision 
 
Within and between run accuracy and precision should be calculated using commonly 
accepted statistical procedures which can confirm the reliability of the analytical method. 
This can be accomplished by analysis of replicate sets of analyte samples of known 
concentrations from a particular matrix. Replicates of three concentrations representing the 
entire range of the calibration curve should be studied i.e. quality control (QC) samples. One 
near the lower limit of quantitation (LOQ), one near the centre, and one near the upper 
boundary of the standard curve. For a method to be considered valid, the mean value should 
be within ±5% of the actual value for analytes in a non-biological matrix or ±15 % in a 
biological matrix [222].   
 
Inter-day precision should also be determined by analysing replicate sets of QC samples over 
a period of a few days. For the data to be valid, the above recommended acceptance criteria 
are used.  
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5.1.2.4. Limit of quantitation (LOQ) and limit of detection (LOD) 
 
The LOQ is the lowest concentration on the standard curve which can be measured with 
acceptable accuracy and precision. The LOQ should be determined using at least 5 
independent standard samples. The mean value should not deviate by more than ±10% in a 
non-biological matrix or ±20% in a biological matrix [222]. Typical signal-to-noise ratio is 
10:1 [224]. 
 
The limit of detection is the amount of solute that can be distinguished with some level of 
certainty from the baseline noise. A signal-to-noise ratio between 3 or 2:1 is generally 
considered acceptable for estimating the detection limit [224] . 
 
5.1.2.5. Specificity 
 
Specificity studies should be conducted to identify the impurities/degradants/matrix and the 
analyte(s) in the sample that is to be analysed. The analyte can be identified by comparing it 
to that of a reference standard. 
 
At times, an extraction procedure has to be utilized. The principle of an extraction is to 
remove an analyte from a matrix which can interfere with the analysis. An extraction can be 
done by using a solvent in which the analyte is highly soluble but where the matrix 
interferants have limited solubility. Extraction methods are often applied to bioanalytical 
procedures and for concentrating trace amounts of analyte. If there is problem of interference 
from excipients following an extraction procedure, chromatography is often able to resolve 
the analyte from the interferants and permit quantitation.   
 
There are two types of extraction methods that are most commonly used i.e. liquid or solid 
phase extraction. Solvent extraction methods provide simple and cost effective procedures 
for separating the analyte from excipients in matrices. However, for this to be possible, two 
immiscible solvents must be used thus reducing the choice of solvents. In a solid phase 
extraction (SPE), the analyte is retained on the solid phase extraction media and the 
interferants are eluted with a solvent with low eluting power. The analyte may finally be 
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washed out with a strong eluting solvent. SPE is often used in separating analytes from 
interferants when liquid-liquid extraction fails. However, an internal standard should always 
be used to compensate for any possible irreversible absorption of analyte onto the extraction 
media. Solid phase columns are , however, generally quite costly [225].   
 
5.1.2.6. Recovery 
 
The recovery, according to Braggio et al [226], is a “measure of the efficiency of the method 
in detecting all the analyte of interest present in the original sample”, by comparing the 
amount found in a spiked sample (spiking occurs before extraction) with the extracted blank 
matrix sample and spiked thereafter. Recovery should be as high and as consistent as 
possible, especially within the concentration range.  
 
The stability of the analyte during sample collection and handling, long-term and short term 
storage should be evaluated. This should be assessed in the matrix and container system used. 
Following the FDA guidelines for bioanalytical method validation [223], all stability 
experiments should use a set of samples prepared from a freshly made stock solution in the 
appropriate solvent and concentrations.   
 
5.2. METHOD DEVELOPMENT AND VALIDATION 
5.2.1. Experimental 
 
RP-HPLC has often been used as the liquid chromatography mode for the analysis of CP. 
This system is coupled with a UV/visible spectrometer for detection. Table 5.1 is a list of 
HPLC conditions used to detect CP in the various in vitro and in vivo samples (extractions 
from plasma, formulations, solvents, etc.). The developments of suitable analytical methods 
to quantitate CP released from topical formulations have been based on some of the listed 
conditions (Table 5.1). However, the mobile phase compositions used by others may not 
give acceptable results if the stationary phase used is slightly different, thus optimization of 
analytical conditions is still required. 
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Table 5.1.  Review of the analytical methods used for the determination of CP. 
 
Column Mobile phase composition Detection  Flow rate, injection vol., temp. Reference 
4.6 mm x 15 cm column that contains packing 
L1 
MeCN:NaH2PO4:MeOH (95:85:20) 
NaHPO4 – 0.05M with pH=2.5 
240nm Flow rate: 1ml/min 
Inj vol: 10 µl 
Temp: ambient 
[17] 
4.6 mm x 15 cm, C18 MeOH:NaH2PO4:MeCN (10:42.5:47.5) 
NaHPO4 – 0.065M with pH=5.5 
240nm Flow rate: 1ml/min 
Inj vol: 10 µl 
Temp: 30 °C 
[4] 
Nova-Pak® C18 column, 4 µm, 150 x 3.9 mm MeCN:H2O (1:1) Scanned from 200 – 
350nm, monitored at 
240nm 
Flow rate: 1 ml/min 
Injection vol: 100 µl 
Temp: ambient 
[227] 
Phenomenex® Luna C18, 5 µm, 150 x 4.6 mm MeOH:KH2PO4: MeCN (10:40:50)   
KH2PO4 – 0.1M with pH=3 
239nm Flow rate: 1 ml/min 
Inject vol: 50 µl 
Temp: 20 °C 
[215] 
Purospher-Lichrocart®, 5 µm, 250 x 4.0 mm Water: MeCN (40:60) 237nm Flow rate: 1 ml/min 
Inject vol: 10 µl 
Temp: 25 °C 
[228] 
2 gradient system: 
Symmetry® C18, 3.5 µm, 75 x 4.6 mm 
Nova-Pak® C18, 4 µm, 150 x 3.9 mm 
 
1.)  MeCN: H2O (18:82) 
2.)  MeOH: H2O (38:88) 
 
240nm 
Flow rate: 1 ml/min 
Inject vol: 5 µl 
Temp: ambient 
[229] 
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Hypersil® ODS, 5µm, 100 x 2.0 mm  MeCN: H2O (55:45) 240nm Flow rate: 1 ml/min 
Inj vol: 20 µl 
Temp: ambient 
[172] 
Phenomenex® Luna C8, 5 µm, 150 x 2.0 mm MeCN: H2O (46:54) 238nm Flow rate: 0.5 ml/min 
Inj vol: 10 µl 
Temp: 22 °C 
[230] 
Nova-Pak® C18, 4 µm, 150 x 3.9 mm MeCN: H2O (50:50) 240nm Flow rate: 1 ml/min 
Inj vol: 15 µl 
Temp: 22 °C 
[231] 
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5.2.1.1. Instrumentation 
 
The HPLC system used was equipped with a separation module (model 2690), a photodiode 
array (PDA) detector (model 2996), an online degasser, and an autosampler (Waters® Co., 
Milford, MA, USA).   
 
Electronic pipettes (ePet, Biohit, Helsinki, Finland) and disposable tips were used for the 
preparation of standard solutions and quality control samples. A precision balance (model 
AG135, Mettler® Toledo, Zurich, Switzerland), ultrasonic bath (model 8845-30, Cole-
Parmer Instruments, Chicago, USA), vortexer (Lab dancer vario, Ika®, Staufen, Germany), 
and a centrifuge (model 5414, Eppendorf Ag, Hamburg, Germany) were used for sample 
preparations. 
 
In the solubility study of CP in the various pH solutions, the Junior Orbit Shaker (Lab-Line 
Instrument Inc., Illinois, USA) and a shaking waterbath maintained at 37 °C were utilized. 
Samples (~0.5 ml) were removed using 5 ml glass syringes and filtered through PVDF 
syringe filters (0.45 µm, Millipore Millex-HV, Millipore Co., Billerica, Massachusetts, USA) 
into amber HPLC vials (Waters® Co., Milford, Massachusetts, USA) Samples from the assay 
of topical formulations were also placed into amber HPLC vials and sealed with a cap before 
analysis.  
 
5.2.1.2. Reagents, chemicals and materials 
 
CP (98 %) and desoxycorticosterone acetate (DOCA) (98 %) were purchased from Sigma-
Aldrich (Atlasville, South Africa). HPLC-grade acetonitrile (UV cutoff 200 nm) and 
methanol (UV cutoff 215 nm) were purchased from Romil Ltd. (Waterbeach, Cambridge, 
UK). HPLC-grade water was purified by reverse osmosis followed by filtration utilizing a 
Milli-Q® system (Millipore Co., Bedford, MA, USA). The water purification system 
comprised of a Milli-Q® Academic A10 with a Quantum™ EX Ultrapure Organex Cartridge 
equipped with Q-Gard® 1 Progard pre-treatment packs. All chemicals used were of analytical 
grade. 
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McIlvaine’s buffer was prepared by dissolving 14.196 g disodium hydrogen phosphate 
(BDH Chemicals Ltd., Poole, England) in 1 L of Milli-Q® water to give a 0.01 M solution, 
and adjusted to the appropriate pHs using 0.05M citric acid solution (PAL Chemicals Ltd., 
Surrey, England). Citric acid solution was prepared by dissolving 10.52 g of C6H8O7 in 1 L 
of Milli-Q® water. Saline was prepared by weighing 9 g of NaCl into 1 L of Milli-Q® water.  
 
5.2.1.3. Column selection 
 
A Luna C8 minibore column with internal diameter of 2.00 mm and a length of 150 mm , 
containing 5 µm particles (Phenomenex, Macclesfield, Cheshire, England) was chosen for 
the analysis of CP and used together with a guard column (C8, Phenomenex, Macclesfield, 
Cheshire, England). 
 
5.2.1.4. Mobile phase selection 
 
An important factor which influences the degree of retention of a particular compound, apart 
from the stationary phase, is the mobile phase. Using RP-HPLC, the more lipophilic a 
mobile phase the more quickly the compound will elute from the column. CP is a neutral 
compound and is non-ionisable [16], thus alteration of the pH of mobile phase was not 
necessary.   
 
5.2.1.5. Internal standard selection 
 
A number of corticosteroids were investigated for use as an internal standard. These were 
fluocinolone acetonide, hydrocortisone acetate, desoxycorticosterone acetate (DOCA), 
norethisterone acetate, ethinyl oestradiol, fluperolone acetate and mometasone furoate.  
 
Utilizing the chromatographic conditions listed in Table 5.2, the most suitable internal 
standards found were DOCA and mometasone furoate. DOCA had a retention time of ~6 
minutes and mometasone furoate ~10 minutes. The other internal standards either came too 
close to the solvent front or eluted at similar times to CP (not resolved). 
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5.2.1.6. UV Detection 
 
The λmax for CP and DOCA were determined from their UV spectra and are shown in Figure 
5.5 and 5.6. CP and DOCA were both detectable at a wavelength of 238nm.   
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Figure 5.5.  UV spectrum of CP 
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Figure 5.6.  UV spectrum of DOCA 
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5.2.1.7. Preparation of mobile phase 
 
The mobile phase was a mixture of acetonitrile and water (46:54 % v/v). Prior to use, the 
mobile phase was filtered with a 0.45 µm Durapore® (PDVF) filter (Millipore, Bedford, MA, 
USA) and degassed under vacuum with an Eyela Aspirator A-2S (Tokyo Rikakikai Co. Ltd., 
Tokyo, Japan) 
 
5.2.1.8. Preparation of standard solutions 
 
Stock solutions were prepared (100 µg/ml) by accurately weighing out approximately 10 mg 
of CP (reference standard) or DOCA (internal standard) on a precision balance (model 
AE163, Mettler Toledo, Zurich, Switzerland) and transferred to a 100 ml volumetric flask. 
The volumetric flask containing CP or DOCA was made up to volume with mobile phase. 
Standard solutions were prepared via serial dilutions of the CP stock solution (0.5, 1, 2.5, 5, 
10, 25, 50, and 100 µg/ml) using mobile phase. The stock and standard solutions were 
sonicated in an ultrasonic bath and then shaken immediately after preparation. High, medium 
and low concentration quality control (QC) standards (75, 15 and 2 µg/ml) were also 
prepared in a similar fashion. A separate stock solution was used to prepare these samples. 
New stock and standard solutions were prepared daily, except for the precision study.  
 
5.2.1.9. Chromatographic conditions 
 
Table 5.2.   HPLC-UV conditions 
Column Phenomenex® Luna C8 (2) column, 150 x 2.1 mm, 5 µm 
Mobile phase Acetonitrile and water (46:54 v/v) 
Flow rate 0.5 ml/min 
Detection wavelength PDA (but assessing samples at 238 nm) 
Injection volume 10 µl 
Retention time ~ 8 minutes 
Column temperature 22 ± 0.5 °C 
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5.2.1.10. Method validation 
5.2.1.10.1. Linearity 
 
The linearity of the analytical method was evaluated over the concentration range of 0.5 – 
100 µg/ml. The peak area ratios of CP/DOCA were plotted against CP concentrations. 
 
5.2.1.10.2. Accuracy and precision 
 
Intra- and inter-day accuracy and precision of the analytical method was assessed over 3 
days using 3 QC standards. Accuracy was assessed by analyzing five replicate injections of 
each QC standard. The precision study assessed the same set of QC standards that were 
stored in the fridge (± 2-8 °C) over the 3 day period. . 
 
5.2.1.10.3. Limits of quantification and detection 
 
Standard stock solutions were diluted to obtain concentrations for the determination of the 
lower limit of quantification (LOQ) and limit of detection (LOD) based on a signal-to-noise 
(S/N) ratio of 10:1 and 3:1 respectively.  
 
5.2.1.10.4. Stability 
 
The stability of CP in solution (± 10 µg/ml; n = 3) was assessed over a period of 12 days 
stored under various conditions. CP solutions were made up in acetonitrile or in mobile 
phase (H2O/ MeCN, 54/46).  
 
5.2.1.11. CP solubility 
 
The solubility of CP was investigated in McIlvaine’s buffer and also in saline solution. The 
McIlvaine’s buffer solutions were comprised of 0.05 M citric acid and 0.1 M disodium 
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hydrogen phosphate (pH of 2.5, 3, 4, 5, 6, 7 and 8). The samples were shaken at a speed of ± 
100 rpm at 37 ± 1 °C in a water bath for 24 hours. This was repeated at room temperature 
(22 ± 1°C) using an Orbit Shaker.  
 
Samples were prepared by accurately weighing out 10 mg of CP which was then transferred 
into a 20 ml test tube, 12 ml of the relevant solutions were then added. The test tube was then 
capped and placed directly onto the Orbit Shaker or into a test tube rack in the water bath. 
One millilitre of the sample was pipetted from the relevant test tube and placed into a glass 
syringe attached with a filter. The sample was then filtered directly into an amber HPLC vial 
and a 100 µL of methanol was included to avoid possible precipitation of CP. The final 
solution was then analysed for CP content. Samples were assessed over a period of 24 hours 
and collected at 2, 4, 6, 12, 18, and 24 hour intervals. 
 
5.2.1.12. Assay of CP content and uniformity 
 
The United States Pharmacopoeia [17] and British Pharmacopoeia [4] specifies that the CP 
content in a cream or ointment formulation should be within the range of 90-115% of the 
labeled CP amount. It is thus necessary to assay the CP content in each formulation prior to 
use in the studies to check the uniformity of the drug content in each dose. The assay was 
performed on three commercially available formulations, Dermovate® cream, Dovate® 
cream and Dermovate® ointment using 2g and 11mg quantities of each of the formulations. 
The larger mass was used to assay the products in accordance with the Pharmacopoeial 
monographs for CP whereas the lesser amount (11 mg) was used to determine the content of 
CP in each dose applied in the various studies. The formulations were dispensed into a 
volumetric flask or test tube using an Eppendorf pipette and weighed to obtain the mass of 
each sample. The assays were carried out as described in the British Pharmacopoeia [4]. The 
internal standard used was DOCA as opposed to beclomethasone dipropionate as per British 
Pharmacopoeia [4].  
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5.2.2. Results and discussion: 
5.2.2.1. Method validation 
5.2.2.1.1. Linearity 
 
The CP standard solutions gave a linear response at the concentration range of 0.5 – 100 
µg/ml with a correlation coefficient of 0.9998 (y = 0.3523x + 0.0708).   
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Figure 5.7. Calibration plot 
5.2.2.1.2. Accuracy and precision 
 
The accuracy of the analytical method for CP was found to be in the range of 94.8-105.8% 
with a relative standard deviation (RSD) of < 5% (as shown in Table 5.3). The results 
showed good intra- and inter-day precision as shown in Table 5.4. 
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Table 5.3.  Intra- and inter-day accuracy  
QC samples 
(n=5) 
Day Actual conc. 
(µg/ml) 
Calculated conc. 
(µg/ml) 
Accuracy Inter-day 
RSD 
(%) 
 1 2.12 2.25 106.13 1.85 
Low 2 1.99 2.03 102.01 3.72 
 3 2.03 2.09 102.96 1.93 
 1 15.90 15.07 94.78 0.18 
Medium 2 14.93 15.51 103.88 0.73 
 3 15.23 15.64 102.69 1.73 
 1 74.2 72.43 97.61 2.54 
High 2 69.65 73.73 105.84 3.66 
 3 71.05 72.30 101.75 4.05 
 
Table 5.4.  Intra- and inter-day precision  
QC 
samples 
(n=5) 
Day 1 
Mean conc. ± SD 
(µg/ml) (RSD%) 
Day 2 
Mean conc. ± SD 
(µg/ml) (RSD%) 
Day 3 
Mean conc. ± SD 
(µg/ml) (RSD%) 
Inter-day 
Mean conc. ± SD 
(µg/ml) (RSD%) 
Low 2.19 ± 0.03 (1.28) 2.05 ± 0.10 (4.85) 2.06 ± 0.05 (2.38) 2.10 ± 0.08 (3.67) 
Medium 15.08 ± 0.39 (2.60) 14.83 ± 0.30 (2.05) 15.40 ± 0.69 (4.49) 15.10 ± 0.29 (1.90) 
High 72.64 ± 0.72 (1.00) 73.70 ± 1.08 (1.46) 73.43 ± 0.19 (0.26) 73.26 ± 0.55 (0.75) 
 
5.2.2.1.3. Limits of quantification and detection 
 
The limit of quantification (LOQ) for CP in mobile phase was found to be 0.5 µg/ml and the 
limit of detection (LOD) was found to be 0.25 µg/ml. 
 
5.2.2.1.4. Stability  
 
Figures 5.8 and 5.9 illustrate the degradation of CP over a period of 12 days under various 
storage conditions. It can be seen that CP is more stable in acetonitrile than in the mobile 
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phase which is a mixture of water and acetonitrile. This indicates that water enhances the 
degradation rate of CP compared to acetonitrile. Temperature does play a role in the slow 
degradation of CP, thus samples in the fridge were found to be more stable than those stored 
at room temperature. 
 
CP samples in acetonitrile were sensitive to light.  
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Figure 5.8.  Stability of CP in acetonitrile under various storage conditions (l = light, d = dark) 
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Figure 5.9.  Stability of CP in mobile phase under various storage conditions (l = light, d = dark) 
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5.2.2.2. CP solubility 
 
Figures 5.10 and 5.11 illustrate the solubility of CP in saline and in McIlvaine’s buffer at the 
various pHs. CP has a higher solubility in saline solution (± 3.5 µg/ml) than in McIlvaine’s 
buffer (highest is ± 2.6 µg/ml). Figures 5.10 indicates that CP is slightly more soluble in an 
acidic medium than in an alkaline medium, and that its solubility increases with an increase 
in temperature from 22 °C to 37 °C.  
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Figure 5.10.  Solubility of CP in McIlvaine’s buffer at the various pHs at 22 °C and 37°C °C 
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Figure 5.11.  Solubility of CP in saline at 22 °C 
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5.2.2.3. Assay of CP content and uniformity in commercially available topical 
formulations. 
 
The CP content of 2 grams of Dermovate® Cream, when expressed as a percentage of the 
theoretical amount of CP, was found to be 102.5 ± 0.7 % with a RSD of 0.7 % (n=3). 
However, when assaying at a smaller quantity equivalent to an application dose of 22 mg, 
the CP content was found to be 102.2 ± 41.2 % with a RSD of 40.25 % (n=3).  
 
A 2 g quantity of Dovate® cream had a CP content of 92.5 ± 1.2 % with a RSD of 1.3 % 
(n=3). A 22mg quantity had a CP content of 102.58 ± 4.5 % with a RSD of 4.4% (n=3). 
Dovate® cream showed that the CP content was within the acceptable range as stated in the 
USP and the homogeneity of CP in this cream formulation showed uniform distribution. 
 
The CP content found in the different masses of the ointment product, 2 g and 22 mg, were 
103.8 ± 2.1 % and 121.8 ± 3.1 %, respectively. The RSD found within three extracted 
samples of each of the 2 g and the 22 mg masses were 2.0 % and 2.6 %, respectively. This 
indicates that CP was more uniformly distributed in the ointment formulation than the two 
cream formulations, Dermovate® and Dovate®. However, the 22 mg quantities of the 
ointment preparations had a CP content that was slightly higher than the limits specified by 
the USP and BP. The USP and BP allow for a CP content not less than 90.0% and not more 
than 115.0% of the labeled claim [4,17].   
 
5.3. HPLC ANALYSIS OF TS SAMPLES 
5.3.1. Experimental 
5.3.1.1. Instrumentation 
 
Eppendorf pipettes and disposable tips, a precision balance, ultrasonic bath, vortex, and a 
centrifuge were used for sample preparations. Extracted samples were also placed into 300 µl 
glass microinserts (Separations, Randburg, South Africa) where each was positioned in an 
amber HPLC vial and capped for analysis. The Waters Alliance® HPLC system was used to 
analyse tape strip samples.  
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5.3.1.2. Reagents, chemicals and materials 
 
CP (a USP reference standard), HPLC-grade ethyl acetate (BDH Chemicals Ltd., Poole, 
England), acetonitrile, methanol, and water were utilized in these studies. The same 
conditions as mentioned in section 5.2.1.9 were used for the analysis of the samples and the 
injection volume was 20µL. 
 
Scotch® Magic tape (no. 810, 24 mm x 50 m, 3M, Pymble, Australia) and Transpore™ 
dressing tape (no. 1527, 24 mm x 5 m, 3M, Isando, South Africa) were assessed. 
 
5.3.1.3. Sample preparation 
5.3.1.3.1. Extraction procedure 
 
Each individual tape strip of approximately 2.2 x 2.2 cm dimensions was placed into a 1.5ml 
polypropylene centrifuge tube with the adhesive side of the tape facing towards the inside of 
the tube. Each tape was extracted with 500 µL of methanol and vortexed for 1 minute. The 
samples were centrifuged for 5 minutes at 12 000 rpm on an Eppendorf centrifuge (Model no. 
5414, Eppendorf Ag, Hamburg, Germany). Approximately 100 µL of the sample was 
pipetted into a microinsert (Separation®, place of manufacturer, etc.) that was placed into an 
HPLC amber vial (Waters®, etc.) and the samples were analysed on an Alliance® HPLC 
system. 
 
5.3.1.3.2. Preparation of standards 
 
A stock solution of 1.25 mg/ml of CP was prepared by accurately weighing out ~25mg of CP 
into a volumetric flask and dissolving it in 20 ml of methanol. Calibration standard solutions 
of 0.01 - 1 mg/ml (0.01, 0.0125, 0.025, 0.0375, 0.05, 0.125, 0.25, 0.5 and 1 mg/ml) in 
methanol were prepared by serial dilution and made up to volume in 5ml volumetric flasks. 
Each tape strip was spiked with 10uL of a standard solution and left to air dry. The tape 
strips were then placed into a microcentrifuge tube and extracted according to the procedure 
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mentioned above. After extracting the spiked tape strips, the final concentration range was 
0.2 - 20 µg/ml (0.2, 0.25, 0.5, 0.75, 1, 2.5, 5, 10 and 20 µg/ml). 
 
A fresh, separate stock solution was used to prepare the quality control (QC) samples on a 
daily basis. Three QC standard solutions of 250, 75 and 30 µg/ml (high, medium and low 
concentrations) were extracted to give final concentrations of 5, 1.5 and 0.6 µg/ml. 
 
5.3.1.3.3. Method validation 
5.3.1.3.3.1. Linearity 
 
Peak areas of CP were plotted against CP concentrations following the analysis of relevant 
samples (n=3). The data were evaluated using linear regression analysis over the 
concentration range of 0.2 – 20 µg/ml. 
 
5.3.1.3.3.2. Accuracy and precision 
 
Intra- and inter-day accuracy and precision of the extraction method was assessed over 3 
days using the 3 QC standards. Accuracy was assessed by analyzing five separate tape strip 
extracts of each QC standard. Precision was assessed using the same QC standard tape strip 
extracts prepared on day 1 that had been stored in the fridge (± 2-8 °C) and evaluated over a 
period of three days. This also served as an indicator of stability. 
 
5.3.1.3.3.3. Limits of quantification and detection 
 
As shown in section 5.2.1.10.3, except extracted tape strip samples were assessed instead of 
CP solutions in this study.  
 
5.3.1.3.3.4. Specificity  
 
Extractions of blank tape strips and tape strips with adhered SC were assessed for specificity. 
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Both Scotch® and Transpore™ tapes were used for the TS and analysed for possible 
interferences. 
 
5.3.1.3.3.5. Recovery 
 
The extraction recovery of CP from the tape strips was assessed by analyzing spiked tape 
strips of high (~5 µg/ml), medium (~1.25 µg/ml) and low (~0.5 µg/ml) concentrations. The 
data from the extracted samples were compared with the standard samples in methanol 
without extraction.  
 
5.3.1.3.3.6. Stability 
 
The short-term stability of the extracted CP samples was assessed over a period of 24 hours 
under different temperature conditions. Samples were protected from light and were stored in 
the fridge or at room temperature. Extracted samples of high (40 µg/ml), medium (25 µg/ml) 
and low (5 µg/ml) concentrations were assessed. 
 
5.3.2. Results and discussion: 
5.3.2.1. Method validation 
5.3.2.1.1. Linearity 
 
The spiked tape strip extracts gave a linear response at the concentration range of 0.2 – 20 
µg/ml with a correlation coefficient of 0.9994 (y =30921x – 7933.4).  
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Figure 5.12.  Calibration plot of extracted tape strip samples 
5.3.2.1.2. Accuracy and precision 
 
The accuracy of the method was found to be in the range of 99.9-105.4% with a RSD of 
<3% (as shown in Table 5.5). The results show good intra- and inter-day precision as 
shown in Table 5.6. 
Table 5.5.  Intra- and inter-day accuracy of TS samples 
QC samples 
(n=5) 
Day Actual conc. 
(µg/ml) 
Calculated conc. 
(µg/ml) 
Accuracy Inter-day 
RSD 
(%) 
 1 0.64 0.67 104.69 0.86 
Low 2 0.59 0.63 106.77 2.58 
 3 0.57 0.60 105.26 1.62 
 1 1.59 1.60 100.63 2.07 
Medium 2 1.47 1.47 100.00 1.68 
 3 1.44 1.49 103.47 2.24 
 1 5.03 5.00 99.40 1.85 
High 2 4.90 4.92 100.41 2.32 
 3 4.80 5.06 105.42 1.09 
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Table 5.6.  Intra- and inter-day precision of TS samples 
QC 
samples 
(n=5) 
Day 1 
Mean conc. ± SD 
(µg/ml) (RSD%) 
Day 2 
Mean conc. ± SD 
(µg/ml) (RSD%) 
Day 3 
Mean conc. ± SD 
(µg/ml) (RSD%) 
Inter-day 
Mean conc. ± SD 
(µg/ml) (RSD%) 
Low 0.63 ± 0.02 (3.67) 0.60 ± 0.02 (3.04) 0.60 ± 0.01 (1.29) 0.61 ± 0.02 (2.58) 
Medium 1.58 ± 0.04 (2.33) 1.48 ± 0.02 (1.47) 1.48 ± 0.03 (2.03) 1.51 ± 0.06 (3.97) 
High 4.81 ± 0.10 (1.97) 4.66 ± 0.05 (1.00) 5.00 ± 0.10 (1.92) 4.82 ± 0.17 (3.48) 
 
5.3.2.1.3. Limits of quantification and detection 
 
The LOD and LOQ values were found to be 0.1 µg/ml and 0.2 µg/ml based upon signal to 
noise ratios of 3:1 and 10:1, respectively.  
 
5.3.2.1.4. Specificity 
 
Analysis of blank tape strips were required in order to determine whether interferences were 
present that could affect the analysis of CP. Interferences were found in the Transpore™ tape 
extract under UV detection as shown in Figure 5.13. Transpore™ tape showed impurity peaks 
over a run time of 22 minutes. Scotch® tape revealed fewer impurity peaks which eluted 
within 5 minutes as shown in Figure 5.14. The impurity peaks from Transpore™ tape 
interfered with the analysis of CP.  
 
Methanol was used as the extraction solvent. Acetonitrile and ethyl acetate could not be used 
because the tape was simply liquefied when immersed into either of these solvents.  
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Figure 5.13.  Extraction of blank Transpore™ tape strip 
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Figure 5.14.  Extraction of a blank Scotch® tape strip 
 
A variety of mobile phases and columns were tested to separate the CP peak from the 
interfering peaks when working with the Transpore™ tape. However, none of the alterations 
were able to resolve CP and thus Scotch® tape was chosen as the adhesive tape for the TS 
studies. 
 
The tape strip sample which included the SC showed no interferences with the elution of CP 
as shown in Figure 5.15. 
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Figure 5.15.  (a) Extraction of blank, stripped Scotch tape and (b) spiked, stripped Scotch® tape. 
5.3.2.1.5. Recovery 
 
The extraction recovery of CP from the tape strips was found to be in the range of 81.6 – 
84.7%.  
 
Table 5.7.  Recovery of CP from tape strips 
QC samples Concentration of 
extracted sample 
(µg/ml) 
Concentration of 
methanolic sample 
(µg/ml) 
Recovery  
(%) 
High 4.06 4.97 81.6 
Medium 1.05 1.24 84.7 
Low 0.34 0.41 82.9 
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5.3.2.1.6. Stability 
 
The stability of CP in extracted tape strip samples were found to be stable for 24 hours 
regardless of whether or not they were stored in the fridge or at room temperature.  
 
5.4. HPLC ANALYSIS OF MD SAMPLES  
5.4.1. Experimental 
5.4.1.1. Instrumentation 
 
The instrumentation used was the same as that described in section 5.3.1.1 
 
5.4.1.2. Reagents, chemicals and materials 
 
The reagents and chemicals were the same as described in section 5.3.1.2. In addition, 
Intralipid® 20% (Fresenius-Kabi, Midrand, South Africa) and HPLC-grade hexane (Burdick 
& Jackson Laboratories Inc., Michigan, USA) were utilized in the MD studies. The same 
analytical method used to assay tape strips was used to assay MD samples.  
 
5.4.1.3. Sample preparation 
5.4.1.3.1. Extraction procedure 
 
Thirty microlitres of CP in Intralipid® (IL) was placed in a 1.5ml polypropylene centrifuge 
tube and 60 µL of acetonitrile (containing 2 µg/ml DOCA) was added. The sample was 
vortexed and centrifuged for 20 minutes at 12 000 rpm on an eppendorf centrifuge. The 
supernatant was removed using a 100 µL pipette (pipetman, Gilson Inc., Middleton, USA) 
and placed into a 300 µL glass microinsert which was previously placed in an amber HPLC 
vial. Twenty microlitres of the sample was then injected onto the Luna C8 column. 
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5.4.1.3.2. Preparation of standards 
 
A 100 µg/ml stock solution was made by accurately weighing ~10 mg of CP or DOCA into 
100 ml volumetric flasks.  
 
The internal standard (DOCA) solution (2µg/ml) was made up to volume with acetonitrile. A 
serial dilution was made to obtain the relevant concentration which gave an AUC value 
corresponding to the AUC of CP approximately in the middle of the calibration 
concentration range.  
 
The reference standard (CP) stock solution was first wetted with 0.5 ml methanol and then 
made up to weight with IL (density = 0.98 g/ml). The standard solutions were all prepared 
via serial dilution and were made up to a final mass of 5 g with IL. 
 
All the solutions were sonicated or shaken immediately after preparation.  
 
5.4.1.4. Method validation 
5.4.1.4.1. Linearity 
 
A calibration curve was constructed using the peak AUC ratios of CP/DOCA versus 
concentration over the concentration range of 0.5 – 100 µg/ml. 
 
5.4.1.4.2. Accuracy and precision 
 
See section 5.3.1.3.3.2 relating to TS. 
  
5.4.1.4.3. Limits of quantification and detection 
 
See section 5.3.1.3.3.3 relating to TS. 
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5.4.1.4.4. Specificity 
 
Extractions of blank IL samples (unspiked with CP and DOCA), were assessed for 
specificity.  
 
5.4.1.4.5. Recovery 
 
The extraction recovery of CP from IL was assessed by comparing spiked IL samples with 
acetonitrile solution samples of the same concentrations. Three concentrations of high, 
medium and low were assessed. 
 
5.4.1.4.6. Stability 
 
See section 5.3.1.3.3.6 on the stability of TS samples. Since IL should not be stored in the 
fridge, Intralipid samples containing CP were stored at room temperature in the dark. 
 
5.4.2. Results and discussion 
 
Five different extraction solvents were assessed i.e. methanol, acetonitrile, hexane, and ethyl 
acetate, for the extraction of Intralipid samples. The results are shown in Table 5.8. 
Acetonitrile was found to be the most appropriate extraction solvent for IL using HPLC-UV.  
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Table 5.8.  Liquid-liquid extraction of CP from IL using various solvents 
Solvent Miscible Observations Problems 
Methanol Yes No separation: cloudy Cannot introduce onto column 
Acetonitrile Yes 2 layers: have precipitate and oil phase 
at the bottom and clear supernatant 
_ 
Hexane No 2 layers: white, opaque layer at the 
bottom and clear supernatant 
CP not found in hexane 
Ethyl acetate No 2 layers: both the bottom and top layers 
are clear 
All the excipients in the IL 
have been extracted into ethyl 
acetate except water. 
 
5.4.2.1. Method validation 
5.4.2.1.1. Linearity 
 
The calibration plot of extracted IL samples gave a linear response with a correlation 
coefficient of 0.9999 (y = 0.0358x +0.0215).  
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Figure 5.16.  Calibration plot of extracted IL samples 
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5.4.2.1.2. Accuracy and precision 
 
The accuracy of the method was found to be in the range of 89.64 – 101.75% with a RSD of 
<5.5%, and intra- and inter-day precision is shown in Tables 5.9 and 5.10, respectively.  
 
Table 5.9.  Accuracy of MD samples 
QC samples 
(n=5) 
Day Actual conc. 
(µg/ml) 
Calculated conc. 
(µg/ml) 
Accuracy Inter-day 
RSD 
(%) 
 1 2.51 2.25 89.64 3.25 
Low 2 2.56 2.49 97.27 5.00 
 3 2.60 2.37 91.15 4.28 
 1 50.20 49.97 99.54 1.77 
Medium 2 51.20 51.63 99.29 4.12 
 3 52.10 52.78 101.31 2.31 
 1 75.30 76.62 101.75 2.02 
High 2 76.80 74.65 97.20 2.47 
 3 78.30 79.55 101.60 3.84 
 
Table 5.10.  Precision study of MD samples 
QC samples 
(n=5) 
Day 1 
Mean conc. ± SD 
(µg/ml) (RSD%) 
Day 2 
Mean conc. ± SD 
(µg/ml) (RSD%) 
Day 3 
Mean conc. ± SD 
(µg/ml) (RSD%) 
Inter-day 
Mean conc. ± SD 
(µg/ml) (RSD%) 
Low 2.32 ± 0.08 (3.48) 2.17 ± 0.08 (3.63) 2.40 ± 0.09 (3.60) 2.29 ± 0.12 (5.08) 
Medium 48.62 ± 1.21 (2.49) 51.63 ± 2.13 (4.12) 48.90 ± 0.51 (1.05) 49.72 ± 1.60 (3.34) 
High 72.92 ± 2.26 (3.09) 74.65 ± 1.84 (2.47) 74.03 ± 2.58 (3.49) 73.87 ± 0.88 (1.19) 
 
5.4.2.1.3. Limits of quantification and detection 
 
The LOQ and LOD of extracted IL samples were 0.5 µg/ml and 0.25 µg/ml, respectively, 
Chapter 5 – Development and Validation of a Quantitative HPLC Method for the Analysis of CP 
 
97 
with an injection volume of 20 µl. An injection volume of 10 µl yielded LOQ and LOD 
values of 1.0 µg/ml and 0.5 µg/ml, respectively.  
 
5.4.2.1.4. Specificity 
 
The extracted blank IL samples showed two peaks relating to constituents of the IL emulsion 
(Figure 5.17). However, these peaks did not interfere with either CP or the internal standard, 
DOCA (Figure 5.18). The extraction method was thus found to be acceptable for the analysis 
of CP in IL.  
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Figure 5.17.  Extraction of blank IL 
 
 
Figure 5.18 Extraction of blank IL spiked with DOCA and CP. 
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5.4.2.1.5. Recovery 
 
The recovery of CP from extracted IL samples was 79.08 ± 1.43 %, as shown in Table 5.11.  
 
Table 5.11.  Extraction efficiency of CP from IL at three different concentrations.  
QC samples Concentration of 
extracted sample 
(µg/ml) 
Concentration of 
acetonitrile sample 
(µg/ml) 
Recovery 
(%) 
High 57.24 73.21 78.19 
Medium 39.52 50.46 78.31 
Low 2.03 2.52 80.73 
 
5.4.2.1.6. Stability  
 
CP is stable in IL after 24 hours storage in the dark at room temperature.  
 
5.5. CONCLUSIONS 
 
The foregoing describes quantitative methods for the determination of CP in 3 different 
media i.e. mobile phase, tape strips and MD samples consisting of CP in IL. The methods 
were found to have the necessary specificity, accuracy and precision and were therefore 
suitable for the quantitative analysis of CP from the various matrices. These analytical 
methods were successfully applied to assess the BA/BE of CP from topical formulations 
containing CP using TS and for the assessment of the permeation of CP through human skin 
using MD.  
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6. CHAPTER 6 
6.1. TAPE STRIPPING 
 
As previously mentioned, in Chapter 4, BE assessment of orally administered products 
intended for the systemic circulation is carried out by measuring plasma drug concentrations 
following administration of a test and reference dosage form to human subjects. However, in 
the case of topical preparations intended for local action (i.e. not intended to be absorbed into 
the systemic circulation), the general BE procedure used for products where the active 
ingredient is intended to be absorbed into the systemic circulation, cannot be used.   
 
Several methods have been developed to study the penetration of active ingredients from 
topical formulations as well as their BA and BE. With the exception of topical corticosteroid 
preparations, BE assessment of topical products usually requires that clinical studies in 
patients be undertaken to compare a new formulation (test) versus an approved product 
(reference). However, clinical efficacy trials are time consuming and expensive [132]. 
Currently, the HSBA is the only acceptable BE method approved by the USA FDA [158] 
and also by many other international regulatory bodies [118,232-234] for the BE assessment 
of topical corticosteroid products. This method was originally developed by McKenzie and 
Stoughton [159], but it is only applicable for assessing topical corticosteroid products which 
produce skin blanching following application to the skin. Hence, alternative methods for the 
BE assessment of other topical dosage forms are needed. 
 
TS is one of the many techniques that can be applied to study the permeation of a topically 
applied drug into the different layers of the epidermis. TS studies of human and animal SC 
have been used to calculate percutaneous absorption profiles and the retention time of the 
drug in the skin. Studies where skin has been stripped to disrupt the SC barrier have also 
been done to assess barrier homeostasis under different conditions. [235-238].   
 
TS has been investigated by several researchers as a surrogate measure for BA and BE 
assessment of topical products [174,239-242]. This is based on the concept of determining 
drug permeation through the SC following application of the product to the skin of human 
subjects. This technique utilizes adhesive tape strips which consecutively remove layers of 
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corneocytes, after which drug content is quantitatively measured in each layer of stripped 
skin or calculated as the cumulative amount present in all the skin strips (Figure 6.1). This 
method is considered to be relatively non-invasive due to the homeostatic nature of the skin. 
The SC for example has been shown to restore itself relatively quickly after disruption  [243]. 
 
In 1998, a draft TS guidance was issued by the USA FDA to assess BE of topical 
dermatological drug products [244]. This draft was later withdrawn due to flaws found in the 
recommended procedures of TS [245]. Data from inter-laboratory comparative studies on the 
same products were found to have conflicting and opposite results [173]. However, in spite 
of the withdrawal of the FDA’s draft guidance [245], TS remains a promising tool and is still 
being investigated and optimized by a number of researchers [174,246,247]. Previously 
published reports have indicated the potential of the TS technique for use in assessing the BE 
of topical preparations. One study showed correlations between the amount of corticosteroid 
in 10 tape strips versus the 90% CI obtained from the HSBA of creams and ointments [248] 
whereas another study [160,249] showed a correlation between the mean amount of 
corticosteroid in 10 tape strips versus the AUEC results obtained from visual HSBA data. 
The above studies, however, did not use the data to assess BE.  
 
Although the total amount of drug found in the stripped skin layers was determined in the 
abovementioned studies, the removed SC thickness was not taken into account. Since the 
total thickness of the SC removed from different sites using the same number of tape strips 
for each site may and usually does vary, a valid comparison between each subject and even 
between the tested sites within a subject cannot be made. Hence, normalization of subject 
skin thickness is necessary and can be undertaken using transepidermal water loss (TEWL) 
[250,251]. 
 
The main objective of the current study was to explore the applicability of standardized TS 
methodology as a viable option for BE assessment of topical dosage forms. The study design 
takes into account skin thickness normalization using TEWL data as well as refinements 
involving dosage application and duration of contact, special attention to removal of excess 
formulation from the skin after dosing as well as control of relative humidity and 
temperature of the study environment. 
 
A pilot study was undertaken to establish the dose duration to be used to assess the BE of CP 
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formulations using TS. This was deemed necessary to ensure the requisite discriminatory 
capability of the method. Subsequently, another pilot study, using the established dose 
duration, was undertaken to estimate the number of subjects required for subsequent pivotal 
studies based on inter-individual variability obtained from area under the curve (AUC) of 
test/reference ratios. Dermovate® cream was used as both the test and reference product.  
 
Subsequently, a pivotal study was conducted to determine whether TS was able to establish 
BE between 2 different topical cream formulations, a test product (Dovate® cream) and a 
reference product (Dermovate® cream). A concurrent pivotal study was also undertaken 
between an ointment formulation (Dermovate® ointment) and the same reference 
formulation previously used (Dermovate® cream). All of the formulations contained 0.05 % 
CP.  
 
According to the USA FDA [118] and most regulatory authorities, the declaration of BE 
between a test and reference product using the 2 one-sided t-test, requires that the 90% CI 
should fall within the range of 80-125%. Hence, these criteria were used to assess BE for our 
studies. 
 
6.1.1. Application of TS 
 
Studies have demonstrated that TS methodology is a promising tool for use in the selection 
and comparison of vehicles for topical drugs [132,172,241,252]. The TS technique has been 
used to analyze biological activity, taking into account binding, decomposition, and 
metabolism of a given drug. Pershing et al [160,249,253] and Tsai et al [248] compared skin 
blanching with the drug content in human SC following topical application of commercial 
corticosteroid products. It was found that there was good correlation between the detected 
penetration behaviour and the biological response of the corticosteroids. This is a good 
indication that TS may be used for determining BA and BE of topical formulations.  
 
Comparative drug uptake by the skin can be assessed by applying test and reference products 
to an anatomical site on a study subject. The SC samples can be obtained at various intervals 
of time following application of the formulation. This facilitates the observation of the drug’s 
absorption and elimination profiles [174]. However, this approach uses different dose 
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durations for each application site which may result in different discriminatory capability at 
each site. This will likely have important implications when attempting to assess BE between 
formulations.    
 
Figure 6.1.  Removal of a layer of SC with an adhesive tape strip 
 
Apart from the potential to use TS to assess BA/BE, Surber et al [254] postulated that the 
data obtained from TS experiments can also provide the following useful information: 
 
1) Chemical penetration into the skin 
2) Chemical permeation through the skin 
3) Chemical elimination from the skin 
4) Pharmacodynamic parameters 
5) Clinical parameters 
 
6.1.2. Factors affecting TS 
6.1.2.1. Seasonal 
 
It has been found that the time of the year affects the adhesiveness of tapes used to strip skin 
[255]. That particular study surmised that accumulation of fluid beneath the applied tape was 
significantly higher during summer than in the winter, thus the dermal peeling force was 
lower in summer than in winter. However, the amounts of corneocytes stripped were larger 
in summer than in winter. This was probably caused by the deterioration of the strength of 
the inter-corneocyte cohesion because of skin hydration   
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6.1.2.2. Individual 
 
The variations in barrier disruption in tape stripped individuals were found to be significant. 
The number of tape strips used was seen to vary between subjects to yield the same TEWL 
content per site [256]. In addition, different anatomical sites have demonstrated that the SC 
physiology is not consistent on each part of the body [257,258].  
 
6.1.2.3. Tape 
 
Various kinds of adhesive tapes have been compared for use in TS. Commercial adhesive 
tapes that are commonly utilized include Tesa® tapes, D-squame®, Transpore™, Micropore®, 
and Scotch® tapes. Results showed that a majority of the tapes successfully stripped the SC 
and induced SC disruption. The tapes did not significantly influence the mass of SC removed, 
but a difference in the degree of barrier disruption to TEWL was observed between some of 
the tape types [258-260]. It has been demonstrated that the choice of tape can alter the 
thickness value (H) in the equation used to determine water diffusivity across the SC 
(equation 6.1 shown in section 6.1.4.2). Stronger adhesive tapes have a higher dermal 
peeling force which cause an increase in destruction of the skin surface and TEWL followed 
by a more noticeable skin irritation [261,262].  
 
6.1.3. Side effects  
 
The occurrence of inflammation in the dermis can be associated with the tape stripping 
procedure. Inflammation is caused by trauma induced by stripping of the outer layer of the 
skin during tape removal which releases the promotors of inflammation from the 
keratinocytes. The irritation was not so great in the skin under the inner part of the tapes, but 
was found to be more severe on the skin under the edge portion of the applied tape [263]. 
Dermal reaction was proven to be greater in summer than in winter [255].  
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6.1.4. Transepidermal water loss 
6.1.4.1. Determination of SC thickness using transepidermal water loss 
 
The SC is not absolutely waterproof i.e. it is a semi-permeable membrane [58]. It allows a 
continuous diffusion of water out of the body, known as TEWL. This is a passive process 
and must be differentiated from active sweating which occurs in response to thermal stress or 
emotion [61]. TEWL is used to estimate SC water barrier function, an increase in TEWL 
reflects impairment in the barrier function of the SC. 
 
6.1.4.2. Rationale for the use of transepidermal water loss 
 
The principle function of the human SC is to restrict the loss of water to the external 
environment. Typical basal values of TEWL in healthy, adult, human skin are in the range of 
5 – 10 g.m-2.h-1. Disruption of the barrier can compromise the role of the SC. The 
measurement of TEWL is an effective marker to evaluate the degree of perturbation by 
physical or chemical attacks, or even the cause of the disease [264].   
 
The following equation is a linearized form of Fick’s first law used to estimate water 
diffusivity across the SC and the membrane thickness [265]. 
 
1/TEWLx  =  [H/( K∆C.D)]  -  [x/( K∆C.D)]   (equation 6.1) 
 
Where TEWLx = transepidermal water flux when x µm of SC has been  
removed by tape-stripping. 
           K  = the SC-viable tissue partition coefficient of water. 
D  = the average apparent diffusivity of drug molecule in SC of thickness H (µm). 
   ∆C = the drug concentration difference across the membrane 
 
It has been shown that, despite the various SC thicknesses, a very consistent barrier to 
TEWL resides in the population of healthy human subjects. The relative efficiency of this 
barrier is a constant i.e. removing a certain fraction of SC thickness from a thick skin has the 
same impact on TEWL as removing the same fraction of thin membrane [250].   
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6.1.4.3. Methods of measuring TEWL 
 
The gravimetric method [61] employs sensitive scales to determine body weight changes. 
TEWL is calculated by subtracting respiratory water loss, and taking into account the weight 
loss that occurs when oxygen is consumed and carbon dioxide is excreted. There are many 
sources of error within the gravimetric method which makes this approach unreliable. 
 
The chamber methods [61] measure TEWL directly by enclosing an area of the skin and 
collecting the water given off. The disadvantage is that the relative humidity in the chamber 
changes during the period of observation and alters passive diffusion. Ventilating the 
chamber can reduce this error, but an extra variation will be introduced which is the drying 
effect of the draught. 
 
The evaporimeter [266] is the most innovative and versatile technique used to measure 
TEWL. This method uses the principle of estimating the vapour-pressure gradient adjacent to 
the surface of the skin. Minimal influence on ambient humidity and temperature surrounding 
the skin is achieved. Water loss is measured electronically with a small probe placed above 
an area of the skin. The instrument is intended for use in the temperature range of 15-40°C 
and the atmospheric pressure range of 98-104 kPa [266]. This instrument measures water 
loss from the skin by relying on the observation that as water evaporates from the skin there 
is a linear decline in water vapour pressure which is directly proportional to the rate of 
evaporation. The TEWL can be measured accurately when concentrated on one site, but 
when assessed over a number of sites it only yields an approximate value [61]. Although 
TEWL may be influenced by a number of variables, experiments have shown that the 
evaporimeter yields repeatable results in vitro and in vivo. 
 
6.1.4.4. Factors affecting TEWL 
6.1.4.4.1. Body temperature 
 
Skin permeability and surface evaporation is increased by heat. TEWL is greater from warm 
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than cold skin. Increasing the ambient temperature also increases skin water loss, although 
some of this effect is probably secondary to a concurrent increase in body temperature and 
fall in ambient relative humidity [61].    
 
6.1.4.4.2. Ambient relative humidity 
 
An increase in ambient humidity leads to a linear fall in skin water loss [267]. This is 
indicative of the passive nature of TEWL.  
 
6.1.4.4.3. Radiant heat 
 
Radiators, when used as a means of thermal control can increase the TEWL by over 50%. 
This is due to an increase in skin surface evaporation. Any instruments, such as phototherapy 
devices which radiate heat can cause a small increase in water loss [61].   
 
6.2. COMPARISON BETWEEN TRANSPORE™ AND SCOTCH® TAPES 
6.2.1. Experimental 
6.2.1.1. Instrumentation 
 
TEWL was assessed by a vapometer (Delfin Technologies Ltd., Kuopio, Finland). Tape 
strips were pre-weighed with a Mettler® Toledo balance (model AG135, Columbus, USA). 
Analysis of tape strips were carried out as shown in section 5.3 
 
6.2.1.2. Materials 
 
TS was performed using Transpore™ dressing tape (3M, Isando, South Africa) and Scotch® 
Magic™ tape (3M, Pymble, Australia) of approximately 2.4 x 2.4 cm dimensions. 
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6.2.1.3. Formulations 
 
Biocort® cream, containing 1% hydrocortisone acetate, (Adcock Ingram Ltd., Johannesburg, 
South Africa) was applied once daily to the stripped area at the end of each TS experiment to 
assist with the healing process and prevent any possible scarring or hyperpigmentation. 
Application of Biocort® was continued daily until the disappearance of any resulting 
pigmentation at the tape stripped site. 
 
6.2.1.4. Subjects 
 
In order to assess the applicability and utility of the different tapes, 3 healthy volunteers (1 
female and 2 males) who met the selection criteria were enrolled after providing informed 
consent. Subjects were required to have no skin disorders and were instructed not to apply 
medicated topical products to the test sites for 2 months before and during the study. The 
subjects were also informed not to apply any emollient products on their forearms 24 hours 
prior to the start of the study. 
 
6.2.1.5. Study design 
 
The volar aspect of the forearm of each subject was washed 1 hour prior to tape stripping. 
Four 2 x 2 cm2 square application sites were demarcated using an adhesive label (Tower®, 
South Africa, Cape Town) on the forearms of the subjects. The labels were cut to the 
appropriate size with a blade prior to the study. The sites were placed 1-2 cm apart and 6cm 
away from the wrist and elbow.  
 
Fifteen individual ~2.4 x 2.4 cm2 squares of Scotch® tape (Scotch® Magic™ Tape, no. 810, 
24 mm x 50 m, 3M, Pymble, Australia) were utilized to sequentially tape strip the SC of the 
exposed square skin sites. The demarcation label remained on the skin during the TS 
procedure and was held intact by Scotch® tape such that all skin stripping was confined to 
the demarcated site only. Each tape strip was weighed on a precision balance (Mettler® 
Toledo, model AG135, Columbus, USA) prior to the study and immediately after stripping 
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to quantitatively determine the weight of the SC removed and to minimize weight loss of the 
stripped skin due to possible changes in water content. The tape strips were removed with a 
rapid movement. The stripping process involved removing consecutive tape strips in 
directions changing in order of a clockwise rotation as shown in Figure 6.2. A pair of forceps 
was used to apply pressure onto the tape and was rubbed backwards and forwards 10 times 
to ensure that each tape strip adhered evenly to the skin site prior to stripping. Fifteen tape 
strips were used per site. 
 
 
Figure 6.2. Direction of tape strip placement and removal. 
All sites were used for the determination of individual SC thickness. TEWL and stripped SC 
weight was used to calculate individual SC thicknesses [250]. A vapometer was used to 
obtain TEWL readings recorded as g/m2/h. 
 
Room temperature (22 ± 1 °C) and humidity (45 ± 2 %) were controlled throughout the 
studies. 
 
6.2.1.6. Data and statistical analysis 
 
The two-tailed t-test (95% CI) was used to assess differences in mass of SC removed 
between the two different tapes. 
 
6.2.2. Results and discussion 
 
The stripped sites showed progressive inflammation from continuous stripping with the 
adhesive tapes. The study subjects reported slight discomfort on the stripped sites after the 
10th strip, especially with the use of Transpore™ tape. 
 
Figure 6.3 shows the pooled data from 3 subjects which compares the total mass of SC 
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removed from 15 tape strips on a single site per subject. The average mass of SC removed 
using Scotch® tape was 3.71 ± 0.74 mg, and for Transpore™, an average mass of 5.17 ± 1.28 
mg. The p-value of 0.20 (>0.05) indicated no significant difference in the mass of SC 
removed between the two different tapes.  
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Figure 6.3. The comparison of SC removed from the two different adhesive tapes. 
Although the Transpore™ tape appears to be slightly more superior in removing and 
disrupting SC compared to the Scotch® tape, components in the Transpore™ tape interfered 
with the HPLC assay for CP (see chapter 5 section 5.3.2.1.4).  
 
Table 6.1 shows the amount of CP removed per tape strip using 15 tape strips of Scotch® 
tape in total. It is therefore evident from the amount of CP found in the strips from 10 
onwards that the use of 15 strips is adequate to remove most of the SC which contains CP 
and hence no more than 15 strips were considered necessary for use in all the TS studies.  
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Table 6.1.  Mean amount of CP removed using Scotch® Magic tape (n = 3 subjects) 
Tape strip no. Amount of CP ± SD (µg) %RSD 
1 0.26 ± 0.09 35.56  
2 0.18 ± 0.06 34.82  
3 0.12 ± 0.06 46.00  
4 0.10 ± 0.08 72.44  
5 0.06 ± 0.05 98.68  
6 0.08 ± 0.07 93.02  
7 0.05 ± 0.04 80.00  
8 0.05 ± 0.05 96.76  
9 0.04 ± 0.06 152.43  
10 0.03 ± 0.04 137.01  
11 0.01 ± 0.03 185.75  
12 0.02 ± 0.04 194.05  
13 0.01 ± 0.02 264.58  
14 0.00 ± 0.01 264.58  
15 0.00 0.00  
 
6.3. PILOT STUDY FOR DOSE DURATION DETERMINATION 
6.3.1. Experimental 
6.3.1.1. Instrumentation 
 
As described in the above section 6.2.1.1 
 
6.3.1.2. Materials 
 
Scotch® Magic™ tape (3M, Pymble, Australia) of 2.4 x 2.4 cm was used in the study. 
 
6.3.1.3. Formulations 
 
A commercially available cream, Dermovate® cream (Glaxo Wellcome, South Africa), 
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containing 0.05% m/m CP was used as the reference product in this study and in subsequent 
studies.  
 
6.3.1.4. Subjects 
 
6 healthy human subjects (2 males and 4 females) who met the same criteria as the subjects 
in section 6.2.1.4 (comparison of tapes) were utilized in this study.  
 
6.3.1.5. Study design 
 
The same tape stripping procedure was used as described in section 6.2.1.5 above. 
 
All formulations were tested on the volar aspect of one of the forearms of each subject. The 
treated sites were placed closer to the mid-section of the volar aspect of the forearm due to 
variations in percutaneous absorption which may occur from different areas on the arm [268]. 
Nine 2 x 2 cm square skin sites on the volar aspect of the forearm were demarcated for the 
application of Dermovate® cream. One site was reserved as a blank to determine each 
subject’s SC thickness and the remaining eight sites were each assigned a dose duration of 
0.5, 1, 2, 4, 6, 8, 10 and 12 hours (Figure 6.4). A dose of ~ 5.5 mg/cm2 of Dermovate® cream 
was applied using a previously calibrated Eppendorf pipette (Eppendorf Ag, Hamburg, 
Germany) (see HSBA chapter 4, section 4.2.1.5) and the cream was spread evenly over the 
demarcated site using a glass rod. The amount applied was chosen by taking into 
consideration a previous FDA guidance [244] which suggested the use of a predetermined 
amount of 5 mg/cm2.  Although different amounts of various formulations have been used by 
other researchers, no explanation has been given as to how those amounts were 
predetermined. To facilitate the quantitative measurement of CP, each individual tape strip 
was analysed separately for CP content, this is in contrast to a number of other studies 
[174,242,246,248] in which groups of tape strips were combined before analysis   
 
The forearm of each subject was protected after application of the relevant product, using a 
non-occlusive armguard to prevent the spreading of the applied topical formulation. The 
armguard was a clear perspex custom-made mould which fitted around the forearm and 
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included holes for ventilation. The arm guard was raised slightly from the skin using 
adhesive strips of 1cm thick sponge. Treated and untreated sites were randomized between 
each subject. The measured doses of cream were applied onto each application site at the 
same time. At the end of the particular dose duration period the excess formulation was 
removed followed by tape stripping of the application site. Prior to stripping the treated sites 
(these sites were not measured for TEWL), cotton wool buds were used to remove the excess 
formulation from each site and the sites were allowed to equilibrate to room conditions for 5 
minutes. The blank site was tape stripped first and the treated sites were then tape stripped at 
the end of each dose duration.  
 
The blank site was used for the determination of individual SC thickness. TEWL and 
stripped SC weight were used for the calculation of individual SC thickness [250]. A 
vapometer was used to take TEWL readings. TEWL measurements were taken prior to the 
stripping procedure and immediately after each stripping. 
 
 
Figure 6.4. Scheme of application of the different dose durations on the volar aspect of the forearm 
6.3.1.6. Data and statistical analysis 
 
The first tape strip was analyzed but not included in the data analysis since the first tape strip 
may still contain some formulation residue remaining on the skin surface and not removed 
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from the skin by swabbing [174]. The CP content of the first tape strip and cotton swabs 
were used to perform a mass balance but were not included in the data analysis. It was 
generally found that when the amounts of CP in the first tape strip plus the amount in the 
cotton swabs were added to the amount of CP recovered at the end of the stripping process, 
the total amount of CP was approximately equal to the applied dose (22 µg/site). For 
example, recovery of CP from Dermovate® cream, Dovate® cream and Dermovate® ointment 
following application of the respective formulations to 30 subjects resulted in a mean amount 
of 20.71 µg CP (%RSD = 17.21),  19.21 µg CP ( %RSD = 14.81), and 22.09 µg CP (%RSD 
= 26.00), respectively (See Appendix III for raw data). 
 
SC thickness (H) was determined from the following equation [250]: 
1/TEWLx = H-x / K.D.ΔC   (equation 6.2) 
where TEWLx is the transepidermal water flux of x µm of SC removed by a tape strip; H is 
the total SC thickness; x is the SC thickness removed by a tape strip i.e. partial of H; K is the 
partition coefficient of water from the SC to viable tissue; D is the average apparent 
diffusivity of water in the SC of thickness, H, and Δ C is the difference of water 
concentration across the membrane. 
 
The SC stripping data were expressed as amount of CP per normalized fraction of SC (x/H) 
removed, based on TEWL determinations. The normalized fraction of SC allows for the 
comparison of data between subjects with varying SC thickness. The area under the curve of 
a plot of amount of CP versus normalized SC fraction was determined. The AUC found was 
then plotted against the dose duration for a dose-sigmoidal response fit to determine ED50. 
Graphpad Prism®, version 4.03, was used to determine the AUCs and ED50.  
 
6.3.2. Results and discussion 
 
Currently, there have been no reports where an appropriate dose duration has been 
determined for use in a BE assessment of topical preparations using tape stripping. Apart 
from a single report [248], the majority of TS studies have generally utilized very long dose 
durations where steady state may have been reached resulting in a lack of discriminatory 
capability to assess similarity or differences between the bioavailability of the active 
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ingredients in the formulations studied [174,242,247,269]. Whereas Tsai et al [248] 
considered the use of a predetermined dose duration, the dose duration used was determined 
from a HSBA study and not from a TS pilot study. We have shown that the appropriate dose 
duration for the same drug may differ between that required for HSBA and TS investigations, 
i.e. 0.5 hrs for HSBA and 2 hrs for TS using CP as the investigative drug. Hence, in the 
absence of appropriate dose duration for a topical drug product being assessed for BE, 
resulting data may be questionable. It is thus considered extremely important to establish the 
requisite dose duration required to provide the necessary sensitivity to confirm BE between 
formulations. This is readily accomplished using the sigmoidal dose-response model [34] 
where the application exposure time or dose duration (ED50) can be established. The 
approach followed is in line with the requirements of the HSBA where a pilot study is 
undertaken in accordance with the FDA guidelines for the assessment of BE of topical 
corticosteroid formulations [158]. The use of an ED50 dose duration has been discussed in 
the HSBA Chapter 4.  
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Figure 6.5. A sigmoidal dose-response curve for the determination of ED50  
 
Figure 6.5 illustrates the graph where AUCs from TS data are plotted against dose durations. 
The ED50 was found to be 2.4 hours for CP in Dermovate® cream. Hence, 2 hours was 
chosen as the dose duration used to compare test and reference products in the subsequent 
BE studies using the tape stripping technique.  
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6.4. PILOT STUDY TO [178,270]: 
6.4.1. VALIDATE TAPE STRIPPING FOR USE IN BIOEQUIVALENCE 
ASSESSMENT 
6.4.2. DETERMINE NUMBER OF SUBJECTS REQUIRED FOR A PIVOTAL 
TAPE STRIPPING STUDY 
6.4.2.1. Experimental 
6.4.2.1.1. Instrumentation 
 
Vide infra section 6.2.1.1. 
 
6.4.2.1.2. Materials 
 
Vide infra section 6.3.1.2. 
 
6.4.2.1.3. Formulations 
 
Dermovate® cream was used as the test and reference product. 
 
6.4.2.1.4. Subjects 
 
7 subjects (2 males and 5 females) who met the previously described inclusion criteria 
(section 6.2.1.4) were enrolled into the study and written informed consent was obtained.  
 
6.4.2.1.5. Study design 
 
The TS procedure previously described (section 6.2.1.5) was followed, with the exception 
that one site was reserved as the blank for the determination of individual SC thickness, two 
sites were used for the test product (Dermovate® cream) and one site was used for the 
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reference product which was also Dermovate® cream (Figure 6.6.). The sites for test and 
reference product application were randomized amongst the subjects. A weighed dose of 5.5 
mg/cm2 was applied onto the assigned skin site with a previously calibrated Eppendorf 
pipette. The preparations on each demarcated skin site were carefully spread using a glass 
rod. The forearm of each subject was protected after application of the relevant product, 
using a non-occlusive armguard to prevent the spreading of the applied topical formulation. 
The preparations were left in contact with the skin for 2 hours before removal. The excess 
formulation was removed by swabbing the application sites using two dry cotton buds per 
treated site. The skin sites were allowed to equilibrate thereafter for 5 min prior to tape 
stripping.   
 
 
Figure 6.6. Scheme of application on the volar aspect of the forearm 
 
6.4.2.1.6. Data and statistical analysis 
 
AUC was determined as described in section 6.3.1.6. BE was assessed using untransformed 
AUC data (Locke’s method - as described in the FDAs HSBA guidance [158]) as well as 
log-transformed data to calculate the 90% CI for the AUCtest/AUCref ratios. The two 
statistical analysis methods were compared, since no method has yet been approved for 
assessing TS data for BE.  
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. 
Inter-individual variability (CV%) of the log-transformed AUCtest/AUCref ratios was 
determined using the following equation: 
CV% = 100*(√eMSE-1)      (equation 6.3) 
For Locke’s method, inter-individual variability of the untransformed AUCtest/AUCref ratios 
was calculated from the equation: 
CV% = 100*√(MSE/mean)     (equation 6.4) 
Statistical data were processed using SAS® (version 9.1.3). 
 
6.4.3. Results and discussion 
6.4.3.1. Validate tape stripping for use in bioequivalence assessment 
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Figure 6.7. Mean TS profiles of the test and reference applications of Dermovate® cream. Penetration of CP 
from Dermovate® cream into the SC for all volunteers (n = 7) 
 
The permeation profile from the TS study comparing the penetration of CP from 
Dermovate® cream used as both test and reference product, is shown in Figure 6.7 where the 
amount of CP found in each tape strip was plotted against the normalized skin fraction. The 
above tape stripping profiles (Figure 6.7) showed fairly similar permeation profiles of CP 
into the SC 
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To achieve BE between an orally administered test and reference product, the USA FDA 
recommends that the 90% CI should fall within the range of 80-125% [118] using log-
transformed data. The specific guidance for topical dermatologic corticosteroids requires the 
use of untransformed data [158]. The 90% CIs found for the TS pilot study were within the 
recommended range of 80-125% thus indicating that the test product (Dermovate® cream) is 
bioequivalent to the reference product (Dermovate® cream). In a previously conducted 
pivotal HSBA study, using Dermovate® cream as both the test and reference products (vide 
infra section 4.3), BE between these two products was confirmed, as expected. Interestingly, 
statistical analysis of this pilot TS data provided the same outcomes as that of the pivotal 
HSBA study (Table 6.2). Hence, TS has been shown to be a feasible tool for application in 
the BE assessment of topical products containing CP.  
 
In this study, two different statistical methods were used where both log-transformed and 
untransformed data were analysed using either AUC data and are shown in Table 6.2. The 
use of Locke’s or the 2 one-sided t-test statistical methods achieved very similar BE results. 
Therefore, the use of either statistical method is applicable for the determination of the 90% 
CI for BE assessment of topical products using TS.   
 
Table 6.2.  BE assessment of identical products (test product – Dermovate® cream, 
reference product – Dermovate® cream) [178] 
 Mean T/R ratio  
(%) 
90% CI 
(%) 
 
Untransformed Log-transformed Untransformed Log-transformed 
HSBA      
Chromameter  104.3 - 90.2 – 120.7 - 
Visual 102.9 - 97.9 – 109.2 - 
TS     
Pilot study 101.8 101.4 88.0-118.3 87.4-117.7 
 
6.4.3.2. Determine the number of subjects required for a pivotal tape stripping study  
 
The inter-individual variability (CV%) values for log-transformed and untransformed 
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AUCtest/AUCref ratios in the pilot study were found to be 14.4% and 13.9%, respectively, 
This indicated that approximately 32 subjects would be required to achieve a power of  80 % 
[271]. On the basis of these data, pivotal TS studies were undertaken using 30 subjects to 
provide a power of at least 80 %. 
 
6.5. BIOEQUIVALENCE PIVOTAL STUDIES USING TAPE STRIPPING [178,270] 
6.5.1. Experimental 
6.5.1.1. Instrumentation 
 
Vide infra section 6.2.1.1 
 
6.5.1.2. Materials 
 
Vide infra section 6.3.1.2 
 
6.5.1.3. Formulations 
 
In this TS study, the test products Dovate® cream and Dermovate® ointment were each 
compared against the reference product Dermovate® cream (vide infra appendix IV). 
 
6.5.1.4. Subjects 
 
The subsequent pivotal TS studies were conducted on 30 healthy human volunteers (15 
males and 15 females, aged 20-36) with skin phototype of II-VI [272] who also met the same 
inclusion/exclusion criteria as in the initial TS study. Written informed consent was obtained 
from each volunteer before the study. The research with human subjects followed the 
recommended guidelines as set out in the Declaration of Helsinki (1964) and associated 
amendments. The study protocol (appendix IV) was approved by the Ethical Standards 
Committee of Rhodes University (Grahamstown, South Africa). 
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6.5.1.5. Study design 
 
The study design used in this pivotal study was the same as that described in section 
6.4.2.1.5 where one site was reserved as the blank for TEWL measurements, two sites for the 
test products (Dovate® cream and Dermovate® ointment) and one site for the application of 
the reference product, Dermovate® cream. The blank and application sites were randomized 
between subjects.  
 
6.5.1.6. Data and statistical analysis 
 
The AUC of a plot of amount of CP versus normalized SC fraction was determined (AUCcorr) 
as previously described in section 6.3.1.6. For comparison purposes, the uncorrected AUC 
(AUCuncorr) as used by previous researchers [174,246] was also determined for each 
formulation. This approach using AUCuncorr involves computing the total amount of drug 
penetrated into the skin per unit area and makes no adjustment for differences in SC 
thickness. 
  
The BE range was determined using untransformed AUC data (Locke’s method - as 
described in the FDAs HSBA guidance [158]) and also log-transformed data to calculate the 
90% CI for the AUCtest/AUCref ratios. 
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6.5.2. Results and discussion 
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Figure 6.8. Mean TS profiles for the three topical products. Penetration of CP from Dovate® cream (purple line), 
Dermovate® ointment (green line) and Dermovate® cream (black line) into the SC for all volunteers (n = 30) 
where the error bars show the SEMs. 
 
 
The mean permeation profiles for the CP creams and ointment are depicted in Figure 6.8. 
The AUCtest/AUCref ratios were obtained from the data used to generate these TS profiles and 
used to determine BE of the test product (Dovate® cream) vs. the reference product 
(Dermovate® cream), and Dermovate® ointment vs. the same reference product (Dermovate® 
cream), all containing 0.05% CP. The mean TS profiles of Dovate® and Dermovate® creams 
from the pivotal study, normalized for skin thickness, were found to be similar.  
 
BE analysis of Dovate® cream vs. Dermovate® cream indicated that the products were 
bioequivalent where the 90% CIs found were within the acceptance limits of 80-125% 
(Table 6.3) using both untransformed (Locke’s method) and log-transformed (2 one-sided t-
test) data. Dermovate® ointment showed bio-inequivalence, as expected, when compared to 
Dermovate® cream as the reference where the 90% CIs using both untransformed and log-
transformed data were outside the acceptance criteria of 80-125 % as shown in Table 6.3. 
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Table 6.3. Pivotal TS studies of CP creams and ointment products using AUCcorr data [178] 
 
 
Although creams and ointments are not pharmaceutically equivalent and BE assessment 
between such products is generally not done, a comparison was undertaken between two 
different types of formulation, Dermovate® ointment (test) and Dermovate® cream 
(reference), to determine whether the TS method was able to discriminate differences 
between these formulations. Dermovate® ointment showed a lower permeation of CP into 
the SC than the creams (Figure 6.8). As expected, Dermovate® ointment was shown to be 
bio-inequivalent to Dermovate® cream using both log-transformed and untransformed 
AUCcorr data. This provided a useful model to show that TS was able to determine that the 
ointment was indeed not bioequivalent when compared to the cream (Table 6.3).  
 
The use of AUCcorr data takes into account the normalized thickness of the SC into which the 
drug has penetrated. The thickness of intact SC on the forearm varies from 5 – 20 µm in 
healthy adults. As a result, normalization of the data is necessary to allow for comparison 
between sites and subjects as demonstrated in a previously published report [250]. TS data 
corrected for skin thickness using TEWL measurements (AUCcorr) and also the uncorrected 
AUC data (AUCuncorr) were investigated and compared for use in the assessment of the BE 
between the topical products.  
 
Figure 6.9 depicts both mean AUCuncorr (Figure 6.9a) and AUCcorr (Figure 6.9b) histograms 
for the different formulations. The AUCuncorr ± SEM from Dovate® cream, Dermovate® 
ointment and Dermovate® Cream were 0.36 ± 0.03 µg/cm2, 0.37 ± 0.03 µg/cm2, and 0.39 ± 
 Mean T/R ratio  
(%) 
90 % CI  
(%) 
Pivotal TS Studies Untransformed Log-transformed Untransformed Log-transformed 
Dovate® Cream vs. 
Dermovate® Cream  
 
93.8 
 
92.8 
 
84.7-103.6 
 
82.9-103.9 
Dermovate® Ointment vs. 
Dermovate® Cream  
 
66.3 
 
55.2 
 
48.8-82.2 
 
46.1-66.1 
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0.03 µg/cm2, respectively (Figure 6.9a). The AUCcorr ± SEM found for Dovate® cream, 
Dermovate® ointment and Dermovate® Cream were 0.051 ± 0.09 µg/(x/H), 0.036 ± 0.07 
µg/(x/H) and 0.055 ± 0.09 µg/(x/H) respectively (Figure 6.9b), where x/H is the fraction of 
SC removed. In Figure 6.9, using AUCuncorr, all three products appear similar, whereas using 
AUCcorr data, the creams appear similar but the ointment quite different.  
 
 
 
Figure 6.9.  A comparison between the use of the AUCuncorr and AUCcorr values of the different formulations. 
Pharmacokinetics obtained from TS, showing the (a) mean AUCuncorr values with SEM and (b) mean AUCcorr 
values with SEM of Dovate® cream (purple), Dermovate® ointment (green) and Dermovate® cream (black) 
for all subjects (n = 30) [178]. 
 
Interestingly, the pivotal studies using AUCuncorr data (log-transformed) resulted in the 90% 
CIs for both studies falling within the acceptance range of 80-125% for the declaration of BE 
for Dovate® Cream vs. Dermovate® cream, and for Dermovate® ointment vs. Dermovate® 
cream. However, when the AUCcorr data were used, more realistic results were obtained 
showing that Dovate® cream was bioequivalent to Dermovate® cream whereas Dermovate® 
ointment was bio-inequivalent to Dermovate® cream. 
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Table 6.4.  Pivotal TS studies of CP creams and ointment products using AUCuncorr data 
[178] 
 Mean T/R ratio 
 (%) 
90% CI 
(%) 
Pivotal TS Studies Untransformed Log-transformed Untransformed Log-transformed 
Dovate® Cream vs. 
Dermovate® Cream 
 
93.4 
 
93.6 
 
86.3 – 101.2 
 
86.22.-101.5 
Dermovate® Ointment vs. 
Dermovate® Cream 
 
95.9 
 
96.3 
 
86.8 – 106.1 
 
86.6 – 107.1 
 
When comparing the two statistical analytical methods, log-transformed AUCuncorr values 
were used and BE was demonstrated for Dovate® cream versus Dermovate® cream. The 
same result was found for these creams using Locke’s method (untransformed data). 
However, Dermovate® ointment (test) was surprisingly shown to be bioequivalent to 
Dermovate® cream (reference) using both statistical methods (Table 6.4) when AUCuncorr 
data was used. It should be noted, that previous studies using TS for BE assessment only 
used log-transformed AUCuncorr data [174,246]. This clearly demonstrates the value of using 
AUCcorr values to enhance the discriminatory capability using the TS method. Additionally, 
the use of either of the two statistical analytical methods are applicable in demonstrating BE 
between products.  
 
6.6. CONCLUSIONS 
 
To date, no statistical methods have been officially recommended for the BE assessment of 
topical products other than for topical corticosteroid products using the HSBA [158]. In light 
of this, 2 different approaches to determine the CIs for the AUCtest/AUCref were used, viz: the 
classical approach using the 2 one-sided t-test [273] with log-transformed data and Locke’s 
method [209] which uses untransformed data. Application of either method provided similar 
results (Tables 6.2, 6.3 and 6.4). 
 
The TS method was successfully used to assess formulations using either log-transformed or 
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untransformed AUCcorr data. The use of AUCcorr data by normalization of the skin thickness 
appears to provide better discriminatory power and should be considered when using the TS 
method for BE assessment. Whilst the TS method has clearly been shown to be a viable 
alternative approach for BE assessment of CP topical products, it is important to optimize the 
TS method to control sources of variability such as: 
 the use of an appropriate dose duration 
 careful removal of residual application prior to skin stripping 
 controlled systematic stripping orientation of each site 
 normalization of individual skin thickness 
 careful control of the dose and application of doses to demarcated skin sites 
 avoidance of areas on the volar aspect of the forearm where increased variability in 
uptake may exist such as areas near the wrist and elbows 
 control of temperature and humidity of the environment where the study is being 
conducted.  
 
The results of these studies illustrate the potential for TS as an alternative method for the BE 
assessment of topical products not intended to be absorbed into the systemic circulation. 
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7. CHAPTER 7 
7.1. MICRODIALYSIS 
 
The determination of in vivo BA of topical drug products has always been a challenge. As a 
result, dermal MD has been developed as one of the several promising in vivo methods 
which could be used to assess cutaneous drug penetration. It facilitates continuous sampling 
of the unbound drug fraction in the extracellular fluid in the skin after topical or systemic 
delivery [274]. This technique first emerged from the neuroscience field [275] where it was 
developed for neurotransmitter sampling in the rat brain. Subsequently, it has been used to 
investigate endogenous substances in the extracellular fluid in the skin [276,277], and has 
progressed for use to study absorption of exogenous substances as well [278,279].  
 
The application of dermal MD to study drug penetration through the skin is based on the use 
of a micro-fibre consisting of a thin semi-permeable membrane which can be introduced into 
the skin and which will imitate the function of a capillary blood vessel as shown in        
Figure 7.1 [280,281,281]. The fibre only allows for the passive diffusion of certain 
molecules across the membrane, based on their molecular size. Different MD membranes are 
available with a range of molecular weight cut-off values. MD membranes typically used for 
the assessment of unbound drug fraction (i.e. free drug) are in the range of 6 – 100 kDa [282], 
whereas the assessment of larger molecules such as proteins require membrane molecular 
weight cut-off values of 100 – 3000 kDa [283]. The dialysis membrane is continuously 
perfused with a suitable physiological solution (perfusate) throughout the experiment. A 
concentration gradient is created between the extracellular fluid in the skin and the perfusate 
which allows for passive diffusion of endogenous and exogenous substances across the 
membrane and into the perfusion medium (microdialysate) [282,284]. Samples of the 
microdialysate can then be collected at specific time intervals and analyzed for the solutes of 
interest.  
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Figure 7.1. Insertion of the MD probe in the skin. 
7.1.1. Recovery and loss 
 
Recovery of a substance partitioning between the perfusate and the surrounding medium of 
the MD membrane depends on the composition of the perfusate and the 
hydrophilic/lipophilic nature of the surrounding medium. The fraction of drug collected in 
the dialysate relative to the surrounding medium of unbound drug is termed “relative 
recovery” (RR) [280] and is calculated using the following equation:  
 
     (equation 7.1) 
 
Initially, the perfusion medium does not contain any drug substances (investigative drug or 
marker, etc.) before being pumped through the MD probe in the skin. The initial 
concentration of the drug in the perfusate is therefore zero, i.e. the value of Cperfusate in 
Equation 7.1 is zero and the equation can be simplified to: 
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      (equation 7.2) 
 
The determination of RR is necessary in order to estimate the true unbound extracellular 
concentration of any drug substance. A low RR of drug could lead to unacceptably long 
sampling periods or the need of a very sensitive analytical assay to quantitatively measure 
very low drug concentrations. MD can be used for collecting a substance in the dialysate or 
to deliver it into the surrounding fluid. The latter MD setup is known as retrodialysis. RR can 
be determined in vitro by both MD and retrodialysis to assess the % of drug lost or gained 
through the membrane [282].  
 
RR can be influenced by the following factors [280,282,285,286]: 
 The physicochemical characteristics of the compound 
 MD instrumentation such as the type of probes, probe material, probe surface area, 
perfusate medium, perfusate flow rate 
 Sampling in biological tissue  in vivo may reduce or increase the transport of drug 
substances across the MD membrane depending on the affinity of the substances for the 
perfusate or for extracellular fluid. 
 Effects of blood flow and metabolism in the tissue, as well as the phenomenon of tissue 
dependent recovery as explained by Ståhle [287] can alter the in vivo recovery of the 
substance.  
 Effect of diffusion and temperature 
 
Most of these factors must be optimized to yield the best possible RR in vitro prior to 
commencing a MD experiment.  
 
However, a main variable associated with in vivo MD of the skin that can not be altered is 
the partition coefficient between tissues and perfusate which is influenced by the 
physicochemical properties of the drug  
 
These properties can influence inter- and intra-individual results.  
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7.1.2. Invasiveness of cutaneous microdialysis 
 
Insertion trauma induced by the introduction of a needle into the skin has been studied and 
found to be variable between species [288,289], type of probe and guide cannula [280]. The 
trauma induced by the implantation of the MD fibre can affect drug recovery and elimination. 
This trauma can cause an increase in blood flow and erythema of the skin at the site of 
needle insertion, as well as histamine release [289-291]. Hence, it is essential for the 
insertion trauma and cutaneous blood flow to stabilize before commencing the MD study. 
Anderson et al. found that the increased blood flow stabilized around 60 min after insertion 
of a probe in humans [290] and histamine levels were normalized after 40 min [277]. The 
use of a local anaesthetic has been shown to reduce the intensity of vascular effects but does 
not alter the time needed for the vascular reaction to return to normal as shown by Groth and 
Serup [289]. Hodges et al [292] investigated the effect of MD needle trauma on cutaneous 
vascular responses in humans with the use of ice or local anaesthesia and has also shown that 
the use of ice/local anaesthesia did not alter the equilibration time. 
 
7.1.3. Drug analysis  
 
The quantitative analysis of drugs in MD samples has always been a challenge. The small 
volume samples collected in MD, often accompanied with low concentration of the drug 
substances of interest, presents a challenge. It is necessary to use a highly sensitive detection 
method with optimal separation technique for these studies. The most commonly used 
separation techniques include liquid chromatography and capillary electrophoresis. 
Ultraviolet, fluorescence, electrochemical and mass spectrometric detection accompanied by 
HPLC have often been utilized to improve the sensitivity and selectivity of the analytical 
method [282,293].  
 
7.1.4. Perfusate composition 
 
The perfusate medium should resemble the tissue/solution surrounding the MD probe as 
much as possible. Hence, the most commonly used perfusate media for MD studies is saline, 
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phosphate buffers and Ringer’s solution [246,294-296]. These perfusates are mostly suitable 
for the study of hydrophilic compounds. However, lipophilic compounds bind to the MD 
membrane material when using hydrophilic perfusates due to the low affinity of these 
compounds for the aqueous perfusion medium [293,297,298]. This in turn leads to a low RR 
of these compounds from the dialysate. The use of lipid emulsions [299-301], or the 
inclusion of albumin [299,302] or cyclodextrins [301,303,304] into the perfusate to prevent 
adhesion of these compounds to the membrane and other MD components have been used to 
improve RR.  
 
7.1.5. Probe depth 
 
Probes are usually inserted over a narrow range of depth in the dermis (0.6 – 1.0 mm) when 
conducting a dermal MD experiment. At the end of the MD experiment, probe depth can be 
measured by a non-invasive technique such as ultra-sound scanning using an instrument, e.g., 
the Dermascan C® (Cortex, Hadsund, Denmark) as shown in Figure 7.2. It is recommended  
that skin thickness and probe depth be measured in three separate scans along the length of 
the probe in situ (i.e. the middle of the probe, and near the entrance and exit points of the 
probe) [281].   
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Figure 7.2.  Cross-sectional scan of the skin showing the position of the MD probe  
7.1.6. Bioequivalence/bioavailability studies 
 
 The MD technique can be used to assess the permeation of topically applied drugs across 
both healthy and diseased or perturbed skin [274,305,306]. MD is therefore potentially a 
useful technique to address the issue of bioequivalence of topically applied formulations. 
Although some researchers have investigated the usefulness of MD as a technique to assess 
the BE of topical formulations [246,294], at present there are no “officially” 
recognized/approved MD methods for BE assessment.  
 
In this chapter, dermal MD was investigated as a possible tool to assess the in vivo BA of a 
topical formulation containing a corticosteroid, CP, and to investigate this method for use in 
BE studies. 
 
 
Probe 
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7.2. IN VITRO MICRODIALYSIS 
7.2.1. Relative recovery study 
7.2.1.1. Experimental  
7.2.1.1.1. Instrumentation 
 
A MD syringe pump system (CMA, model 400, Chromatography Sciences Company, 
Quebec, Canada) was used to perfuse vehicle from 2.5 ml Exmire microsyringes (Aurora 
Borealis Control BV, Schoonebeek, The Netherlands). Blue tubing adapters (CMA MD AB, 
Stockholm, Sweden) were used to connect the syringes to the MD probes. 
 
A custom-designed perspex cell was developed in–house for use in the RR studies. The cell 
(Figure 7.3) comprised of 3 components, i.e. 2 identical inlet and outlet blocks and the main 
block, which is situated in the middle of the cell, and accommodates an enclosed circular 
chamber into which the surrounding medium was filled. Both inlet and outlet blocks had a 
small circular opening in the centre through which the linear MD probe was introduced. The 
inlet and outlet tubes were connected to the main chamber to permit filling and removal of 
the surrounding medium. Four holes were drilled into each block to accommodate the 4 bolts 
which secure the inlet and outlet blocks to the main cell. Leakages were prevented from the 
chamber by positioning rubber o-rings at each end of the circular chamber. The cell was 
placed on top of a shaker (The Chemical Rubber Company, Cleveland, Ohio, USA) during 
the relevant experiments.   
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Figure 7.3.  Cell for in vitro MD studies [307] 
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7.2.1.1.2. Reagents, chemicals and materials 
 
CP was purchased from Symbiotec Pharmalab P.V.T. Ltd. (Pigdamber, Maharastra, India). 
Saline solution was prepared by dissolving 9 g of NaCl (Rochelle Chemicals, Johannesburg, 
South Africa) in one litre of HPLC-grade water (filtered by Milli-Q® system, Millipore Co., 
Bedford, MA, USA) using a 1 L volumetric flask. The NaCl used to make the saline was of 
analytical reagent grade.  
 
One litre of sterile lipid emulsion, IL, consisting of purified soybean oil (200 g), purified egg 
phospholipids (12 g) glycerol anhydrous (22 g), sodium hydroxide (used to adjust the pH of 
the emulsion to 8) and water for injection was purchased from Fresenius Kabi (Midrand, 
South Africa) and used before the expiration date. 
 
Linear MD probes (Figure 7.4) were manufactured in-house no more than 24 hours prior to 
the study. The MD probes were all composed of portex tubing (inner diameter 0.5 mm and 
outer diameter 0.63 mm, Scientific Laboratory Suppliers Ltd, UK, Nottingham), with a 
stainless steel guidewire included (outer diameter 100 µm, Metalann, Belgium, Meslin-I-
‘Eveque) and a dialysis membrane (Haemophan fibre dialysis cartridges, Al wall GFS plus 
12, Gambro, Leuven, Belgium). The membrane’s internal diameter was 210µm with a 
molecular weight cut-off value of 5 kDa. The components of the MD probes were assembled 
with the use of cyanoacrylate glue (Bostik® Ltd, Swindon, England). 
 
 
Figure 7.4.  A linear MD probe [307] 
 
The MD probes were connected to the MD glass microsyringes with blue tubing adapters 
and a CMA 400 precision MD pump was used to deliver the perfusate through the MD 
probes.  
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7.2.1.1.3. Study design 
 
Lipophilic drugs tend to adhere to various components of a MD system [293,297,298], hence 
a retrodialysis experiment was done to determine possible CP interactions with components. 
Standard CP solutions of 1 µg/ml in IL and 3 µg/ml in saline were perfused through the MD 
system with air as the surrounding medium (n = 4).  
 
Standard CP solutions of 3 µg/ml, 1.5 µg/ml, 0.75µg/ml and 0.5µg/ml in saline were used as 
the surrounding medium in the perspex cell, which was mounted on a shaker. IL was used as 
the perfusate (n=4).  
 
A similar experiment was also carried out where the standard solutions were made up in IL 
and used to replace the saline solution as the surrounding medium in the cell at 
concentrations of 1, 30, 50 and 80 µg/ml. 
 
The perfusate (IL) was pumped at a flow rate of 1.0 µL/min. Dialysate samples were 
collected every hour over a period of 5 hours. The samples were collected, extracted from 
the IL and analysed using a validated HPLC system as previously described in section 5.4. 
When saline was used as the perfusate, the dialysate samples were analysed by direct 
injection into the HPLC system without extraction. All the experiments were performed at 
room temperature. 
 
7.2.1.1.4. Data and statistical analysis 
 
RR of CP was analysed and the mean, standard deviation and CV% were determined.  
 
7.2.1.2. Results and discussion 
 
The retrodialysis experiment where a saline solution containing CP (3 µg/ml) was perfused 
through the MD probe with air as the surrounding medium resulted in no drug being found in 
the dialysate over a period of 5 hours (n = 4). This indicated that CP, an extremely  lipophilic 
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drug, adhered aggressively to the MD probe as shown by others [293,297,298]. To overcome 
this adherence by CP to the MD probe, IL with CP was investigated as an alternative 
medium and perfused through the MD probe with air as the surrounding medium. In this 
case 102.6 % of the drug was recovered in the dialysates (%RSD = 2.9; n=4). This clearly 
indicated the preference of CP for IL compared to its affinity for either the membrane or 
other system components such as the tubing, etc.  
 
A MD system similar to Kurosaki et al [300] and Carneheim [299] was constructed where IL 
was the perfusate and the surrounding medium was a solution of CP in saline. The RR was 
found to be in the range of 210.66 – 215.05 % (Table 7.1). The RR is very high because the 
drug has a much higher affinity for the IL emulsion (perfusate) than for the aqueous saline 
solution. This indicated that IL would be a suitable perfusate for use in in vivo MD studies.  
 
Table 7.1  RR of CP using in vitro MD (perfusate = IL, surrounding medium = saline 
solution of CP) 
Concentrations (µg/ml) RR (%) CV (%) 
0.5 209.23 5.96 
0.75 215.06 1.38 
1.5 214.42 3.66 
3.0 210.66 6.73 
 
 
CP recovery using IL (containing 1 µg/ml of CP) as the surrounding medium and perfusing 
with IL (drug-free) did not show the presence of any CP in the dialysate. This was 
presumably due to a relatively low concentration of drug being transported across the 
membrane during the sampling intervals. On the other hand, the average RR of CP using 30, 
50 and 80 µg/ml was ~ 2.05 %, whereas the in vitro retrodialysis study recovered ~ 97.27 % 
of CP (as shown in Table 7.2). Mass balance calculations resulted in 99.32 % indicating the 
suitable solubility of CP in IL and the feasibility of using that medium as a vehicle for MD 
studies. The low recovery from the MD experiments may be due to a slow release of CP 
from the components of IL. The results of this study are similar to those obtained by Rojas et 
al [308] when investigating the RR of triamcinolone acetonide using albumin solution as the 
perfusate. The low RR of triamcinolone was attributed to the drug being highly bound to 
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protein in the perfusate. 
 
Table 7.2.  RR of CP using in vitro retrodialysis and MD where IL was the vehicle for both 
the perfusing and surrounding medium.  
Concentrations (µg/ml) Microdialysis (%) Retrodialysis (%) 
30 2.18 96.80 
50 2.07 97.46 
80 1.90 97.55 
 
7.2.2. Release of CP from commercial formulations 
 
Whereas dissolution testing is a standard technique to assess drug release from solid oral 
dosage forms, various methods have been reported for the assessment of the release of drugs 
from semi-solid dosage forms such as creams, ointments, gels, etc. [309-311]. However, 
with the exception of Chamboko [230] and Mandimika [312], the use of MD to evaluate 
drug release from these formulations has not previously been published.  
 
The use of in vitro MD to assess the release of CP from various commercial formulations 
was investigated in this research project. 
 
7.2.2.1. Experimental 
7.2.2.1.1. Instrumentation 
 
Vide infra section 7.2.1.1.2. In these experiments the perspex cell and shaker were replaced 
with a hollow glass cylinder surrounding the MD membrane. The cylinder had a length of 6 
cm and an internal diameter of 4 mm (as shown in Figure 7.5). The inner opening of the 
cylinder was filled with the formulation. This alternative arrangement facilitated the 
introduction and positioning of the formulation which was not possible using the perspex cell 
due to the viscosity of the CP formulations and the relatively narrow opening in the perspex 
cell. 
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Figure 7.5.  Setup of MD probe in the glass cylinder. 
 
7.2.2.1.2. Reagents, chemicals and materials 
 
IL 20%, a lipid emulsion, was purchased from Fresenius Kabi (Midrand, South Africa) and 
used as the perfusate. The MD probes were constructed in-house as previously mentioned 
above in section 7.2.1.1.2 
 
7.2.2.1.3. Formulations 
 
Dermovate® cream (Glaxo Wellcome, Midrand, South Africa), Dovate® cream (Aspen 
Pharmacare, Port Elizabeth, South Africa) and Dermovate® ointment (Sekpharma, 
Johannesburg, South Africa,) each containing 0.05% CP were purchased from a local 
pharmacy (Wallaces Pharmacy, Grahamstown, South Africa). In vitro release of CP from 
these three formulations was assessed using MD. 
 
7.2.2.1.4. Study design` 
 
The relevant commercial formulation (~0.45g of cream or ointment) was placed into the 
previously described glass cylinders used as a holding cell. The dosage forms comprised the 
surrounding medium around the membrane of the MD probe and IL was used as the 
perfusate. The membrane was thus in contact with the relevant formulation inside the “cell”. 
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The evaluation of the release of CP from each commercial formulation was assessed using 
four replicates (n = 4).  
 
The perfusate was pumped at a flow rate of 1.0 µL/min. Dialysate samples were collected 
hourly over a period of 5 hours. The samples were collected and analysed using a validated 
HPLC system as described in Chapter 5 section 5.4. All experiments were carried out at 
room temperature (22 ± 1 °C) 
 
7.2.2.1.5. Methods used to compare release profile data 
7.2.2.1.5.1. Model-dependent methods 
 
In vitro drug release/dissolution from a pharmaceutical dosage form has been recognized as 
an important element in drug development. When a new dosage form is developed, it is 
important to ensure that drug dissolution/release from the dosage form is appropriate for its 
intended therapeutic use. As a result, drug release from a dosage form can be described by 
various kinetic models which allow for comparison between dissolution profiles between 
products. To investigate the mechanism of drug release from the commercially available 
topical formulations, the release data were analyzed using zero-order kinetic, first-order 
kinetic, and Higuchi models [313]. The various mathematical models and equations that 
describe the release profiles in this study are summarized in Table 7.3.  
 
Table 7.3.  Mathematical representation of models used to describe the release profiles 
from the topical formulations.   
Model Equation 
Zero-order Qt = k0t 
First-order lnQt = lnQ0 – k1t 
Higuchi Qt = kHt1/2 
 
The abovementioned kinetic models were used to assess the release of CP from the various 
dosage forms. The best fit to a relevant equation was identified by evaluating the coefficient 
of determination (R2). The closer the R2 value is to 1, the better the fit.  
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7.2.2.1.5.2. Statistical methods - ANOVA 
 
Statistical methods take into account both the variability and correlation structure of the 
release profile during comparison of products.  
 
The one-way analysis of variance (ANOVA) compares the mean release data at each time 
point. This method takes into account the variability in the profile data and ignores the 
correlation between the time points. It is a risk which may incorrectly conclude that the mean 
profiles are different (where the nominal 5% level for comparison can be higher). This 
problem can be resolved to some extent by employing a Bonferroni-type adjustment to 
ensure that the over-all significance level of comparison remains at the 5% level. 
Comparison may only be statistically significant at some time points and it is difficult to 
conclude whether the mean profiles are actually different. Even though the use of one-way 
ANOVA is straightforward, it is also rather inefficient, tedious to perform and ambiguous in 
interpretation [314]. The one-way ANOVA method with Tukey’s post hoc test was used to 
assess the differences in in vitro drug release from the formulations even though it is not 
recommended due to the limitations mentioned above. Graphpad® prism version 4 was used 
to obtain the ANOVA results. 
 
The alternative to the one-way ANOVA method is the two-way ANOVA model which 
involves the use of formulation and time data as class variables. However, the assumption of 
independence in the ANOVA model is violated because issues with multiple comparisons 
and correlation between dissolution time points arise. Furthermore, the addition of the 
interaction effect between time and formulation variables fitted into the ANOVA model 
makes it difficult to interpret the outcome [314].  
 
7.2.2.1.5.3. Mathematical comparison methods 
 
To determine similarity and dissimilarity between the reference and test formulations, the 
profile data were analysed using the difference factor (f1) and similarity factor (f2)  described 
by Moore and Flanner [315]. These factors are usually used in the case of drug dissolution 
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studies.  
 
The difference factor (f1) measures the percent error between the curves over all time points 
using the following equation:  
f1 = {[Σt=1n |Rt - Tt|]/[Σt=1n Rt]} · 100   (equation 7.3) 
where: 
n 
 
   =  number of sampling points 
Rt    =  percentage dissolved of the reference product at time t 
Tt    = percentage dissolved of the test product at time t 
 
In order to show similarity in the dissolution profiles, the f1 values should be close to 0 and 
lower than 15 (0 - 15). f1 is zero when the test and reference drug release profiles are 
identical and increase proportionally [313].  
 
The similarity factor (f2) can be obtained from the following equation:  
 
f2 = 50 · log {[1 + (1/n) Σt=1n wt(Rt – Tt)2]-0.5 · 100}    (equation 7.4) 
 
where wt is an optional weight factor. The similarity factor value range is 0-100 and when 
the value of f2 is > 50, the test and reference profiles are considered to be similar whereas at 
f2 values < 50, dissimilarity between the profiles increases. This method is only applicable to 
dissolution profiles comparing three or more time points. However, not more than one 
measurement should be used after 85 % release of the active ingredient from both products 
[313]. 
 
The similarity factor (f2) has been adopted by the FDA [316-319] and EMEA [320] as a 
criterion for the assessment of the similarity between two in vitro dissolution profiles of 
immediate release solid oral dosage forms. The equation differs slightly from the one 
proposed by Moore and Flanner in the weight factor as shown below: 
 
f2 = 50 · log {[1 + (1/n) Σt=1n (Rt – Tt)2]-0.5 · 100}    (equation 7.5) 
 
Equations 7.3 and 7.5 were utilized to determine the similarity in drug release profiles of the 
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three topical formulations. 
 
7.2.2.2. Results and discussion 
 
Dissolution testing is extremely useful for the assessment of drug release from a dosage form 
and serves as a prerequisite for understanding the BA of the drug in vivo. It is also used as a 
quality assurance tool during regular production and to meet regulatory requirements before 
marketing the product.[321].  
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Figure 7.6.  Drug release profiles of the three commercially available topical formulations each containing 
0.05% of CP (n=4 for each profile). 
 
The release of CP from the three commercially available topical products (Dermovate® 
cream, Dermovate® ointment and Dovate® cream) are depicted in Figure 7.6. Visual 
comparison of the profiles show that Dovate® cream has a similar release pattern as the 
innovator product Dermovate® cream, whereas the ointment formulation appears to release 
CP quite differently to the cream formulations.  
 
ANOVA results comparing the different formulations are shown in Table 7.4. No differences 
were found in drug release at the different time points between Dovate® cream and 
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Dermovate® cream (p-value > 0 .05). Some differences were found in the release pattern at 
time points 4, 5 and 6 hours when comparing Dermovate® ointment to Dermovate® cream 
(p-value < 0.05). Dermovate® ointment vs. Dovate® cream showed differences at time 3, 4, 5 
and 6 hours. The results indicate that the release of CP from Dermovate® cream is equivalent 
to Dovate® cream, and confirm that the release of CP from the cream formulations are 
different to the ointment formulation after 3 hours.  
 
Table 7.4.  One-way ANOVA results comparing the release profiles of the three 
formulations (T – test product, R – reference product). 
95% Confidence 
Interval 
Comparison 
between 
formulations 
Sampling 
Time 
Mean 
Difference 
P-value 
Lower 
limit 
Upper 
limit 
Summary 
  
1 -0.08855 P > 0.05 -4.776 3.005 Not significant 
2 -1.203 P > 0.05 -4.683 2.277 Not significant 
3 0.8150 P > 0.05 -2.665 4.295 Not significant 
4 -0.9728 P > 0.05 -4.453 2.507 Not significant 
5 0.2995 P > 0.05 -3.180 3.779 Not significant 
Dovate® 
cream (T) 
vs. 
Dermovate® 
cream (R) 
6 0.6908 P > 0.05 -2.789 4.171 Not significant 
1 -1.347 P > 0.05 -4.827 2.133 Not significant 
2 0.3770 P > 0.05 -3.103 3.857 Not significant 
3 3.056 P > 0.05 -0.4240 6.536 Not significant 
4 8.967 P < 0.001 5.487 12.45 Significant 
5 14.97 P < 0.001 11.50 18.45 Significant 
Dermovate® 
ointment (T) 
vs. 
Dermovate® 
cream (R) 
6 20.13 P < 0.001 16.65 23.61 Significant 
1 -2.232 P > 0.05 -5.712 1.247 Not significant 
2 -0.826 P > 0.05 -4.306 2.654 Not significant 
3 3.871 P < 0.05 0.3901 7.350 Significant 
4 7.994 P< 0.001 4.514 11.47 Significant 
5 15.27 P < 0.001 11.79 18.75 Significant 
Dermovate® 
ointment (T) 
vs.   
Dovate® 
cream (R) 
6 20.82 P < 0.001 17.34 24.30 Significant 
 
 
Table 7.5 compares the similarities and release profile data using the various mathematical 
models i.e. a difference factor (f1) and a similarity factor (f2). CP release from Dovate® cream 
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is similar to Dermovate® cream where the f1 value is near zero (4.2) and the f2 value tending 
towards 100 (93.6).When comparing the cream formulation to the ointment formulation, (B) 
and (C), differences in CP release between the two formulations are shown in Table 7.5. It is 
seen that the f1 values indicated a difference between the formulations (f1 >15), whereas the 
f2 values showed dissimilarity in their release profiles (f2 < 50). The use of f2 values are 
recommended since they have been shown to be more sensitive for profile dissimilarity 
compared to differences shown by f1 values [322]. Hence, the f2 results are more reliable 
indicators for drug release profile comparison.  
 
Table 7.5.  Comparison of the release profiles pertaining to the three commercially 
available formulations using difference (f1) and similarity factors (f2) (T = test product, R= 
reference product).  
 Comparison between release profiles f1 value f2 value 
A Dovate® cream (T) vs. Dermovate® cream (R) 4.2 93.6 
B Dermovate® ointment (T) vs. Dermovate® cream (R) 44.2 47.9 
C Dermovate® ointment (T) vs. Dovate® cream (R) 46.0 48.3 
 
 
The release of CP from the cream and ointment bases were assessed by fitting the release 
data with a regression line pertaining to zero-order, first-order, and the Higuchi drug release 
model. As mentioned earlier, the closer the R2 value is to 1 the better the data fits that 
particular model. Table 7.6 depicts the drug release data of all three CP formulations and 
suggests that CP follows zero order drug release kinetics from each of the formulations. 
 
Table 7.6. Comparison of the release kinetics of CP using the various mathematical models.  
 R2-values 
Formulation Zero-order First-order Higuchi 
Dermovate® Cream 0.984 0.937 0.938 
Dermovate® Ointment 0.997 0.958  0.973  
Dovate® Cream 0.985 0.901 0.941 
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The release rates of CP from the cream base formulations were 1.12 µg/cm2.hr and 1.14 
µg/cm2.hr for Dermovate® cream and Dovate® cream, respectively. The release of CP from 
the ointment base was considerably slower at 0.45 µg/cm2.hr.  
 
The comparison between the cream formulations shows that CP release from these two 
commercially available creams is very similar. ANOVA results, difference factors (f1) and 
the similarity factors (f2) between the cream formulations all confirm the similarity between 
the products. The aforementioned comparison parameters also showed significant 
differences in the release of CP from the cream formulations when compared to the ointment 
formulation.   
 
Furthermore, comparison of the release of CP from the three commercial formulations using 
in vitro MD correlated well with the TS study. This indicates that an in-vitro-in-vivo 
correlation (IVIVC) may be possible using in vitro MD to assess release rates from topical 
formulations and to correlate the results with in vivo BA data from TS studies. In vitro MD 
may therefore be a useful tool to assess the release of CP from different formulation bases.  
 
7.3. IN VIVO MICRODIALYSIS 
7.3.1. Experimental 
7.3.1.1. Equipment  
 
The same MD equipment as previously described was used (section 7.2.1.1.1).  
 
PVC custom-made chambers Figure 7.7 were used (3.5 x 2.3 x 2.5 cm) as reservoirs to apply 
liquid preparations containing CP to the skin.   
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Figure 7.7.  PVC custom-made chamber 
 
7.3.1.2. Reagents, chemicals and materials 
 
Ethanol (96 %, v/v)(Merck, Wadeville, South Africa) was used to sterilize the probes and all 
associated surgical equipment used in these in vivo MD studies. IL, a lipid emulsion, was 
used as the perfusate.  
 
Linear MD probes were fabricated in-house as previously described with the exception that 
only 1 side of the membrane was connected with a length of Portex tubing (30 cm).and 
prepared one day prior to the study (see Figure 7.8) .  
 
 
Figure 7.8.  Linear MD probes used for in vivo MD studies [307] 
7.3.1.3. Formulations 
 
CP (Symbiotec Pharmalab P.V.T. Ltd., Pigdamber, Maharastra, India) was dissolved in 
ethanol to achieve 1, 2 and 4 % m/v ethanolic solutions. An extemporaneous 1% m/m 
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Dermovate cream was prepared by incorporating a weighed amount of CP into the 
Dermovate® cream. The cream was assayed prior to use. In addition a 2% m/v solution of CP 
made up in a 50/50 mixture of propylene glycol/ethanol was also prepared. 
7.3.1.4. Subjects 
 
An in vivo MD study using 10 healthy human volunteers (4 males and 6 females, aged 18-26) 
who met the necessary inclusion/exclusion criteria (appendix V) with skin phototype I-III 
[323] was undertaken .Written informed consent was obtained from each volunteer before 
the study. The research with human subjects followed the recommended guidelines as set out 
in the Declaration of Helsinki (1964). The study protocol was approved by the Ethical 
Standards Committee of Rhodes University (Grahamstown, South Africa). 
 
7.3.1.5. Study design 
7.3.1.5.1. In vivo microdialysis method 
 
A total of four sites were used on the arm and one linear MD probe was inserted into each 
site in the skin using a 23G cannula (Crown®, Pretoria, South Africa) as a guide. Entry and 
exit points were marked ensuring that a length of 30 mm of the membrane of the MD probe 
was placed intra-dermally. An ice pack (Medac (Pty) Ltd, Cape Town, South Africa) was 
placed directly on the skin for a few minutes to induce a local anaesthetic effect at the needle 
insertion site and subsequently removed prior to inserting the needle guide. The probes 
which were previously sterilized in ethanol (70% v/v) were inserted through the cannula. 
Once the MD probes were in place, the cannulae were removed. The IL, used as the 
perfusate, was perfused at 1.0 µl/min for approximately 1 hour to allow for equilibration. 
During the equilibration period, the probes were secured in place with an epoxy-based glue 
gel (Super Glue, Genkem®, Johannesburg, South Africa) and custom-made PVC reservoirs 
(Figure 7.7 and step 5 of Figure 7.9) were glued to the application sites on the skin using 
clear adhesive glue (Bostik®, Cape Town, South Africa). The sequences of the procedure are 
shown in Figure 7.9 below. 
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Figure 7.9.  Procedure of in vivo MD setup. 
After the equilibration period, the study was initiated by filling the PVC chambers with ~4 
ml of 4% m/v CP ethanolic solution. IL was perfused through the MD probes at a rate of 1.0 
µl/min. Dialysate samples were collected every 30 minutes for 4 hours. The samples were 
immediately extracted and analysed using a validated HPLC system (section 5.4). 
 
At the end of the sampling period, the probes were detached from the pump but not removed 
from the skin and the excess ethanolic solution along with the PVC reservoirs were carefully 
removed. The skin sites were then gently wiped with alcohol swabs. Prior to the removal of 
   
1) Insertion of needles into the skin 2) Insertion of MD probes through the 
needles 
    
    3) Needles removed         4) Securing MD probes into place 
   
   5) Positioning of sample vials and     6) Initiation of the MD study  
  PVC chambers  
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the MD probes from the skin, the depth of the probes were measured in triplicate by 
ultrasound scanning at 20MHz using the A-mode of the Dermascan C® ultrasound scanner 
(Cortex Technologies, Hadsund, Denmark). The probes were then carefully removed from 
the skin and the sites were gently wiped with alcohol swabs and cotton pads to remove any 
remaining residue. Biocort® cream (1% m/m hydrocortisone acetate, Adcock Ingram Ltd, 
Bryanston, South Africa) was provided to each subject to treat the application sites on the 
arm as a prophylactic measure against post-traumatic skin inflammation. A post-study 
medical follow-up examination of the sites of each subject was performed twice weekly for a 
month. 
 
7.3.1.5.2. Choice of delivery system and CP concentration for topical application 
 
 
Figure 7.10.  Flow diagram of in vivo MD experiments conducted 
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The above experiments (Figure 7.10) were carried out to determine the minimun 
concentration of CP that must be applied to the skin in order for a detectable amount of CP to 
be present in the dialysate. A further objective was to investigate the effect of formulation on 
the penetration of CP into the skin.  Dermovate® cream (0.05%) and the 1% m/m re-enforced 
Dermovate cream, were initially tested by applying sufficient of the respective cream to 
cover the application site (3 cm x 1 cm) and the MD procedure described above was used. 
However, the presence of CP was not found in the dialysate samples following application 
onto either stripped or intact skin.The 1 % and 2 % CP ethanolic solutions were also assessed 
by MD using the PVC chambers filled with ~ 4 ml of respective solution and applied to the 
skin as described previously. Once again, the presence of CP could not be detected in the 
dialysate samples. The concentration of CP was subsequently increased to 4% m/v 
(Formulation E) which resulted in the appearance of CP in the dialysate samples.  
 
As a result of these findings, the 4% m/v CP ethanolic solution was subsequently chosen to 
compare the penetration of CP into the skin following application to tape stripped and also to 
intact skin. Scotch® Magic tape was used to tape strip the relevant application sites until the 
TEWL reached ~60 g/m2hr in order to remove a substantial amount of the SC at the intended 
site of CP application. 
 
A further study using a 2% m/v solution of CP in 50/50 propylene glycol/ethanol applied to 
the skin was undertaken concurrently with the application of a 4% m/v ethnanolic solution of 
CP.  
 
7.3.1.5.3.  Methods to increase detection of CP following MD 
 
Initially, one of the objectives was to assess BE using MD to compare the bioavailability of 
CP from three commercially available dosage forms (Dermovate® cream, Dovate® cream 
and Dermovate® ointment). However, the concentration of CP in these products was too low 
to allow detection of CP release into the skin. The concentration of CP in the dialysate 
following application of the above formulations was below the LOQ (0.5 µg/ml) of the 
HPLC method, this was despite the fact that the same HPLC method was sensitive enough 
for use during the TS studies and also to assay the various formulations and preparations 
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which were investigated. Various approaches to enhance detection of CP following 
application of CP preparations to the skin were considered, such as: 
 
 Increasing the length of the MD membrane under the skin in order to increase the area 
for more uptake of the drug into the perfusate. 
 Introducing two MD probes into one test site to increase the volume of sample 
collected.  
 
7.3.1.5.4. Assessment of the presence of CP reservoirs in the skin using the HSBA 
 
A separate study was performed on three volunteers to determine whether a reservoir 
containing CP exists after application of the 4% m/v ethanolic solution of CP. The objective 
of this study was to investigate whether the very low concentrations of CP following MD 
were due to the formation of reservoirs in the SC. The volunteers were tested for skin 
blanching prior to commencing this study. Dermovate® cream was applied to a small area of 
the forearm of each subject and inspected for blanching 6 hours after application, this was 
used as the inclusion criterion. 
 
Following in vivo MD using the 4% m/v ethanolic solution of CP (Study E), a plastic film 
was wrapped around the volar aspect of the forearm of each subject, covering the application 
sites, This was done12 hours after termination of the MD experiment and was left on for 2 
hours. 
 
7.3.1.5.5. The assessment of the bioavailability of a 4% m/v CP ethanolic solution 
 
Finally, the 4% m/v ethanolic solution was used to assess the BA of CP into the skin using 
MD. The uptake of CP by the skin was assessed on the volar aspect of one forearm in each of 
10 healthy human subjects. Ethanol was chosen because of its pharmaceutical acceptability 
gleaned from its ubiquitous use in pharmaceutical products and also in cosmetic preparations 
[106].  
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7.3.1.6. Statistical analysis 
 
The mean, standard deviation and intra- and inter-individual variability following the in vivo 
MD study using 4% m/v ethanolic solution of CP in 10 subjects, were determined. 
Differences in penetration of CP between subjects, gender and application sites on the 
forearm were assessed using one-way ANOVA and the two-tailed t-test (95% confidence 
interval) where relevant. These two statistical analyses and AUC from 0 – 4 hrs were 
determined using GraphPad® Prism version 4.03. 
 
7.3.2. Results and discussion 
7.3.2.1. Choice of delivery system and CP concentration for topical application  
7.3.2.1.1. Applications A to E  
 
The presence of CP in dialysate samples was not detected in any of the samples following 
the application of any of the following preparations: Dermovate® cream (0.05 %), 1% m/m 
extemporaneously re-enforced Dermovate cream, 1% and 2% m/v CP ethanolic solutions to 
either stripped or intact skin. Although CP may have penetrated the skin following 
application of the various preparations described above, this could not be confirmed using 
the developed HPLC method in view of the lack of sensitivity to detect very low 
concentrations of CP. The HPLC method used has an LOQ of 0.5 µg/ml and coupled with 
the fact that very low sample volumes are collected in the MD samples, it is clear that much 
higher concentrations of CP would need to be applied to the skin in order to detect its 
presence following MD.  
 
It has been shown that partial removal of the SC (tape stripped skin) allows more penetration 
of applied drug into the skin [274], therefore studies using the applications denoted in Figure 
7.10 A, B and E1 were conducted on stripped as well as on intact skin to investigate whether 
the removal of SC will facilitate the detection of CP by enhancing penetration. However, 
partial removal of the SC did not appear to enhance the penetration of CP from any of the 
preparations. Since CP is a lipophilic drug, the removal of the SC will most probably not 
enhance penetration into the hydrophilic epidermis. Similarly, the use of a penetration 
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enhancer, ethanol, alters the SC which essentially also removes the barrier (or some of it) and 
no enhancing effects were seen there as well.. 
 
Approaches to enhance/increase the amount of drug penetration into the skin include the use 
of a penetration enhancer into the formulation or increasing the concentration of drug in the 
formulation [91]. Hence, both approaches were investigated by using increased 
concentrations of CP such as a 1% m/m cream and 1%, 2% and 4% m/v CP ethanolic 
solutions of the corticosteroid and also a 2 % CP preparation containing propylene glycol in 
addition to ethanol as a penetration enhancer. 
 
The 4% m/v CP ethanolic solution was investigated together with the 2% m/v CP solution 
containing both ethanol and propylene glycol in the same human subject. MD was carried 
out as previously described and the results are depicted in Figure 7.11. As can be seen from 
the MD profile below and the associated AUCs, the amount of CP which diffused through 
the skin from the 4% m/v ethanolic solution (AUC = 2.39 µg/ml.hr) was greater which 
diffused into the skin following application of the 2% m/v propylene glycol/ethanol solution 
(AUC = 1.41µg/ml.hr) up to 2 hours. This is in agreement with the hypothesis that suggests 
that increasing the concentration of the active in the preparation will increase the amount of 
drug that diffuses into the the skin [91]. It has also been shown that the use of propylene 
glycol enhances the penetration of corticosteroids into the skin after topical application 
[92,93]. However, in this case, the use of propylene glycol/ethanol solution had a similar 
penetration enhancing effect when compared to using ethanol only.  
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Figure 7.11.  Comparison between the 2% m/v CP in 50/50 PG/EtOH solution and the 4% m/v CP ethanolic 
solution using in vivo MD. 
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7.3.2.2. Methods to increase detection of CP following MD 
 
Although considerations were given to increasing the length of the probes for insertion under 
the skin, due to practical limitations such as using a considerably longer needle as a guide, 
the above was not pursued.  
 
The use of 2 probes inserted into each site was also considered as a method to improve 
detection of CP in the skin following MD. Although the volume collected using 2 probes will 
be twice that of a single probe maintained at the same flow rate, the concentration of CP will 
remain the same. Whereas, a larger dialysate volume would be collected using 2 probes and 
could facilitate and improve the detection limit by pooling and concentrating the combined 
samples, concentrating the IL extract also resulted in an increase in interference from the 
other extracted components in the lipid emulsion (perfusate) and the detection limit was not 
improved. 
 
7.3.2.3. Assessment of the presence of a CP reservoir in the skin using the HSBA 
 
When a plastic film was used to wrap around the volar aspect of the forearm of each subject, 
12 hours after an MD investigation following the application of a 4% m/v CP ethanolic 
solution to the skin for 4 hours, no blanching was seen 2 hours after removal of the occluding 
film. Hence, the presence of a CP reservoir could not be established. Although, 
corticosteroid reservoirs in the skin can be readily seen following occlusion of the 
application sites when semi-solid formulations of the corticosteroid are used [324-327], it 
may be concluded that following application of an ethanolic solution, unlike the application 
of semi-solid formulations, the corticosteroid appears to penetrate beyond the SC. Hence, the 
low recovery of CP in the dialysate is unlikely to be influenced by a reservoir effect. 
 
7.3.2.4. The assessment of the bioavailability of a 4% m/v CP ethanolic solution 
 
Following application of a 4% m/v CP ethanolic solution to the skin of 10 volunteers, 
concentrations of CP were detected in the MD dialysate samples at various times. Figures 
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7.12 and 7.13 below depict the penetration of CP in the forearms of human subjects. After 
the topical application of the solution (t = 0hrs), concentrations of CP, although relatively 
low, were rapidly detected in the dialysate samples. Figure 7.13 illustrates that CP penetrates 
the skin from ethanol at a fairly constant rate. It was interesting to note that soon after (~ 15 
min) applying the 4% m/v ethanolic solution onto the skin sites, the erythemic response from 
the needle insertion trauma faded and the skin began to whiten indicating that skin blanching 
was occurring. This is consistent with the skin blanching response observed following 
application of Dermovate® cream used in the HSBA studies described in Chapter 4. This is a 
clear indication that CP penetrated the skin at a relatively rapid rate from the ethanolic 
solution, although at low concentrations. 
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Figure 7.12.  Penetration profiles of CP into the skin for each subject. 
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Figure 7.13.  Mean concentration of CP penetrated through the skin of 10 subjects 
 
Although a relatively high concentration of CP was applied to the MD sites, the percentage 
of CP recovered from the skin was relatively low. The reasons for this low recovery could be 
due to a number of factors such as protein binding [308], very slow diffusion of the bulk 
amount entering the SC and the exertion of a “barrier” effect within the SC. From Fig 1.12, it 
is seen that the average concentration of CP appears to be quite steady up to 4 hours and in 
some cases even beyond. This supports the appearance of relatively low concentrations of 
CP from the relatively high CP concentration applied as a result of somewhat restricted 
diffusion within the SC  
 
As shown in Table 7.7, the intra-individual variation (CV%) ranged between 10.17 – 
121.65% and the inter-individual variation was found to be 50.56 %. The inter-individual 
AUCs0-4 ranged from 0.74 ± 0.90 µg/ml.hr to 3.30 ± 1.24 µg/ml.hr. It is therefore apparent 
that even within the same subject and using a confined area of the body (volar aspect of the 
forearm) the penetration of CP varies. In spite of this, when the data were statistically 
analysed according to the one-way ANOVA, no significant differences were found when 
comparing the penetration profile of CP between subjects (p-value > 0.05).  
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Table 7.7.  Intra- and inter-individual MD data of 10 subjects 
Subject no. AUC ± SD (µg/ml.hr) CV (%) 
1 2.13 ± 1.52 71.34 
2 1.41 ± 0.14 10.17 
3 2.96 ± 1.64 55.43 
4 3.30 ± 1.24 37.60 
5 2.78 ± 0.37 13.20 
6 1.23 ± 0.29 23.67 
7 1.58 ± 1.62 102.90 
8 0.74 ± 0.90 121.65 
9 1.04 ± 0.94 90.39 
10 0.97 ± 1.07 109.46 
Mean data of 10 subjects 1.81 ± 0.92 50.56 
 
When the data were re-visited, close inspection of the profiles suggested the possibilities of 
“outliers”. For example, the following Table 7.8 lists the resulting data which appear to be 
anomalous and may be considered as “outliers”. 
 
Table 7.8.  “Outliers” data 
Subject no. Site Time (hrs) Concentration (µg/ml) 
1 C 1.5 4.80 
2 - - - 
3 A 3.5 5.83 
4 D 3.0 4.31 
5 A 3.0 2.45 
6 D 4.0 0.51 
7 C 2.5 6.13 
8 D 3.0 3.14 
9 C 3.0 1.30 
10 D 1.0 2.78 
 
The following profile (Figure 7.14) shows the profile obtained after the removal of “outlier” 
data superimposed on the original profile where all data were included. It is therefore 
apparent that the removal of the so-called anomalous data had no significant effect on the 
profile. Furthermore, the variability was only slightly reduced from a CV% of 50.56 to 48.52.  
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Figure 7.14.  Comparison between profiles containing all data and data in which “outliers” were removed. 
 
Figure 7.15 illustrates the penetration of CP into the skin when comparing male and female 
subjects. No differences were observed in the dermal penetration of CP between genders (p-
value = 0.1058)  
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Figure 7.15.  Comparison between male and female mean concentration of CP penetrated through the skin 
However, when the “outliers” were removed as described above, and the profiles (Figure 
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7.16) of mean male vs. mean female without the “outliers” were compared, a significant 
difference was seen with a p-value of 0.0016 using the two-tailed t-test. The corresponding 
profiles are shown below. However, it should be noted that amongst the ten subjects used, 
six were females and four were males. Data removed to obtain the profile below involved a 
single data point removed per subject in 3 of the 4 males, whereas a single data point was 
removed in each of the six females. The resulting data had the effect of lowering the female 
profiles. Processing data in this way is clearly disproportionate and the significance of the 
findings showing differences between male and female subjects is questionable.  
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Figure 7.16.  Comparison between male and female mean concentration of CP penetrated through the skin 
after the removal of “outlier” data. 
 
The following profiles (Figure 7.17) were obtained when comparisons were made between 
sites A to D i.e sites arranged from the elbow to the wrist. No differences were observed (p-
value = 0.8159). Removal of the “outlier” data had no effect on the results (p-value = 
0.1880). 
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Figure 7.17.  Comparison of CP penetration between the four sites. 
 
Figure 7.18 depicts the flux of CP from the extracellular fluid of the skin through the 
membrane of the MD probe into the perfusate. To determine the flux of CP from the 
surrounding medium into the perfusate, the slope of the plot (Figure 7.18 was determined. 
The flux of CP was found to be 0.15 µg/cm2.hr. The permeation coefficient was calculated 
from equation P = J/C0 and found to be 3.68 x 10-6 cm/hr where P is the permeation 
coefficient, J is the flux and C0, the starting concentration which was based on the 
concentration of CP applied at the site. However, CP recovery following MD indicated that 
considerably less than the total amount applied had been collected up to the end of the MD 
sampling time of 4 hours, implying that not all the CP had penetrated through the skin in that 
time. Hence, the value of the permeation coefficient is probably considerably lower than that 
calculated above which is based on complete recovery (i.e. penetration of the entire amount 
of CP applied).    
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Figure 7.18.  Flux of CP through the membrane of the MD probe in vivo. 
 
The depth of each MD membrane was measured using the Dermascan®. The MD probes 
were inserted at a mean depth of 0.692 ± 0.128 mm from the surface of the skin as depicted 
in Table 7.9 below. No correlation between AUCs and probe depth were observed.  
 
Table 7.9.  Probe depth measurement (n = 4 for each subject) 
Subject Mean (mm) SD (mm) CV (%) 
1 0.81 0.051 6.27 
2 0.67 0.034 4.96 
3 0.95 0.17 18.01 
4 0.66 0.12 18.76 
5 0.79 0.040 4.99 
6 0.63 0.046 7.23 
7 0.63 0.066 10.34 
8 0.59 0.098 16.63 
9 0.64 0.038 5.94 
10 0.518 0.024 4.609 
All subjects 0.692 0.128 18.422 
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7.4. CONCLUSIONS 
 
The in vitro retrodialysis experiments indicated that the CP adhered to the MD probe when 
saline was used as the perfusate, but when IL replaced saline as the perfusate, CP was 
completely recovered in the dialysate. Since lipophilic substances are known to have high 
affinity to bind to membranes and other components, the use of IL therefore has the 
additional advantage of overcoming those limitations. Further in vitro experiments to 
investigate CP recovery confirmed that IL was an acceptable perfusate for use in MD studies 
on CP as shown in the mass balance reconciliation calculations. 
 
In vitro MD indicated the potential of this technique for use to assess the release of CP from 
various formulations where it was shown that the release from two cream preparations, 
Dermovate® cream and Dovate® was similar whereas the release from Dermovate® ointment 
was different. These findings corresponded well with those data obtained from the 
previously conducted TS bioequivalence studies, which suggests the possible use of in vitro 
MD as a tool for the assessment of BA/BE of topical products. 
 
Various mathematical models and ANOVA as well as the evaluation of f1 and f2 used in 
dissolution studies were investigated to compare the release profiles from the various 
formulations. ANOVA, f1 and f2 showed their applicability in determining similarities and 
differences in CP release between products. Application of mathematical models to describe 
the release kinetics of CP from the formulations provided useful information on the possible 
release mechanisms. 
 
In vivo MD was used to assess the BA of CP penetration into the skin from various 
preparations. Previous reports have described the use of vivo MD to assess BE of topical 
dosage forms [246,294]. However, one of the important challenges when using in vivo MD is 
the requirement to have a sufficiently sensitive analytical method to quantitatively measure 
extremely low concentrations of the investigative drug. The findings in this research on CP 
penetration into the skin has clearly indicated that BE assessment of CP formulations, whilst 
feasible in the light of the current findings, will be highly dependent on the availability of a 
sufficiently sensitive analytical method to detect and measure concentrations of CP in the 
low ng/ml and even pg/ml ranges. The concentration of current CP formulations are 0.05% 
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and CP released from the commercial formulation, Dermovate® cream, could not be detected 
using MD. However, it was shown that provided the concentration of CP was much higher, 
such as the 4% application used, MD studies would be feasible to assess BE. A further 
challenge is to find a suitable physiologically compatible perfusate in which the investigative 
drug dissolves. The usual perfusates consisting of saline solutions or similar physiologically 
acceptable electrolyte/buffer solutions etc. could not be used due to the insolubility of CP in 
such media. Intralipid®, a lipid emulsion which is used in Total Parenteral Nutrition (TPN) 
and is a sterile preparation which is physiologically acceptable was chosen as the perfusate 
since the solubility of CP was found to be in the order required.  
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8. CHAPTER 8 
8.1. CONCLUDING REMARKS 
 
The HSBA/VCA was once again shown to be a reliable tool for the BA/BE assessment of a 
topical corticosteroid formulation containing CP when either visual or chromametric 
assessment was used. The findings indicated that either of the assessment methods is equally 
suitable for skin blanching assessment. However, for visual assessment, observers must be 
well-trained, and for chromameter assessment, the optimized handling of the instrument 
must be assured. Furthermore, an optimized screening procedure involving the application of 
the reference formulation for 2 dose durations, D1 and D2, was used to screen subjects. 
Profiles from both the D1 and D2 applications were subsequently evaluated to establish 
whether the AUECs of D2/D1 > 1.25 in order to identify potential “detectors”. This screening 
procedure differs from that recommended in the FDA guidance where only a simple 
qualitative response is used to include subjects based on the appearance or non-appearance 
of a blanching response. This a priori identification of potential “detectors” has the 
advantage of using less subjects in the pivotal study and therefore obviates the need to 
unnecessarily include subjects, who in spite of responding in the initial screening, may not 
comply with the inclusion requirements for “detectors”. 
 
The development and validation of an HPLC-UV analytical method for the quantitative 
determination of CP in the various matrices (i.e. from mobile phase and extractions from 
creams, ointment, tape strips and IL samples) was in compliance with the FDA requirements 
as per guidelines. The same analytical method, apart from some minor differences in sample 
preparation, was successfully applied to assess samples obtained from TS studies, in vitro 
and also for the in vivo MD samples. However, a more sensitive analytical method will be 
required for the detection of CP when assessing the BA/BE of commercial CP formulations 
in view of the very low content (0.05 % m/m) of CP in those products. The method 
developed, however, had the necessary sensitivity to detect and monitor the appearance of 
CP by in vivo MD following the application of a 4 % m/v ethanolic solution of the 
corticosteroid. 
 
TS proved to be a useful technique for the assessment of BA/BE of clobetasol propionate 
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products and was shown to have the potential for use to assess other topical products for 
local use apart from only those containing topical corticosteroids. It is recommended that it is 
necessary to conduct a dose-response pilot study in order to establish a relevant 
discriminatory dose duration for the product under investigation for use in a subsequent BE 
assessment. Normalization of skin thickness using TEWL is important and shown to be 
necessary to compare TS data between subjects. Furthermore, to reduce variability of the 
method, several other factors have been identified and described for the optimization of the 
TS procedure. It is also important to use AUCcorr data (correction of TS data using skin 
fraction to normalize SC thickness between subjects) as this was shown to have a significant 
influence and affect the resultant data for BE assessment. The statistical analysis of TS data 
for BE indicated that either log-transformed or untransformed data could be used since 
similar results were obtained using either method.  
 
To date, reports in the literature have described the application of microdialysis for the 
assessment of the BA/BE of topically applied hydrophilic drugs. Furthermore only a few 
reports have been published where MD has been used to monitor lipophilic drugs in 
dialysates, either in vitro or in vivo in animals. Since CP is highly insoluble in aqueous media, 
an alternate perfusate (IL) was investigated for use in the MD investigations. It was found 
that CP could be detected in dialysate samples obtained from healthy human subjects using 
in vivo MD following the application of a 4 % m/v ethanolic CP solution and using IL as 
perfusate. IL proved to be an appropriate perfusate for the recovery of CP with the advantage 
of reducing adsorption/adherence to the membrane and/or other components of the MD 
system.  
 
A novel approach to monitor and assess the in vitro release of CP from commercially 
available topical dosage forms was investigated using MD. Similarities and differences were 
evaluated using a number of mathematical models to establish the respective release 
mechanisms, and the f1 and f2 factors used in the comparison of dissolution profiles were 
applied to the in vitro MD release data comparing the various formulations. The in vitro MD 
results concurred with previously obtained data from the BE studies using TS. This suggests 
that in vitro MD systems may be useful to investigate BA/BE of topical formulations.  
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1. BACKGROUND INFORMATION 
 
1.1 Molecular Structure 
 
The molecular structure of clobetasol 17-propionate is represented below. 
 
 
clobetasol 17-propionate 
 
1.2 Mode of Action and Uses 
 
Clobetasol 17-propionate is a highly potent synthetic corticosteroid that has anti-
inflammatory, antipruritic, and vasoconstrictive properties. Its anti-inflammatory effect is 
thought to be due to its ability to control biosynthesis of potent mediators of inflammation. It 
stimulates phospholipase A(2) inhibitory proteins and subsequently blocks the release of 
arachidonic acid, which is a common precursor to leukotrienes and prostaglandins [1]. 
 
Clobetasol 17-propionate is used in the topical treatment of various skin disorders such as 
eczema, some forms of psoriasis and seborrhoeic dermatitis [2].  
 
1.3 Pharmacokinetics 
 
To achieve a therapeutic effect, it is necessary that the topically applied drug enters the 
epidermis or the dermis of the skin.  Skin penetration and permeation of the drug after topical 
administration depend on the physicochemical properties of the drug molecule, the function 
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of the skin as a transport barrier and the composition of the delivery vehicle [4, 5, 6].  
Topical use particularly under an occlusive dressing or when the skin is broken, systemic 
effects may occur if sufficient clobetasol 17-propionate is absorbed.  Clobetasol 17-
propionate is rapidly distributed to all body tissues.  It can cross the placenta to varying 
degrees and may be excreted in small amounts in breast milk.  The synthetic corticosteroids 
exhibits less extensive protein binding and tend to have longer half-lives when compared to 
the other corticosteroids.  Metabolism of clobetasol 17-propionate occurs in the liver and is 
excreted via the urine and bile [2].   
 
1.4 Adverse Effects 
 
Upon topical application of clobetasol 17-propionate, one may experience burning sensation, 
pruritus and stinging of the skin.  Headache and other irritation symptom(s) may occur [1]. 
 
1.5 Contraindications 
 
Administration should be avoided in persons who exhibit hypersensitivity to clobetasol 17-
propionate or to any ingredient in the preparation or to other corticosteroids.  It is 
contraindicated in the presence of acute dermatological infections e.g. scalp infection [1].   
 
2. STUDY PRODUCTS 
 
2.1 Description 
 
 Reference Product 
Generic Name - 
Commercial Name Dermovate® Cream 
Dosage Form Cream 
Strength 0.05% m/m 
Manufacturer GlaxoWellcome, South Africa 
Batch/Lot No. 255573 
Expiry Date 01/2009 
Description White cream 
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Dosage 30µL (±11mg) per application site 
 
2.2 Supply, Storage and Use 
 
Sufficient products should be timeously supplied to the Biopharmaceutics Research Institute 
prior to study.  Clobetasol 17-propionate is available in cream, ointment or lotion dosage 
forms.  It should be used externally only.  The product should be kept in the container it 
came in, tightly closed and stored at room temperature away from excess heat and moisture 
[3].   
 
3. OBJECTIVES 
 
The objective of this pilot study is to measure the skin blanching efficacy for the 
determination of the dose duration-response relationship of clobetasol 17-propionate.  The 
assessment of the blanching will be done with the use of a chromameter and visually. Data 
from this study is required for the application times in the pivotal bioequivalence study.  This 
study is equivalent to producing a standard curve in the assay.  The outcome of this pilot 
study provides information to determine the parameters of ED50, D1 and D2 that will be used 
in the pivotal study.   
 
The study will be conducted according to the FDA Guidance for Industry: Topical 
Dermatologic Corticosteroids, dated February 1997.   
 
4. STUDY POPULATION AND MEDICAL ASSESSMENT 
 
4.1 Inclusion Criteria 
 
Only the subjects that meet the following criteria will be included in the study: 
 
1. Mentally competent subjects who are available for the entire study period and willing to 
adhere to the protocol requirements and able to give informed consent by signing the 
informed consent form, which is also signed by a witness. 
2. Subjects demonstrating adequate vasoconstriction to topical corticosteroids, i.e. 
‘responders’. 
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3. Male or female between 18 and 50 years of age. 
4. Normal in terms of dermatological medical history at the pre-study screening medical, 
or in the case of an abnormality, the medical practitioner considers the abnormality to 
be clinically insignificant. 
5. Normal in terms of dermatological examination at the pre-study screening medical, or 
in the case of an abnormality, the medical practitioner considers the abnormality to be 
clinically insignificant. 
 
4.2 Exclusion Criteria 
 
Subjects that meet one or more of the following criteria will be excluded from the study: 
 
1. Individuals smoking within one week of study. 
2. Caffeine intake greater than 500mg per day prior to or during the study.  (A cup of 
coffee contains about 85mg of caffeine) 
3. Clinically significant history of alcoholism or drug abuse. 
4. Use of topical dermatologic drug therapy on ventral forearms, including prior dosing of 
topical corticosteroid in pharmacodynamic study to a particular skin site, within one 
month prior to study. 
5. Adverse reactions to topical or systemic corticosteroids. 
6. Any current or past medical condition, including active dermatitis or any other 
dermatologic condition, which might significantly affect pharmacodynamic response to 
the administered drug. 
7. Persons who would require shaving ventral forearms to insure consistent dose on skin 
surface. 
8. Use of any vasoactive (constrictor or dilator) medication, prescription or OTC, that 
could modulate blood flow.  Examples of such drugs include nitroglycerin, 
antihypertensives, antihistamines, NSAID’s, aspirin, and OTC cough/cold products 
containing antihistamines and/or either phenypropanolamine or phentolamine. 
9. Any obvious difference in skin color between arms. 
10. Any mental deficiency or handicap. 
11. Any contact allergy to the label adhesive on labels used to demarcate application sites. 
12. Consumption of alcohol or other enzyme inducing agents within 24 hours of the start of 
the study (all barbiturates, corticosteroids, phenylhydantoins, etc.) 
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13. Participation in natural or artificial sunbathing within 6 weeks of the study start date. 
 
4.3 Subject restrictions 
 
1. No exercise with either arm and no strenuous exercise overall, for study duration. 
2. No bathing or showering during the periods of drug application and assessment of skin 
blanching. 
3. No use of creams, emollients, or similar products on forearms for 24 hours prior to and 
throughout the study. 
4. No alcohol may be taken by subjects from 24 hours prior to product application until 
the last visual assessment has been completed. 
5. No caffeine intake greater than 500mg per day during the study.  (A cup of coffee 
contains about 85mg of caffeine) 
6. No prescription medication and OTC medication (e.g. cold preparations, vitamins, 
natural products used for therapeutic benefits, antacids) will be allowed for at least one 
week prior to the study. 
With the exception of study products no concomitant medication will be taken by 
subjects during the study. 
7. Smoking will not be permitted during the course of the study. 
 
Subjects will be informed of the above restrictions and each subject will be specifically 
questioned on these points prior to product application.  Any deviations from the above 
restrictions which are made known to the investigators either voluntarily or on questioning 
will be recorded on the appropriate case report form.  A decision as to whether the affected 
subject continues with the study will be taken by the study investigators. 
 
4.4 Criteria for Removal from the Study 
 
Any subject may be withdrawn from the study at any time due to the following: 
 
1. Voluntary withdrawal by the subject due to any reason. 
2. Illness or injury during the study if regarded as clinically important by the study 
physician, Principal or Co-investigator. 
3. Any adverse reactions or signs of toxicity if regarded as clinically important by the 
Appendix I 
 
174 
study physician, Principal or Co-investigator. 
4. Failure of the subject to comply with or be uncooperative towards any study 
requirements or restrictions if regarded as clinically important by the study physician, 
Principal or Co-investigator. 
 
5. STUDY PROCEDURE 
 
5.1 Pre- and Post-Study Medical Screening 
 
Pre-study and post-study evaluations will be conducted as listed in the following table: 
 
Note: Pre-study screening will be conducted not more than 14 days prior to start of the 
study.  Post-study follow-up will be conducted within 48 hours of the final blanching 
assessment, termination or withdrawal from the study. 
 
Screening Tests Pre-study Post-study 
Medical History 1 5 
Physical Examination  6 
Dermatological Assessment 2  
Blanching Response 3  
Adhesive sensitivity 4  
 
1. Medical History: Demographic data (date of birth, sex, age), emotional (psychiatric), skin, alcohol 
consumption, smoking habits, dietary habits, medications, allergies, illnesses (hypertension, circulatory 
diseases) and sporting commitments. 
2. Dermatological: General assessment of the skin and any dermatological condition(s) which may 
influence the barrier function of the skin and the impact on the absorption of the clobetasol 17-propionate.  
Assessment of skin colour difference between the two arms which may influence the measurement of the 
blanching efficacy. 
3. Blanching response: Assessment of subject’s ability to blanch after topical application of clobetasol 
17-propionate 0.05% cream. 
4. Adhesive sensitivity: Assessment of subject’s sensitivity to adhesive on application site demarcation 
tape. 
5. Medical History:  Since start of study. 
6. Physical Examination:  Examination of forearms and applications sites. 
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If any study related abnormalities are observed at the post-study medical, appropriate follow-
up action will be taken and re-examination conducted until the abnormality returns to normal 
or until the study physician considers the abnormality to be clinically insignificant. 
 
5.2 Blanching Response and Adhesive Label Sensitivity Screening 
 
Screening for blanching response and adhesion label sensitivity will be conducted no less 
than 24 hours prior to the start of the study.  Volunteers will be assessed on their ability to 
blanch in response to the topical application of the corticosteroid.  They will also be assessed 
on their tolerance to the adhesive on medical tape used to demarcate the application site. 
 
About 11mg of clobetasol 17-propionate cream 0.05% will be applied to a site (11 X 11 mm) 
on the upper arm demarcated by an adhesive label.  Six hours after application, the medical 
tape will be removed slowly and residual cream removed by gently washing with soap and 
water.  Application sites will be assessed for blanching four hours later. 
 
Volunteers who exhibit blanching will be categorized as poor, good or excellent responders 
on the basis of visual observations and will qualify as candidates for the study.  Volunteers 
who do not blanch will not qualify.  The majority of subjects enrolled into the study will be 
good responders and the remaining subjects will be made up of similar numbers of poor and 
excellent responders. 
 
5.3 Check-in and Confinement 
 
Subjects will check-in at the Biopharmaceutics Research Institute (BRI) at 07:00 hours on 
the morning of the study day when they undergo a brief medical examination, inclusion and 
exclusion criteria check and study restriction check. 
 
Subjects accepted into the study will then be prepared for application of the study product.  
Following application, subjects will stay in the BRI clinic for the course of the study.  On the 
last day, the subjects will be allowed to leave the BRI clinic after the first assessment of the 
day and they will be instructed to return at specified times for the rest of the assessments 
until completion of the study.  However, if a subject is experiencing adverse reaction(s) the 
affected subject will need to remain at the BRI until alternative supervision outside the clinic 
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has been arranged. 
 
5.4 Posture and Physical Activity 
 
Subjects will not be restricted with respect to posture during the study.  However, the 
application sites on the ventral forearm will be protected by custom made guards to avoid 
contact with any material or bodily contact, until the subjects are told by the study observers 
that they are permitted to remove them.  Strenuous physical exercise will not be allowed 
particularly on the forearms. 
 
5.5 Food and fluids 
 
Subjects will not be restricted with respect to food and fluid intake except for those listed in 
the restricted terms. 
 
5.6 Subject Monitoring 
 
1. The study physician will be contactable by phone for the duration of the study. 
2. Subjects will be asked open-ended questions about their health at the time of each 
assessment and any adverse reactions will be recorded. 
3. Subjects will be reminded of study restrictions at the time of each assessment. 
 
6. PILOT STUDY 
 
6.1 Study design 
 
1. Dose duration-response study is based solely on the reference product, with 
randomization of dose duration skin sites. 
2. Dose durations of 0.25 to 6 hours will be used for the application of the product onto 
the specified sites. 
3. Untreated control sites on each arm will also be utilised to enable correction of active 
drug skin sites for color changes during the study unrelated to drug exposure. 
4. Chromameter and visual measurement of the pharmacodynamic response to the topical 
corticosteroid will be measured at various time periods. 
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5. A minimum of twelve subjects will be enrolled. 
 
6.2 Method of Application and Removal 
 
The method of a staggered application with synchronized removal of the topical 
corticosteroid will be used.  The product will be applied to skin sites at different times and 
removed simultaneously. 
 
Just prior to the first application time of the product, sufficient eppendorf (0.2ml) pipettes 
will be filled with the product.  The settings (3 on the dial of the eppendorf) for the correct 
amount (11 mg) of the product required for application on each site will be adjusted.  The 
Epperdorf pipettes will be used to ensure that an accurate amount of product is applied to 
each application site for each subject.   
 
Eight application sites will be demarcated on the ventral surface of each forearm using 
adhesive labels with 1.1cm x 1.1cm squares punched out at appropriate intervals (2.5cm).  
The eight application sites will be aligned in a straight line on the ventral-side of the forearm 
from the elbow joint to the wrist.  The product will be applied to the eight sites on each 
forearm according to the appropriate application template (See appendix 1).  The twelve 
subjects will be evenly divided (four subjects per group) and will be allocated a certain 
template per group of subjects.   
 
The product will be applied to the first subject at 08:00 and to subsequent subjects at five 
minutes intervals thereafter.  Approximately 11mg of the product will be applied to each site 
from the preloaded eppendorf pipettes at the start of each appropriate dose durations.  
Individual doses of the product will be spread evenly over the application site using a glass 
rod.  The product will be applied according to the three different application templates to 
ensure that no discernable pattern in blanching can be perceived by observers during the 
course of the study. 
 
Removal of the product will be done by gently washing all the skin sites with soap and water 
then blotting dry with a non-abrasive towel, thereafter allowing the forearm to air-dry for at 
least five minutes prior to assessment 
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6.3 Visual and Chromameter Assessment of Blanching 
 
Skin blanching will be assessed at time 0, 2, 4, 6, 8, 10, 12, 14, 18, 22 and 26 hours after 
product removal.  Time 0 equals time of product removal.  After the removal of the product 
and the adhesive label, the forearms will be air- dried for 5 minutes to allow equilibration 
with the room environment prior to the time zero reading.   
 
Visual assessment of blanching over the whole application site will be based on a subjective 
0 – 4 intensity scale as given below: 
 0 = No discernible blanching  
 1 = Faint blanching 
 2 = Faint – to – moderate blanching 
 3 = Moderate – to – strong blanching 
 4 = Strong – to – intense (maximal) blanching 
 
Each subject will be assessed and assigned a blanching score to each site at each assessment 
time by comparing skin at the site of application with adjacent skin unaffected by blanching.   
 
A mechanically mounted chromameter will be used for the assessment of blanching over the 
whole application site.  The chromameter will be aligned into position directly over and 
covering the application site with the measuring head.  The same orientation of the 
chromameter will be maintained to get accurate readings for each assessment time for each 
site.  Three consecutive readings will be taken on the each site without moving the 
chromameter.  The three readings will be automatically averaged by the chromameter and 
the mean value reported.   
 
Visual and chromameter assessment will be made with the forearm placed horizontally in 
front of the observer with the medial surface facing upwards and illuminated by normal 
fluorescent lighting.  A total of ten assessments, including pre-dose baseline assessment, will 
be made for each subject over the duration of the study. 
 
The exact clock times for assessments will be calculated according to the time of product 
application (see appendix 2).  The actual clock time of assessments will be recorded for each 
subject.  Any deviation from the assessment schedule of more than 10 minutes will be 
Appendix I 
 
179 
reported as a protocol deviation.   
 
6.4 Study Day Activities and Procedures 
 
1. Study sessions will begin at approximately the same time each study day (within one 
hour). 
2. Verification by history of adequate washout of excluded drugs. 
3. The forearm should be free of any dirt or particulate matter before the study, thus it will 
be necessary for the forearms to be clean.  Subjects will be instructed to use soap and 
water to clean their forearms and then blot them dry with non-abrasive towel, not less 
than 2 hours prior to the application of the product.   
4. Eight application sites of identical surface area (1.44 cm2) will be demarcated with an 
adhesive label on the ventral side of each forearm.  The application sites will be spaced 
as close as 2.5cm and will not be closer than 3 – 4cm to the wrist and elbow joint. 
5. The product will be applied to the sites according to the pre-determined application 
templates (see appendix 1) designed for each group of subjects.  The three different 
application templates consist of six dose durations that will be equally divided between 
the two arms i.e. 0.25, 0.5, 1, 2, 4 and 6 hours. 
6. The application templates include two randomly assigned, untreated control sites that 
will be used per arm for the studies based on chromameter readings.  The use of 
untreated control sites will enable the correction of active drug skin sites for any color 
changes during the study unrelated to drug exposure. 
7. Application of the product to the first subject will be at the following times: 08:00, 
10:00, 12:00, 13:00, 13:30, 13:45 and 14:00.  Subsequent subjects will be done at 5 
minute intervals.   
8. A protective, non-occlusive guard will be used for each forearm to cover the application 
sites to prevent smearing or removal of the topical product from the skin sites.   
9. Prior to the measurement of the pharmacodynamic response at the end of the 
application period, the non-occlusive guards, and the adhesive labels, and the remaining 
topical corticosteroid will be removed.  Removal of the product will be done by gently 
washing all the skin sites with soap and water then blotting dry with a non-abrasive 
towel, thereafter allowing the forearm to air-dry for at least five minutes prior to 
assessment at time zero.   
10. Opposite sides of the demarcated application sites and the corresponding sites on the 
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chromameter base will be marked with reference marks to ensure the exact placement 
of the chromameter over the site for successive readings.   
11. The site closest to the wrist will be labeled as site 1 and the site closest to the elbow 
joint will be site 8. 
12. Measurements will be done using the mechanically mounted chromameter and visually 
by the observers, which will start at site 1 to site 8 on the left arm before proceeding to 
the right arm.   
13. Assessment will be done according to the pre-determined assessment times as shown in 
appendix 2.  Assessment will begin for subject 1 at the following times: On day 1 - 
14:05, 16:00, 18:00, 20:00, 22:00, and on day 2 – 09:00, 12:00, 14:00, 16:00.  The 
subsequent subjects will be assessed at 5 minute intervals.   
14. The results of the blanching assessment will be recorded on the forms shown in 
appendix 2 for each subject.   
 
Note: At least one reading scheduled between 5pm and midnight. 
 
6.5 Data Analysis 
 
The chromameter raw data of each skin blanching response vs. time profile will be adjusted 
with the baseline value and the untreated control site at that site.  Adjustment with the 
baseline value will be the difference between the measurement after product removal and the 
baseline measurement for all treated and untreated sites on that arm.  Adjustment with the 
untreated control site will be calculated by taking the treated baseline-adjusted site reading 
and subtracting it from the average of the untreated control site reading on that arm.  The 
area under the effect curve (AUEC) for each baseline-adjusted, untreated control site-
corrected dose duration will be calculated using the trapezoidal rule.   
AUEC vs. dose duration data will be fitted based on the assumption of a nonlinear mixed 
effect model using suitable software.  The pharmacokinetic parameters (ED50, D1 and D2) 
will be obtained from this model.  D1 and D2 (33% and 67% respectively of the maximal 
response) will represent the sensitive portion of the dose duration-response curve.   
 
The AUEC for each vasoconstriction time profile will be calculated using the visual data as 
well.  The dose duration-response data will also be fitted based on the assumption of a 
nonlinear mixed effect model using suitable software, thus ED50, D1 and D2 will also be 
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determined. 
 
From the skin blanching response vs. time profiles, the following pharmacokinetic 
parameters will be derived as described in the FDA Guidance: 
 
1. Emax: The maximum blanching effect observed in a subject’s skin blanching vs. 
time profile following the application of the product. 
2. Tmax: The skin blanching assessment time at which the Emax was attained.  If this 
occurs at more than one time point, it is defined as the first time point with this value 
(hour). 
3. AUEC(0-26): This is the area under the effect curve for time 0 – 24 hours.  This can be 
obtained using the trapezoidal rule. 
4. ED50: Dose duration at which 50% of the maximum effect is obtained. 
5. D1:  The shorter dose duration calibrator i.e. equal approximately 0.5 times ED50. 
6. D2:  The longer dose duration calibrator i.e. equal approximately 2 times ED50. 
 
The study data and summary results will be arranged in the format as depicted in the FDA 
Guidance. 
6.6 Statistical Analysis 
 
The mean, standard deviation and coefficient of variation will be calculated for the following 
data: 
 
1. Skin blanching response at each time point for each dose duration using individual 
means. 
2. Emax, Tmax and AUEC(0 – 26) 
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APPENDIX 1 
Application Template 
 
 
 
TEMPLATE 1 
Subject’s Right Arm Subject’s Left Arm 
 
Proximal 
(elbow) 
 
 
 
 
Distal 
(wrist) 
Ventral 
8 – 0.25 
7 – 0.5 
6 – UT 
5 – 1 
4 – 2 
 3 – UT 
2 – 4 
1 – 6 
Ventral 
8 – 0.25 
7 – 0.5 
6 – UT 
5 – 1 
4 – 2 
 3 – UT 
2 – 4 
1 – 6 
 
Proximal 
(elbow) 
 
 
 
 
Distal 
(wrist) 
 
 
 
 
TEMPLATE 2 
Subject’s Right Arm Subject’s Left Arm 
 
Proximal 
(elbow) 
 
 
 
 
Distal 
(wrist) 
Ventral 
8 – UT 
7 – 2 
6 – 4 
5 – UT 
4 – 6 
 3 – 1 
2 – 0.5 
1 – 0.25 
Ventral 
8 – UT 
7 – 2 
6 – 4 
5 – UT 
4 – 6 
 3 – 1 
2 – 0.5 
1 – 0.25 
 
Proximal 
(elbow) 
 
 
 
 
Distal 
(wrist) 
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TEMPLATE 3 
Subject’s Right Arm Subject’s Left Arm 
 
Proximal 
(elbow) 
 
 
 
 
Distal 
(wrist) 
Ventral 
8 – 2 
7 – 0.5 
6 – 1 
5 – 0.25 
4 – UT 
 3 – 6 
2 – 4 
1 – UT 
Ventral 
8 – 2 
7 – 0.5 
6 – 1 
5 – 0.25 
4 – UT 
 3 – 6 
2 – 4 
1 – UT 
 
Proximal 
(elbow) 
 
 
 
 
Distal 
(wrist) 
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APPENDIX 2 
Product Application Times 
 
APPLICATION TIMES  
 
 
Subject 1:                          Template 1 
Application Times (hours 
before drug removal) 
6 4 2 1 0.5 0.25 Removal 
Clock Time 08:00 10:00 12:00 13:00 13:30 13:45 14:00 
Actual Time        
 
Subject 2:                          Template 2 
Application Times (hours 
before drug removal) 
6 4 2 1 0.5 0.25 Removal 
Clock Time 08:05 10:05 12:05 13:05 13:35 13:50 14:05 
Actual Time        
 
Subject 3:                          Template 3 
Application Times (hours 
before drug removal) 
6 4 2 1 0.5 0.25 Removal 
Clock Time 08:10 10:10 12:10 13:10 13:40 13:55 14:10 
Actual Time        
 
Subject 4:                          Template 1 
Application Times (hours 
before drug removal) 
6 4 2 1 0.5 0.25 Removal 
Clock Time 08:15 10:15 12:15 13:15 13:45 14:00 14:15 
Actual Time        
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Subject 5:                          Template 2 
Application Times (hours 
before drug removal) 
6 4 2 1 0.5 0.25 Removal 
Clock Time 08:20 10:20 12:20 13:20 13:50 14:05 14:20 
Actual Time        
 
Subject 6:                          Template 3 
Application Times (hours 
before drug removal) 
6 4 2 1 0.5 0.25 Removal 
Clock Time 08:25 10:25 12:25 13:25 13:55 14:10 14:25 
Actual Time        
 
Subject 7:                          Template 1 
Application Times (hours 
before drug removal) 
6 4 2 1 0.5 0.25 0 
Clock Time 08:30 10:30 12:30 13:30 14:00 14:15 14:30 
Actual Time        
 
Subject 8:                          Template 2 
Application Times (hours 
before drug removal) 
6 4 2 1 0.5 0.25 0 
Clock Time 08:35 10:35 12:35 13:35 14:05 14:20 14:35 
Actual Time        
 
Subject 9:                                                                                            Template 3 
Application Times (hours 
before drug removal) 
6 4 2 1 0.5 0.25 0 
Clock Time 08:40 10:40 12:40 13:40 14:10 14:25 14:40 
Actual Time        
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Subject 10:                          Template 1 
Application Times (hours 
before drug removal) 
6 4 2 1 0.5 0.25 0 
Clock Time 08:45 10:45 12:45 14:45 14:15 14:30 14:45 
Actual Time        
 
Subject 11:                          Template 2 
Application Times (hours 
before drug removal) 
6 4 2 1 0.5 0.25 0 
Clock Time 08:50 10:50 12:50 14:50 14:20 14:35 14:50 
Actual Time        
 
Subject 12:                          Template 3 
Application Times (hours 
before drug removal) 
6 4 2 1 0.5 0.25 0 
Clock Time 08:55 10:55 12:55 14:55 14:25 14:40 14:55 
Actual Time        
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STUDY PARTICIPATION INFORMED CONSENT FORM 
INFORMED CONSENT 
 
I  ..........................................................................................   born on  ............................. 
Current address ............................................................................................ 
............................................................................................ 
hereby give permission that the formulations stated below be administered to me during the course of this study. 
Reference Product: Dermovate® Cream (Clobetasol 17-Propionate 0.05%)   
My consent is given freely and I realise that it may be withdrawn at any time, without penalty to me. 
I have been fully informed by .................................................................................... regarding the possible 
adverse effects of the drug, procedures to be used in this study and the risks thereof, as detailed in the “Patient 
Information Brochure”. 
 
 I undertake to comply with all the relevant conditions contained in the Patient Information Brochure and 
confirm that I accept any consequences arising as a result of my withholding or misrepresenting any 
information required of me.  I agree to undergo the necessary pre- and post-study medical screenings as 
listed in the Patient Information Brochure. 
 I undertake to inform the supervising medical personnel immediately of any symptoms - expected or 
unexpected - which I might experience. 
 I agree to my medical records being reviewed in the event of an audit, enquiry, monitoring and/or 
inspection on the understanding that my anonymity will be maintained. 
 I have been informed that protocol violation may result in my exclusion from the study and forfeiture of 
the agreed upon remuneration. I acknowledge that instructions relating to my participation in this study 
have been communicated to me both verbally and in writing, and that I understand them. 
 I also declare that I have made the necessary arrangements regarding the attendance of lectures and other 
academic activities. 
 I acknowledge that I will receive R200.00 for full participation in this study and that I will receive a pro-
rated amount if I withdraw from the study before the end.   
 Signing this consent form does not in any way waive my individual legal rights. 
 
Sign  Volunteer ..................................................................... Date: ...............................................  
Sign Witness   ..................................................................... 
Signature of person who conducted Informed Consent Discussion ……………………………………. 
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PATIENT INFORMATION BROCHURE 
 
Protocol No. WL1: A Pilot Dose Duration-Response Study of Clobetasol 17-
Propionate 0.05% Cream in Healthy Volunteers. 
 
Introduction 
 
You have been invited to take part in a research study.  Before you decide whether or not to 
participate, it is important for you to understand why the study is being done and what it will 
involve if you agree to participate. 
 
Please read this document carefully.  It provides information about this study to help you 
decide if you wish to participate.  Discuss it with your friends and relatives if you wish.  
Please feel free to ask for explanations on anything that you do not understand.  You will be 
given as much time as you need to decide on whether you would like to participate or not.   
 
Your participation is completely voluntary.  You do not have to give any reasons for not 
wanting to participate or withdrawing during the study.  If you decide to take part in the 
study, you will be asked to confirm your agreement by signing the consent form.  
 
Purpose of the study 
 
The rate and extent of drug absorption from a drug formulation taken orally can be assessed 
indirectly from blood samples.  However, this can not be applied to topical formulations that 
are meant for local use with no intent of entry into the systemic circulation. 
 
The use of topical corticosteroids results in vasoconstriction which manifests as a change in 
skin colour and can be detected by the eye.  This vasoconstriction is also known as skin 
blanching phenomenon.  Cornell and Stoughton have shown that the intensity of the induced 
blanching is directly proportional to the clinical efficacy of the corticosteroid.  Because this 
method is acceptable (to the FDA) for testing such formulations it forms a basis of 
comparison against other available methods such as tape stripping, suction blister formation 
and microdialysis to mention some.   
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Study Drug – Clobetasol 17-Propionate cream 0.05% 
 
Clobetasol 17-propionate is a highly potent synthetic corticosteroid that has anti-
inflammatory, antipruritic, and vasoconstrictive properties. It is used in the topical treatment 
of various skin conditions such as eczema, some forms of psoriasis and seborrhoeic 
dermatitis.  Clobetasol 17-propionate is indicated for use in short courses for skin conditions 
which do not respond satisfactorily to less active steroids.   
 
Duration of the study 
 
The whole study will last for approximately two days.  You will need to stay within the BRI 
clinic for the first day and night.  On the second day, you will be allowed to leave the clinic 
but must return approximately 10 minutes before the next specified assessment time until 
completion of the study.    
 
Blanching Response Study Procedure 
 
 On the morning of the study you must check into the BRI clinic at 7:00am to undergo a 
brief medical examination, inclusion and exclusion criteria check and study restriction 
check.    You will then be prepared for product application by having adhesive labels 
applied to your forearms.   
 From 7.30 onwards you will have cream applied to small areas of your forearms. This 
cream will be left in contact with the skin for a period of 6 hours. 
 After 6 hours the adhesive labels will be gently removed and your forearms washed 
with soap and water and then dried. 
 Skin blanching will be assessed at the following time intervals: 5 minutes after washing 
and then again at 2, 4, 6, 8, 19, 22, 24 and 26 hours after washing. You will be given a 
timetable of your scheduled assessment times. 
 Assessments will be done visually and by a chromameter.   
 
You are not restricted with regard to food and drink or activities during the study period as 
long as you abide by the study restrictions.  Professional medical assistance (registered 
medical practitioner and/or a registered nurse) will be available throughout the course of the 
study.  Should any new and significant information about the study medication become 
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available during the course of the study, this will be communicated to you. 
 
Side Effects and Contraindications 
 
Upon application of the cream on the skin, you may experience burning sensation, stinging 
of the skin and itching.   
 
Potent corticosteroid creams should only be used for short courses.  Prolonged and intensive 
treatment with the corticosteroid cream may cause local atrophic changes such as stretch 
marks, thinning of the skin, loss of elasticity and blanching effect.  However, these are more 
likely to occur on the face, the use of occlusive dressings e.g. plasters, or where skin folds 
are present.   
 
Administration should be avoided in persons who exhibit allergic responses to clobetasol 17-
propionate or to any ingredient in the preparation or to other corticosteroids.  It is 
contraindicated in the presence of acute dermatological infections e.g. scalp infection.  It is 
also contraindicated in pregnancy.   
 
Subject Inclusion Criteria 
 
6. Mentally competent subjects who are available for the entire study period and willing to 
adhere to the protocol requirements and able to give informed consent by signing the 
informed consent form, which s also signed by a witness. 
7. Subjects demonstrating adequate vasoconstriction to topical corticosteroids, i.e. 
‘responders’. 
8. Male or female between 18 and 50 years of age. 
9. Normal in terms of dermatological medical history at the pre-study screening medical, 
or in the case of an abnormality, the medical practitioner considers the abnormality to 
be clinically insignificant. 
10. Normal in terms of dermatological examination at the pre-study screening medical, or 
in the case of an abnormality, the medical practitioner considers the abnormality to be 
clinically insignificant. 
 
Subject Exclusion Criteria 
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14. Smoking within one week of study. 
15. Caffeine intake greater than 500mg per day prior to or during the study.  (A cup of 
coffee contains about 85mg of caffeine) 
16. Clinically significant history of alcoholism or drug abuse. 
17. Use of topical dermatologic drug therapy on ventral forearms, including prior dosing of 
topical corticosteroid in pharmacodynamic study to a particular skin site, within one 
month prior to study. 
18. Adverse reactions to topical or systemic corticosteroids. 
19. Any current or past medical condition, including active dermatitis or any other 
dermatologic condition, which might significantly affect pharmacodynamic response to 
the administered drug. 
20. Persons who would require shaving ventral forearms to insure consistent dose on skin 
surface. 
21. Use of any vasoactive (constrictor or dilator) medication, prescription or OTC, that 
could modulate blood flow.  Examples of such drugs include nitroglycerin, 
antihypertensives, antihistamines, NSAID’s, aspirin, and OTC cough/cold products 
containing antihistamines and/or either phenypropanolamine or phentolamine. 
22. Any obvious difference in skin color between arms. 
23. Any mental deficiency or handicap. 
24. Any contact allergy to the label adhesive on labels used to demarcate application sites. 
25. Consumption of alcohol or other enzyme inducing agents within 24 hours of the start of 
the study (all barbiturates, corticosteroids, phenylhydantoins, etc.) 
26. Participation in natural or artificial sunbathing within 6 weeks of the study start date. 
 
Restrictions during the study 
 
8. No exercise with either arm and no strenuous exercise overall, for study duration. 
9. No bathing or showering during the periods of drug application and assessment of skin 
blanching. 
10. No use of creams, emollients, or similar products on forearms for 24 hours prior to and 
throughout the study. 
11. No alcohol may be taken by subjects from 24 hours prior to product application until 
the last visual assessment has been completed. 
Appendix I 
 
193 
12. No caffeine intake greater than 500mg per day during the study.  (A cup of coffee 
contains about 85mg of caffeine) 
13. No prescription medication and OTC medication (e.g. cold preparations, vitamins, 
natural products used for therapeutic benefits, antacids) will be allowed for at least one 
week prior to the study. 
With the exception of study products no concomitant medication will be taken by 
subjects during the study. 
14. Smoking will not be permitted during the course of the study. 
 
Criteria for Removal from the Study 
 
5. Voluntary withdrawal by the subject due to any reason. 
6. Illness or injury during the study if regarded as clinically important by the study 
physician, Principal or Co-investigator. 
7. Any adverse reactions or signs of toxicity if regarded as clinically important by the 
study physician, Principal or Co-investigator. 
8. Failure of the subject to comply with or be uncooperative towards any study 
requirements or restrictions if regarded as clinically important by the study physician, 
Principal or Co-investigator. 
 
Remuneration 
 
You will receive a gratuity of R200.00 for full participation in this study.  Payment following 
withdrawal from the study will be calculated on a pro-rated basis. 
 
 
 
For any questions or queries please contact the principal investigating researcher: 
Genevieve Au (BPharm. R.U.) 
Email:  g02a1351@campus.ru.ac.za 
Cell:  072 612 0972 
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1. BACKGROUND INFORMATION 
 
1.1 Molecular Structure 
 
The molecular structure of clobetasol 17-propionate is represented below. 
 
 
clobetasol 17-propionate 
 
1.2 Mode of Action and Uses 
 
Clobetasol 17-propionate is a highly potent synthetic corticosteroid that has anti-
inflammatory, antipruritic, and vasoconstrictive properties. Its anti-inflammatory effect is 
thought to be due to its ability to control biosynthesis of potent mediators of inflammation. It 
stimulates phospholipase A(2) inhibitory proteins and subsequently blocks the release of 
arachidonic acid, which is a common precursor to leukotrienes and prostaglandins [1]. 
 
Clobetasol 17-propionate is used in the topical treatment of various skin disorders such as 
eczema, some forms of psoriasis and seborrhoeic dermatitis [2].  
 
1.3 Pharmacokinetics 
 
To achieve a therapeutic effect, it is necessary that the topically applied drug enters the 
epidermis or the dermis of the skin.  Skin penetration and permeation of the drug after topical 
administration depend on the physicochemical properties of the drug molecule, the function 
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of the skin as a transport barrier and the composition of the delivery vehicle [4, 5, 6].  
Topical use particularly under an occlusive dressing or when the skin is broken, systemic 
effects may occur if sufficient clobetasol 17-propionate is absorbed.  Clobetasol 17-
propionate is rapidly distributed to all body tissues.  It can cross the placenta to varying 
degrees and may be excreted in small amounts in breast milk.  The synthetic corticosteroids 
exhibits less extensive protein binding and tend to have longer half-lives when compared to 
the other corticosteroids.  Metabolism of clobetasol 17-propionate occurs in the liver and is 
excreted via the urine and bile [2].   
 
1.4 Adverse Effects 
 
Upon topical application of clobetasol 17-propionate, one may experience burning sensation, 
pruritus and stinging of the skin.  Headache and other irritation symptom(s) may occur [1]. 
 
1.5 Contraindications 
 
Administration should be avoided in persons who exhibit hypersensitivity to clobetasol 17-
propionate or to any ingredient in the preparation or to other corticosteroids. It is 
contraindicated in the presence of acute dermatological infections e.g. scalp infection [1].   
 
2. STUDY PRODUCTS 
 
2.1 Description 
 
 Test Product Reference Product 
Generic Name Clobetasol 17-Propionate Clobetasol 17-Propionate 
Dosage Form Cream Cream 
Strength 0.05% m/m 0.05% m/m 
In-House Batch # WL2-01 WL2-02 
Expiry Date 01/2009 01/2009 
Description White cream White cream 
Dosage 12µL (±11mg) per 
application site 
12µL (±11mg) per 
application site 
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2.2 Supply, Storage and Use 
 
Sufficient products will be obtained by the investigator at a retail outlet prior to the study.  
Clobetasol 17-propionate is available in cream, ointment or lotion dosage forms.  However, 
only the cream will be utilized in this study.  It should be used externally only.  The product 
should be kept in the container it came in, tightly closed and stored at room temperature 
away from excess heat and moisture [3].   
 
3. OBJECTIVES 
 
The objective of the pivotal study is to measure the skin blanching efficacy to determine the 
in vivo bioequivalence between the test and reference products, and for the comparison of the 
two assessment methods.  The two assessment techniques involve measuring with a 
chromameter or visually by trained individuals.  The data generated from the studies will be 
used to calculate the 90% confidence interval using Locke’s method for the difference 
between the test and reference product.  Furthermore, the data will be used for the 
comparison of the two assessment methods.   
 
The study will be conducted according to the FDA Guidance for Industry: Topical 
Dermatologic Corticosteroids, dated February 1997. 
 
4. STUDY POPULATION AND MEDICAL ASSESSMENT 
 
4.1 Inclusion Criteria 
 
Only the subjects that meet the following criteria will be included in the study: 
 
11. Mentally competent subjects who are available for the entire study period and willing to 
adhere to the protocol requirements and able to give informed consent by signing the 
informed consent form, which is also signed by a witness. 
12. Subjects demonstrating adequate vasoconstriction and qualify as a ‘detector’. 
13. Male or female between 18 and 50 years of age. 
14. Normal in terms of dermatological medical history at the pre-study screening medical, 
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or in the case of an abnormality, the medical practitioner considers the abnormality to 
be clinically insignificant. 
15. Normal in terms of dermatological examination at the pre-study screening medical, or 
in the case of an abnormality, the medical practitioner considers the abnormality to be 
clinically insignificant. 
 
4.2 Exclusion Criteria 
 
Subjects that meet one or more of the following criteria will be excluded from the study: 
 
27. Individuals smoking within one week of study. 
28. Caffeine intake greater than 500mg per day prior to or during the study.  (A cup of 
coffee contains about 85mg of caffeine) 
29. Clinically significant history of alcoholism or drug abuse. 
30. Use of topical dermatologic drug therapy on ventral forearms, including prior dosing of 
topical corticosteroid in pharmacodynamic study to a particular skin site, within one 
month prior to study. 
31. Adverse reactions to topical or systemic corticosteroids. 
32. Any current or past medical condition, including active dermatitis or any other 
dermatologic condition, which might significantly affect pharmacodynamic response to 
the administered drug. 
33. Persons who would require shaving ventral forearms to insure consistent dose on skin 
surface. 
34. Use of any vasoactive (constrictor or dilator) medication, prescription or OTC, that 
could modulate blood flow.  Examples of such drugs include nitroglycerin, 
antihypertensives, antihistamines, NSAID’s, aspirin, and OTC cough/cold products 
containing antihistamines and/or either phenypropanolamine or phentolamine. 
35. Any obvious difference in skin color between arms. 
36. Any mental deficiency or handicap. 
37. Any contact allergy to the label adhesive on labels used to demarcate application sites. 
38. Consumption of alcohol or other enzyme inducing agents within 24 hours of the start of 
the study (all barbiturates, corticosteroids, phenylhydantoins, etc.) 
39. Participation in natural or artificial sunbathing within 6 weeks of the study start date. 
 
Appendix II 
 
201 
4.3 Subject restrictions 
 
15. No exercise with either arm and no strenuous exercise overall, for study duration. 
16. No bathing or showering during the periods of drug application and assessment of skin 
blanching. 
17. No use of creams, emollients, or similar products on forearms for 24 hours prior to and 
throughout the study. 
18. No alcohol may be taken by subjects from 24 hours prior to product application until 
the last visual assessment has been completed. 
19. No caffeine intake greater than 500mg per day during the study.  (A cup of coffee 
contains about 85mg of caffeine) 
20. No prescription medication and OTC medication (e.g. cold preparations, vitamins, 
natural products used for therapeutic benefits, antacids) will be allowed for at least one 
week prior to the study. 
With the exception of study products no concomitant medication will be taken by 
subjects during the study. 
21. Smoking will not be permitted during the course of the study. 
 
Subjects will be informed of the above restrictions and each subject will be specifically 
questioned on these points prior to product application.  Any deviations from the above 
restrictions which are made known to the investigators either voluntarily or on questioning 
will be recorded on the appropriate case report form.  A decision as to whether the affected 
subject continues with the study will be taken by the study investigators. 
 
4.4 Pre- and Post-Study Medical Screening 
 
Pre-study and post-study evaluations will be conducted as listed in the following table: 
 
Note: Pre-study screening will be conducted not more than 14 days prior to start of the 
study.  Post-study follow-up will be conducted within 48 hours of the final blanching 
assessment, termination or withdrawal from the study. 
 
Screening Tests Pre-study Post-study 
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Medical History 1 5 
Physical Examination  6 
Dermatological Assessment 2  
Blanching Response 3  
Adhesive sensitivity 4  
 
1. Medical History: Demographic data (date of birth, sex, age), skin, alcohol consumption, smoking habits, 
dietary habits, medications, allergies, illnesses (hypertension, circulatory diseases) and sporting 
commitments. 
2. Dermatological: General assessment of the skin and any dermatological condition(s) which may 
influence the barrier function of the skin and the impact on the absorption of the clobetasol 17-propionate.  
Assessment of skin colour difference between the two arms which may influence the measurement of the 
blanching efficacy. 
3. Blanching response: Assessment of subject’s ability to blanch after topical application of clobetasol 
17-propionate 0.05% cream to determine if they meet the criteria of being a ‘detector’. 
4. Adhesive sensitivity: Assessment of subject’s sensitivity to adhesive on application site demarcation 
tape. 
5. Medical History:  Since start of study. 
6. Physical Examination:  Examination of forearms and applications sites. 
 
If any study related abnormalities are observed at the post-study medical, appropriate follow-
up action will be taken and re-examination conducted until the abnormality returns to normal 
or until the study physician considers the abnormality to be clinically insignificant. 
 
4.5 Blanching Response and Adhesive Label Sensitivity Screening 
 
Screening for blanching response and adhesion label sensitivity will be conducted no less 
than 24 hours prior to the start of the study.  Volunteers will be assessed on their ability to 
blanch in response to the topical application of the corticosteroid over 24 hours at a 
controlled room temperature of ±22°C.  They will also be assessed on their tolerance to the 
adhesive on medical tape used to demarcate the application site. 
 
The following screening protocol will be utilized for the selection of possible ‘detectors’ for 
the pivotal blanching studies: 
1. The volunteer’s arms shall be washed 1 hour prior to product application. 
2. Application of the reference product will start approximately 7:00am in the morning. 
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3. Two application sites (1.1cm x 1.1cm) on the side of each forearm will be demarcated 
with a label. 
4. The sites will be situated approximately 3cm away from the elbow joint and towards the 
side of the arm.   
5. Baseline reading for each demarcated site and untreated site will be measured by the 
chromameter. 
6. The method of a staggered application with synchronized removal of the topical 
corticosteroid will be used. 
7. 11mg of the reference cream will be applied to the 2 application sites on each forearm. 
8. Two dose durations will be used per arm.  Each site will be assigned one dose duration 
i.e. site 1 will be assigned the dose duration of 18-minutes (D1) and site 2 will be 72-
minutes (D2). 
9. The product will be removed by gentle washing with a mild soap and water, and will 
then be blotted dry gently with a paper towel. 
10. Chromameter and visual assessment will be carried out at 0, 6, 8, 12 and 24 hours after 
product removal on the treated and untreated sites. 
 
Individual dose duration-response will be based on the D2 /D1 ratio of AUEC values of the 
reference product.  The minimum value should be 1.25 in order to qualify as a ‘detector’.   
 
4.6 Criteria for Removal from the Study 
 
Any subject may be withdrawn from the study at any time due to the following: 
 
9. Voluntary withdrawal by the subject due to any reason. 
10. Illness or injury during the study if regarded as clinically important by the study 
physician, Principal or Co-investigator. 
11. Any adverse reactions or signs of toxicity if regarded as clinically important by the 
study physician, Principal or Co-investigator. 
12. Failure of the subject to comply with or be uncooperative towards any study 
requirements or restrictions if regarded as clinically important by the study physician, 
Principal or Co-investigator. 
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5. STUDY PROCEDURE 
 
5.1 Study design 
 
6. The pivotal study is based on the reference product and the test product, with 
randomization of sites. 
7. Dose durations of 18, 36 and 72 minutes will be used for the application of the products 
onto the specified sites. 
8. Untreated control sites on each arm will also be utilised to enable correction of active 
drug skin sites for color changes during the study unrelated to drug exposure. 
9. Chromameter and visual measurement of the pharmacodynamic response to the topical 
corticosteroid will be measured at various time periods. 
10. Room temperature will be controlled to be at ±22°C. 
11. A minimum of sixty ‘detectors’ will be enrolled in groups of 12. 
12. The study will be conducted on each group on different days as recruitment permits. 
 
5.2 Check-in and Confinement 
 
Subjects will check-in at the Biopharmaceutics Research Institute (BRI) clinic at 05:30 hours 
on the morning of the study day when they undergo a brief medical examination, inclusion 
and exclusion criteria check and study restriction check. 
 
Subjects accepted into the study will then be prepared for application of the study product.  
Following application, subjects will stay in the BRI clinic for the first day and night of the 
study.  The final day of the study, the subjects will be allowed to leave the BRI clinic after 
the first assessment of the day and they will be instructed to return at specified times for the 
rest of the assessments until completion of the study.  The duration of the study lasts for 36 
hours.  However, if a subject is experiencing adverse reaction(s) the affected subject will 
need to remain at the BRI clinic until alternative supervision outside the clinic has been 
arranged. 
 
 
 
Appendix II 
 
205 
5.3 Product Application and Removal 
 
The method of a staggered application with synchronized removal of the topical 
corticosteroid will be used i.e. the products will be applied to skin sites at different times and 
removed simultaneously.  Application of the products will be done by trained individuals 
other than the visual assessors and volunteers.   
 
Just prior to the first application time of the product, sufficient eppendorf® (0.2ml) pipettes 
will be filled with the product.  The settings (3 on the dial of the eppendorf®) for the correct 
amount ( 12µL )of the product required for application on each site will be adjusted.  The 
eppendorf® pipettes will be used to ensure that an accurate amount of product is dispensed to 
each application site for each subject.   
 
Eight application sites will be demarcated on the ventral surface of each forearm using 
adhesive labels with 1.1cm x 1.1cm squares punched out at appropriate intervals (2.5cm).  
The eight application sites will be aligned in a straight line on the ventral-side of the forearm 
from the elbow joint to the wrist.  The product will be applied to the sites on each forearm 
according to the selected application template (See appendix 1).  The twelve subjects will be 
evenly divided (three subjects per group) and will be allocated a certain template per group 
of subjects.   
 
The product will be applied to the first subject at 07:00 hours and to subsequent subjects at 
five minutes intervals thereafter.  Approximately 11mg of the product will be applied to each 
site from the preloaded eppendorf pipettes at the start of each appropriate dose durations.  
Individual doses of the product will be spread evenly over the application site using a glass 
rod.  The products will be applied according to the four different application templates to 
ensure that no discernable pattern in blanching can be perceived by observers during the 
course of the study. 
 
Removal of the product will be done by gently washing all the skin sites with soap and water 
then blotting dry with a non-abrasive towel, thereafter allowing the forearm to air-dry for at 
least five minutes prior to assessment 
 
 
Appendix II 
 
206 
5.4 Visual and Chromameter Assessment of Blanching 
 
Skin blanching will be assessed at time 0, 2, 4, 6, 8, 10, 12, 15, 22, 25 and 30 hours after 
product removal.  Time 0 equals time of product removal.  After the removal of the product 
and the adhesive label, the forearms will be air-dried for 5 minutes to allow equilibration 
with the room environment prior to the time zero reading.   
 
Visual assessment of blanching over the whole application site will be based on a subjective 
0 – 4 intensity scale as given below: 
 0 = No discernible blanching  
 1 = Faint blanching 
 2 = Faint – to – moderate blanching 
 3 = Moderate – to – strong blanching 
 4 = Strong – to – intense (maximal) blanching 
 
Each subject will be assessed and assigned a blanching score to each site at each assessment 
time by comparing skin at the site of application with adjacent skin unaffected by blanching.   
 
A patented, mechanically mounted chromameter will be used for the assessment of 
blanching over the whole application site.  The chromameter will be aligned into position 
directly over and covering the application site with the measuring head.  The same 
orientation of the chromameter will be maintained to get accurate readings for each 
assessment time for each site.  Three consecutive readings will be taken on the each site 
without moving the chromameter.  The three readings will be automatically averaged by the 
chromameter and the mean value reported.   
 
Visual and chromameter assessment will be made with the forearm placed horizontally in 
front of the observer with the medial surface facing upwards and illuminated by normal 
fluorescent lighting.  A total of ten assessments, including pre-dose baseline assessment, will 
be made for each subject over the duration of the study. 
 
The exact clock times for assessments will be calculated according to the time of product 
application (see appendix 2).  The actual clock time of assessments will be recorded for each 
subject.  Any deviation from the assessment schedule of more than 10 minutes will be 
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reported as a protocol deviation.   
 
5.5 Study Day Activities and Procedures 
 
15. Study sessions will begin at approximately the same time each study day (within one 
hour). 
16. Verification by history of adequate washout of excluded drugs. 
17. The forearm should be free of any dirt or particulate matter before the study, thus it will 
be necessary for the forearms to be clean.  Subjects will be instructed to use soap and 
water to clean their forearms and then blot them dry with non-abrasive towel, not less 
than 2 hours prior to the application of the product.   
18. Eight application sites of identical surface area (1.21 cm2) will be demarcated with an 
adhesive label on the ventral side of each forearm.  The application sites will be spaced 
as close as 2.5cm and will not be closer than 3 – 4cm to the wrist and elbow joint. 
19. The product will be applied to the sites according to the pre-determined application 
templates (see appendix 1) designed for each group of subjects.   
20. The application templates include two randomly assigned, untreated control sites that 
will be used per arm for the studies based on chromameter readings.  The use of 
untreated control sites will enable the correction of active drug skin sites for any color 
changes during the study unrelated to drug exposure. 
21. Application of the products to the first subject will be at the following times: 07:00, 
07:36, and 07:54.  Subsequent subjects will be done at 5 minute intervals.   
22. A protective, non-occlusive guard will be used for each forearm to cover the application 
sites to prevent smearing or removal of the topical product from the skin sites.   
23. Prior to the measurement of the pharmacodynamic response at the end of the 
application period, the non-occlusive guards, and the adhesive labels, and the remaining 
topical corticosteroid will be removed.  Removal of the product will be done by gently 
washing all the skin sites with soap and water then blotting dry with a non-abrasive 
towel, thereafter allowing the forearm to air-dry for at least five minutes prior to 
assessment at time zero.   
24. Opposite sides of the demarcated application sites and the corresponding sites on the 
chromameter base will be marked with reference marks to ensure the exact placement 
of the chromameter over the site for successive readings.   
25. The site closest to the wrist will be labeled as si
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joint will be site 8. 
26. Measurements will be done using the mechanically mounted chromameter and visually 
by the observers, which will start at site 1 to site 8 on the left arm before proceeding to 
the right arm.   
27. Assessment will be done according to the pre-determined assessment times as shown in 
appendix 2.  Assessment will begin for subject 1 at the following times: On day 1 – 
08:17, 10:17, 12:17, 14:17, 16:17, 18:17, 20:17, 23:17 and on day 2 – 06:17, 09:17, and 
14:17.  The subsequent subjects will be assessed at 5 minute intervals.   
28. The actual time and/or results of the blanching assessment will be recorded on the 
forms shown in appendix 3 for each subject.   
 
Note: At least one reading scheduled between 5pm and midnight. 
 
5.6 Posture and Physical Activity 
 
Subjects will not be restricted with respect to posture during the study.  However, the 
application sites on the ventral forearm will be protected by custom made guards to avoid 
contact with any material or bodily contact, until the subjects are told by the study observers 
that they are permitted to remove them.  Strenuous physical exercise will not be allowed 
particularly on the forearms. 
 
5.7 Food and fluids 
 
Subjects will not be restricted with respect to food and fluid intake except for those listed in 
the restricted terms. 
 
5.8 Subject Monitoring 
 
4. The study physician will be contactable by phone for the duration of the study. 
5. Subjects will be asked open-ended questions about their health at the time of each 
assessment and any adverse reactions will be recorded. 
6. Subjects will be reminded of study restrictions at the time of each assessment. 
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6 Data Analysis 
 
The chromameter raw data of each skin blanching response vs. time profile will be adjusted 
with the baseline value and the untreated control site at that site.  Adjustment with the 
baseline value will be the difference between the measurement after product removal and the 
baseline measurement for all treated and untreated sites on that arm.  Adjustment with the 
untreated control site will be calculated by taking the treated baseline-adjusted site reading 
and subtracting it from the average of the untreated control site reading on that arm.  The 
area under the effect curve (AUEC) for each baseline-adjusted, untreated control site-
corrected dose duration will be calculated using the trapezoidal rule.  AUEC vs. dose 
duration data will be fitted based on the assumption of a nonlinear mixed effect model using 
suitable software.   
 
Only the data of the “detectors” i.e. subjects whose AUEC values at D1 and D2 are both 
negative and meet the dose duration-response criterion below, will be included in the data 
analysis.  The dose duration-response criterion is: 
 
AUEC at D2 / AUEC at D1 ≥ 1.25 
Where: 
AUEC at D2 = 0.5 [AUEC at D2 (left arm) + AUEC at D2 (right arm)]; 
AUEC at D1 = 0.5 [AUEC at D1 (left arm) + AUEC at D1 (right arm)]; 
 
The bioequivalence comparison should be based on the AUEC values generated from the 
values obtained at the different assessment times.  These values should be computed 
according to the dose duration corresponding approximately to ED50 of the test and reference 
product.   
 
7 Statistical Analysis 
 
The 90% confidence interval will be calculated to determine the bioequivalence between the 
test and reference product.  The 90% confidence interval will be calculated for the ratio of 
the average AUEC response of the test product (average of four replicates) to the average 
AUEC response of the reference product (average of four replicates) using Locke’s method.  
The data used to calculate the confidence interval requires the average AUEC values of the 
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detectors only.  In addition, the data will be plotted to produce a graph of response vs. time to 
illustrate whether visual assessment is comparable to chromameter assessment.   
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APPENDIX 1 
APPLICATION TEMPLATES 
 
TEMPLATE 1 
 
ANTECUBITAL FOSSA 
Right Arm Left Arm 
site no. treatment type site no. treatment type 
8 D1 8 D2 
7 T 7 R 
6 UNT 6 UNT 
5 R 5 T 
4 UNT 4 UNT 
3 T 3 R 
2 D2 2 D1 
1 R 1 T 
WRIST 
 
 
TEMPLATE 2 
 
ANTECUBITAL FOSSA 
Right Arm Left Arm 
site no. treatment type site no. treatment type 
8 UNT
 
8 UNT 
7 R 7 T 
6 D2 6 D1 
5 T 5 R 
4 R 4 T 
3 D1 3 D2 
2 T 2 R 
1 UNT 1 UNT 
WRIST 
 
 
TEMPLATE 3 
 
ANTECUBITAL FOSSA 
Right Arm Left Arm 
site no. treatment type site no. treatment type 
8 T 8 R 
7 D1 7 D2 
6 R 6 T 
5 UNT 5 UNT 
4 D2 4 D1 
3 T 3 R 
2 UNT 2 UNT 
1 R 1 T 
WRIST 
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TEMPLATE 4 
 
ANTECUBITAL FOSSA 
Right Arm Left Arm 
site no. treatment type site no. treatment type 
8 R 8 T 
7 UNT 7 UNT 
6 T 6 R 
5 D2 5 D1 
4 UNT 4 UNT 
3 R 3 T 
2 T 2 R 
1 D1 1 D2 
WRIST 
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APPENDIX 2 
 
PRODUCT APPLICATION AND REMOVAL SCHEDULE 
      
  
Reference 
Product 
Reference 
Product 
Test  
Product 
Reference 
Product 
 
Subject no. D2 ED50 ED50 D1 Wash Off 
1 7:00 7:36 7:36 7:54 8:12 
2 7:05 7:41 7:41 7:59 8:17 
3 7:10 7:46 7:46 8:04 8:22 
4 7:15 7:51 7:51 8:09 8:27 
5 7:20 7:56 7:56 8:14 8:32 
6 7:25 8:01 8:01 8:19 8:37 
7 7:30 8:06 8:06 8:24 8:42 
8 7:35 8:11 8:11 8:29 8:47 
9 7:40 8:16 8:16 8:34 8:52 
10 7:45 8:21 8:21 8:39 8:57 
11 7:50 8:26 8:26 8:44 9:02 
12 7:55 8:31 8:31 8:49 9:07 
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APPENDIX 3 
 
 
ASSESSMENT TIMES AND ACTUAL TIMES 
Subject Day 1 
no. 
Clock 
Time 
Actual 
Time 
Clock 
Time 
Actual 
Time 
Clock 
Time 
Actual 
Time 
Clock 
Time 
Actual 
Time 
Clock 
Time 
Actual 
Time 
Clock 
Time 
Actual 
Time 
Clock 
Time 
Actual 
Time 
Clock 
Time 
Actual 
Time 
1 08:17   10:17   12:17   14:17   16:17   18:17   20:17   23:17   
2 08:22   10:22   12:22   14:22   16:22   18:22   20:22   23:22   
3 08:27   10:27   12:27   14:27   16:27   18:27   20:27   23:27   
4 08:32   10:32   12:32   14:32   16:32   18:32   20:32   23:32   
5 08:37   10:37   12:37   14:37   16:37   18:37   20:37   23:37   
6 08:42   10:42   12:42   14:42   16:42   18:42   20:42   23:42   
7 08:47   10:47   12:47   14:47   16:47   18:47   20:47   23:47   
8 08:52   10:52   12:52   14:52   16:52   18:52   20:52   23:52   
9 08:57   10:57   12:57   14:57   16:57   18:57   20:57   23:57   
10 09:02   11:02   13:02   15:02   17:02   19:02   21:02   00:02   
11 09:07   11:07   13:07   15:07   17:07   19:07   21:07   00:07   
12 09:12   11:12   13:12   15:12   17:12   19:12   21:12   00:12   
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ASSESSMENT TIMES AND ACTUAL 
TIMES 
Subject Day 2 
no. 
Clock 
Time 
Actual 
Time 
Clock 
Time 
Actual 
Time 
Clock 
Time 
Actual 
Time 
1 06:17   09:17   14:17   
2 06:22   09:22   14:22   
3 06:27   09:27   14:27   
4 06:32   09:32   14:32   
5 06:37   09:37   14:37   
6 06:42   09:42   14:42   
7 06:47   09:47   14:47   
8 06:52   09:52   14:52   
9 06:57   09:57   14:57   
10 07:02   10:02   15:02   
11 07:07   10:07   15:07   
12 07:12   10:12   15:12   
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STUDY PARTICIPATION INFORMED CONSENT FORM 
A DOUBLE-BLIND SKIN BLANCHING PIVOTAL STUDY OF CLOBETASOL 17-
PROPIONATE 0.05% CREAM IN HEALTHY VOLUNTEERS 
Study no. WL2 Protocol version  2 
 
 
INFORMED CONSENT 
I  ..........................................................................................   born on  ............................. 
Current address ............................................................................................ 
............................................................................................ 
hereby give permission that corticosteroid formulations, containing 0.05% of the active ingredient clobetasol 
propionate, be administered to me during the course of this study. 
My consent is given freely and I realise that it may be withdrawn at any time, without penalty to me. 
I have been fully informed by .................................................................................... regarding the possible 
adverse effects of the drug, procedures to be used in this study and the risks thereof, as detailed in the “Patient 
Information Brochure”. 
 
 I undertake to comply with all the relevant conditions contained in the Patient Information Brochure and 
confirm that I accept any consequences arising as a result of my withholding or misrepresenting any 
information required of me.  I agree to undergo the necessary pre- and post-study medical screenings as 
listed in the Patient Information Brochure. 
 I undertake to inform the supervising medical personnel immediately of any symptoms - expected or 
unexpected - which I might experience. 
 I agree to my medical records being reviewed in the event of an audit, enquiry, monitoring and/or 
inspection on the understanding that my anonymity will be maintained. 
 I have been informed that protocol violation may result in my exclusion from the study and forfeiture of 
the agreed upon remuneration. I acknowledge that instructions relating to my participation in this study 
have been communicated to me both verbally and in writing, and that I understand them. 
 I also declare that I have made the necessary arrangements regarding the attendance of lectures and other 
academic activities. 
 I acknowledge that I will receive R200.00 for full participation in this study and that I will receive a pro-
rated amount if I withdraw from the study before the end.   
 Signing this consent form does not in any way waive my individual legal rights. 
 
Sign  Volunteer ..................................................................... Date: ...............................................  
Sign Witness   ..................................................................... 
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PATIENT INFORMATION BROCHURE 
A Double-Blind Pivotal Study of Clobetasol 17-Propionate 0.05% Cream in Healthy Volunteers. 
Study No. WL2           protocol version 2 
 
Introduction 
 
You have been invited to take part in a research study.  Before you decide whether or not to 
participate, it is important for you to understand why the study is being done and what it will 
involve if you agree to participate. 
 
Please read this document carefully.  It provides information about this study to help you 
decide if you wish to participate.  Discuss it with your friends and relatives if you wish.  
Please feel free to ask for explanations on anything that you do not understand.  You will be 
given as much time as you need to decide on whether you would like to participate or not.   
 
Your participation is completely voluntary.  You do not have to give any reasons for not 
wanting to participate or withdrawing during the study.  If you decide to take part in the 
study, you will be asked to confirm your agreement by signing the consent form.  
 
Purpose of the study 
 
The rate and extent of drug absorption from a drug formulation taken orally can be assessed 
indirectly from blood samples.  However, this can not be applied to topical formulations that 
are meant for local use with no intent of entry into the systemic circulation.   
 
The purpose of this study is to determine the in vivo bioequivalence of two formulations 
containing 0.05% clobetasol 17-propionate by measuring the skin blanching response and 
comparing the two assessment methods (visually and with a chromameter).  The use of 
topical corticosteroids results in vasoconstriction which manifests as a change in skin colour 
and can be detected by the eye.  This vasoconstriction is also known as skin blanching 
phenomenon.  Cornell and Stoughton have shown that the intensity of the induced blanching 
is directly proportional to the clinical efficacy of the corticosteroid.  Because this method is 
acceptable (to the FDA) for testing such formulations it forms a basis of comparison against 
other available methods such as tape stripping, suction blister formation and microdialysis to 
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mention some.    
 
Study Drug – Clobetasol 17-Propionate cream 0.05% 
 
Clobetasol 17-propionate is a highly potent synthetic corticosteroid that has anti-
inflammatory, antipruritic, and vasoconstrictive properties. It is used in the topical treatment 
of various skin conditions such as eczema, some forms of psoriasis and seborrhoeic 
dermatitis.  Clobetasol 17-propionate is indicated for use in short courses for skin conditions 
which do not respond satisfactorily to less active steroids.   
 
Duration of the study 
 
The whole study will last for approximately two days.  You will need to stay within the BRI 
clinic for the first day and night.  On the second day, you will be allowed to leave the clinic 
but must return approximately 10 minutes before the next specified assessment time until 
completion of the study.    
 
Blanching Response Study Procedure 
 
 On the morning of the study you must check into the BRI clinic at 6:00am to undergo a 
brief medical examination, inclusion and exclusion criteria check and study restriction 
check.    You will then be prepared for product application by having adhesive labels 
applied to your forearms.   
 From 7:00am onwards you will have cream applied to small areas of your forearms. 
This cream will be left in contact with the skin for a certain period of time. 
 After 72-minutes the adhesive labels will be gently removed and your forearms washed 
with a mild soap and water and then dried. 
 Skin blanching will be assessed at the following time intervals: 5 minutes after washing 
and then again at 2, 4, 6, 8, 10, 12, 15, 21, 26 and 32 hours after removal of the creams. 
You will be given a timetable of your scheduled assessment times. 
 Assessments will be done visually and by a chromameter.   
 
You are not restricted with regard to food and drink or activities during the study period as 
long as you abide by the study restrictions.  Professional medical assistance (registered 
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medical practitioner and/or a registered nurse) will be available throughout the course of the 
study.  Should any new and significant information about the study medication become 
available during the course of the study, this will be communicated to you. 
 
Side Effects and Contraindications 
 
Upon application of the cream on the skin, you may experience burning sensation, stinging 
of the skin and itching.   
 
Potent corticosteroid creams should only be used for short courses.  Prolonged and intensive 
treatment with the corticosteroid cream may cause local atrophic changes such as stretch 
marks, thinning of the skin, loss of elasticity and blanching effect.  However, these are more 
likely to occur on the face, the use of occlusive dressings e.g. plasters, or where skin folds 
are present.   
 
Administration should be avoided in persons who exhibit allergic responses to clobetasol 17-
propionate or to any ingredient in the preparation or to other corticosteroids.  It is 
contraindicated in the presence of acute dermatological infections e.g. scalp infection.  It is 
also contraindicated in pregnancy.   
 
Subject Inclusion Criteria 
 
16. Mentally competent subjects who are available for the entire study period and willing to 
adhere to the protocol requirements and able to give informed consent by signing the 
informed consent form, which s also signed by a witness. 
17. Subjects must be able to demonstrate adequate vasoconstriction to the topical 
corticosteroids and meet the criteria to be a ‘detector’. 
18. Male or female between 18 and 50 years of age. 
19. Normal in terms of dermatological medical history at the pre-study screening medical, 
or in the case of an abnormality, the medical practitioner considers the abnormality to 
be clinically insignificant. 
20. Normal in terms of dermatological examination at the pre-study screening medical, or 
in the case of an abnormality, the medical practitioner considers the abnormality to be 
clinically insignificant. 
Appendix II 
 
220 
 
Subject Exclusion Criteria 
 
40. Smoking within one week of study. 
41. Caffeine intake greater than 500mg per day prior to or during the study.  (A cup of 
coffee contains about 85mg of caffeine) 
42. Clinically significant history of alcoholism or drug abuse. 
43. Use of topical dermatologic drug therapy on ventral forearms, including prior dosing of 
topical corticosteroid in pharmacodynamic study to a particular skin site, within one 
month prior to study. 
44. Adverse reactions to topical or systemic corticosteroids. 
45. Any current or past medical condition, including active dermatitis or any other 
dermatologic condition, which might significantly affect pharmacodynamic response to 
the administered drug. 
46. Persons who would require shaving ventral forearms to insure consistent dose on skin 
surface. 
47. Use of any vasoactive (constrictor or dilator) medication, prescription or OTC, that 
could modulate blood flow.  Examples of such drugs include nitroglycerin, 
antihypertensives, antihistamines, NSAID’s, aspirin, and OTC cough/cold products 
containing antihistamines and/or either phenypropanolamine or phentolamine. 
48. Any obvious difference in skin color between arms. 
49. Any mental deficiency or handicap. 
50. Any contact allergy to the label adhesive on labels used to demarcate application sites. 
51. Consumption of alcohol or other enzyme inducing agents within 24 hours of the start of 
the study (all barbiturates, corticosteroids, phenylhydantoins, etc.) 
52. Participation in natural or artificial sunbathing within 6 weeks of the study start date. 
 
Restrictions during the study 
 
22. No exercise with either arm and no strenuous exercise overall, for study duration. 
23. No bathing or showering during the periods of drug application and assessment of skin 
blanching. 
24. No use of creams, emollients, or similar products on forearms for 24 hours prior to and 
throughout the study. 
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25. No alcohol may be taken by subjects from 24 hours prior to product application until 
the last visual assessment has been completed. 
26. No caffeine intake greater than 500mg per day during the study.  (A cup of coffee 
contains about 85mg of caffeine) 
27. No prescription medication and OTC medication (e.g. cold preparations, vitamins, 
natural products used for therapeutic benefits, antacids) will be allowed for at least one 
week prior to the study. 
With the exception of study products no concomitant medication will be taken by 
subjects during the study. 
28. Smoking will not be permitted during the course of the study. 
 
Criteria for Removal from the Study 
 
13. Voluntary withdrawal by the subject due to any reason. 
14. Illness or injury during the study if regarded as clinically important by the study 
physician, Principal or Co-investigator. 
15. Any adverse reactions or signs of toxicity if regarded as clinically important by the 
study physician, Principal or Co-investigator. 
16. Failure of the subject to comply with or be uncooperative towards any study 
requirements or restrictions if regarded as clinically important by the study physician, 
Principal or Co-investigator. 
 
Remuneration 
 
You will receive a gratuity of R200.00 for full participation in this study.  Payment following 
withdrawal from the study will be calculated on a pro-rated basis. 
 
 
 
For any questions or queries please contact the principal investigating researcher: 
Genevieve Au (BPharm. R.U.) 
Email:  g02a1351@campus.ru.ac.za 
Cell:  072 612 0972 
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ADVERTISMISEMENT 
 “LADIES and GENTLEMEN” 
CLINICAL STUDY VOLUNTEERS 
The Biopharmaceutics Research Group is looking for 
HEALTHY FEMALE and MALE VOLUNTEERS 
to participate in clinical studies on medicated creams applied to the skin. 
If You 
1. Are Healthy, and Over 18 Years of Age 
2. Respond positively to a simple test to see if your skin 
temporarily pales on the application of a medicated 
(corticosteroid) cream to a small area on your arm. 
 
Then You May Be Eligible to Participate 
You Will Be Remunerated For Participating 
 
If You Are Interested Please Contact Genevieve as soon as 
possible for More Information 
  Preferably by E-mail at: g02a1351@campus.ru.ac.za  
      Or  by Phone at: 046 -6038189 (work) 
                                  
This advert has been approved by the Rhodes University Ethical Standards Committee 
Please take a tear-off slip below 
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MASS BALANCE OF TS STUDY DATA 
 
Please refer to the data included in the attached CD 
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RESEARCH PROTOCOL 
 
APPLICATION OF TAPE STRIPPING FOR THE ASSESSMENT OF THE 
BIOAVAILABILITY OF CLOBETASOL PROPIONATE IN HEALTHY 
VOLUNTEERS 
 
STUDY NUMBER: WL_TS1 
PROTOCOL VERSION 1 
NOVEMBER 2007 
Reference product Dermovate® Cream 
(Clobetasol propionate 0.05% m/m) 
Glaxo Wellcome 
South Africa 
Test products Dovate® Cream 
(Clobetasol propionate 0.05% m/m) 
Aspen Pharmacare 
South Africa 
 Dermovate® Ointment 
(Clobetasol propionate 0.05% m/m) 
Sekpharma 
South Africa 
Principal Investigator Wai Ling Au 
BPharm  (Rhodes) 
Biopharmaceutics Research Group (BRG) 
Faculty of Pharmacy 
Rhodes University 
Grahamstown 6140 
South Africa 
 
 
Supervisor Professor Isadore Kanfer 
BSc (Pharm), BSc (Hons), PhD (Rhodes) 
Rhodes University 
Grahamstown, 6140 
South Africa 
 
 
 Appendix IV 
 
227 
 APPROVAL OF PROTOCOL 
 
  
Study number WL_TS1 
  
Study title Application of tape stripping for the assessment of the bioavailability of 
clobetasol propionate in healthy volunteers 
Reference 
product 
Dermovate® Cream 
(Clobetasol propionate 0.05% m/m) 
Glaxo Wellcome, South Africa 
 
 
Test product Dovate® Cream 
(Clobetasol propionate 0.05% m/m) 
Aspen Pharmacare, South Africa 
 Dermovate® Ointment 
(Clobetasol propionate 0.05% m/m) 
Sekpharma, South Africa 
 
 
 
__________________________ ___________________________ 
Principal Investigator 
Wai Ling Au 
BPharm (Rhodes) 
Date (yyyy-mm-dd) 
  
  
__________________________ ___________________________ 
Supervisor 
Professor Isadore Kanfer 
BSc (Pharm), BSc (Hons), PhD (Rhodes) 
Date (yyyy-mm-dd) 
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INVESTIGATORS AND FACILITIES 
 
   
Position Name and qualifications Contact address 
   
Principal Investigator/ 
Study site/Statistics/ 
Final report 
 
Wai Ling Au 
BPharm (Rhodes) 
Rhodes University 
Faculty of Pharmacy 
Biopharmaceutics Research Group 
PO Box 94 
Grahamstown 6140 
South Africa 
Tel:. +27 (0) 72 612 0972 
Fax:. +27 (0) 46 636 1205 
Email:. g02a1351@campus.ru.ac.za 
   
Supervisor Professor Isadore Kanfer 
BSc (Pharm), BSc (Hons), PhD 
(Rhodes) 
Rhodes University 
Faculty of Pharmacy 
Dean and Head of Pharmaceutics 
PO Box 94 
Grahamstown 6140 
South Africa 
Tel:. +27 (0) 46 603 8381 
Fax:. +27 (0) 46 636 1205 
Email:. i.kanfer@ru.ac.za 
   
Study nurse Sr. Kay Wentworth 
BCur (UPE) 
Rhodes University 
Biopharmaceutics Research Institute 
PO Box 94 
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1 BACKGROUND INFORMATION 
1.1 Clobetasol propionate 
1.1.1 Molecular structure 
Clobetasol propionate is a synthetic corticosteroid that has a molecular weight of 467.0g/mol.  The molecular 
structure of clobetasol propionate is represented below.  The empirical formula for clobetasol propionate is 
C25H32ClFO5 [1]. 
 
 
Fig. 1 Chemical structure of clobetasol propionate 
 
1.1.2 Mode of action and uses 
The mode of action of corticosteroids is still not clear, however there are a few postulations on their anti-
inflammatory activities.  One hypothesis that has been widely accepted proposed that the inflammatory 
process results from the release of hydrolytic enzymes of the lysosomes and that the glucocorticoids stabilize 
lysosomal membranes, preventing the rupture of the organelles with the accompanying effect of release of 
hydrolytic enzymes and consequent development of inflammation [2,3].  It has been investigated in view of 
the fact that prostaglandins have been recovered from several types of inflammatory reactions and are 
capable of mediating most of the components of inflammation, the possibility arises that corticosteroids may 
owe their anti-inflammatory activity to part of the inhibition of prostaglandin biosynthesis process [4].    
There are suggestions that corticosteroids inhibit the release of prostaglandin by preventing the transport of 
prostaglandin from inside the fat cell to the extracellular space where it would normally act on the blood 
vessels [5].  It was also postulated that the corticosteroids block arachidonic acid release from phospholipids 
from the production of lipocortin which inhibits the activity of phospholipase A2 [6,7].  The activity of topical 
corticosteroids is thought to be due to the binding of the drug to steroid receptors located in the cytoplasm or 
on the outside of the nuclear membrane to form complexes that enter the cell nucleus.  These complexes then 
bind to DNA and modify transcription of mRNA and subsequent synthesis of proteins ultimately responsible 
for specific effects such as anti-inflammatory activities [8,9].  It is also said that corticosteroids inhibit DNA 
synthesis in many types of cells thus assists in the treatment of proliferative inflammations such as keloids 
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[10].  These postulations may perhaps be responsible for one of the anti-inflammatory effects of the 
corticosteroids, since the arachidonic acid cascade generates several inflammatory mediators.  As mentioned 
earlier, clobetasol 17-propionate is a highly potent synthetic corticosteroid, and it was found that high-
potency corticosteroids appear to bind more effectively to the receptors [11]. 
 
Clobetasol propionate is a highly potent synthetic topical corticosteroid that has anti-inflammatory, anti-
pruritic and vasoconstrictive properties.  It is generally used for short term management of various skin 
disorders.  It is widely used in the management of various skin disorders such as eczema, some forms of 
psoriasis (moderate to severe) and seborrhoeic dermatitis [1,11,].   
 
1.1.3 Pharmacokinetics 
Pharmacokinetics after topical application of drugs differs from pharmacokinetics after all other routes of 
administration in that the site of action (the skin) is accessible to immediate drug analysis.  The development of 
new topical glucocorticoids has two aims [12]:  
1) To produce preparations which assure sufficiently high concentrations at the site of action in the skin, and  
2) To keep systemic corticosteroid load as low as possible to reduce the risk of systemic effects.  
 
The pharmacokinetic properties of topical corticosteroids remain poorly understood.  However, it is certain that 
the corticosteroids are metabolized in the liver and in other tissues, and are excreted via urine.  Most derivatives 
of this class of drug are absorbed through the skin into dermal blood vessels, with some of the compound being 
metabolized and excreted as occurs when they are systemically administered.  Some compounds are 
metabolized extensively during skin absorption, for many, metabolism will be small or undetectable [13]. 
Cutaneous metabolism occurs at the epidermis where certain enzymes found in the liver (including a 
cytochrome P450 system) may be induced.  The corticosteroids may undergo hydrolysis and sulphate 
conjugation within the epidermis [8].   
. 
1.1.4 Adverse effects 
Upon topical application of clobetasol 17-propionate, one may experience burning sensation, pruritus and 
stinging of the skin.  Headache and other irritation symptom(s) may occur [1].   
 
The onset of local side effects from topical corticosteroids is due to application on the same skin site over a 
long period of time at reasonably high concentrations.  The more common local side effects consist of 
atrophy, striae, purpura, acne, and telangiectases.  The less commonly occurring side effects are local 
hypertrichosis hypopigmentation, and allergic contact dermatitis [14,15].  Systemic side effects usually occur 
due to an increase in steroid penetration through the skin by applying the corticosteroids to large surface 
areas, under occlusion, higher concentrations or more potent derivatives especially in children [16-18].  The 
potential systemic adverse effects upon topical administration include hypothalamic-pituitary-adrenal (HPA) 
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axis suppression, retarded growth in children, and hyperglycemia [15,19].  Majority of the side effects are 
reversible upon stopping or reducing the potency of the topical corticosteroid used. 
 
1.1.5 Contraindications 
Administration should be avoided in persons who exhibit hypersensitivity to clobetasol 17-propionate or to 
any ingredient in the preparation or to other corticosteroids.  It is contraindicated in the presence of acute 
dermatological infections e.g. scalp infection [1].   
 
A copy of the product information leaflet of the topical formulation to be used in this study is located in 
Appendix I. 
 
1.2 Tape stripping technique 
1.2.1 Overview of tape stripping 
Tape stripping is a non-invasive technique employed to study the penetration, the distribution and the 
dermatopharmacokinetics of topically applied drugs and cosmetics products [20-23] within the stratum 
corneum.  It is commonly used to disrupt the epidermal barrier to enhance the delivery of drugs in vivo 
[24,25] and to obtain information about stratum corneum function [22].  Tape stripping has been used 
extensively in dermatological and pharmaceutical fields to measure the stratum corneum mass and thickness, 
to collect stratum corneum lipids and protein samples, detect proteolytic activity associated with the stratum 
corneum, quantitatively estimate enzyme levels and activities in the stratum corneum and allow the detection 
of metal in the stratum corneum [22].  Although in use for over five decades there are no universally accepted 
protocols for tape stripping [26], however it has been identified to be of sufficient utility to have been 
proposed by the FDA as part of a standards method to evaluate the bioequivalence of topical dermatological 
dosage forms [27]. 
 
1.2.2 Principles of tape stripping 
Tape stripping involves the sequential removal of microscopic layers (typically 0.5 - 1 µm) of the stratum 
corneum [21,28] by placing a strip of adhesive tape onto the skin surface with uniform pressure, which is 
then removed [20,21].  Drug uptake into the stratum corneum in vivo can be measured by harvesting the 
stratum corneum previously exposed to a topical product with adhesive tapes, which are subsequently 
extracted and quantified for drug concentration by a validated analytical method [29].  The number of tape 
strips needed to remove the stratum corneum varies with age, gender, anatomical site, skin condition and 
possibly ethnicity [22].  Tape stripping is putatively simple, inexpensive and has been described as a 
minimally invasive technique [20]. 
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1.2.3 Invasiveness of tape stripping 
Although tape-stripping is considered to be essentially non-invasive, stripped sites in certain dark-skinned 
individuals may remain hyperpigmented for several months after healing.  This effect will be communicated 
to the human volunteers before entering the study [21]. 
2 STUDY PRODUCTS 
2.1 Description 
 Reference product Test products 
 
   
Commercial 
name 
Dermovate® cream Dovate® cream Dermovate® ointment 
Generic name Clobetasol propionate cream Clobetasol propionate cream Clobetasol propionate 
ointment 
Dosage form cream cream ointment 
Strength 0.05% m/m 0.05% m/m 0.05% m/m 
Manufacturer Glaxo Wellcome, South 
Africa 
Aspen Pharmacare, South 
Africa 
Sekpharma, South Africa 
MCC 
registration 
details 
F/13.4.1/176 27/13.4.1/0316 F13.4.1/175 
Expiry date 01/2009 05/2009 04/2009 
Description A white to off-white cream 
free from lumps and visible 
impurities 
A soft, smooth, white cream A soft greyish-white 
translucent mass, free of 
lumps and foreign particles 
Dosage ± 5 mg per 1cm2 application 
site 
± 5 mg per 1cm2 application 
site 
± 5 mg per 1cm2 application 
site 
 
2.2 Supply, storage and use 
Sufficient products will be timeously supplied to the clinic by the principle investigator prior to the study.  
Clobetasol 17-propionate is available in cream, ointment or lotion dosage forms.  It should be used externally 
only.  The product should be kept in the container it came in, tightly closed and stored at room temperature 
away from excess heat and moisture [30].  Dispensing and administration of test products will be recorded 
and administered only to subjects for the purpose of this study. 
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3 OBJECTIVES 
The objective of this study is to measure dermal concentrations of clobetasol propionate using tape stripping 
to assess in vivo bioavailability from topical cream and ointment formulations and therefore obtain valuable 
information which will lay the foundation in an attempt to determine bioequivalence of clobetasol propionate 
topical formulations using these two techniques.  In addition, the technique will be compared for its 
effectiveness in the assessment of dermal bioavailability. 
 
 
4 STUDY POPULATION AND MEDICAL ASSESSMENT 
4.1 Number of subjects 
Similar studies have made use of 6 - 18 human subjects for this type of study [25,31-35] with equal numbers 
of male and female subjects.  This study will make use of approximately 15 human subjects and will make 
use of male and female subjects.  Three application sites on the right arm of the subjects will be used for the 
tape stripping studies.  Preliminary statistical analysis (Section 8) will be performed on the subjects 
completing the study.  If needed, an add-on study of up to 10 subjects will be conducted to obtain a degree of 
variability of less than 30% if possible.  If no further study is required, preliminary statistical analysis will be 
finalised and presented in the final report.  If an add-on study is conducted, data for all evaluable subjects 
from both Group 1 and Group 2 will be used in preparation of the final report.  Homogeneity testing will be 
conducted between the two groups. 
 
4.2 Inclusion/Exclusion criteria 
Inclusion criteria 
Only those subjects meeting the following criteria will be included in the study: 
i. Female subjects who are using reliable contraception or abstaining. 
ii. Subjects who are aged between 18 and 50. 
iii. Subjects who are in general good health. 
iv. Subjects who will be available for the entire study period. 
 
Exclusion criteria 
Subjects meeting the following criteria will be excluded from the study. 
i. Female subjects who are breast feeding. 
ii. Female subjects who are contemplating becoming pregnant in the time immediately following the 
study. 
iii. Female subjects who are pregnant. 
iv. Subjects who have a known allergy/hypersensitivity to clobetasol propionate or any corticosteroid. 
v. Subjects who have any history of drug or alcohol abuse. 
vi. Subjects who have any mental deficiency or handicap. 
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vii. Subjects who have hairy ventral forearm surfaces and/or abrasions on the underside of their 
forearms. 
viii. Subjects who have engaged in any sun-tanning or taken any sunny vacations within the last month. 
ix. Subjects who have participated in another topical corticosteroid dermal microdialysis or tape 
stripping study within 2 months of the study date. 
x. Subjects who have used any topical corticosteroid within the last three months. 
xi. Subjects who suffer from any allergic conditions (hayfever, allergic rashes, asthma or childhood 
eczema). 
xii. Subjects who suffer from any skin disorder such as psoriasis, eczema or other relevant skin 
disorder. 
xiii. Subjects who take regular medicine or tablets or used any creams within the last week 
(contraceptive pills excluded). 
xiv. Subjects with a history of any neurological, kidney or liver disorders. 
 
4.3 Subject restrictions 
i. No prescription medication and OTC medication (e.g. cold preparations, vitamins, natural 
products used for therapeutic benefits, antacids, herbal or traditional remedies) will be allowed 
for at least one week prior to the study. 
ii. With the exception of study product no concomitant medication may be taken by subjects 
during the study. 
iii. No alcohol may be taken by subjects from 24 hours prior to product application and during the 
study. 
iv. No strenuous physical activity may be undertaken by subjects from 12 hours before product 
application and during the study. 
v. Subjects must not smoke more than 10 cigarettes per day and will not be allowed to smoke 
during the study. 
vi. Subjects must refrain from applying emollients, skin conditioning creams and/or tanning lotions 
to their forearms for a period of 24 hours prior to the scheduled time of product application. 
 
Subjects will be informed of the above restrictions and each subject will be specifically questioned on these 
points prior to product application.  Any deviations from the above restrictions which are made known to the 
investigators either voluntarily or on questioning will be recorded on the appropriate CRF (Appendix VI). A 
decision as to whether the affected subject continues with the study will be taken by the principal investigator 
and the supervisor in consultation with the study nurse. 
 
4.4 Criteria for removal from the study 
Any subject may be withdrawn from the study at any time due to the following: 
i. Voluntary withdrawal by the subject due to any reason. 
 Appendix IV 
237 
      
ii. Illness or injury during the study if regarded as clinically significant by the principal 
investigator and the supervisor in consultation with the study nurse. 
iii. Any adverse event or signs of toxicity if regarded as clinically significant by the principal 
investigator and the supervisor in consultation with the study nurse. 
iv. Failure of the subject to comply with or be uncooperative towards any study requirements or 
restrictions if regarded as clinically significant by the principal investigator and the supervisor 
in consultation with the study nurse.  
Subjects withdrawn or dropped out of the study will be fully documented and accounted for in the CRF. 
 
 
5 STUDY PROCEDURE 
5.1 Pre- and post-study medical screening 
Pre-study screening will be conducted not more than 30 days prior to the start of the study. The pre-study 
evaluations will be conducted as listed in the table below. 
 
Screening test Pre-study Post-study 
   
Medical history √1 √4 
Dermatological assessment √2 √5 
Adhesive sensitivity √3 x 
 
1. Medical history: Demographic data (date of birth, age, sex, origin), skin (dermatological), allergies, alcohol 
consumption, smoking habits, dietary habits and sporting commitments. 
2. Dermatological:  General assessment of the volar aspect of the forearm and any dermatological condition which may 
influence the barrier function of the skin and impact on the absorption of topically applied topical 
corticosteroids. 
3. Adhesive sensitivity:  Assessment of subject’s sensitivity to adhesive on application site demarcation tape. 
4. Medical history: Since start of study. 
5. Dermatological: Examination of forearms and application sites. 
 
If any study related abnormalities are observed at the post-study medical, appropriate follow-up action will 
be taken and re-examination and re-testing conducted until the abnormality returns to normal or until the 
study nurse considers the abnormality to be clinically insignificant. 
 
5.2 Medical tape sensitivity screening 
No less than 2 days prior to the start of the study, volunteers will undergo an assessment of their tolerance to 
the adhesive on medical tape used to demarcate application sites and for tape stripping procedures. 
The following screening protocol will be utilised. 
i. The forearm of the subject will be washed 1 hour prior to the adhesion of the medical tape. 
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ii. Adhesion of the medical tape will occur at 0800 hours. 
iii. Two different types of adhesive tapes to be employed as templates and for tape stripping will be 
used on the right arm. 
iv. The medical tapes will be removed after four hours. 
v. The forearm of the subject will be assessed for allergies to the adhesive medical tapes. 
  
Subjects who exhibit allergies will not be eligible as candidates for the study.   
 
5.3 Check-in and confinement 
Subjects will check-in at the clinic (Room T17) in the Faculty of Pharmacy building, Rhodes University, 
Grahamstown at 0800 hours or 1400 hours of the study day when they will undergo a brief medical 
examination, inclusion and exclusion criteria check and study restriction check.  Subjects accepted into the 
study will then be prepared for product application.  Subjects will remain in the study room for the entire 
duration of the study. 
 
5.4 Study design 
The study will comprise of a single phase sequential design conducted on 15 subjects in the first instance, 
followed by another 10 subjects if necessary (see section 4.1). A maximum of four subjects will be studied on 
any study day and the time between the first and the fifteenth subject is expected to be approximately 1 week.  
A total of four application sites will be employed on the right arm on each subject for the tape stripping study 
as shown in the diagram below.  The application of the formulations will be randomized between sites and 
individuals.  The duration of the study for each subject will be approximately 4 hours. 
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Templates for use with the tape stripping study will be affixed on the right arm of the subjects using adhesive 
labels and Scotch® tape.  These will be used to demarcate (2 cm x 2 cm) the stratum corneum sampling site.  
The templates will be designed to have four sampling sites, three sites for the application of the formulations 
and the other for use as control.  One formulation will be applied to one application site and after a 120 
minute exposure period the excess drug will be removed by wiping with a cotton swab.  Adhesive tapes (3M 
Scotch® Magic tape no.810) will be applied concurrently to both application sites with uniform pressure and 
then subsequently removed.  15 successive strips will be made from each site.  Transepidermal water loss 
measurements will be recorded from the control application site.  The tape stripping procedure will take 
approximately 1 hour. 
 
5.5 Pre-study day activities and procedures 
This study is dependent on a number of preparations prior to the study.  The following is a list of items that 
will be made available at least 24 hours prior to the study. 
i. Calibration standards and mobile phase for clobetasol propionate analysis will be prepared. 
ii. The required number of tape strips will be cut for stratum corneum harvesting. 
iii. The checklist will be performed (Appendix II). 
iv. The general setup of the clinic will be ensured. 
 
5.6 Study day activities and procedures 
i. Adhesive tape strips (3M Scotch® Magic Tape no.810) for the tape striping study will be 
weighed out in the morning prior to start of study. 
ii. The adhesive label template (2 x 2 cm) for use with tape stripping will be affixed onto the right 
forearm with 3M Scotch® Magic Tape (no.810) tapes to delineate the application sites on the 
stratum corneum. 
iii. The reference and test formulations (20 mg) will each be applied to the assigned application 
sites while one site will be reserved as control. 
iv. Excess formulation will be removed from the application site after a 120 minute exposure 
period using two cotton buds and allowed to air dry for 10 minutes. 
v. Tape strips will be applied with uniform pressure to both sites and then subsequently removed. 
vi. 15 successive strips will be removed from each site. 
vii. The removal of strips will be done in a clockwise manner (N, E, S, W) ensuring that equal 
amount of stratum corneum is removed in each of the 4 sites. 
viii. Transepidermal water loss measurements will be measured from the control site after each tape 
strip. 
ix. Each tape strip will be weighed after tape stripping. 
x. The template will be removed from the subject. 
xi. The forearm will be rinsed to remove any residual drug. 
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The actual time of study procedures and/or results/comments obtained during the study will be recorded on 
the ‘Registration of Data during Tape Stripping Form’ (Appendix III).   
 
5.8 Product application 
Just prior to the product application, an Eppendorf® (0.5 ml) pipette will be filled with either the reference or 
test products.  The products will be dispensed twice (3 on the dial of the Eppendorf® dispenser) at each 
application site to allow ± 20 mg of the products (corresponding to 0.01 mg of clobetasol propionate) to be 
applied at each site for tape stripping.  The Eppendorf® dispenser will be used to ensure that an accurate 
amount of test product is dispensed to each application site for each subject.  A pre-weighed glass rod will be 
used to spread the product and weighed following the spreading to determine the accurate amount of 
formulation applied to each site. Application of the test product will be done by the principal investigator. 
 
5.9 Posture and physical activity 
Strenuous exercises will not be permitted as described in section 4.3. 
 
5.10 Food and fluids 
Subjects will not be restricted with respect to food and fluid intake.  
 
5.11 Subject monitoring 
The principal investigator will be present at all times during the study.  Subjects will be asked open-ended 
questions about their health at the time of each assessment and any discomfort observed during the 
experience will be recorded in the CRF (Appendix VI).  The study nurse will be contactable by phone for the 
duration of the study. 
 
6 SAMPLE ANALYSIS 
Samples will be analysed for clobetasol propionate using a validated extraction procedure and HPLC 
analytical method.  Analysis will be done within 48 hours after sample collection. Samples will be kept in the 
fridge at (4 – 8 °C) to prevent any degradation. 
 
 
7 DATA ANALYSIS 
Individual tape strip amount vs. fraction of skin thickness profiles will be generated and the individual total 
dermal drug amount will be calculated for the tape stripping study.  Deletion of data from analysis will be 
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justified.  All individual subject data will be documented and individual tape strip amount vs. fraction of skin 
thickness curves will be presented in linear/linear and log/linear scale. 
 
7.1 Statistical analysis 
Pharmacokinetic and statistical parameters will be determined by the principal investigator using GraphPad 
Prism version 4.  The statistical analysis will estimate the variance associated with subject-to-subject 
variability .  Summary statistics such as median, minimum and maximum will be given. 
 
8 ETHICAL AND REGULATORY REQUIREMENTS 
8.1 Ethical and institutional review 
Approval by the Rhodes University Ethical Standards Committee (RUESC) (departmental) will be obtained 
before the study commences.  The original signed copy of the ethical approval will be retained by the 
principal investigator. 
 
The study will be conducted in accordance with the recommendations of the guidelines as set out in the 
Declaration of Helsinki (1964) and its amendments of Tokyo (1975), Venice (1983), Hong Kong (1989), 
Somerset West (1996) and Edinburgh (2000), according to ICH Good Clinical Practice (GCP) guidelines and 
in compliance with the Biopharmaceutics Research Group’s (BRG) SOPs, RUESC requirements and 
guidelines on the conduct of clinical trials in South Africa. 
 
8.2 Written informed consent 
Preceding the study, the nature, purpose and risk of participating in the study will be explained to all 
volunteers.  If volunteers desire, they will be given time to consider the information and any questions that 
they might have will be answered.  They will also be informed that they may withdraw from the study at any 
time without penalty to themselves (other than a reduced remuneration) but that they will be encouraged to 
be committed to completing the study prior to their enrolment.  They will sign a consent form in the presence 
of a witness.  Subjects will receive written, detailed instructions concerning the study performance and 
restrictions. 
 
8.3 Case report form 
The Case Report Form (CRF) for this study will be designed and supplied by the principal investigator 
(Appendix VI).  All case report forms will be quality assured and all major events such as final acceptance of 
a subject, adverse events and final release from the study will be signed by both the principal investigator and 
the study nurse. 
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8.4 Record retention 
All source documents, study reports and other study documentation for which the principal investigator is 
responsible will be archived and retained by the Faculty of Pharmacy, Biopharmaceutics Research Group.  
Results will be published in the scientific journals and/or presented in a thesis submitted to Rhodes 
University in fulfilment of the requirement for the degree of Master of Science (Pharmacy) after the 
completion of the study. 
 
8.5 Insurance 
Subjects will be insured against any permanent adverse effect on their health which may arise in connection 
with the conduct of the study.  A copy of the insurance certificate (Appendix VII) will be provided to 
RUESC (departmental) as part of the application to conduct this study. Adequate insurance cover in the event 
of negligence on the part of principal investigator, the supervisor and the study nurse will be ensured. 
 
8.6 Termination of the study 
The principal investigator reserves the right to terminate the study in the interests of subject welfare 
following consultation with the supervisor and the study nurse.  The supervisor may terminate the study at 
any time for scientific or safety reasons.  If the study is prematurely terminated or suspended for any reason 
the principal investigator will promptly explain to the subjects, take appropriate steps as deemed necessary 
under the circumstances to assure the subjects and where applicable follow up with therapy and inform the 
RUESC (departmental). 
 
8.7 Adherence to protocol 
Excluding an emergency situation in which proper treatment is required for the protection, safety and well-
being of study subjects, the study will be conducted as described in the approved protocol.  Any deviation 
from the protocol will be recorded and explained. 
 
Should amendments to the protocol be required, the amendments will be documented and signed by the 
principal investigator and the supervisor.  If the protocol amendment(s) has an impact on the safety of 
subjects, such as a change in dosing regimen or additional formulations, the amendment will be submitted to 
the RUESC (departmental) for approval. 
 
8.8 Blinding 
Subjects will not be blinded and will be informed about the products for use at the application sites. 
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8.9 Adverse events/Adverse drug reactions 
Subjects will be questioned on their health status at check-in, during the course of the study and before 
leaving the clinic at the end of the study.  During the study, open-ended questions will be asked.  If any 
adverse events are reported, the principal investigator together with the study nurse will monitor the adverse 
event, initiate appropriate treatment if required and decide whether or not to withdraw the subject from the 
study.  Signs and symptoms of any adverse events which occur during the study will be fully documented in 
the appropriate CRF (Appendix VI).  If necessary adverse events will be referred to a suitably qualified 
medical practitioner for assessment and follow up. 
 
Adverse events (which include illnesses, subjective and objective signs and symptoms that have appeared or 
worsened during the course of the study) will be assessed by the principal investigator and the supervisor in 
consultation with the study nurse during and after the study to determine whether or not they are related to 
the investigational test product (i.e. ADR), to the study procedure or other.  The outcome of this assessment 
will be recorded in the appropriate CRF (Appendix VI). 
 
AEs classified as severe or serious will be reported to the supervisor/study nurse, Rhodes University Ethical 
Standards Committee (departmental) within 24 hours. 
 
ADRs classified as serious and unexpected will be subject to expedited reporting as detailed in the ICH E2A 
and E2B guidelines on Clinical Safety Data Management and Data Elements for Transmission of Individual 
Case Report Forms respectively. 
 
 
9 REPORTS 
A full report on the study will be compiled by the principal investigator in the format requested by the 
supervisor and submitted to the supervisor.  The analytical report will include results for all standard and 
quality control samples.  A representative number of chromatograms or other raw data will be included 
covering the whole concentration range for all standards and quality control samples.  The validation report 
will also be submitted. 
 
ABBREVIATIONS 
ADR Adverse Dug Reaction 
AE Adverse Effect/Event 
ANOVA Analysis of Variance 
AUC Area Under the Curve 
BRG Biopharmaceutics Research Group 
Cmax Maximum Concentration 
CRF Case Report Form 
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CRO Clinical Research Organisation 
GCP Good Clinical Practice 
ICH International Conference of Harmonisation 
IRB Internal Review Board 
QA Quality Assurance 
RUESC Rhodes University: Ethical Standards Committee 
SOP Standard Operating Procedure 
tmax Maximum Time 
HPLC High Pressure Liquid Chromatography 
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APPENDIX I 
PRODUCT INFORMATION LEAFLET 
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APPENDIX II 
CHECKLIST 
SUBJECT NAME  SUBJECT INITIALS  DAT
E 
 
STUDY NUMBER WL_TS1 VOLUNTEER 
REFERENCE 
   
3M Micropore™ tape (1530)  
3M Scotch® tape (810)  
Alcohol swabs  
Biological waste container (yellow)  
Calculator  
Cotton swabs  
Eppendorf® preparations  
Glass rod  
Human subject under study  
Pen/marker  
Pre-cut Scotch® tape (810)  
Ruler  
Scissors  
Protective arm guards (non-occlusive)  
Soap and towel  
Templates for sampling  
Thermometer  
Timer  
Tweezers  
CHECKED BY: SIGNATURE: 
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APPENDIX III 
REGISTRATION OF DATA DURING TAPE STRIPPING EXPERIMENTS 
Date  Subject initials  
Subject/Volunteer name  Volunteer Reference  
Age  Study number WL_TS1 
Sex  
Race  
Formulation  
Applied dose  
Site  
Principal Investigator  
Assistant principal 
investigator 
 
Room temperature  
Relative Humidity  
 
TIME SCHEDULE 
Task Time start Time stop Comment 
Forearm wash 
   
Demarcation of sites on right arm 
   
Application and removal of product: 
   
      Control (site _______ ) N/A N/A  
      Reference ( site _______ ) 
   
Test 1, Dovate®  (site _______ ) 
   
      Test 2, Dermovate®  (site _______ ) 
   
Stripping of application sites: 
   
      Control (TEWL) 
   
      Reference 
   
      Test 1 
   
      Test 2 
   
Removal adhesive labels and tapes 
   
Forearm wash 
   
 
 
 
 
 
WRIST              ELBOW 
 
                                                        
 
  
  
Mass of rod + 
Cream/ointment =        ___________          ___________          ___________       ____________ 
   
Mass of rod = ______________ 
 
     A 
 
B 
 
C 
 
D 
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MASS OF STRATUM CORNEUM AND TEWL 
 
CONTROL 
Tape strip 
no. 
Mass before Mass after Mass of stratum 
corneum 
TEWL 
1     
2     
3     
4     
5     
6     
7     
8     
9     
10     
11     
12     
13     
14     
15     
 
 
REFERENCE PRODUCT 
Tape strip no. Mass before Mass after Mass of stratum corneum 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
11    
12    
13    
14    
15    
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TEST PRODUCT (Dovate®) 
Tape strip no. Mass before Mass after Mass of stratum corneum 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
11    
12    
13    
14    
15    
 
TEST PRODUCT (Dermovate®) 
Tape strip no. Mass before Mass after Mass of stratum corneum 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
11    
12    
13    
14    
15    
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APPENDIX IV 
INFORMATION FOR VOLUNTEERS BROCHURE 
 
APPLICATION OF TAPE STRIPPING FOR THE ASSESSMENT OF THE BIOAVAILABILITY 
OF CLOBETASOL PROPIONATE IN HEALTHY VOLUNTEERS 
 
STUDY NUMBER: WL_TS1 
PROTOCOL VERSION 1 
BROCHURE VERSION WLTS1 
NOVEMBER 2007 
 
1 Study objective 
The study involves research to assess the rate and extent to which clobetasol propionate diffuse into the skin 
from a topical product, using tape stripping as a measure of efficacy.  This study will provide valuable insight 
for use in the assessment of sameness and differences of proprietary clobetasol propionate formulations. 
  
Reference product Dermovate® Cream 
Drug Clobetasol propionate 0.05% m/m 
Company Glaxo Wellcome 
 
South Africa 
  
Test product Dovate® Ointment 
Drug Clobetasol propionate 0.05% m/m 
Company Aspen Pharmacare 
 
South Africa 
  
Test product Dermovate® Ointment 
Drug Clobetasol propionate 0.05% m/m 
Company Sekpharma Ltd. 
 
South Africa 
 
The study will involve approximately 15 subjects. 
 
2 Ethical considerations and standards of practice 
Innovator drug companies who develop a new drug have patent protection for the drug for a number of years, 
typically 15 - 20.  Once the patent has expired, generic drug companies are permitted to make and market 
their own products as competitors to the innovator's product, usually at a substantially reduced cost.  
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However, a prerequisite for registration with national drug registration bodies (and subsequent marketing) is 
that the rate and extent to which the drug is absorbed from the generic product is shown to be equivalent to 
that from the innovator product.  This is an indirect way of demonstrating that the generic product will be as 
effective clinically as the innovator and is demonstrated by what are known as ‘comparative bioavailability 
or bioequivalence studies’. 
 
 
2.1 Ethical and institutional review 
Approval by the Rhodes University Ethical Standards Committee (RUESC) (departmental) is required before 
the study can commence.  The study will be conducted in accordance with guidelines set out in the 
Declaration of Helsinki (1964) and its amendments of Tokyo (1975), Venice (1983), Hong Kong (1989), 
Somerset West (1996) and Edinburgh (2000).  This Declaration sets out ethical principles, which protect your 
rights participating in such studies.  Guidelines on the conduct of clinical trials in South Africa will be 
adhered to. 
 
The study will also be conducted according to the ICH (International Conference on Harmonisation) 
Guidelines for GCP (Good Clinical Practice), the Biopharmaceutics Research Group’s Standard Operating 
Procedures and the requirements of RUESC. 
 
2.2 Written informed consent 
Preceding the study, the nature, purpose and risk of participating in the study will be explained to you.  
Should you wish, you will be given time overnight to consider the information and any questions that you 
might have will be answered. The nature of the insurance cover will also be explained.  If you decide to 
participate in the study you will sign a consent form in the presence of a witness.  You are encouraged to 
consult your parents or personal medical doctor for approval in this study. 
 
3 Voluntary nature of participation 
Your participation in this study is entirely voluntary and you may withdraw from the study at any time, 
without prejudice.  Should you decide to participate, we ask that you try to be committed to completing the 
study if at all possible.  Should you encounter any problems along the way, please speak to me so that every 
effort can be made to assist you. 
 
4 Dates and duration of the study phases 
The study consists of one phase only which will last for approximately four hours. 
 
5 Place of study 
The study will be conducted in the clinic (Room T17) in the Faculty of Pharmacy building at Rhodes 
University.  Room T17 is on the top floor of the Pharmaceutical and Chemical Sciences building in Artillery 
Road on the Rhodes University campus. The principal investigator, supervisor and the study nurse will be 
suitably qualified, trained and experienced to perform the study procedures. 
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6 Background information 
Clobetasol propionate is used in the management and treatment of patients with skin disorders such as 
psoriasis, eczema and dermatitis.  It is for adult use only.  The cream must be applied sparingly once to twice 
daily to affected areas only. 
 
Tape stripping is a technique also employed to study the penetration of drugs to the skin.  Tape stripping 
involves the sequential removing of microscopic layers (typically 0.5 - 1 µm) of outer dead layers skin 
(stratum corneum) by placing an adhesive tape strip onto the skin surface with uniform pressure which is 
then subsequently removed.  Tape stripping is simple and has been described as a minimal invasive technique.  
Although tape stripping is considered to be essentially non-invasive, stripped sites may remain darker than 
usual for several months after healing. 
 
7 Study design 
 
Templates for use with the tape stripping study will be affixed on your right arm with Scotch® tape (810).  
These will be used to demarcate (2 cm x 2 cm) the stratum corneum sampling site.  The templates will be 
designed to have three sampling sites, two sites for the application of the formulations and the other for use 
as control.  The test formulation will be applied to one application site and after a 120 minute exposure 
period the excess drug will be removed by wiping with a cotton swab.  Adhesive tapes (3M Scotch® Magic 
Tape no.810) will be applied concurrently to both application sites with uniform pressure and then 
subsequently removed.  15 successive strips will be made from each site.  The amount of moisture loss 
measurements will be recorded from the control application site using a small instrument which is placed on 
the skin.  This is also entirely pain free.   
 
8 Adverse effects 
For topical preparations, delayed hypersensitivity may occur at the site of the application, but this is 
uncommon.  It is advised that clobetasol propionate cream preparations should not be used on open wounds 
or lesions on the skin or near the eye.  The skin reactions are however reversible on discontinuation of 
therapy.  Clobetasol propionate must not be administered to healthy or ill individuals who have an allergy to 
this compound or to any of the ingredients in the formulation. In this study, a single application to a limited 
area is unlikely to invoke any adverse effects but procedures will be in place to address any discomfort noted 
during and after the study.   
 
Tape stripping technique is safe and no adverse reactions have been reported so far. Although tape stripping 
is considered to be essentially non-invasive, stripped sites may remain hyperpigmented for several months 
after healing. 
 
9 Conditions of participation in the study   
To participate in this study you must:- 
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i. Undergo and pass a medical assessment which includes giving a general medical history, 
recording of vital signs, body height and weight measurements and an assessment of your skin. 
ii. Undergo a skin test to assess any possible allergy or sensitivity to the adhesive in the medical 
tape that will be used.  After 3 hours the tape is removed, the forearm washed and the skin 
inspected for any signs of reaction to the tape adhesive. 
iii. Fulfil certain inclusion and exclusion criteria which have been set out in the protocol. 
iv. Agree to be fully committed to the study and conscientiously abide by the restrictions required 
of you as listed in section 11. 
 
NB: It is extremely important that you divulge any past medical history and abide by the rules for 
participation in this study.  This is to protect you from unnecessary risks and to help ensure the 
reliability of the data gathered. 
 
10 Volunteer inclusion/exclusion criteria 
You will be considered for this study if you are aged between 18 and 50, in general good health, available for 
the entire study period and if female you are on reliable contraception or abstaining from sex. 
 
Please do not consider participating in this study if you 
i. are breast feeding. 
ii. are contemplating becoming pregnant in the time immediately following the study. 
iii. are pregnant. 
iv. have a known allergy/hypersensitivity to clobetasol propionate or any corticosteroid. 
v. have any history of drug or alcohol abuse. 
vi. have any mental deficiency or handicap. 
vii. have hairy ventral forearm surfaces and/or abrasions on the underside of their forearms. 
viii. have engaged in any sun-tanning or taken any sunny vacations within the last month. 
ix. have participated in another corticosteroid dermal microdialysis or tape stripping study within 2 
months of the study date. 
x. have used any corticosteroids within the last three months. 
xi. suffer from any allergic conditions (hayfever, allergic rashes, asthma or childhood eczema). 
xii. suffer from any skin disorder such as psoriasis, eczema or other relevant skin disorder. 
xiii. take regular medicine or tablets or used any creams within the last week (contraceptive pills 
excluded). 
xiv. have a history of any neurological, kidney or liver disorders. 
 
11 Study restrictions  
 
Restricted item 
 
Duration of restriction 
 
Examples of restriction 
 
Comments 
Prescription From 1 week before the start of 
the study, until the end of the 
- all medication obtained 
on prescription 
This includes all long 
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Restricted item 
 
Duration of restriction 
 
Examples of restriction 
 
Comments 
drugs study. - antibiotics, vaccinations 
- anti-inflammatories 
- anti-asthmatic drugs 
- anti-acne drugs etc. 
term medication. 
Over-the-
counter (OTC) 
drugs 
 
 
From 1 week before the start of 
the study, until the end of the 
study. 
- anti-flu drugs, sports 
supplements, antacids, 
paracetamol 
- vitamins, minerals 
-homeopathics 
This includes herbs, 
natural products & all 
medications that can be 
bought without a 
prescription. 
Alcohol From 24 hours before the start 
of the study and during the 
study. 
 
No alcohol for a total of just 
over 2 days  
All alcoholic drinks and 
alcohol containing foods. 
It is important that this 
requirement is taken 
seriously and observed, 
as alcohol can 
significantly affect the 
liver. 
Strenuous 
Physical Exercise 
From 12 hours before the start 
of the study. 
Rugby 
Squash 
Rowing 
Gym 
Tennis etc. 
Light exercise such as 
walking is permitted. 
Smoking No smoking will be permitted 
during the study. 
Cigarettes No cigars or pipe 
smoking. 
Moisturising 
creams 
You must refrain from applying 
any type of skin conditioning 
creams to your forearms from 
24 hours before the study until 
the end of the study 
All skin creams, e.g. 
moisturizers, Vaseline, 
medicated creams, 
aqueous cream and 
tanning lotions. 
This could interfere with 
the absorption of the 
study formulation. 
 
NB: Random checks will be done to ascertain whether you have managed to adhere to the above restrictions.  
If you have not been able to adhere to the study restrictions please inform us immediately or else you may not 
be able to participate with a reduced remuneration as detailed in section 15. 
 
12 Procedures and duration of the study 
The study consists of a single phase. The procedures and duration of the study are detailed below. 
i. On the morning or afternoon of the study you must check into the clinic (Room T17) in the 
Faculty of Pharmacy building at 0800 or 1400 hours respectively. At check-in you will be:- 
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a. questioned and undergo a brief medical examination to establish whether you still fulfil all 
the inclusion and exclusion criteria since your pre-study medical examination and that you 
have complied with the study restrictions. 
b. prepared for product application by having medical tape applied to your forearms. 
ii. The study will commence at 0800 or 1400 hours and you will be expected to remain in the 
clinic throughout the course of the study. 
iii. You are not restricted with regard to food and drink during the study period. 
iv. Professional medical assistance (registered study nurse and/or a registered nurse) will be 
available throughout the course of the study. 
v. Should any new and significant information about the study medication become available 
during the course of the study, this will be communicated to you. 
vi. A tube of 0.1% m/m hydrocortisone cream will be given to you to self medicated your arm 
twice daily for 2 weeks. 
 
13 Benefits 
Since you have been screened as healthy before the start of the study, there is no medical benefit to you from 
participating in this study. 
 
14 Financial compensation 
You will receive a gratuity of R 100.00 for full participation in the study.  Payment following withdrawal 
from the study will be calculated on a pro-rated basis. 
 
15 Adverse medical events 
You will be monitored prior to, during and after each study day for any adverse events whether or not they 
are thought to be related to the investigational products or procedures.  If any adverse events are reported, the 
study nurse will decide whether or not to withdraw you from the study and what treatment is appropriate.  In 
addition, the Rhodes University Ethical Standards Committee (departmental) will be notified of any serious 
adverse events (SAEs).  All adverse events will be monitored and treated until recovery to your pre-study 
status.  You will be referred to a medical doctor if necessary and all medical costs will be covered by the 
BRG.  All adverse events will be monitored and treated appropriately until a satisfactory outcome is attained. 
 
16 Insurance 
You are covered by an insurance policy taken out by the BRG, in case of claims arising from the medication 
or procedures as outlined in the protocol, and in case of negligence on the part of the BRG.  If you have 
personal insurance e.g. life insurance /assurance your participation in this study may affect your policy. You 
are advised to determine this prior to participating in the study.  If you need any assistance in this regard 
please feel free to contact me.  During the clinical study you are not entitled to participate in other studies and 
you should not participate in any other study/s for thirty (30) days after completion of this study to ensure 
that there are no interactions.  Insurance policies will be available from the principal investigator for scrutiny. 
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17 Confidentiality 
Your medical history and physical examination records and any other information or data generated during 
this study will be kept confidential.  However, you must agree that all the above mentioned documentation 
and data can be released for any lawful purpose and released for publication in scientific journals and/or 
presentation in a thesis submitted to Rhodes University in fulfilment of the requirement for the degree of 
Master of Science (Pharmacy) after the completion of the study.  In such cases your name will be removed 
from all documentation to ensure your anonymity.  In signing the consent form for the study, you agree to the 
granting of access to your medical data. Your medical data will be provided to you upon request and you will 
be informed of significant abnormalities identified before or after the study. 
 
Your consent is also required to permit the study staff to consult with any medical practitioner who is 
normally responsible for your care if the need arises.  The onus, however, is on you to inform such a 
practitioner of your intention to participate in such a study, should you so wish. 
 
18 Amendments/Changes 
Should there be any changes made to the trial protocol these will be communicated to you verbally and in 
writing in time to enable you to reconsider your decision to participate in the study. 
 
19 Withdrawal  
You may withdraw from the study at any time due to the following: 
i. Voluntary withdrawal by yourself due to any reason. 
ii. Illness or injury during the study if regarded as clinically significant by the principal 
investigator and the supervisor in consultation with the study nurse. 
iii. Any adverse event or signs of toxicity if regarded as clinically significant by the principal 
investigator and the supervisor in consultation with the study nurse. 
iv. Failure to comply with or be uncooperative towards any study requirements or restrictions if 
regarded as clinically significant by the principal investigator and the supervisor in consultation 
with the study nurse.  
It is your right to withdraw from the study at any time. However, by signing the Informed Consent form and 
participating in the study, you agree to be committed to completing the study if at all possible. 
 
20 Termination of the study 
The BRG reserves the right to terminate the study prematurely in the interests of your welfare. 
 
21 Emergency contacts 
You are obliged to notify the principal investigator as soon as possible if you are unable to follow the 
procedures or if you suffer any adverse event we have not told you about.  In particular, you should make 
every effort to contact me if you suffer a Serious Adverse Events (SAEs) or need to take additional 
medication of any kind.  This applies to out of hours, as to normal work time. 
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In such cases of medical emergencies during the study, or if you have any urgent questions relating to 
adverse effects or unrelated illness, please feel free to telephone the study nurse, Sr. Kay Wentworth at any 
time at the following phone numbers: 
 
Work 046 603 8189 Home 046 622 6384 Cell 072 299 8230 
 
22 Contacts for additional information 
The following individuals are responsible for conducting this study and as such may be approached for more 
information: 
Portfolio Name Contact details 
    
Principal Investigator Wai Ling Au Work 046 603 8412 
 
BPharm (Rhodes) Cell 072 612 0972 
  Email g02a1351@campus.ru.ac.za 
    
Supervisor Professor Isadore Kanfer Work 046 603 8381/8382 
 
BSc (Pharm), BSc (Hons), PhD (Rhodes) Email i.kanfer@ru.ac.za 
 
If you have questions about this study which have not been answered adequately by the principal investigator, 
supervisor or the study nurse, you should first discuss them with your doctor.  After you have consulted your 
doctor and are still dissatisfied you may contact the Rhodes University Ethics Standards Committee 
(departmental) at: 
 
Professor Beverley Wilson 
Rhodes University Ethics Standards Committee (departmental) 
RHODES UNIVERSITY 
Tel:. 046 603 8381 
Fax:. 046 636 1205 
Email:. b.wilson@ru.ac.za 
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APPENDIX V 
STUDY PARTICIPATION INFORMED CONSENT FORM 
APPLICATION OF TAPE STRIPPING FOR THE ASSESSMENT OF THE BIOAVAILABILITY OF 
CLOBETASOL PROPIONATE IN HEALTHY VOLUNTEERS 
STUDY NUMBER: WL_TS1 
PROTOCOL VERSION 1 
CONSENT VERSION 1 
NOVEMBER 2007 
 
I ........................................................................................... Born on............................. 
 
Present address ............................................................................................ 
............................................................................................ 
hereby give permission that the tape stripping procedure to be conducted as described to me by the principal 
investigator and that the formulation stated below be applied to my skin during the course of this study. 
 
Reference product: Dermovate® Cream (clobetasol propionate 0.05% m/m) – Glaxo Wellcome, South Africa 
Test products:  Dovate® Cream (clobetasol propionate 0.05% m/m) – Aspen Pharmacare, South Africa 
Dermovate® Ointment (clobetasol propionate 0.05% m/m) – Sekpharma South Africa. 
 
My consent is given freely and I realise that it may be withdrawn at any time, without penalty to me.  
Furthermore, I understand that I do not give up any of my legal rights by signing this consent form. 
 
I have been fully informed by .................................................................................... regarding the possible 
adverse effects of the medication, procedures to be used in this study and the risks thereof, as detailed in the 
“Information for Volunteers Brochure”.  I will receive a copy of the information brochure and signed consent 
form for my records. 
I undertake to comply with all the relevant conditions contained in the Information to Volunteers Brochure 
and confirm that I understand that it is important not to withhold or misrepresent any information asked of 
me.  I agree to undergo the necessary pre- and post-study medical investigations as listed in the protocol. 
 
I undertake to inform the study nurse and the principal investigator immediately of any symptoms - expected 
or unexpected - which I might experience. 
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I agree to my medical records being reviewed in the event of an audit, enquiry, monitoring and/or inspection 
on the understanding that my anonymity will be maintained. 
 
I agree and consent that the BRG may consult with any study nurse who is normally responsible 
for care of study subjects. 
_____ 
Initial 
 
I have been informed that if I do not adhere to the protocol, it may result in my exclusion from the study and 
forfeiture of the agreed upon remuneration.  I acknowledge that instructions relating to my participation in 
this study have been communicated to me both verbally and in writing, and that I understand them. 
 
I also declare that I have made the necessary arrangements regarding the attendance of lectures and other 
academic activities. 
 
I understand that a policy to cover volunteers in clinical studies against death or disablement arising as a 
direct result of participation in such clinical studies has been taken out by the Biopharmaceutics Research 
Group.  I accept the conditions of the policy as set out in the insurance policies. 
 
I acknowledge that I will receive R 100.00 for full participation in this study and that I will receive a pro-
rated amount if I withdraw from the study before it has been completed. 
 
__________________________ ___________________________ 
Signature of volunteer Date (yyyy-mm-dd) 
  
  
  
__________________________ ___________________________ 
Signature of a witness Date (yyyy-mm-dd) 
  
  
  
__________________________ ___________________________ 
Principal Investigator 
Wai Ling Au 
BPharm (Rhodes) 
Date (yyyy-mm-dd) 
 
Contact details of subject  
Telephone number  
Cell number  
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APPENDIX VI 
CASE REPORT FORM 
 
APPLICATION OF TAPE STRIPPING FOR THE ASSESSMENT OF THE BIOAVAILABILITY OF 
CLOBETASOL PROPIONATE IN HEALTHY VOLUNTEERS 
STUDY NUMBER: WL_TS1 
PROTOCOL VERSION 1 
CASE REPORT FORM VERSION 1 
NOVEMBER 2007 
 
 
 
Reference product Dermovate® Cream (clobetasol propionate 0.05% m/m) – Glaxo 
Wellcome, South Africa 
Test product Dovate® Cream (clobetasol propionate 0.05% m/m) – Aspen 
Pharmacare, South Africa  
 Dermovate® Ointment (clobetasol propionate 0.05% m/m) – 
Sekpharma, South Africa 
  
Principal Investigator Wai Ling Au 
BPharm (Rhodes) 
Supervisor Professor Isadore Kanfer 
BSc (Pharm), BSc (Hons), PhD (Rhodes) 
 
 
 
 
Subject initials  
Volunteer reference number  
Study subject number  
Date of screening medical  
 
 
Pre-study examiner: 
Name and initials  
Qualifications  
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MEDICAL HISTORY  
 
DEMOGRAPHIC DATA 
Birth Date  Age in Years Sex (M/F) Origin Other 
   White Black Oriental  Indian  
Height (m) 
 
 
Weight (kg) 
 
 
BMI (Body Mass Index) 
To be calculated by BRG 
Investigators 
Not required 
 
REVIEW OF PAST ILLNESS 
 Describe Abnormalities System/Site Illness? 
Y/N 
 
Skin -Connective Tissue    
Any other illness?    
    
 
GENERAL SYSTEMS EXAMINATION 
 Describe Abnormalities System/Site Illness? 
Y/N 
 
Skin - General    
Skin - Forearms    
Medical tape allergy pass    
 
INCLUSION/EXCLUSION CRITERIA 
(NB: Unshaded areas - acceptable: Shaded areas - unacceptable) 
 YES NO 
Will you be available for the entire study period?   
Are you in general good health?   
Are you aged between 18 and 50?   
Do you have eczema or scratch marks on the underside of your forearms?   
Do you suffer from any skin disorder such as psoriasis or other relevant skin disorder?   
Do you suffer from any neurological, kidney or liver disorders?   
Do you suffer from any allergic conditions (hayfever, allergic rashes, asthma or childhood 
eczema)? 
  
Have you engaged in any sun-tanning or taken any sunny vacations within the last month?   
Do you take any regular medicine (prescription or OTC)?   
Have you taken any medicine or tablets or used any creams within the last week 
(contraceptive pills excluded)? 
  
Have you participated in another corticosteroid dermal study within 2 months of the study 
date? 
  
Have you used any corticosteroids within the last three months?   
Do you have any mental deficiency or handicap?   
Are you pregnant?   
Have any history of drug or alcohol abuse?   
Are you contemplating becoming pregnant in the time immediately following the study?   
Are you breastfeeding?   
Are you using reliable contraception (The contraceptive pill, minipill, IUD or abstinence)?   
Do you have a known allergy/hypersensitivity to clobetasol propionate or any other 
corticosteroids? 
  
 Appendix IV 
267 
VOLUNTEER ACCEPTABILITY /COMMENTS WITH REGARDEXAMINATION/INCLUSION/ 
EXCLUSION CRITERIA 
Acceptable   Not Acceptable  
Notes/Comments   
   
   
   
 
 
Sign                                                                                           Date  ___________________________________                                            
Principal Investigator          (dd/mm/yy) 
 
 
POST-STUDY REPORT/MEDICAL 
 
SUBJECT/STUDY STATUS 
 
Study Completed   Study Not Completed  
Comments (If “no” give reasons and procedure/follow-up undertaken) 
   
   
 
Sign                                                                                                            Date  _______________________                                            
Study nurse                                                                       (dd/mm/yy) 
 
 
CLINICAL EXAMINATION/SUBJECT RELEASE 
 
Test Status/Comments 
 
Medical Update 
 
 Application Site 
Assessment 
 
Subject Released  Subject Retained for Further Investigation  
 
 
Sign                                                                                                            Date  _______________________                                            
                        Study nurse                                    (dd/mm/yy) 
 
 
Sign                                                                                                            Date  _______________________                                           
                                             Principal Investigator                                    (dd/mm/yy) 
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APPENDIX VII 
CERTIFICATE OF INSURANCE 
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APPENDIX VIII 
SCREENING MEDICAL CONSENT FORM 
 
APPLICATION OF TAPE STRIPPING FOR THE ASSESSMENT OF THE BIOAVAILABILITY OF 
CLOBETASOL PROPIONATE IN HEALTHY VOLUNTEERS 
STUDY NUMBER: WL_TS1 
PROTOCOL VERSION 1 
CONSENT FORM VERSION 1 
NOVEMBER 2007 
 
I ........................................................................................... Born on........................... 
 
Present address ............................................................................................ 
............................................................................................   
hereby: 
i. Confirm that my consent is given freely and I realise that it may be withdrawn at any time, 
without penalty to me. 
ii. Confirm that I have read the information contained in Appendix A and have been informed of 
the tests to be undertaken. 
iii. Confirm that I have been informed of the general procedure for clinical studies undertaken by 
the BRG. 
iv. Confirm that I have attended an informed consent session specific for the clinical study for 
which I am volunteering at which the contents of the ‘Information for Volunteers’ Brochure, 
Version WLTS1 were explained to me and a copy given to me to take home and read before 
making my decision. 
v. Recognise that undergoing a screening medical does not ensure automatic inclusion into the 
clinical study. 
vi. Agree to my medical records being reviewed in the event of an audit or enquiry on the 
understanding that my anonymity will be maintained. 
 
__________________________ ___________________________ 
Signature of volunteer Date (yyyy-mm-dd) 
  
  
__________________________ ___________________________ 
Principal Investigator 
Wai Ling Au 
BPharm (Rhodes) 
Date (yyyy-mm-dd) 
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APPENDIX IX 
VERBAL DELIVERY OF INFORMATION TO STUDY VOLUNTEERS 
 
The announcement will be posted around campus. 
 
Students then contact the principal investigator directly and relay their interest in participating in the study.  
A short and factual explanation is given of the study and female participants are specifically asked whether 
they are using reliable contraception (the contraceptive pill, minipill or an IUD) and whether any participant 
suffers from eczema or psoriasis. 
 
The principal investigator will provide the participants an information brochure regarding the study. The 
information brochure will be given to the particpants no less than 2 days prior to the study; this allows ample 
time for the reading through of this information. 
 
At the first meeting in the clinic room in the Faculty of Pharmacy building, 30 minutes are allocated to a 
verbal explanation of the study and any questions.  This provides an undisturbed physical environment and 
the time allocation of 30 minutes is realistic.  
 
Study volunteers will be given approximately 2 days in which to consider the written information and 
formulate questions.  Should there be any additional questions regarding the preceding verbal information, 
study volunteers have an opportunity to consider these answers before a final decision is made with regard to 
participation. 
 
Should the study volunteer continue to be interested in participating, the study volunteer signs the study 
participation informed consent form as well as the screening medical consent form which are also signed by 
the principal investigator and in the presence of a witness if required.  Study volunteers are hereby included 
in the study and are given a copy of the Information for Volunteers Brochure and the signed consent forms as 
well as written instructions. 
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ADVERTISEMENT 
VALID 1 DECEMBER – 13 DECEMBER 2007 
 
CLINICAL STUDY VOLUNTEERS 
 
The Biopharmaceutics Research Group is looking for 
HEALTHY FEMALE and MALE 
VOLUNTEERS 
to participate in clinical studies on a 
medicated cream applied to the skin 
using tape stripping 
If You Are: 
1. Over 18 years 
2. Generally healthy and currently medicine free 
3. Willing to spend half a day in the clinic 
Then You May Be Eligible to Participate 
You Will Be Remunerated For Participating 
If You Are Interested Please Contact Genevieve as soon as 
possible for More Information: 
Preferably by E-mail at: g02a1351@campus.ru.ac.za 
Or by Phone at: 046 603 8412 
 
This advert has been approved by the Rhodes University Ethical Standards Committee 
 
Please take a tear-off slip below 
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AMENDMENTS TO THE TS RESEARCH PROTOCOL 
 
APPLICATION OF TAPE STRIPPING FOR THE ASSESSMENT OF THE 
BIOAVAILABILITY OF CLOBETASOL PROPIONATE IN HEALTHY 
VOLUNTEERS 
 
STUDY NUMBER: WL_TS1 
PROTOCOL VERSION 1 
NOVEMBER 2007 
Amendment no. 1 (30 June 2008) 
1. Section 4.1  Number of Subjects 
From: If needed, an add-on study of up to 10 subjects will be conducted to obtain a 
degree of variability of less than 30% if possible. 
To: If needed, an add-on study of up to 15 subjects will be conducted to obtain a degree 
of variability of less than 30% if possible. 
2. Section 5.4  Study Design 
From: The study will comprise of a single phase sequential design conducted on 15 
subjects in the first instance, followed by another 10 subjects if necessary (see section 
4.1) 
To: The study will comprise of a single phase sequential design conducted on 15 
subjects in the first instance, followed by another 15 subjects if necessary (see section 
4.1) 
 
 
 
 
__________________________ ___________________________ 
Principal Investigator 
Wai Ling Au 
BPharm (Rhodes) 
Date (yyyy-mm-dd) 
  
  
  
__________________________ ___________________________ 
Supervisor 
Professor Isadore Kanfer 
BSc (Pharm), BSc (Hons), PhD (Rhodes) 
Date (yyyy-mm-dd) 
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RESEARCH PROTOCOL 
 
APPLICATION OF DERMAL MICRODIALYSIS FOR THE ASSESSMENT OF 
THE BIOAVAILABILITY OF CLOBETASOL PROPIONATE IN HEALTHY 
VOLUNTEERS 
 
STUDY NUMBER: WL_002 
PROTOCOL VERSION 2 
November 2008 
  
Reference product Clobetasol Propionate Ethanolic Solution 
(Clobetasol propionate 4% m/v) 
Rhodes University 
South Africa 
  
  
Principal Investigator Wai Ling Au 
BPharm  (Rhodes) 
Biopharmaceutics Research Group (BRG) 
Faculty of Pharmacy 
Rhodes University 
Grahamstown 6140 
South Africa 
  
Supervisor Professor Isadore Kanfer 
BSc (Pharm), BSc (Hons), PhD (Rhodes) 
Rhodes University 
Grahamstown, 6140 
South Africa 
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FINAL APPROVAL OF PROTOCOL 
 
 
 
Study number 
 
WL_002 
 
 
Study title Application of dermal microdialysis for the assessment of the 
bioavailability of clobetasol propionate in healthy volunteers 
 
Reference 
product 
Clobetasol Propionate Ethanolic Solution 
(Clobetasol propionate 4% m/v) 
Rhodes University, South Africa 
 
 
 
 
__________________________ ___________________________ 
Principal Investigator 
Wai Ling Au 
BPharm (Rhodes) 
Date (yyyy-mm-dd) 
  
  
  
__________________________ ___________________________ 
Supervisor 
Professor Isadore Kanfer 
BSc (Pharm), BSc (Hons), PhD (Rhodes) 
Date (yyyy-mm-dd) 
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1 BACKGROUND INFORMATION 
1.1 Clobetasol propionate 
1.1.1 Molecular structure 
Clobetasol propionate is a synthetic corticosteroid that has a molecular weight of 467.0g/mol.  The molecular 
structure of clobetasol propionate is represented below.  The empirical formula for clobetasol propionate is 
C25H32ClFO5 [1]. 
 
 
Fig. 1 Chemical structure of clobetasol propionate 
 
1.1.3 Mode of action and uses 
The mode of action of corticosteroids is still not clear, however there are a few postulations on their anti-
inflammatory activities.  One hypothesis that has been widely accepted proposed that the inflammatory 
process results from the release of hydrolytic enzymes of the lysosomes and that the glucocorticoids stabilize 
lysosomal membranes, preventing the rupture of the organelles with the accompanying effect of release of 
hydrolytic enzymes and consequent development of inflammation [2,3].  It has been investigated in view of 
the fact that prostaglandins have been recovered from several types of inflammatory reactions and are 
capable of mediating most of the components of inflammation, the possibility arises that corticosteroids may 
owe their anti-inflammatory activity to part of the inhibition of prostaglandin biosynthesis process [4].    
There are suggestions that corticosteroids inhibit the release of prostaglandin by preventing the transport of 
prostaglandin from inside the fat cell to the extracellular space where it would normally act on the blood 
vessels [5].  It was also postulated that the corticosteroids block arachidonic acid release from phospholipids 
from the production of lipocortin which inhibits the activity of phospholipase A2 [6,7].  The activity of topical 
corticosteroids is thought to be due to the binding of the drug to steroid receptors located in the cytoplasm or 
on the outside of the nuclear membrane to form complexes that enter the cell nucleus.  These complexes then 
bind to DNA and modify transcription of mRNA and subsequent synthesis of proteins ultimately responsible 
for specific effects such as anti-inflammatory activities [8,9].  It is also said that corticosteroids inhibit DNA 
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synthesis in many types of cells thus assists in the treatment of proliferative inflammations such as keloids 
[10].  These postulations may perhaps be responsible for one of the anti-inflammatory effects of the 
corticosteroids, since the arachidonic acid cascade generates several inflammatory mediators.  As mentioned 
earlier, clobetasol 17-propionate is a highly potent synthetic corticosteroid, and it was found that high-
potency corticosteroids appear to bind more effectively to the receptors [11]. 
 
Clobetasol propionate is a highly potent synthetic topical corticosteroid that has anti-inflammatory, anti-
pruritic and vasoconstrictive properties.  It is generally used for short term management of various skin 
disorders.  It is widely used in the management of various skin disorders such as eczema, some forms of 
psoriasis (moderate to severe) and seborrhoeic dermatitis [1,11,].   
 
1.1.3 Pharmacokinetics 
Pharmacokinetics after topical application of drugs differs from pharmacokinetics after all other routes of 
administration in that the site of action (the skin) is accessible to immediate drug analysis.  The development of 
new topical glucocorticoids has two aims [12]:  
1) To produce preparations which assure sufficiently high concentrations at the site of action in the skin, and  
2) To keep systemic corticosteroid load as low as possible to reduce the risk of systemic effects.  
 
The pharmacokinetic properties of topical corticosteroids remain poorly understood.  However, it is certain that 
the corticosteroids are metabolized in the liver and in other tissues, and are excreted via urine.  Most derivatives 
of this class of drug are absorbed through the skin into dermal blood vessels, with some of the compound being 
metabolized and excreted as occurs when they are systemically administered.  Some compounds are 
metabolized extensively during skin absorption, for many, metabolism will be small or undetectable [13]. 
Cutaneous metabolism occurs at the epidermis where certain enzymes found in the liver (including a 
cytochrome P450 system) may be induced.  The corticosteroids may undergo hydrolysis and sulphate 
conjugation within the epidermis [8].   
. 
1.1.4 Adverse effects 
Upon topical application of clobetasol 17-propionate, one may experience burning sensation, pruritus and 
stinging of the skin.  Headache and other irritation symptom(s) may occur [1].   
 
The onset of local side effects from topical corticosteroids is due to application on the same skin site over a 
long period of time at reasonably high concentrations.  The more common local side effects consist of 
atrophy, striae, purpura, acne, and telangiectases.  The less commonly occurring side effects are local 
hypertrichosis hypopigmentation, and allergic contact dermatitis [14,15].  Systemic side effects usually occur 
due to an increase in steroid penetration through the skin by applying the corticosteroids to large surface 
areas, under occlusion, higher concentrations or more potent derivatives especially in children [16-18].  The 
potential systemic adverse effects upon topical administration include hypothalamic-pituitary-adrenal (HPA) 
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axis suppression, retarded growth in children, and hyperglycemia [15,19].  Majority of the side effects are 
reversible upon stopping or reducing the potency of the topical corticosteroid used. 
 
1.1.5 Contraindications 
Administration should be avoided in persons who exhibit hypersensitivity to clobetasol 17-propionate or to 
any ingredient in the preparation or to other corticosteroids.  It is contraindicated in the presence of acute 
dermatological infections e.g. scalp infection [1].   
 
1.2 Dermal microdialysis sampling 
1.2.1 Rationale for dermal microdialysis sampling 
During recent decades the advantages of cutaneous and percutaneous drug delivery has gained increasing 
attraction for novel drug formulations.  The percutaneous route may be an attractive solution for systemic 
delivery of very potent drugs with low oral bioavailability, low systemic clearance and narrow therapeutic 
window, due to the avoidance of hepatic first-pass metabolism and potential of long-term controlled release.  
However, the greatest potential for the topical administration route is targeted drug delivery to the skin itself, 
where dramatically higher skin-to-plasma ratios are attained compared to systemic drug delivery.  This route 
of administration can therefore maintain therapeutically effective drug concentrations in the target organ 
without the risk of inducing side-effects due to high systemic exposures [20].   
 
In the clinical setting, there are currently no sampling techniques which can be used to demonstrate dermal 
bioavailability or bioequivalence of topically applied agents which are both minimally invasive and which 
also give an indication of tissue concentration at a target site in the skin with time.  Dermal microdialysis has 
the potential to address the gap in available sampling techniques due to its minimally invasive nature and its 
ability to generate concentration-time profiles at the target site with good resolution provided a sufficiently 
sensitive analytical method is available [21]. 
 
1.2.2 Overview of microdialysis 
Microdialysis is a technique for sampling of endogenous and exogenous substances in the extracellular space 
in living tissue [22,23].  The technique was originally developed in neuropharmacological sciences but has 
now been used extensively in other tissues in animal models and human studies [21,23].  In human studies, 
this technique has been employed in adipose tissue, brain, heart, lung, solid tumours, skin etc [20,24,25].  
Initial clinical studies using microdialysis have demonstrated the suitability of this method for the 
measurement of drug concentrations in the interstitium of target tissues and allow for the description of 
relative changes of concentration-time courses of solutes against a baseline [25].  The figure below shows a 
linear microdialysis probe inserted into the dermis prior to topical application [22]. 
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1.2.3 Principles of microdialysis 
A microdialysis fibre consists of a semipermeable membrane forming a thin hollow ‘tube’ (typically 0.22 
mm ID), which functionally resembles a blood vessel.  The fibre allows the passage of molecules with a 
volume smaller than the cut-off value of the membrane.  The fibre has one end connected to an impermeable 
tube which leads to a micropump and the other end to an efferent sampling tube.  For dermal microdialysis, 
the probe is implanted in the dermis of the skin via a guide cannula.  The microdialysis fibre is slowly 
perfused with physiological solution, which equilibrates with extracellular fluid of the surrounding tissue 
exchanging substances smaller than the cut-off value of the membrane during the passage through the fibre.  
Entering the microdialysis fibre, the solution is termed perfusate and following dialysis of substances, the 
solution exiting the fibre is termed dialysate [20].  The diffusion of substances across the dialysis membrane 
will occur by passive diffusion, driven across the membrane by the concentration gradient and the speed of 
equilibrium is consequently proportional to the size of the gradient and diffusion rate of the medicine in the 
medium, in addition to the surface area of the fibre membrane.    Using continuous flow through the probe, 
compounds will be recovered by the membrane and sampled for further analysis.  As substances are able to 
diffuse in both directions through the membrane, microdialysis can principally be used to both extract and 
deliver substances in tissues [20]. 
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The figure above depicts the principle of microdialysis sampling by a linear probe [23].  The perfusate is 
pumped through the probe at a preset, low flow rate.  During the passage through the membrane, the 
diffusion of small molecules will take place. 
 
1.2.4 Insertion trauma and invasiveness of dermal microdialysis sampling 
Dermal microdialysis sampling has been described by authors as a minimally invasive technique [21,23].  
The insertion of microdialysis probes creates slight but reversible trauma which initially causes an acute 
inflammatory reaction characterised by increased blood flow, erythema and skin thickness.  This is caused by 
the use of a 23G guide cannula/hypodermic needle for insertion of the linear microdialysis probe.  An 
equilibration time of 60 minutes has been reported to be sufficient to allow the skin to normalise [23].  
Histological examination of skin biopsies showed no signs of an inflammatory reaction in the tissue around 
the probe 8 to 10 hours after probe insertion.  Ice is used to induce anaesthesia during probe insertion to 
provide minimum discomfort to the human volunteer.  No significant discomfort is observed when the 
cannulae have been removed.  Hydrocortisone 0.1% m/m cream applied twice daily for 2 weeks is used to 
arrest any residual inflammation after the completion of the study.  Sterile techniques will be employed 
during the study to ensure the minimum risk of skin infections. 
 
 
2 STUDY PRODUCTS 
2.1 Description 
 Reference product 
  
Commercial name - 
Generic name Clobetasol propionate ethanolic solution 
Dosage form Ethanolic Solution 
Strength 4% m/v 
Manufacturer Rhodes University, South Africa 
MCC registration 
details 
-  
Expiry date -  
Description A clear, slightly yellow solution 
Dosage infinite dose 
 
2.2 Supply, storage and use 
Extemporaneous clobetasol propionate ethanolic solution will be freshly prepared on the day before the study 
commences and stored in the refrigerator. Sufficient products will be timeously supplied to the clinic by the 
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principle investigator prior to the study.  It should be used externally only.  The product should be kept in the 
container, tightly closed and stored at room temperature away from excess heat and moisture [26].  
Dispensing and administration of reference products will be recorded and administered only to subjects for 
the purpose of this study. 
 
3 OBJECTIVES 
The objective of this study is to measure dermal concentrations of clobetasol propionate using microdialysis 
to assess in vivo bioavailability from an extemporaneous topical ethanolic solution and therefore obtain 
valuable information which will lay the foundation in an attempt to determine bioavailability and 
bioequivalence of other clobetasol propionate topical formulations using this technique.  In addition, the 
technique will be assessed for its effectiveness in the assessment of dermal bioavailability. 
 
4 STUDY POPULATION AND MEDICAL ASSESSMENT 
4.1 Number of subjects 
Similar studies have made use of 6 - 18 human subjects for this type of study [27-31] with equal numbers of 
male and female subjects.  This study will make use of approximately 10 human subjects and will make use 
of an equal number of male and female subjects.  Four application sites on the left arm of the subjects will be 
used for the microdialysis study.  Preliminary statistical analysis (Section 8) will be performed on the 
subjects completing the study.  If needed, an add-on study of up to 14 subjects will be conducted to obtain a 
degree of variability of less than 30% if possible.  If no further study is required, preliminary statistical 
analysis will be finalised and presented in the final report.  If an add-on study is conducted, data for all 
evaluable subjects from both Group 1 and Group 2 will be used in preparation of the final report.  
Homogeneity testing will be conducted between the two groups. 
 
4.2 Inclusion/Exclusion criteria 
Inclusion criteria 
Only those subjects meeting the following criteria will be included in the study: 
 Female subjects who are using reliable contraception or abstaining. 
 Subjects who are aged between 18 and 50. 
 Subjects who are in general good health. 
 Subjects who will be available for the entire study period. 
 
Exclusion criteria 
Subjects meeting the following criteria will be excluded from the study. 
 Female subjects who are breast feeding. 
 Female subjects who are contemplating becoming pregnant in the time immediately following the study. 
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 Female subjects who are pregnant. 
 Subjects who have a known allergy/hypersensitivity to clobetasol propionate or any corticosteroid. 
 Subjects who have a known allergy/hypersensitivity to eggs/soy/nuts products (Intralipid®). 
 Subjects who have any history of drug or alcohol abuse. 
 Subjects who have any mental deficiency or handicap. 
 Subjects who have hairy ventral forearm surfaces and/or abrasions on the underside of their forearms. 
 Subjects who have engaged in any sun-tanning or taken any sunny vacations within the last month. 
 Subjects who have participated in another topical corticosteroid dermal microdialysis study within 2 
months of the study date. 
 Subjects who have used any topical corticosteroid within the last three months. 
 Subjects who suffer from any allergic conditions (hayfever, allergic rashes, asthma or childhood eczema). 
 Subjects who suffer from any skin disorder such as psoriasis, eczema or other relevant skin disorder. 
 Subjects who take regular medicine or tablets or used any creams within the last week (contraceptive pills 
excluded). 
 Subjects who test positive for HIV and Hepatitis B*. 
 Subjects with a history of any neurological, kidney or liver disorders. 
 
4.3 Subject restrictions 
i. No prescription medication and OTC medication (e.g. cold preparations, vitamins, natural products 
used for therapeutic benefits, antacids, herbal or traditional remedies) will be allowed for at least one 
week prior to the study. 
ii. With the exception of study product no concomitant medication may be taken by subjects during the 
study. 
iii. No alcohol may be taken by subjects from 24 hours prior to product application and during the study. 
iv. No strenuous physical activity may be undertaken by subjects from 12 hours before product application 
and during the study. 
v. Subjects must not smoke more than 10 cigarettes per day and will not be allowed to smoke during the 
study. 
vi. Subjects must refrain from applying emollients, skin conditioning creams and/or tanning lotions to 
their forearms for a period of 24 hours prior to the scheduled time of product application. 
 
Subjects will be informed of the above restrictions and each subject will be specifically questioned on these 
points prior to product application.  Any deviations from the above restrictions which are made known to the 
investigators either voluntarily or on questioning will be recorded on the appropriate CRF (Appendix V). A 
decision as to whether the affected subject continues with the study will be taken by the principal investigator 
and the supervisor. 
                                                 
*
 The process outlining HIV and Hepatitis B testing is located in the Screening Medical and HIV Testing Consent Form (Appendix VII). 
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4.4 Criteria for removal from the study 
Any subject may be withdrawn from the study at any time due to the following: 
i. Voluntary withdrawal by the subject due to any reason. 
ii. Illness or injury during the study if regarded as clinically significant by the principal investigator and 
the supervisor. 
iii. Any adverse event or signs of toxicity if regarded as clinically significant by the principal investigator 
and the supervisor. 
iv. Failure of the subject to comply with or be uncooperative towards any study requirements or 
restrictions if regarded as clinically significant by the principal investigator and the supervisor.  
v. Subjects withdrawn or dropped out of the study will be fully documented and accounted for in the CRF. 
 
5 STUDY PROCEDURE 
5.1 Pre- and post-study medical screening 
Pre-study screening will be conducted not more than 30 days prior to the start of the study. Post-study 
follow-up will be conducted within 48 hours after removal of the microdialysis probes from the forearm of 
the subject either at the end of the study or termination of the study or withdrawal from the study.  Pre-study 
and post-study evaluations will be conducted as listed in the table below. 
 
Screening test Pre-study Post-study 
   
Medical tests √1 x 
Medical history √2 √5 
Dermatological assessment √3 √6 
Adhesive sensitivity √4 x 
 
1Medical tests:  HIV, Hepatitis B and pregnancy test 
2Medical history:  Demographic data (date of birth, age, sex, origin), skin (dermatological), allergies, alcohol 
consumption, smoking habits, dietary habits and sporting commitments. 
3Dermatological:  General assessment of the volar aspect of the forearm and any dermatological condition 
which may influence the barrier function of the skin and impact on the absorption of topically applied topical 
corticosteroids. Ultrasound scanning of the texture of the subject’s skin of the forearm. 
4Adhesive sensitivity: Assessment of subject’s sensitivity to adhesive on application site. 
5Medical history:  Since start of study. 
6Dermatological: Examination of forearms and application sites. 
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If any study related abnormalities are observed at the post-study medical, appropriate follow-up action will 
be taken and re-examination and re-testing conducted until the abnormality returns to normal or until the 
principal investigator considers the abnormality to be clinically insignificant. 
 
5.2 Medical tape and clear adhesive glue sensitivity screening 
Not more than 30 days prior to the start of the study, volunteers will undergo an assessment of their tolerance 
to the adhesive on medical tapes and glue used to demarcate application sites. 
The following screening protocol will be utilised. 
i. The forearm of the subject will be washed 1 hour prior to the applications. 
ii. Application of the tape and glue will occur at 0700 hours. 
iii. Six hours after application, the medical tapes and glue will be removed. 
iv. The forearm of the subject will be assessed for allergies to the adhesives. 
  
Subjects who exhibit allergies will not be eligible as candidates for the study.   
 
5.3 Check-in and confinement 
Subjects will check-in at the Biopharmaceutics Research Group (BRG) clinic, Pharmaceutical Sciences and 
Chemistry Building, Rhodes University, Grahamstown at 0700 hours on the morning of the study day when 
they will undergo a brief medical examination, inclusion and exclusion criteria check and study restriction 
check.  Subjects accepted into the study will then be prepared for product application.  Subjects will remain 
in the study room for the entire duration of the study. 
 
5.4 Study design 
The study will comprise of a single phase sequential design conducted on 10 subjects in the first instance, 
followed by another 14 subjects if necessary (see section 4.1). A maximum of two subjects will be studied at 
any one time on any study day and the time between the first and the tenth subject is expected to be 
approximately 6 weeks.  A total of 4 probes and application sites will be employed on the left arm for the 
microdialysis study as shown in the diagram below.  The duration of the study for each subject will be 
approximately 7 hours. 
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Microdialysis probes prepared as described in section 5.6 will be inserted approximately 0.6 to 0.8 mm 
beneath the skin surface for a distance of 3 cm as described in section 5.7.  Probes will be inserted parallel to 
each other across the volar aspect of the left forearm approximately 3 cm apart using 23G x 1½" hypodermic 
needles as guide cannulae.  Anaesthesia will be obtained by the application of an ice pack to the area of 
cannulation.  No other anaesthetic will be necessary and the procedure during and after probe insertion is 
essentially pain-free [23].  Probes will remain in place for no longer than 7 hours. 
 
5.5 Pre-study day activities and procedures 
This study is dependent on a number of preparations prior to the study.  The following is a list of items that 
will be made available at least 24 hours prior to the study. 
 The linear microdialysis probes will be manufactured in-house no more than 24 hours before the study 
(Section 5.6). 
 Extemporaneous 4% m/v clobetasol propionate ethanolic solution (25 ml) will be prepared no more 
than 24 hours before the study.  
 Microlitre glass (300 µl) inserts, 1.5 ml amber HPLC vials and caps will be prepared for use with the 
analytical procedure. 
 Calibration standards and mobile phase for clobetasol propionate analysis will be prepared. 
 Pre-weighed sampling vials or centrifuge tubes will be labelled and ready for sample collection. 
 Sterilisation solution (70% v/v ethanol) will be prepared. 
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 CMA microdialysis syringes, a pair of stainless steel scissors, a pair of tweezers, spatula, and a glass 
rod will be left sterilising overnight in sterilisation solution. 
 The checklist will be performed (Appendix I). 
 The general setup of the clinic will be ensured. 
 
5.6 Linear microdialysis probe manufacture 
The linear probes used for the study will be manufactured in-house by the principal investigator.  The probes 
will be prepared no longer than 24 hours prior to each study day.  The following manufacturing protocol will 
be used to prepare the linear probes for the study. 
i. The desired lengths of the Portex® tube (30 cm), Hemophane, (8 cm) and stainless steel wire (9 cm) 
will be cut. 
ii. Stainless steel wire will be degreased with acetone. 
iii. Hemophane fibres which will be carefully threaded with the stainless steel wire, which will provide 
mechanical strength to the probe assembly. 
iv. A length of Portex® tube will be glued with cyanoacrylate glue (Loctite®) to one end of the Hemophane 
fibre - stainless steel wire setup.  This assembly will now be referred to as the probe. 
v. Probes will be left to dry overnight. 
vi. Preliminary leak tests will be performed with double-distilled water. 
vii. Blue tubing connectors will be attached to the Portex® end of the probes. 
viii. Probes will be stored in a clean glass petri dish with cover and conveyed to the clinic. 
ix. Six probes will be manufactured in the unlikely event that a probe fails the preliminary leak test. 
x. The probes will be sterilised by soaking in 70% v/v ethanol for 20 minutes before use in subjects. 
 
5.7 Study day activities and procedures 
5.7.1 Microdialysis study 
1. Study sessions will begin at approximately 0700 hours each study day. 
2. Verification by history of adequate washout of excluded drugs. 
3. Checklist will be confirmed (Appendix I). 
4. CMA microdialysis syringes pre-sterilised over night (Section 5.5) will be flushed and filled with 
sterile intralipid 20% (perfusate). 
5. Probes will be connected to the syringes and a final 20 drop leak test will be manually performed using 
perfusate prior to installing the syringes into the CMA microdialysis pumps. 
6. The syringes connected to the probes will be housed in the CMA microdialysis pump and aligned. 
7. Subjects will be advised to take a bathroom visit. 
8. The left forearm of the subject will be rinsed with mild soap and water and then blotted dry with a non-
abrasive towel. 
9. Subjects will be requested to lie on a bed. 
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10. The wrist will be loosely restricted using a bandage to prevent any sudden jerk during and after the 
insertion of the probes. 
11. Four parallel application sites aligned in a straight line from the elbow joint to the wrist will be 
demarcated on the ventral surface of the forearm of the subject using a permanent marker. 
12. Entry and exit points through which the guide cannulae (23G x 1½") will be inserted will be marked on 
the forearm at the ends of each application site. 
13. Ice packs will be placed on each application site and by employing sterile technique, guide cannulae 
will be inserted between 0.6 - 0.8 mm below the surface of the skin for a distance of 3 cm transversally 
across the volar forearm in parallel at the four sites.  The application of ice pack at each site on the 
forearm may have to be repeated during the insertion process. 
14. Care will be taken to maintain placement in the superficial dermis in order to minimise intra-probe 
depth variability. 
15. Probes which have been sterilised by soaking into 70% v/v solution will be taken from the ethanol bath 
and the Hemophane portion introduced through the guide cannulae. 
16. The guide cannulae will then be removed leaving the Hemophane portion of the probe in the dermis 
with the Hemophane/Portex® junction abutting the dermal insertion point. 
17. Portex® tubing at the end of each probe will be secured on the arm with Micropore™ tape. 
18. Entry and exit points will be sealed with a drop of cyanoacrylate glue. 
19. A reservoir (3.2 x 2.0 cm) will be adhered over each demarcated site using Bostik® clear adhesive glue 
on the forearm. 
20. Perfusion of the probes will commence at 1µl/min for 60 minutes. 
21. Blank samples will be collected for 60 minutes at a perfusion rate of 1 µl/min . 
22. Approximately 4ml of the product will be applied to each site from an Eppendorf® pipette (Section 5.8).  
23. Samples of perfusate will be collected continuously in 30 minute aliquots in a period of 4 hours i.e. 8 
samples at a perfusion rate of 1 µl/min. 
24. At the end of the last sampling period, the Portex® tubing will be severed from the pump setup and if 
necessary will be further secured on the forearm of the subject. 
25. The reservoirs and its contents will be removed from the forearm of the subjects. 
26. Ultrasound scanning will be conducted to determine the exact depth of each probe underneath the 
surface of the skin. 
27. Probes will be carefully removed from the forearm of the subject ensuring that both the Hemophane 
fibre and the stainless steel wire are removed. 
28. The application site area will be dressed with alcohol swabs and small adhesive plasters. 
29. Subjects will receive a 0.1% m/m hydrocortisone cream to be used twice daily for 2 weeks on the 
forearm to reduce any swelling caused by the insertion of the probes. 
30. The CMA microdialysis syringes, stainless steel scissors, tweezers, and spatula will be left sterilising 
overnight for use with the next subject. 
 
NB: There will be no re-use of apparatus inserted into subjects.  Such apparatus will be discarded as 
biological waste. 
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The actual time of study procedures and/or results/comments obtained during the study will be recorded on 
the ‘Registration of Data during Microdialysis Form’ (Appendix II).  
 
5.8 Product application 
Just prior to the product application, the setting will be adjusted to 4 ml on the dial of the Eppendorf® pipette 
to ensure that the correct volume of the product will be dispensed once into each reservoir for microdialysis, 
respectively.   The Eppendorf® pipette will be used to ensure that an accurate volume of the solution is 
dispensed to each application site for each subject.  Application of the product will be done by the principal 
investigator. 
 
5.9 Posture and physical activity 
Subjects will be expected to lie on a bed for the duration of the microdialysis procedure with the forearm 
restricted loosely with a bandage.  Subjects will not be able to walk around for the whole duration of the 
microdialysis study except for the initial bathroom visit.  The duration of the entire study will last for 
approximately 7 hours.  Strenuous exercises will not be permitted as described in section 4.3. 
 
5.10 Food and fluids 
Subjects will not be restricted with respect to food and fluid intake.  However subjects will be advised to 
keep fluid intake to a minimum, so as to not develop the urge to visit the bathroom frequently during the 
study. 
 
5.11 Subject monitoring 
The principal investigator will be present at all times during the study.  Subjects will be asked open-ended 
questions about their health at the time of each assessment and any discomfort observed during the 
experience will be recorded in the CRF (Appendix V).   
 
6 SAMPLE ANALYSIS 
Samples will be analysed for clobetasol propionate using a validated extraction procedure and a suitable 
analytical method.  Analysis will be done within 48 hours after sample collection. Extracted samples will be 
kept in the fridge at (4 – 8 °C) to prevent any degradation. 
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7 DATA ANALYSIS 
For the microdialysis study, concentration-time profiles will be generated and the AUC will be calculated 
using the trapezoidal rule.  The data used to estimate AUC will be reported. Deletion of data from analysis 
will be justified.  All individual subject data will be documented and the individual dermal concentration-
time curves will be presented in linear/linear and log/linear scale. 
 
7.1 Statistical analysis 
Pharmacokinetic and statistical parameters will be determined by the principal investigator using GraphPad® 
Prism version 4.  The statistical analysis will estimate the variance associated with subject-to-subject 
variability and the probe-to-probe variability within the subjects.  Summary statistics such as median, 
minimum and maximum will be given. 
 
8 ETHICAL AND REGULATORY REQUIREMENTS 
8.1 Ethical and institutional review 
Approval by the Rhodes University Departmental Ethical Standards Committee (RUDESC) will be obtained 
before the study commences.  The original signed copy of the ethical approval will be retained by the 
principal investigator. 
 
The study will be conducted in accordance with the recommendations of the guidelines as set out in the 
Declaration of Helsinki (1964) and its amendments of Tokyo (1975), Venice (1983), Hong Kong (1989), 
Somerset West (1996) and Edinburgh (2000), according to ICH Good Clinical Practice (GCP) guidelines and 
in compliance with the Biopharmaceutics Research Group’s (BRG) SOPs, RUDESC requirements and 
guidelines on the conduct of clinical trials in South Africa. 
 
8.2 Written informed consent 
Preceding the study, the nature, purpose and risk of participating in the study will be explained to all 
volunteers.  If volunteers desire, they will be given time to consider the information and any questions that 
they might have will be answered.  The nature of the insurance cover will also be explained.  They will also 
be informed that they may withdraw from the study at any time without penalty to themselves (other than a 
reduced remuneration) but that they will be encouraged to be committed to completing the study prior to their 
enrolment.  They will sign a consent form in the presence of a witness.  Subjects will receive written, detailed 
instructions concerning the study performance and restrictions. 
 
 Appendix V 
294 
8.3 Case report form 
The Case Report Form (CRF) for this study will be designed and supplied by the principal investigator 
(Appendix V).  All case report forms will be quality assured and all major events such as final acceptance of 
a subject, adverse events and final release from the study will be signed by the principal investigator. 
 
8.4 Record retention 
All source documents, study reports and other study documentation for which the principal investigator is 
responsible will be archived and retained by the Faculty of Pharmacy, Biopharmaceutics Research Group.  
Results will be published in the scientific journals and/or presented in a thesis submitted to Rhodes 
University in fulfilment of the requirement for the degree of Doctor of Philosophy (Pharmacy) after the 
completion of the study. 
 
8.5 Insurance 
Subjects will be insured against any permanent adverse effect on their health which may arise in connection 
with the conduct of the study.  A copy of the insurance certificate (Appendix VI) will be provided to 
RUDESC as part of the application to conduct this study. Adequate insurance cover in the event of 
negligence on the part of principal investigator and the supervisor will be ensured. 
 
8.6 Termination of the study 
The principal investigator reserves the right to terminate the study in the interests of subject welfare 
following consultation with the supervisor.  The supervisor may terminate the study at any time for scientific 
or safety reasons.  If the study is prematurely terminated or suspended for any reason the principal 
investigator will promptly explain to the subjects, take appropriate steps as deemed necessary under the 
circumstances to assure the subjects and where applicable follow up with therapy and inform the RUDESC. 
 
8.7 Adherence to protocol 
Excluding an emergency situation in which proper treatment is required for the protection, safety and well-
being of study subjects, the study will be conducted as described in the approved protocol.  Any deviation 
from the protocol will be recorded and explained. 
 
Should amendments to the protocol be required, the amendments will be documented and signed by the 
principal investigator and the supervisor.  If the protocol amendment(s) has an impact on the safety of 
subjects, such as a change in dosing regimen or additional formulations, the amendment will be submitted to 
the RUDESC for approval. 
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8.8 Blinding 
Subjects will not be blinded and will be informed about the products for use at the application sites. 
 
8.9 Adverse events/Adverse drug reactions 
Subjects will be questioned on their health status at check-in, during the course of the study and before 
leaving the clinic at the end of the study.  During the study, open-ended questions will be asked.  If any 
adverse events are reported, the principal investigator will monitor the adverse event, initiate appropriate 
treatment if required and decide whether or not to withdraw the subject from the study.  Signs and symptoms 
of any adverse events which occur during the study will be fully documented in the appropriate CRF 
(Appendix V).  If necessary adverse events will be referred to a suitably qualified medical practitioner for 
assessment and follow up. 
 
Adverse events (which include illnesses, subjective and objective signs and symptoms that have appeared or 
worsened during the course of the study) will be assessed by the principal investigator and the supervisor 
during and after the study to determine whether or not they are related to the investigational test product (i.e. 
ADR), to the study procedure or other.  The outcome of this assessment will be recorded in the appropriate 
CRF (Appendix V). 
 
AEs classified as severe or serious will be reported to the supervisor, Rhodes University Ethical Standards 
Committee within 24 hours. 
 
ADRs classified as serious and unexpected will be subject to expedited reporting as detailed in the ICH E2A 
and E2B guidelines on Clinical Safety Data Management and Data Elements for Transmission of Individual 
Case Report Forms respectively. 
 
9 REPORTS 
A full report on the study will be compiled by the principal investigator in the format requested by the 
supervisor and submitted to the supervisor.  The analytical report will include results for all standard and 
quality control samples.  A representative number of chromatograms or other raw data will be included 
covering the whole concentration range for all standards and quality control samples.  The validation report 
will also be submitted. 
 
ABBREVIATIONS 
ADR Adverse Dug Reaction 
AE Adverse Effect/Event 
ANOVA Analysis of Variance 
AUC Area Under the Curve 
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BRG Biopharmaceutics Research Group 
Cmax Maximum Concentration 
CRF Case Report Form 
CRO Clinical Research Organisation 
HPLC High Pressure Liquid Chromatography 
GCP Good Clinical Practice 
ICH International Conference of Harmonisation 
IRB Internal Review Board 
QA Quality Assurance 
RUDESC Rhodes University: Departmental Ethical Standards Committee 
SOP Standard Operating Procedure 
tmax Maximum Time 
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APPENDIX I 
CHECKLIST 
SUBJECT NAME  SUBJECT INITIALS  DATE  
STUDY NUMBER WL_002 VOLUNTEER 
REFERENCE 
   
2.5 ml microdialysis syringes (labelled were necessary)  
23G 1½” intravenous needles  
3M Micropore™ tape (1530)  
Alcohol swabs  
Bandages  
Sharps and biological waste container   
Calculator  
CMA 400 microdialysis pumps setup  
Cotton swabs  
Cyanoacrylate glue (Loctite® glue) and Clear adhesive glue (Bostik®)  
Electrical cables and power supply  
25ml of a 4%m/v clobetasol propionate ethanolic solution  
Green cloth underlay  
Human subject under study  
Ice packs  
Pen/marker  
Perfusate solution – Intralipid 20%  
Prepared probes attached to blue connectors (leaks pre-checked with water) in glass dish  
Pre-weighed and labelled sampling vials/centrifuge tubes  
Ruler  
Scissors  
Snack/Lunch/Supper  
Soap and towel  
Sterile gloves  
Sterilisation solution (70% v/v ethanol)  
Sterilisation trays  
PVC Reservoirs  
Thermometer  
Timer  
Tweezers  
Ultrasound scanner setup  
CHECKED BY: SIGNATURE: 
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APPENDIX II 
REGISTRATION OF DATA DURING MICRODIALYSIS EXPERIMENTS 
Date  Subject initials  
Subject/Volunteer name  Volunteer Reference  
Age  Study number WL_002 
Sex  
Race  
Formulation  
Applied dose  
Site  
Principal Investigator  
Assistant principal 
investigator 
 
Room temperature  
Relative Humidity  
 
 
TIME SCHEDULE 
Task Time start Comments 
Confirm checklist   
Fill syringes with perfusate   
Connect probes to syringes   
Preliminary leak check (20 drops)   
Confirm Inclusion and Exclusion 
criteria 
  
Confirm consent form   
Flush and align syringes in CMA 400 
pump 
  
Bathroom visit (volunteer!!)   
Forearm wash   
Wrist bandage to be placed   
Mark entry and exit points on arm   
Probes put in ethanol soak (20 mins)   
Ice pack retrieval   
Insertion 1   
Insertion 2   
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Insertion 3   
Insertion 4   
Probe insertions (4 probes)   
23G intravenous needle removal   
Seal entry and exit points (15 mins)   
Place reservoirs over probes   
Secure Portex® on the arm with 
Micropore™ 
  
Stabilise flow at 1.0 µl/min and collect 
blank solutions (60 minutes) 
  
Application of reference formulation 
and commence sampling every 30 
minutes at a flow rate of 1.0 µl/min for 4 
hours 
  
End of microdialysis sampling   
Cut the Portex® tubing to the pump   
Remove the templates from the arm   
Ultrasound scanning   
Probes out of arm   
Dress area with alcohol swabs and 
bandages 
  
Ethanol soak of equipment   
End of study   
 
ULTRASOUND SCANNING 
 Probe 1 (mm) Probe 2 (mm) Probe 3 (mm) Probe 4 (mm) 
 Skin Probe Skin Probe Skin Probe Skin Probe 
Scan 1(a)         
Scan 2(b)         
Scan 3(c)         
Mean         
Std Dev         
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APPENDIX III 
INFORMATION FOR VOLUNTEERS BROCHURE 
 
APPLICATION OF DERMAL MICRODIALYSIS FOR THE ASSESSMENT OF THE 
BIOAVAILABILITY OF CLOBETASOL PROPIONATE IN HEALTHY VOLUNTEERS 
 
STUDY NUMBER: WL_002 
PROTOCOL VERSION 2 
BROCHURE VERSION WL02 
November 2008 
 
1 Study objective 
The study involves research to assess the rate and extent to which clobetasol propionate diffuse into the skin 
from an extemporaneous topical ethanolic solution, using dermal microdialysis as a measure of efficacy.  
This study will provide valuable insight for future use in the assessment of amount of drug penetrated into the 
skin and the sameness of generic and proprietary clobetasol propionate formulations. 
  
Reference product Clobetasol Propionate Ethanolic Solution 
Drug Clobetasol propionate 4% m/v 
Company Rhodes University 
 South Africa 
 
The study will involve approximately 10 subjects. 
 
2 Ethical considerations and standards of practice 
Innovator drug companies who develop a new drug have patent protection for the drug for a number of years, 
typically 15 - 20.  Once the patent has expired, generic drug companies are permitted to make and market 
their own products as competitors to the innovator's product, usually at a substantially reduced cost.  
However, a prerequisite for registration with national drug registration bodies (and subsequent marketing) is 
that the rate and extent to which the drug is absorbed from the generic product is shown to be equivalent to 
that from the innovator product.  This is an indirect way of demonstrating that the generic product will be as 
effective clinically as the innovator and is demonstrated by what are known as ‘comparative bioavailability 
or bioequivalence studies’. 
 
 
2.1 Ethical and institutional review 
Approval by the Rhodes University Departmental Ethical Standards Committee (RUDESC) is required 
before the study can commence.  The study will be conducted in accordance with guidelines set out in the 
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Declaration of Helsinki (1964) and its amendments of Tokyo (1975), Venice (1983), Hong Kong (1989), 
Somerset West (1996) and Edinburgh (2000).  This Declaration sets out ethical principles, which protect your 
rights participating in such studies.  Guidelines on the conduct of clinical trials in South Africa will be 
adhered to. 
 
The study will also be conducted according to the ICH (International Conference on Harmonisation) 
Guidelines for GCP (Good Clinical Practice), the Biopharmaceutics Research Group’s Standard Operating 
Procedures and the requirements of RUDESC. 
 
2.2 Written informed consent 
Preceding the study, the nature, purpose and risk of participating in the study will be explained to you.  
Should you wish, you will be given time overnight to consider the information and any questions that you 
might have will be answered. The nature of the insurance cover will also be explained.  If you decide to 
participate in the study you will sign a consent form in the presence of a witness.  You are encouraged to 
consult your parents or personal medical doctor for approval in this study. 
 
3 Voluntary nature of participation 
Your participation in this study is entirely voluntary and you may withdraw from the study at any time, 
without prejudice.  Should you decide to participate, we ask that you try to be committed to completing the 
study if at all possible.  Should you encounter any problems along the way, please speak to me so that every 
effort can be made to assist you. 
 
4 Dates and duration of the study phases 
The study consists of one phase only which will run over a day.  The study will be conducted from 0700 
hours until 1400 hours. 
 
5 Place of study 
The study will be conducted in the Biopharmaceutics Research Group (BRG) clinic in the Pharmaceutical 
Sciences and Chemistry Building at Rhodes University.  The principal investigator and the supervisor will be 
suitably qualified, trained and experienced to perform the study procedures. 
 
6 Background information 
Clobetasol propionate is used in the management and treatment of patients with skin disorders such as 
psoriasis, eczema and dermatitis.  It is for adult use only.   
 
Microdialysis is a technique for sampling of natural and foreign substances in the space surrounding cells in 
living tissue.  The technique was originally developed for brain research but has now been used extensively 
in other tissues in animal models and human studies.  In human studies, this technique has been employed in 
adipose tissue, brain, heart, lung, solid tumours, skin etc.  A microdialysis fibre consists of a semipermeable 
membrane forming a thin hollow ‘tube’ (typically 0.22 mm ID), which acts like a capillary.  The fibre has 
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one end connected to a tube which leads to a micropump and the other end to sampling tube.  The probe is 
implanted in the dermis or the middle layer of the skin via a needle.  The microdialysis fibre is slowly 
perfused with Intralipid and substance in the skin will diffuse across the membrane into the Intralipid which 
is collected and analysed.  Substances move across the dialysis membrane will occur by passive diffusion. 
 
 
 
Dermal microdialysis sampling is described as a minimally invasive technique.  The insertion of the 
microdialysis probes creates acute inflammatory reaction characterised by increased blood flow, erythema 
and swelling demonstrated with the use of a linear microdialysis probe by a 23G needle.  This procedure has 
been shown to be safe and no irritations with the probes have been noted to date.  Ice is used as anaesthesia 
providing minimum discomfort.  No more discomfort is observed when the needle has been removed.  You 
will be supplied with a tube of hydrocortisone 0.1% m/m cream to apply twice daily for 2 weeks to arrest any 
residual inflammation after the completion of the study.  Sterile techniques will be employed during the study 
to ensure the minimum risk of skin infections. 
 
Study design 
On the left arm, four very thin microtubules which are 0.2 mm in diameter (microdialysis probes) will be 
inserted approximately between 0.6 - 0.8 mm beneath the skin and approximately 3 cm apart.  Ice will be 
used as a means of anaesthesia to allow for minimum discomfort when the probes are inserted into the skin 
by means of a needle.  Pain should be minimal – if at all.  Once the microdialysis probes are in place, you 
will not be able to move freely, but will have to remain lying on a bed or sitting in an arm chair with the 
opportunity to watch TV or read.  During the study, the washout liquid which is pumped through the probes 
will be collected every 30 minutes.  The microdialysis study will conclude at 1400 hours, after the position of 
the probes under the skin has been ascertained by means of an ultrasound scanner.  This is a quick pain free 
non-invasive technique which uses high frequency sound to measure the depth of the probe in the skin.  
Thereafter the probes will be removed from the skin and the area where the probes were inserted will be 
covered by small adhesive plaster strips.   
 
8 Adverse effects 
For topical preparations, delayed hypersensitivity may occur at the site of the application, but this is 
uncommon.  It is advised that clobetasol propionate cream preparations should not be used on open wounds 
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or lesions on the skin or near the eye.  The skin reactions are however reversible on discontinuation of 
therapy.  Clobetasol propionate must not be administered to healthy or ill individuals who have an allergy to 
this compound or to any of the ingredients in the formulation. In this study, a single application to a limited 
area is unlikely to invoke any adverse effects but procedures will be in place to address any discomfort noted 
during and after the study.   
 
Microdialysis technique is safe and no adverse reactions such as irritation or allergic reactions to the probes 
have been reported so far. The insertion of microdialysis probes creates slight but reversible swelling.  This is 
caused by the use of the needle for insertion of the linear microdialysis probe.  No reactions have been 
reported to date in tissue around the probe 8 to 10 hours after probe insertion. Ice is used to induce 
anaesthesia during probe insertion to provide minimum discomfort. No significant discomfort is observed 
when the needles have been removed. Sterile techniques will be employed during the study to ensure the 
minimum risk of skin infections.  
 
9 Conditions of participation in the study   
To participate in this study you must:- 
 Undergo and pass a medical assessment which includes giving a general medical history, recording of 
vital signs, body height and weight measurements and an assessment of your skin. 
 Undergo a skin test to assess any possible allergy or sensitivity to the adhesive in the medical tape and 
clear glue that will be used.  After 6 hours the tape and glue is removed, the forearm washed and the 
skin inspected for any signs of reaction. 
 Fulfil certain inclusion and exclusion criteria which have been set out in the protocol. 
 Agree to be fully committed to the study and conscientiously abide by the restrictions required of you 
as listed in section 11. 
 
NB: It is extremely important that you divulge any past medical history and abide by the rules for 
participation in this study.  This is to protect you from unnecessary risks and to help ensure the reliability of 
the data gathered. 
 
10 Volunteer inclusion/exclusion criteria 
You will be considered for this study if you are aged between 18 and 50, in general good health, available for 
the entire study period and if female you are on reliable contraception or abstaining from sex. 
 
Please do not consider participating in this study if you 
xv. are breast feeding. 
xvi. are contemplating becoming pregnant in the time immediately following the study. 
xvii. are pregnant. 
xviii. have a known allergy/hypersensitivity to clobetasol propionate or any corticosteroid. 
xix. have any history of drug or alcohol abuse. 
xx. have any mental deficiency or handicap. 
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xxi. have hairy ventral forearm surfaces and/or abrasions on the underside of their forearms. 
xxii. have engaged in any sun-tanning or taken any sunny vacations within the last month. 
xxiii. have participated in another corticosteroid dermal microdialysis study within 2 months of the 
study date. 
xxiv. have used any corticosteroids within the last three months. 
xxv. suffer from any allergic conditions (hayfever, allergic rashes, asthma or childhood eczema). 
xxvi. suffer from any skin disorder such as psoriasis, eczema or other relevant skin disorder. 
xxvii. take regular medicine or tablets or used any creams within the last week (contraceptive pills 
excluded). 
xxviii. test positive for HIV and Hepatitis B•. 
xxix. have a history of any neurological, kidney or liver disorders. 
xxx. have a known allergy/hypersensitivity to egg, soy and/or nut products. 
 
11 Study restrictions  
 
Restricted item 
 
Duration of restriction 
 
Examples of restriction 
 
Comments 
Prescription 
drugs 
From 1 week before the start of 
the study, until the end of the 
study. 
- all medication obtained 
on prescription 
- antibiotics, vaccinations 
- anti-inflammatories 
- anti-asthmatic drugs 
- anti-acne drugs etc. 
This includes all long 
term medication. 
Over-the-
counter (OTC) 
drugs 
 
 
From 1 week before the start of 
the study, until the end of the 
study. 
- anti-flu drugs, sports 
supplements, antacids, 
paracetamol 
- vitamins, minerals 
-homeopathics 
This includes herbs, 
natural products & all 
medications that can be 
bought without a 
prescription. 
Alcohol From 48 hours before the start 
of the study and during the 
study. 
 
No alcohol for a total of just 
over 2 days  
All alcoholic drinks and 
alcohol containing foods. 
It is important that this 
requirement is taken 
seriously and observed, 
as alcohol can 
significantly affect the 
liver. 
Strenuous 
Physical Exercise 
From 48 hours before the start 
of the study. 
No strenuous exercise for a 
total of almost 2 days. 
Rugby 
Squash 
Rowing 
Gym 
Light exercise such as 
walking is permitted. 
                                                 
•
 The process outlining HIV and Hepatitis B testing is located in the Screening Medical and HIV Testing Consent Form 
 Appendix V 
307 
 
Restricted item 
 
Duration of restriction 
 
Examples of restriction 
 
Comments 
Tennis etc. 
Smoking No smoking will be permitted 
during the study. 
Cigarettes No cigars or pipe 
smoking. 
Moisturising 
creams 
You must refrain from applying 
any type of skin conditioning 
creams to your forearms from 
24 hours before the study until 
the end of the study 
All skin creams, e.g. 
moisturizers, Vaseline, 
medicated creams, 
aqueous cream and 
tanning lotions. 
This could interfere with 
the absorption of the 
study formulation. 
 
NB: Random checks will be done to ascertain whether you have managed to adhere to the above restrictions.  
If you have not been able to adhere to the study restrictions please inform us immediately or else you may not 
be able to participate with a reduced remuneration as detailed in section 15. 
 
12 Procedures and duration of the study 
The study consists of a single phase. The procedures and duration of the study are detailed below. 
On the morning of the study you must check into the clinic at 0700 hours. At check-in you will be:- 
 questioned and undergo a brief medical examination to establish whether you still fulfil all the 
inclusion and exclusion criteria since your pre-study medical examination and that you have complied 
with the study restrictions. 
 You will be instructed to use the bathroom because when the study starts your wrist will be restricted 
and you will not be able to leave the bed or the chair for approximately 6 hours. 
 The study will commence at 0730 hours and you will be expected to remain in the clinic throughout the 
course of the study. 
 Entertainment and lunch will be provided. 
 You are not restricted with regard to food and drink during the study period although minimum fluid 
intake will be advised so as not to develop an urge to visit the bathroom during the study. 
 Should any new and significant information about the study medication become available during the 
course of the study, this will be communicated to you. 
 A tube of 0.1% m/m hydrocortisone cream will be given to you to self medicated your arms twice daily 
for 2 weeks. 
 
13 Benefits 
Since you have been screened as healthy before the start of the study, there is no medical benefit to you from 
participating in this study. 
 
14 Financial compensation 
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You will receive a gratuity of R 500.00 for full participation in the study.  Payment following withdrawal 
from the study will be calculated on a pro-rated basis from the start of the study at 0700 hours to the end of 
the study at approximately 1400 hours. 
 
15 Adverse medical events 
You will be monitored prior to, during and after each study day for any adverse events whether or not they 
are thought to be related to the investigational products or procedures.  If any adverse events are reported, the 
principal investigator/supervisor will decide whether or not to withdraw you from the study and what 
treatment is appropriate.  In addition, the Rhodes University Departmental Ethical Standards Committee will 
be notified of any serious adverse events (SAEs).  All adverse events will be monitored and treated until 
recovery to your pre-study status.  You will be referred to a medical doctor if necessary and all medical costs 
will be covered by the BRG.  All adverse events will be monitored and treated appropriately until a 
satisfactory outcome is attained. 
 
16 Insurance 
You are covered by an insurance policy taken out by the BRG, in case of claims arising from the medication 
or procedures as outlined in the protocol, and in case of negligence on the part of the BRG.  If you have 
personal insurance e.g. life insurance /assurance your participation in this study may affect your policy. You 
are advised to determine this prior to participating in the study.  If you need any assistance in this regard 
please feel free to contact me.  During the clinical study you are not entitled to participate in other studies and 
you should not participate in any other study/s for thirty (30) days after completion of this study to ensure 
that there are no interactions.  Insurance policies will be available from the principal investigator for scrutiny. 
 
17 Confidentiality 
Your medical history and physical examination records and any other information or data generated during 
this study will be kept confidential.  However, you must agree that all the above mentioned documentation 
and data can be released for any lawful purpose and released for publication in scientific journals and/or 
presentation in a thesis submitted to Rhodes University in fulfilment of the requirement for the degree of 
Doctor of Philosophy (Pharmacy) after the completion of the study.  In such cases your name will be 
removed from all documentation to ensure your anonymity.  In signing the consent form for the study, you 
agree to the granting of access to your medical data. Your medical data will be provided to you upon request 
and you will be informed of significant abnormalities identified before or after the study. 
 
Your consent is also required to permit the study staff to consult with any medical practitioner who is 
normally responsible for your care if the need arises.  The onus, however, is on you to inform such a 
practitioner of your intention to participate in such a study, should you so wish. 
 
18 Amendments/Changes 
Should there be any changes made to the trial protocol these will be communicated to you verbally and in 
writing in time to enable you to reconsider your decision to participate in the study. 
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19 Withdrawal  
You may withdraw from the study at any time due to the following: 
 Voluntary withdrawal by yourself due to any reason. 
 Illness or injury during the study if regarded as clinically significant by the principal investigator and 
the supervisor. 
 Any adverse event or signs of toxicity if regarded as clinically significant by the principal investigator 
and the supervisor. 
 Failure to comply with or be uncooperative towards any study requirements or restrictions if regarded 
as clinically significant by the principal investigator and the supervisor.  
 It is your right to withdraw from the study at any time. However, by signing the Informed Consent 
form and participating in the study, you agree to be committed to completing the study if at all possible. 
 
20 Termination of the study 
The BRG reserves the right to terminate the study prematurely in the interests of your welfare. 
 
21 Emergency contacts 
You are obliged to notify the principal investigator as soon as possible if you are unable to follow the 
procedures or if you suffer any adverse event we have not told you about.  In particular, you should make 
every effort to contact me if you suffer a Serious Adverse Events (SAEs) or need to take additional 
medication of any kind.  This applies to out of hours, as to normal work time. 
 
In such cases of medical emergencies during the study, or if you have any urgent questions relating to 
adverse effects or unrelated illness, please feel free to telephone the supervisor at any time at the following 
phone numbers or contact via email: 
 
Work 046 603 8399 Cell 082 802 1845 Email i.kanfer@ru.ac.za 
 
22 Contacts for additional information 
The following individuals are responsible for conducting this study and as such may be approached for more 
information: 
Portfolio Name Contact details 
    
Principal Investigator Wai Ling Au Work 046 603 8412 
 BPharm (Rhodes) Cell 072 612 0972 
  Email g02a1351@campus.ru.ac.za 
    
Supervisor Professor Isadore Kanfer Work 046 603 8399 
 BSc (Pharm), BSc (Hons), PhD 
(Rhodes) 
Email i.kanfer@ru.ac.za 
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If you have questions about this study which have not been answered adequately by the principal investigator, 
supervisor, you should first discuss them with your doctor.  After you have consulted your doctor and still 
dissatisfied you may contact the Rhodes University Ethics Standards Committee (departmental) at: 
 
Ms Carmen Oltmann 
Chairperson: Rhodes University Departmental Ethics Standards Committee 
RHODES UNIVERSITY 
Tel:. 046 603 8494 
Fax:. 046 636 1205 
Email:. c.oltmann@ru.ac.za 
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APPENDIX IV 
STUDY PARTICIPATION INFORMED CONSENT FORM 
 
APPLICATION OF DERMAL MICRODIALYSIS FOR THE ASSESSMENT OF THE BIOAVAILABILITY 
OF CLOBETASOL PROPIONATE IN HEALTHY VOLUNTEERS 
 
STUDY NUMBER: WL_002 
PROTOCOL VERSION 2 
CONSENT VERSION 2 
November 2008 
 
I ........................................................................................... Born on............................. 
 
Present address ............................................................................................ 
............................................................................................ 
hereby give permission that the necessary probes may be inserted into the surface of my skin and the 
microdialysis procedure conducted as described to me by the principal investigator and that the formulation 
stated below be applied to my skin during the course of this study. 
 
Reference product: Clobetasol Propionate Ethanolic Solution (Clobetasol propionate 4% m/v) – Rhodes 
University, South Africa 
 
My consent is given freely and I realise that it may be withdrawn at any time, without penalty to me.  
Furthermore, I understand that I do not give up any of my legal rights by signing this consent form. 
 
I have been fully informed by .................................................................................... regarding the possible 
adverse effects of the medication, procedures to be used in this study and the risks thereof, as detailed in the 
“Information for Volunteers Brochure”.  I will receive a copy of the information brochure and signed consent 
form for my records. 
 
I undertake to comply with all the relevant conditions contained in the Information to Volunteers Brochure 
and confirm that I understand that it is important not to withhold or misrepresent any information asked of 
me.  I agree to undergo the necessary pre- and post-study medical investigations as listed in the protocol. 
 
I undertake to inform the principal investigator immediately of any symptoms - expected or unexpected - 
which I might experience. 
 
I agree to my medical records being reviewed in the event of an audit, enquiry, monitoring and/or inspection 
on the understanding that my anonymity will be maintained. 
 
 
I agree and consent that the BRG may consult with consultants/supervisor who are normally 
responsible for care of study subjects. 
_____ 
Initial 
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I have been informed that if I do not adhere to the protocol, it may result in my exclusion from the study and 
forfeiture of the agreed upon remuneration.  I acknowledge that instructions relating to my participation in 
this study have been communicated to me both verbally and in writing, and that I understand them. 
 
I also declare that I have made the necessary arrangements regarding the attendance of lectures and other 
academic activities. 
 
I understand that a policy to cover volunteers in clinical studies against death or disablement arising as a 
direct result of participation in such clinical studies has been taken out by the Biopharmaceutics Research 
Group.  I accept the conditions of the policy as set out in the insurance policies. 
 
I acknowledge that I will receive R 500.00 for full participation in this study and that I will receive a pro-
rated amount if I withdraw from the study before it has been completed. 
 
 
 
 
 
 
 
 
 
 
 
 
__________________________ ___________________________ 
Signature of volunteer Date (yyyy-mm-dd) 
  
  
  
__________________________ ___________________________ 
Signature of a witness Date (yyyy-mm-dd) 
  
  
  
__________________________ ___________________________ 
Principal Investigator 
Wai Ling Au 
BPharm (Rhodes) 
Date (yyyy-mm-dd) 
 
 
Contact details of subject  
Telephone number  
Cell number  
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APPENDIX V 
CASE REPORT FORM 
 
APPLICATION OF DERMAL MICRODIALYSIS FOR THE ASSESSMENT OF THE BIOAVAILABILITY 
OF CLOBETASOL PROPIONATE IN HEALTHY VOLUNTEERS 
 
STUDY NUMBER: WL_002 
PROTOCOL VERSION 2 
CASE REPORT FORM VERSION 2 
November 2008 
 
 
 
Reference product Clobetasol Propionate Ethanolic Solution (clobetasol propionate 4% 
m/v) – Rhodes University, South Africa 
  
Principal Investigator Wai Ling Au 
BPharm (Rhodes) 
Supervisor Professor Isadore Kanfer 
BSc (Pharm), BSc (Hons), PhD (Rhodes) 
 
 
 
 
Subject initials  
Volunteer reference number  
Study subject number  
Date of screening medical  
 
 
Pre-study examiner: 
Name and initials  
Qualifications  
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MEDICAL HISTORY (to be completed by the principal investigator) 
 
DEMOGRAPHIC DATA 
Birth Date  Age in Years Sex (M/F) Origin Other 
   White Black Oriental  Indian  
Height (m) 
 
 
Weight (kg) 
 
 
BMI (Body Mass Index) 
To be calculated by BRG 
Investigators 
Not required 
 
REVIEW OF PAST ILLNESS 
 Describe Abnormalities System/Site Illness? 
Y/N 
 
Skin -Connective Tissue    
Any other illness?    
    
 
PHYSICAL EXAMINATION (to be completed by the examining principal investigator) 
 
VITAL SIGNS 
Blood Pressure - Supine (mmHg) Pulse (beats/min) Oral Temperature °C 
   
 
GENERAL SYSTEMS EXAMINATION 
 Describe Abnormalities System/Site Illness? 
Y/N 
 
Skin - General    
Skin - Forearms    
Medical tape allergy pass    
 
INCLUSION/EXCLUSION CRITERIA 
(NB: Unshaded areas - acceptable: Shaded areas - unacceptable) 
 YES NO 
Will you be available for the entire study period?   
Are you in general good health?   
Are you aged between 18 and 50?   
Do you have eczema or scratch marks on the underside of your forearms?   
Do you suffer from any skin disorder such as psoriasis or other relevant skin disorder?   
Do you suffer from any neurological, kidney or liver disorders?   
Do you suffer from any allergic conditions (hayfever, allergic rashes, asthma or childhood 
eczema)? 
  
Have you engaged in any sun-tanning or taken any sunny vacations within the last month?   
Do you take any regular medicine (prescription or OTC)?   
Have you taken any medicine or tablets or used any creams within the last week 
(contraceptive pills excluded)? 
  
Have you participated in another corticosteroid dermal study within 2 months of the study 
date? 
  
Have you used any corticosteroids within the last three months?   
Do you have any mental deficiency or handicap?   
Are you pregnant?   
Have any history of drug or alcohol abuse?   
Are you contemplating becoming pregnant in the time immediately following the study?   
Are you breastfeeding?   
Are you using reliable contraception (The contraceptive pill, minipill, IUD or abstinence)?   
Do you have a known allergy/hypersensitivity to clobetasol propionate or any other 
corticosteroids? 
  
Have you ever had a reaction to a local anaesthetic injection at the dentist or in casualty? 
Are you allergic to any soy/egg/nut products? 
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VOLUNTEER ACCEPTABILITY /COMMENTS WITH REGARDEXAMINATION/INCLUSION/ 
EXCLUSION CRITERIA 
Acceptable   Not Acceptable  
Notes/Comments   
   
   
   
 
 
Sign                                                                                           Date  ___________________________________                                            
Principal Investigator          (dd/mm/yy) 
 
 
POST-STUDY REPORT/MEDICAL 
 
SUBJECT/STUDY STATUS 
 
Study Completed   Study Not Completed  
Comments (If “no” give reasons and procedure/follow-up undertaken) 
   
   
 
Sign                                                                                                            Date  _______________________                                     
principal  investigator                                                     (dd/mm/yy) 
 
 
CLINICAL EXAMINATION/SUBJECT RELEASE 
 
Test Status/Comments 
 
Medical Update 
 
 Application Site 
Assessment 
 
Subject Released  Subject Retained for Further Investigation  
 
 
Sign                                                                                                            Date  _______________________                                            
                                             Principal Investigator                                    (dd/mm/yy) 
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APPENDIX VI 
CERTIFICATE OF INSURANCE 
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APPENDIX VII 
SCREENING MEDICAL AND HIV TESTING CONSENT FORM 
 
APPLICATION OF DERMAL MICRODIALYSIS FOR THE ASSESSMENT OF THE BIOAVAILABILITY 
OF CLOBETASOL PROPIONATE IN HEALTHY VOLUNTEERS 
 
STUDY NUMBER: WL_002 
PROTOCOL VERSION 2 
HIV CONSENT FORM VERSION 1 
November 2008 
 
I ........................................................................................... Born on........................... 
 
Present address ............................................................................................ 
............................................................................................   
hereby: 
vii. Confirm that my consent is given freely and I realise that it may be withdrawn at any time, 
without penalty to me. 
viii. Confirm that I have read the information contained in Appendix III and have been informed of 
the tests to be undertaken. 
ix. Confirm that I have been informed of the general procedure for clinical studies undertaken by 
the BRG. 
x. Confirm that I have attended an informed consent session specific for the clinical study for 
which I am volunteering at which the contents of the ‘Information for Volunteers’ Brochure, 
Version WL02 were explained to me and a copy given to me to take home and read before 
making my decision. 
xi. Recognise that undergoing a screening medical does not ensure automatic inclusion into the 
clinical study. 
xii. Agree to my medical records being reviewed in the event of an audit or enquiry on the 
understanding that my anonymity will be maintained. 
xiii. Agree to be screened for Hepatitis B. 
xiv. Agree to be screened for the Human Immunodeficiency Virus (HIV), which causes Aquired 
Immunodeficiency Syndrome (AIDS), and with respect to this test: 
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a. I understand the information contained in the attached three-page HIV Informed Consent 
Document (Appendix A) 
b. I freely consent to the withdrawal of blood from me. 
c. I freely consent to the testing of that blood. 
d. I understand that the results will be kept confidential, except for the disclosure by the BRG of any 
reactive result to the doctor whom performed the screening medical or a doctor of my choice. 
e. I have read the information in this document about what a test result means. 
f. I understand that the BRG will pay for one session of pre- and post-test counselling which will be 
conducted by the St Raphael Centre at 11 Donkin Street, Grahamstown 6139. 
g. I understand that I should contact the principal investigator or a doctor of my choice for further 
information and counselling if required. 
h. I understand that I have the right to request and receive a copy of this form. 
 
 
 
 
 
__________________________ ___________________________ 
Signature of volunteer Date (yyyy-mm-dd) 
  
  
__________________________ ___________________________ 
Principal Investigator 
Wai Ling Au 
BPharm (Rhodes) 
Date (yyyy-mm-dd) 
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Appendix A  HIV SCREENING TEST INFORMATION SHEET 
 
ALL CLINICAL STUDY VOLUNTEERS MUST READ THIS INFORMATION SHEET BEFORE 
THE TEST FOR HIV IS DONE 
 
INTRODUCTION 
This document contains the information that you have a right to be given before agreeing to be tested for HIV 
antibodies.  The HIV antibody test (sometimes called the “AIDS test”) is a test that will tell you whether or 
not you have been infected with Human Immunodeficiency Virus (HIV). Below we set out your rights with 
respect to this test, information about HIV and AIDS and the AIDS test, any why the BRG wants to test you 
for HIV antibodies before it decides whether or not to include you in a clinical study. 
 
WHAT ARE MY RIGHTS? 
Your rights are: 
 Not to be tested for the HIV without your free and informed consent. 
 To be given all material information on the harms, risks and benefits of taking, or not taking, the AIDS 
test. 
 To refuse to take the test. If you do this, you will not be able to participate in a clinical study. 
 You will receive pre-test counselling which is private and confidential, and which will inform you 
more about the test and it’s implications before you consent to the test.  Pre-test counselling will be at 
the expense of the BRG. 
 To have your test result treated confidentially. The result will be made available to your doctor only 
with your prior consent.  A test result will also be stored by the BRG.  You have the right to access this 
information to check that it is correct. 
 To one session of post-test counselling at the expense of the BRG, whether the test is positive or 
negative.  After this you will be referred to a healthcare provider who will provide you with further 
counselling and treatment if a positive result is obtained. 
 
WHAT IS HIV? 
HIV is the virus that causes AIDS.  While infected with HIV, and before a person develops AIDS, he or she 
will feel well or healthy.  During this time, the person will be able to infect other people with the virus. 
 
WHAT IS AIDS? 
AIDS is the name for a number of illnesses that develop as a result of being infected with HIV.  The HIV 
attacks the immune system and leaves it unable to fight various illnesses.  More than half of the people 
infected with the HIV will get AIDS within 10 years of infection. 
 
When you are sick with AIDS, you can usually no longer work.  AIDS is a serious disease that eventually 
leads to death. 
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WHAT IS THE HIV TEST? 
The HIV test checks your blood for antibodies to the HIV.  The test cannot tell you the date you were 
infected, or by whom you were infected.  A sample of blood will be drawn from you.  It will be sent to a 
pathologist’s laboratory, where it will be tested. 
 
HOW DO I BECOME INFECTED WITH THE VIRUS THAT CAUSES AIDS? 
Almost all cases of infection result from sexual intercourse.  The HIV is transmitted in this way from one 
person to another through semen and vaginal fluids. The HIV can also be passed on to babies through the 
mother’s blood or through breast-feeding.  Although rare, the HIV can be transmitted by contact with 
infected blood - for example, through blood transfusions, through sharing needles during drug-of-abuse use 
or by inadvertent needle-stick injuries or spillage, where health care workers are especially at risk.  Most 
cases of infection are transmitted from women to men, or from men to women. Men and women of all ages, 
races and religious beliefs can be infected with the HIV.  Homosexual transmission also occurs. 
 
IS THERE A CURE FOR HIV AND AIDS? 
There is no known cure for HIV or AIDS. Modern medical science, as well as traditional healers, have 
searched for cures for the HIV.  So far these efforts have been unsuccessful. 
 
However, should you be HIV positive, by adopting a healthy life-style and having your HIV managed 
properly by health care workers, you can greatly enhance your quality of life before AIDS sets in.  It is 
therefore of the utmost importance that you keep yourself both mentally and physically healthy in spite of 
being HIV positive. It is also possible that a cure may be found over this time. 
 
WHY DOES THE BRG NEED TO TEST FOR THE HIV? 
The BRG conducts clinical tests on pharmaceutical formulations. These tests involve administering 
medications to study subjects and taking blood samples from each subject at various intervals during the 
study.  Blood samples are then centrifuged and prepared for analysis, when the concentration of medication 
in each sample is measured.  During the clinical and analytical process numerous people handle each blood 
sample e.g. the nurse who takes the sample, the technician who prepares the sample immediately after it is 
taken and the analyst who prepares the sample for analysis.  The BRG is duty bound to ensure that the 
individuals who handle these blood samples are not at risk from contracting the HIV.  The BRG must also 
ensure that subjects who participate in the study are not at risk from contracting the HIV virus through any 
possible accidental contact with any blood while participating in the study.  In addition, the BRG must satisfy 
import/export authorities in South Africa and the receiving country that samples in any shipment across 
international borders are non-infectious. 
 
IS THE TEST ALWAYS CORRECT?  CAN THERE BE MISTAKES? 
The tests are usually very accurate, and are performed by registered pathology laboratories.  If your test result 
shows that you are infected with the HIV, you can have this confirmed by having further tests done at your 
own expense, or by going to the nearest clinic or public hospital for a free HIV test. 
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WHAT DOES IT MEAN IF THE TEST IS NEGATIVE? 
If your test result is negative, this does not mean that you may not become infected in the future.  If you 
engage in unprotected sex, you may be infected at some time in the future. You should think very seriously 
about the ways in which you can ensure that you are not infected in the future. In particular, you should 
consider using safer sexual practices, for example, a condom. 
 
There is a time of approximately six weeks after infection when an HIV test will not detect the HIV.  This 
happens because the test for antibodies cannot detect them for a short while after infection.  This time is 
called the “window period”. If you are in the “window period” your test results will be negative, although 
you are actually infected with the HIV. 
 
The chance of being in the “window period” is very small.  If you suspect that you may have become 
infected recently and are in the “window period”, you can arrange to be tested again in about three or more 
months’ time at your own expense, or go to the nearest clinic or public hospital for a free test and counselling. 
 
WHAT DOES IT MEAN IF THE TEST IS POSITIVE? 
If your test result is positive, this means that you have been infected with the HIV.  A positive test result will 
mean that you will not be able to participate in any clinical study conducted by the BRG.  The implications of 
a positive test result should be discussed with your doctor or the doctor who conducted your screening 
medical.  The BRG will pay for one session for you to discuss these implications with a doctor. 
 
WHAT ARE THE HARMS AND RISK OF THE AIDS TEST? 
Many people do not understand the facts about infection with the HIV.  This has led to people infected with 
the HIV being stigmatised and isolated by their families and communities.  Some people have committed 
suicides.  A positive test can lead to difficulties in seeking housing bonds, employment, as well as medical 
and dental treatment.  Psychological difficulties might also arise.  For these reasons, the BRG will keep your 
test results confidential. 
 
WHAT ARE THE BENEFITS OF THE AIDS TEST? 
If the test is negative, this can reassure you and help you make sure you do not become infected with the HIV.  
A positive test result can offer an opportunity to get early treatment, to change life plans and to prevent 
infection of your sexual partners. 
 
NOTIFICATION OF TEST RESULTS 
If your test result is negative:  You will be considered for inclusion into the clinical study. 
If your test is positive: Because a trained person should deliver that information so that you can understand 
clearly what the test result  means, you are asked in Appendix B of this document to designate the doctor 
who conducted the screening medical or a doctor or clinic of your choice to deliver the test result to you. 
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Consequently it is of the utmost importance that you think carefully about the person who should receive the 
results.  Should you not know who to name, please ask someone for assistance or suggestions. 
 
You will be advised to contact the designated doctor or clinic, so that they can discuss the meaning of the test 
result with you. Please note that if you are asked or receive a letter to contact the designated doctor, that this 
does not automatically mean that the AIDS test result is positive, as many other medical impairments may 
lead to you not being able to participate in the clinical study and which should require further medical follow-
up for your benefit. 
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Appendix B 
This page must be detached from the document and taken with you when you go for your HIV test. 
 
Section 1 must be completed by you, the clinical study volunteer. 
Sections 2 and 3 must be completed by the person drawing the blood sample. 
 
Section 1: To be completed by the clinical study volunteer. 
 
I designate: i. The doctor who conducted the screening medical as the person to deliver a positive test result to me. 
 
 
Signature of person being tested ____________________________________ Date ________________________________ 
 
OR 
 
I designate: ii The following doctor or clinic to deliver a positive  test result to me. 
 
Name ____________________________________________________________________________________________________
__ 
  
Addres
s 
____________________________________________________________________________________________________
__ 
  
 ____________________________________________________________________________________________________
__ 
  
Signature of person being tested ___________________________________
_ 
Date _______________________________
_ 
 
 
To be completed by the person drawing the blood sample. 
(Please retain this document and forward to the BRG together with the HIV test results) 
 
Section 2: Identification of applicant for all pathological tests (must always be completed) 
 
Passport/Identity Number of person being tested:                
 
 
Name of person being tested __________________________________________________________________________________ 
  
Address __________________________________________________________________________________ 
  
 __________________________________________________________________________________ 
  
Signature of person being tested ____________________________________ Date ________________________________ 
 
Section 3:  Identification of and declaration by person drawing the sample. 
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Name of person drawing the sample _____________________________________________________________________________ 
  
Practice number _____________________________________________________________________________ 
  
Address _____________________________________________________________________________ 
  
 _____________________________________________________________________________ 
  
Signature of person being tested ___________________________________ Date ________________________________ 
 
I have satisfied myself that the person being tested has received the Informed Consent Document, and I have verified the identity of the 
applicant and that he/she has freely consented to have the sample drawn and tested for HIV antibodies. 
 
I have inspected the following document to verify the identity of the volunteer: 
 
 valid South African identity document 
 
 valid South African passport 
 
 valid temporary South African identity document 
 
 foreign passport 
 
 
 
Signature of person drawing the 
sample 
____________________________________ Date ________________________________ 
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APPENDIX VIII 
VERBAL DELIVERY OF INFORMATION TO STUDY VOLUNTEERS 
 
The announcement will be posted around campus. 
 
Students then contact the principal investigator directly and relay their interest in participating in the study.  
A short and factual explanation is given of the study and female participants are specifically asked whether 
they are using reliable contraception (the contraceptive pill, minipill or an IUD) and whether any participant 
suffers from eczema or psoriasis. 
 
The principal investigator then mails the participants information brochure to the participants to the place of 
residence of the study volunteer.  As the announcement is made 1 - 2 weeks before the commencement of the 
study, ample time is allowed for the reading through of this information. 
 
At the first meeting in the Seminar Room in the Faculty of Pharmacy building 30 minutes are allocated to a 
verbal explanation of the study and any questions.  This provides an undisturbed physical environment and 
the time allocation of 30 minutes is realistic. 
 
Study volunteers are then shown the clinic unit where the study will take place as well as the needles for the 
insertion of the probes etc. Thereafter questions from the study volunteers are answered. 
 
Study volunteers will be given approximately 7 days in which to consider the written information and 
formulate questions.  Should there be any additional questions regarding the preceding verbal information, 
study volunteers have an opportunity to consider these answers before a final decision is made with regard to 
participation. 
 
Should the study volunteer continue to be interested in participating, the two days on which the study will be 
conducted are arranged.  Thereafter the study volunteer signs the study participation informed consent form 
as well as the screening medical and HIV testing consent form which are also signed by the principal 
investigator and in the presence of a witness if required.  Study volunteers are hereby included in the study 
and are given a copy of the Information for Volunteers Brochure and the signed consent forms as well as 
written instructions regarding the 2 pre-arranged study days. 
 
The study volunteers will then be contacted to see the principal investigator for medical screening as outlined 
in the protocol. 
 
 Appendix V 
326 
ADVERTISEMENT 
VALID 10 MARCH – 30 AUGUST 2009 
 
 
CLINICAL STUDY VOLUNTEERS 
 
The Biopharmaceutics Research Group is looking for 
HEALTHY FEMALE and MALE 
VOLUNTEERS 
to participate in clinical studies on a 
medicated ethanolic solution applied to 
the skin using microdialysis 
If You Are: 
1. Over 18 years 
2. Generally healthy and currently medicine free 
3. Willing to spend a day in the clinic 
Then You May Be Eligible to Participate 
You Will Be Remunerated For Participating 
If You Are Interested Please Contact Genevieve as soon as 
possible for More Information: 
Preferably by E-mail at: g02a1351@campus.ru.ac.za 
Or by Phone at: 046 603 8412 
 
This advert has been approved by the Rhodes University Ethical Standards Committee 
 
Please take a tear-off slip below 
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